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Abstract 
Heart disease is the leading cause of death worldwide.  Despite considerable progress in 
the prevention and treatment of heart disease it remains a highly prevalent source of patient 
morbidity and mortality.  The heart has the ability to change in shape, size, structure and 
function in response to adverse stimuli in a process known as cardiac remodelling which is 
intended to be an adaptive response initially but can become detrimental leading to 
eventual heart failure (HF).  The mechanisms underlying the progression from remodelling 
to HF remain poorly understood.  Remodelling in the heart is known to be associated with 
alterations in cardiac gene expression for which transcription factors play a significant role.  
It has been reported that the RUNX family of transcription factors which play important 
roles in developmental pathways, have been increasingly implicated in disease and in 
tissue injury.  One member of this family of transcription factors, RUNX1, has been shown 
to be up-regulated in heart tissue taken from human patients with MI.  Despite this 
knowledge, a precise quantitative measure of the altered expression of Runx in the heart in 
terms of regional and temporal changes using an animal model has not been previously 
explored.  Therefore the aim of the work presented in this thesis was to investigate the 
altered expression of the Runx genes in two different experimental animal models of heart 
disease: a mouse model of myocardial infarction (MI) and a rat model of hypertension and 
altered left ventricular (LV) mass to assess the changes in Runx expression in response to 
the different cardiac disease types.   
For this study a mouse model of MI was developed using the well-established coronary 
artery ligation (CAL) method and the phenotype of this model was characterised at 
different time points by assessing survival trends, performing in vivo functional 
measurements (pressure-volume (PV) loop methodology and electrocardiograms) with 
assessment of structural alterations of remodelling using histological and morphometric 
measurements.  The model was found to exhibit many of the clinical features consistent 
not only with other published murine model data but also those of human MI.  The mouse 
MI model was then used to measure Runx gene expression in the hearts using real time 
quantitative reverse transcription PCR (qRT-PCR) and immunohistochemistry (IHC) 
methods.  This was to assess whole heart and regional expression differences, how 
expression levels change over time as the MI develops, assessment of expression patterns 
of the different Runx gene members and exploration of potential links with Runx 
expression and possible functional relevance to the heart.  In the mouse model, Runx genes 
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were found to be up-regulated in response to MI with highest levels confined to the areas 
within and around the infarct and peri-infarct region by 4 weeks post-MI extending into the 
remote regions by 8 weeks.  Runx levels were found to be highest in the hearts with the 
greatest dysfunction.   
The second model of heart disease for assessing changes in Runx was a rat model of 
hypertension, with congenic sub-strains of this model showing altered LV mass also tested.  
The congenic rat strains were specifically bred models of rat with a chromosome 14 
substitution.  This contained a quantitative trait locus (QTL) from either normotensive or 
hypertensive strains for genes associated with LV mass.  These models were analysed 
using in vivo PV methodology to assess function without influence from blood pressure 
(BP) loading conditions (to assess whether the QTL is BP-dependent) and structural 
remodelling in the form of cardiac fibrosis was measured histologically.  The data revealed 
enhanced systolic function with diastolic dysfunction and cardiac fibrosis in hypertensive 
animals consistent with other published models.  The chromosome 14 congenic rat strains 
showed a BP-independent diastolic dysfunction or improved function linked to cardiac 
fibrosis.  Furthermore, in contrast to the MI model, the levels of Runx1 were significantly 
down-regulated in the rat models of hypertension and altered LV mass indicating potential 
differences in the triggers for altered expression between volume-overload versus pressure-
overload models of heart disease.   
Overall this thesis has shown the altered expression of Runx genes in two different animal 
models of heart disease which has not been previously explored and indicates potential for 
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The primary function of the heart is to maintain circulation of blood to the organs and 
tissues of the body.  The inability to supply the oxygen and nutrients necessary to support 
the needs of the body is the major consequence of heart disease and constitutes the basis of 
heart failure (HF).  Heart disease is currently the leading cause of morbidity and mortality 
worldwide (WHO, 2011).  In order to understand the complex nature of heart disease for 
the research of novel treatments it is important to understand the basic functioning of the 
heart and its adaptive capabilities as an organ during normal and pathological conditions. 
1.1 Cardiac EC coupling 
The mammalian heart is divided into a right and left side and has four chambers; two atria 
and two ventricles.  The right and left ventricles (which receive blood from the right and 
left atrium respectively) represent two synchronous muscular pumps contracting in a timed 
fashion.  Contraction occurs at the level of the individual contractile cells of the heart, the 
cardiomyocytes, by a process known as excitation-contraction (EC) coupling which is the 
sequence of events from electrical excitation of the cardiomyocyte to mechanical 
contraction of the heart.  During this process, calcium ions (Ca2+) play a pivotal role.  The 
main stages of EC coupling are described below and depicted in Figure 1.1. 
1.1.1 Initiation and Ca2+ influx 
The process of EC coupling is initiated by the cardiac action potential which is an 
electrical impulse that rapidly alters cell membrane potential.  The action potential 
originates from the pacemaker cells of the sinoatrial (SA) node located in the right atrium 
and is quickly transmitted to the atrioventricular (AV) node (a small mass of cells located 
in the lower atrial septum) and through fast-conduction muscle fibres known as the Bundle 
of His to the Purkinje fibres which supply the signal to the ventricular cardiomyocytes.  
This occurs rapidly from one cardiomyocyte to the next via gap junctions as a wave 
propagation system.  The action potential creates a wave of depolarisation along the 
surface cell membrane (the sarcolemma) of the cardiomyocytes along distinct invagination 
structures that extend into the cell called transverse tubules (T-tubules).  This triggers the 
opening of voltage-gated L-type Ca2+ channels located along the T-tubules (Bers & Perez-
Reyes, 1999).  This allows Ca2+ to enter the cell which contributes to the plateau phase of 
the action potential.  Both extracellular and intracellular Ca2+ is absolutely essential for EC 
coupling as was first discovered by the physiologist Sydney Ringer in the early 1880s 
when he found that an isolated frog heart ceased to beat when Ca2+ was accidentally 
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removed from the solution that perfused the heart (Ringer, 1882a;Ringer, 1882b;Ringer, 
1883a;Ringer, 1883b).  
1.1.2 Calcium-induced calcium release 
1.1.2.1 Background to calcium-induced calcium release 
Ca2+ entry into the cell triggers a release of Ca2+ from the intracellular Ca2+ store organelle, 
the sarcoplasmic reticulum (SR); this is known as calcium-induced calcium release 
(CICR).  CICR was demonstrated in the 1970s and 1980s through a series of experiments 
performed by Fabiato and Fabiato who demonstrated that in skinned canine 
cardiomyocytes where the sarcolemmal membrane was removed (therefore lacked T-
tubules allowing intracellular Ca2+ to be equilibrated with a known Ca2+ concentration in 
the bathing fluid), the skinned cells were found to relax at 0.02-0.03 µM Ca2+, contract 
moderately at 0.1 µM Ca2+ and contract maximally at 0.3 µM Ca2+ (Fabiato & Fabiato, 
1975).  This revealed that contractions were induced by Ca2+-triggered release of Ca2+ 
from the SR and that the amount of Ca2+ released is a function of the amount of trigger 
Ca2+ (Ca2+ entering the cell through the L-type channel).  They later revealed that at high 
trigger Ca2+ concentrations (10 µM for 150 ms) CICR could be inhibited (Fabiato, 1985).  
1.1.2.2 Ca2+ release from the SR 
There are two distinct domains of the SR; the junctional domain which contains the 
channels for Ca2+ release from the SR and the longitudinal domain which contains the 
channel for Ca2+ uptake into the SR (Franzini-Armstrong, 1970;Winegrad, 1965).  Ca2+ is 
released from the SR during CICR via release channels on the junctional SR known as 
ryanodine receptors (RyR).  RyR are proteins (~ 2.3 million Dalton with the functional 
tetramer visible at the electron microscope level; (Saito et al., 1988)) and are located 
within nanometers of the sarcolemma of a T-tubule placing them in extremely close 
proximity with L-type Ca2+ channels.  The ratio for number of RyR per L-type Ca2+ 
channel ranges from 8:1 in rat, 6:1 in humans and 4:1 in guinea pig (Bers & Stiffel, 1993).  
Inward flux of Ca2+ across the entire cell leads to release of Ca2+ from the SR (typically no 
greater than 50% of the SR Ca2+ content however this is dependent on available SR Ca2+ 
(Shannon et al., 2000)) but a substantial fraction is released into the cytosol.  The 
intracellular free Ca2+ concentration ([Ca2+]i) rises from 0.1 µM to ~ 0.5-2.0 µM of which 
75-90% comes from the SR release and the remaining 10-25% comes from the inward 
current through the L-type Ca2+ channel (Eisner et al., 1998).  The total cytosolic Ca2+ 
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([Ca2+]total = [Ca2+]i plus bound Ca2+) required for half-maximal activation of contraction is 
approximately 70 µmol l-1 cytosol (Bers, 2002).   
1.1.3 Ca2+-mediated cross-linking and contraction 
The intracellular rise in [Ca2+]i allows Ca2+ ions to bind to the myofilament protein 
troponin C which is bound to another myofilament protein called tropomyosin as part of 
the tropomyosin-troponin complex.  At rest (Ca2+ unbound to troponin C) this complex is 
bound to the actin (thin) filament of the contractile sarcomere apparatus and in doing so 
obscures the myosin-binding sites on the actin.  When Ca2+ binds to troponin C it causes a 
shift in the tropomyosin-troponin complex shifting it deeper into the actin groove thereby 
exposing the myosin-binding sites.  Myosin can then subsequently bind to actin forming a 
cross-bridge and via adenosine triphosphate (ATP) hydrolysis the myosin head pulls the 
actin filament to the centre of the sarcomere causing it to shorten and contract the cell 
(Layland et al., 2005).  
1.1.4 Relaxation and Ca2+ extrusion 
In order for the cardiomyocyte to relax (which is important to allow the heart to fill with 
blood again) [Ca2+]i must be restored back to resting levels.  This is necessary to allow 
Ca2+ to dissociate from troponin and allow the tropomyosin-troponin complex to return to 
its position where it obscures the actin binding sites and prevents myosin binding.  The 
majority of Ca2+ is transported out of the cytosol by four different pathways:  
(i)  The SR Ca2+ ATPase (SERCA) pump located on the surface membrane of the SR 
which transports Ca2+ back into the SR.  SERCA is regulated by an inhibitory protein 
called phospholamban (PLN) which in its basal unphosphorylated state inhibits SERCA by 
decreasing the affinity of SERCA to Ca2+ (James et al., 1989;Voss et al., 1994).  In its 
phosphorylated state, PLN enhances the activity of SERCA by increasing the pump’s 
affinity for Ca2+ (James et al., 1989) and permits resequestration of Ca2+ back into the SR. 
(ii)  The sodium-calcium exchanger (NCX) is a sarcolemmal pump which moves 1 Ca2+ 
ion out of the cell in exchange for 3 Na+ ions into the cell; this mechanism is driven by 
both transmembrane voltage and by Na+ and Ca2+ concentration gradients (Blaustein & 
Lederer, 1999). 
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(iii)  The sarcolemmal Ca2+ ATPase is also a sarcolemmal pump which hydrolyses ATP 
to transport Ca2+ out of the cell.  This contributes to a sarcolemmal current which is small 
in comparison to that of the NCX (Caroni & Carafoli, 1981). 
(iv)  The mitochondrial uniporter is a pore in the inner membrane of mitochondria which 
moves cytosolic Ca2+ into the mitochondria down an electrochemical gradient (Kirichok et 
al., 2004). 
 
Figure 1.1  Ca2+ transport in the ventricular cardiomyocyte. 
Schematic representation of Ca2+ transport within the cardiomyocytes with inset showing the time course of the rabbit 
ventricular cardiomyocytes action potential (black line), intracellular Ca2+ transient (blue line) and contraction (red 
dashed line).  Red arrows indicate means of Ca2+ entry into the cell and green arrows indicate means of Ca2+ extrusion 
from the cell.  ATP (ATPase); NCX (Na+/Ca2+ exchanger); PLB (phospholamban); SR (sarcoplasmic reticulum); RyR 
(ryanodine receptor).  Taken from (Bers, 2002). 
1.1.4.1 Proportions of Ca2+ extrusion by each mechanism 
The proportion of Ca2+ extruded by each mechanism is different and varies between 
species; in rabbit cardiomyocytes the proportions of Ca2+ extruded are approximately as 
follows: 70% by SERCA, 28% by the NCX and 2% by the Ca2+ ATPase and the 
mitochondrial uniporter (Bassani et al., 1994).  In rat cardiomyocytes, approximately 92% 
is through SERCA, 7% through NCX and 1% through the Ca2+ ATPase and mitochondrial 
uniporter (Bassani et al., 1994).  The proportions in the mouse are very similar to the rat 
(Li et al., 1998).  These differences are largely due to a greater activity of SERCA in 
rodents (due to greater number of SERCA molecules) (Hove-Madsen & Bers, 1993).  The 
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entire process from Ca2+ influx to contraction and Ca2+ extrusion is then repeated for 
further contraction and relaxation of cardiomyocytes which forms the basic pumping 
mechanism of the heart. 
1.2 Cardiovascular disease (CVD) 
Disease of the cardiovascular system occurs when the normal structure and functioning of 
the heart becomes compromised which can eventually lead to HF.  The heart is an adaptive 
organ and is capable of adapting to disease or injury through alterations to its structural 
properties and functional ability in order to maintain normal cardiac output (CO) within 
physiological limits.  This process is known as cardiac remodelling and refers to changes 
in the size, shape and function of the heart in response to cardiac load or injury (Cohn et 
al., 2000).  This tends to be beneficial initially but in the longer term it often becomes 
maladaptive and results in further deterioration of function (Colucci, 1997).  As a result, 
cardiac remodelling is a central feature in the development of HF.  Remodelling is a 
progressive process characterised by a complex array of cellular and molecular changes 
which are largely dependent on the underlying stimuli (Kehat & Molkentin, 2010).  The 
main features of remodelling involve changes in the size of the individual cardiomyocytes, 
cellular apoptosis of cardiomyocytes, changes in the molecular phenotype of the 
cardiomyocytes (e.g. altered gene expression) and alterations in the quantity and 
composition of the extracellular matrix (ECM) (Colucci, 1997).  Remodelling occurs 
differently in response to different cardiac disease types and details of each remodelling 
process for two common cardiac diseases relevant to this thesis; MI and hypertension 
with hypertrophy, will be discussed in the sections that follow. 
1.2.1 Myocardial Infarction 
1.2.1.1 Definition and prevalence 
MI (also known as a heart attack) is defined as the death of a region of myocardium in the 
heart due to an obstruction of a coronary artery (Thygesen et al., 2007).  MI is one of the 
main forms of coronary heart disease (CHD) (Thygesen et al., 2007) which is the 
collective term for cardiac diseases characterised by narrowing of the coronary blood 
vessels leading to disruption in the supply of adequate circulation to the heart (Cohen & 
Hasselbring, 2007).  CHD in the form of MI is the leading cause of HF and represents the 
largest cause of mortality in the U.K. (Scarborough et al., 2011).  Although CHD mortality 
has fallen in recent years (by 32% between 2001and 2009) it continues to be a serious 
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public health problem with death rates reaching 88,000 each year in the UK (Scarborough 
et al., 2011). 
1.2.1.2 Main cause of MI 
MI is caused by an accumulation of fatty and fibrous deposits along the interior of a 
coronary artery which over time can progress to considerable thickening and hardening of 
the arterial wall (Cohen & Hasselbring, 2007).  While usually asymptomatic for decades, it 
may eventually become a serious problem if the plaque inside the artery suddenly ruptures 
causing a thrombus formation that can partially or completely obstruct coronary blood 
flow. 
1.2.1.3 Post-MI remodelling 
MI is a complex disease which progresses through a number of distinct stages.   
(i)  Ischaemia and cell death 
A blockage or occlusion of the coronary blood flow results in oxygen deprivation to a 
region of the myocardium (defined as ischaemia).  The consequences of ischaemia can 
vary depending on the extent and duration of the ischaemia.  During ischaemia, the oxygen 
and nutrient deprivation disrupts normal oxidative phosphorylation leading to a reduction 
in ATP necessary for normal function.  If the ischaemic episode is brief (<30 min in rodent 
models) (Ferdinandy et al., 2007) and reperfusion of blood is restored it is possible for the 
injured cardiomyocytes to regain normal structure and function but with time (i.e. not 
immediate) - in this case the myocardium is said to be stunned (Kloner & Jennings, 2001).  
Hibernating myocardium refers to an adaptive reduction of contractile function in response 
to a reduction of blood flow which is not regarded as a consequence to the energy deficit 
but rather an adaptive mechanism to maintain cardiomyocyte integrity and viability 
(Heusch & Schulz, 2002).  Prolonged ischaemia can lead to irreversible cell death 
(infarction).  This usually occurs within hours of the insult as a result of oxygen 
deprivation and depletion of ATP.  For continuous functioning, the myocardium is 
absolutely dependent on aerobic metabolism for the production of energy in the form of 
ATP.  During normoxia, ATP is produced in the mitochondria by oxidative 
phosphorylation; however during oxygen and substrate deprivation (ischaemia) this leads 
to a rapid decline in the production of ATP without which the cell cannot survive.  This 
leads to a multitude of subsequent processes that can lead to cell death by three main 
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methods: necrosis, apoptosis and autophagy (although autophagy is less understood in the 
context of MI) (Marambio et al., 2010;Olivetti et al., 1997;Wencker et al., 2003).   
Necrosis is a form of cell death characterised by loss of ATP, cell swelling, organelle 
swelling and membrane damage.  Depletion of ATP leads to an accumulation of AMP 
which triggers the activation of glycolytic enzymes and a switch to anaerobic metabolism 
and lactate production.  Increased lactate in the cell leads to accumulation of water and 
resultant osmotic stress to the cell eventually leading to organelle and cell swelling with 
resultant sarcolemmal membrane damage (damage to phospholipids and ion channels) (de 
Zwaan et al., 2001). 
Apoptosis is a form of ‘programmed cell death’ during which the cell instructs its own 
death.  This is different to necrosis which is considered a passive or accidental process.  
Apoptosis is rare in normal myocardium, occurring in 0.01-0.001% of normal human 
cardiomyocytes (Soonpaa & Field, 1998) increasing to 0.12-0.70% in human HF (van 
Empel et al., 2005).  It is triggered by neurohormonal factors, cytokines and extracellular 
factors which can activate apoptosis via the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signalling pathway or via the stress activated protein kinase 
(SAPK) pathway (Mani & Kitsis, 2003;Negoro et al., 2001). 
Autophagy is a highly-conserved process in which intracellular membrane-bound 
organelles called lysosomes that contain enzymes can break down the cell’s own structures 
through activation of these enzymes.  During ischaemia, lysosomes are activated and can 
hydolyse the organelle/cell membranes which can lead to osmotic stress and further 
sarcolemmal disruption (de Zwaan et al., 2001). 
The process of LV remodelling following cardiomyocyte death is summarised in the flow-
diagram in Figure 1.2 below.   
(ii)  Inflammation 
Cardiomyocyte necrosis triggers the recruitment of various inflammatory cells to the 
infarcted area such as macrophages, monocytes and neutrophils to repair the damaged 
myocardium.  The localised area of dead myocardium is referred to as the infarct.  Necrotic 
cardiomyocytes activate the complement system and leads to free-radical generation 
causing a cascade of signalling molecules known as cytokines to be released by the dying 
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cells.  Examples of cytokines involved include interleukin-8 and C5a which recruit 
neutrophils to the infarcted region that release potent protease enzymes and phagocytose 
necrotic cardiomyocytes and cellular debris.  Transforming growth factor-beta 1 (TGF-β1) 
and gamma-interferon (γ-interferon) then recruit monocytes to the area which differentiate 
into macrophages, important for scavenging (phagocytosing) the dead cells (Frangogiannis 
et al., 2002;Nian et al., 2004).  As part of the cell clean-up process (neutrophils and 
macrophages engulfing dead cardiomyocytes), neutrophils release enzymes called serine 
proteases and matrix metalloproteinases (MMP) which break down the collagen fibres 
holding the cardiomyocytes together (Siwik & Colucci, 2004).  This leads to infarct 
expansion.   
(iii)  Infarct expansion 
Infarct expansion (infarct thinning and LV chamber dilation) can occur within hours of the 
infarction.  There are several mechanisms responsible for infarct expansion including (i) 
cell stretching due to increased sarcomere length, (ii) reduction in inter-cellular space such 
as the capillary beds which causes cells to be closer together in the infarcted region, but is 
predominantly due to (iii) the sliding movement of the cardiomyocytes also known as 
‘slippage’ (Rohde et al., 1999).  Side-slippage of cardiomyocytes occurs because of the 
loss of collagen holding the cells together therefore allowing them to slip (Whittaker et al., 
1991).  Cardiomyocyte cell death also contributes to the process allowing the neighbouring 
viable cells to slip (Gajarsa & Kloner, 2011).   
(iv)  Cardiac fibrosis 
Cardiac fibrosis is the deposition of collagen in the heart in response to stimuli and can be 
one of two main types: reactive or reparative.  Reactive fibrosis refers to the collagen of 
abnormal thickness and density which occupies the perivascular or interstitial space which 
was previously devoid of collagen whereas reparative fibrosis refers to the replacement of 
lost/dead cardiomyocytes (‘scarring’) and is often seen as a patchy distribution and serves 
to preserve the structural integrity of the myocardium.  Infarct expansion during MI can 
trigger myofibroblasts to proliferate and deposit collagen into the thinned tissue 
continually to form a scar (where dead tissue is replaced by collagen) which resists further 
expansion (Sun & Weber, 2000).  Therefore cardiac fibrosis in MI is largely a reparative 
fibrosis.  The collagen deposition is a compensatory response to stabilise the distending 
forces and support the thinned myocardium (French & Kramer, 2007). 




Figure 1.2  Representation of the pathways of LV remodelling post-MI. 
ECM, extracellular matrix; RAAS, renin-angiotensin-aldosterone system; CO, cardiac output; SVR, systemic vascular 
resistance; LV, left-ventricular and AII, angiotensin II.  Figure taken from (Sutton & Sharpe, 2000) 
(v)  Cardiac hypertrophy 
Cardiac hypertrophy is the enlargement of cardiomyocytes in response to external stimuli 
and there are two main forms: eccentric and concentric.   
Eccentric hypertrophy refers to the in-series addition of sarcomeres (increase in 
cardiomyocyte length) and occurs under conditions of volume-overload (e.g. MI) causing a 
decrease in the ventricular wall thickness. Chamber dilatation leads to an increase in 
systolic and diastolic wall stress; this occurs because the increase in LV radius increases 
the wall stress and oxygen demand by Laplace’s law (Pfeffer et al., 1991a).  Elevated wall 
stress triggers eccentric hypertrophy (end-to-end lengthwise cell enlargement) in the non-
infarcted myocardium by causing altered expression of genes which encode contractile 
proteins (e.g. β myosin heavy chain) for assembly of new sarcomeres (Sadoshima et al., 
1992).   
Kirsty K. Foote, 2012  Chapter 1  
28 
 
Concentric hypertrophy is the in-parallel addition of sarcomeres (increase in 
cardiomyocyte width) and typically occurs under conditions of pressure-overload causing 
an increase in ventricular wall thickness although this can also occur in volume overload.   
Hypertrophy in MI is mainly eccentric:  Hypertrophy is an adaptive response aimed to 
compensate for the functional loss of the infarcted myocardium (Pfeffer & Braunwald, 
1990).  Therefore, early acute chamber dilation is largely due to infarct expansion (in the 
infarct region) whereas late dilation is the result of eccentric hypertrophy of the non-
infarcted regions.  Eccentric hypertrophy is therefore secondary to infarct expansion and 
while they both contribute to dilation of the chamber, they differ in the mechanism by 
which their dilatory effect comes about: infarct expansion leads to dilation through 
slippage and loss of cardiomyocytes in the infarcted region whereas eccentric hypertrophy 
contributes to dilation through elongation of surviving cardiomyocytes in the non-infarcted 
regions by addition of sarcomeres (infarct expansion can result in stretching of existing 
sarcomeres which is different to the addition of more) (Weisman et al., 1988).  Eccentric 
hypertrophy is considered beneficial initially as it can maintain or in some cases improve 
contractility in the non-infarcted region; this has been demonstrated in isolated 
cardiomyocytes from the non-infarcted septum in mice 10-wk post-MI with eccentric 
hypertrophy (22.5% increase in cell length but no change in cell width versus sham) which 
showed improved contractility with a 24.6% increase in the Ca2+ amplitude compared to 
sham (Mork et al., 2009).  Over time however the LV chamber becomes so dilated that it 
begins to severely impair contractile function which is the most common cause of HF.  A 
summary of the time course of events of post-MI remodelling is summarised below in 
Figure 1.3 showing an example from a murine experimental model of MI. 
 
 




Figure 1.3  Timeline of LV remodelling after MI. 
Example LV remodelling timeline showing major events which occur post-MI.  This is an example from a mouse MI 
model showing the three main phases of remodelling; early phase (<72h), proliferative phase (3-7 days) and late phase 
(>1-wk).  Times may vary depending on the extent of the injury.  Figure generated from studies by (Wang et al., 
2006;Yang et al., 2002). 
1.2.1.4 Progression to HF 
LV remodelling and HF have both been extensively studied but the mechanisms 
underlying the transition from one to the other remain unclear.  One of the main 
mechanisms is chamber dilation as described above; it is however also believed to be 
linked to characteristics of the peri-infarct myocardium (Jackson et al., 2002;Jackson et al., 
2003).  This refers to the region of myocardium found at the immediate periphery of a 
developing infarct (also termed border zone) where an interface exists between ischaemic 
and viable tissue.  The peri-infarct myocardium consists of viable surviving 
cardiomyocytes intermingled with dead necrotic cells and are potential substrates for life-
threatening ventricular arrhythmias (Pinto & Boyden, 1999).  Fibroblasts and inflammatory 
monocytes may also be present in the peri-infarct zone although they are predominantly 
found within the infarct region.  Furthermore, close contact between thin-walled infarct 
and viable myocardium results in an abnormally increased radius of curvature of the 
myocardium at the infarct margin, leading to elevated wall stress and associated energy 
demands in the peri-infarct (Buda et al., 1986;Guccione et al., 2001).  Energetic 
insufficiency in the peri-infarct can expand to the rest of the LV and lead to global LV 
dysfunction and potentially HF.  The peri-infarct is believed to play a major role in the 
development from compensated LV remodelling to HF.  Understanding altered function in 
the peri-infarct myocardium at the cellular level is important for gaining a better insight 
into the mechanisms underlying the progression of heart failure.  Studies have shown that 
cardiomyocytes isolated from this region demonstrate: (i) altered calcium handling, 
including decreased SR Ca2+ accumulation (Licata et al., 1997), (ii) altered ionic currents 
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(Pu et al., 2000) and (iii) limited cell shortening due to impaired contractile elements 
(Licata et al., 1997). 
1.2.2 Hypertension 
1.2.2.1 Definition and prevalence of hypertension 
Human hypertension is considered the largest cause of CVD worldwide (Hajjar et al., 
2006).  It has been estimated that between 1999-2002, 28.6% of the US population had 
hypertension (Hajjar et al., 2006).  The Health Survey of England in 2010 revealed that the 
incidence of hypertension was 31.5% in men and 29.0% in women living in England, U.K. 
(NHS Information Centre, 2010).  Hypertension is a chronic, progressive disease 
characterised by an elevation in arterial BP sufficient to increase the incidence of stroke (4-
6 fold), HF (2-3 fold) and renal failure (Schocken et al., 2008).  Although hypertension is a 
major risk factor for MI, the two diseases can occur independently of one another and 
exhibit very different phenotypes, therefore for the purpose of this thesis they will be 
referred to separately.  Clinically, hypertension is diagnosed when repeated measurements 
of resting brachial artery pressure exceed 140/90 mmHg in patients under 50 years of age, 
or 160/95 mmHg in patients older than 50 years (Levick, 2010).  However hypertension is 
emerging as a complex disease and some believe that it cannot be defined by BP limits 
alone and should incorporate the cardiac and vasculature abnormalities associated with the 
disease (Giles et al., 2005). 
1.2.2.2 Classification of hypertension 
Hypertension can be classified as either primary (essential) which means high BP with no 
underlying medical cause which is the most common form affecting the majority of cases 
(90-95%) (Carretero & Oparil, 2000), or secondary (remaining 5-10%) which means it is 
secondary to another medical condition affecting the arteries, kidneys, heart or endocrine 
system (O'Brien et al., 2007).  Despite the debates on the exact definition it is generally 
accepted that the hallmark of hypertension is the narrowing and stiffening of the arteries 
which supply blood to the body’s tissues (Izzo, Jr. & Shykoff, 2001).  At an early stage this 
is characterised by an increase in vascular tone (ability to constrict) and is reversible with 
the administration of vasodilator drugs.  However as the disease progresses the structure of 
the arterial tunica media (middle) layer changes; in mild hypertension rearrangement of the 
vascular smooth muscle myocytes occurs with a modest increase in the ECM which 
narrows the lumen by ~10% with little change in wall area, this is known as inward 
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eutrophic remodelling (Intengan & Schiffrin, 2001).  At this stage vasodilator drugs are 
ineffective to rectify the abnormal resistance.  In severe hypertension remodelling of the 
tunica media continues with hypertrophy (increased cell size) and hyperplasia (increased 
cell numbers) of the smooth muscle myocytes in addition to their rearrangement previously 
undergone (Amann et al., 1995).  The overall consequence is the narrowing of the artery 
with reduced compliance (stiffer) leading to an increase in the total peripheral resistance 
(TPR) and increased mean arterial pressure (MAP). 
1.2.2.3 Main causes of hypertension 
The causes of hypertension have not been fully elucidated but are linked to both genetic 
and environmental factors: 
Genetic factors have been shown to be important factors as it is estimated that 30-60% of 
BP phenotypic variation among individuals is genetically determined (Shih & O'Connor, 
2008).  Genetic links are also reflected by the familial and racial tendencies observed in the 
disease: i.e. hypertension is highly heritable (Doris & Fornage, 2005) and hypertension is 
more common among patients of Afro-Caribbean or African descent compared to 
Caucasians (Primatesta et al., 2000).  Studies using identical twins further support a 
genetic link as monozygotic twins have substantially greater similarities in LV mass than 
dizygotic twins (Adams et al., 1985).  It is very rare that just a single gene is involved and 
is usually multiple genes linked at distinct chromosomal regions known as quantitative trait 
loci (QTL) which will be covered in more detail in Chapter 5.   
Environmental factors that have been linked to hypertension include high dietary salt 
(Na+) intake, low dietary potassium (K+) intake, obesity, stress and alcohol consumption 
(Dickinson et al., 2006).  High dietary Na+ is considered one of the highest risk factors as 
plasma [Na+] is known to be elevated by ~2-3 mM in hypertensive patients (normal plasma 
[Na+] is 136-145 mM, abnormal plasma [Na+] in hypertension ≥147 mM) (Herrera & 
Garvin, 2005).  The mechanism by which high Na+ leads to hypertension is believed to 
occur by the following: high plasma [Na+] stimulates the adrenal cortex and the brain 
causing release of a substance called ouabain, an endogenous hormone and potent inhibitor 
of the Na+/K+  pump of the vascular smooth muscle cells.  Inhibition of the Na+/K+ pump 
causes partial depolarisation which increases the open probability of the L-type Ca2+ 
channels.  The rise in intracellular [Na+] reduces Ca2+ excretion from the cell by the NCX 
leading to increased [Ca2+] and resulting increased vascular tone (Blaustein et al., 2007).  
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Ouabain has the same effect on cardiomyocytes exerting a positive inotropic effect by the 
same mechanism - inhibition of the Na+/K+ pump (Muller-Ehmsen et al., 2003).  Other 
factors which link Na+ to hypertension are reduced expression of the α2 Na+ pump subunits 
and reduced expression of NCX1 which have also been shown to cause hypertension 
(Blaustein et al., 2006). 
Impaired Na+ renal handling is also believed to play a pivotal role in causing 
hypertension although it is not clear if this is genetically linked (Liu et al., 2011).  Under 
normal conditions, high [Na+] triggers a drop in circulating renin-angiotensin II-
aldosterone (RAA) levels which reduces distal tubular Na+ reabsorption to maintain the 
Na+ balance.  A large amount of Na+ is filtered into the nephron (25,000 mmol/day) and 
99% of this is reabsorbed.  Approximately ~65% of the reabsorption occurs in the 
proximal tubule, ~25% through the thick ascending Loop of Henle, ~5% through the distal 
tubule and ~5% through the principal cells of the collecting duct (Zhao et al., 2009).  There 
are two hypotheses which have been proposed to explain the imbalance.  Firstly, RAA 
levels are higher in hypertensive patients which would explain the inappropriate retention 
of Na+, however not all hypertensive patients demonstrate elevated RAA levels (Williams, 
1982).  The second hypothesis is that there is a defect in the gene(s) encoding essential 
renal ion channels or transporter proteins – this hypothesis is substantiated by the 
observation that normal rats develop hypertension when transplanted with kidneys from 
SHR with narrow afferent renal arterioles (Rettig, 1993). 
Other factors which can be risk factors for the cause of hypertension include stress as this 
can lead to temporary periods of increased BP which can heighten an individual’s 
susceptibility to developing hypertension (Dickinson et al., 2006).   
Overall hypertension has become regarded as a multifactorial disease and is likely to be 
caused as a result of complex interactions between dietary, neural, hormonal and renal 
mechanisms. 
1.2.2.4 Structural remodelling in the heart during hypertension 
Hypertension affects a number of systems of the body including the vasculature, the heart, 
the kidneys and the brain.  The structural impact on the heart is largely in response to 
pressure overload.  The narrowed, stiffened arteries raise MAP creating an elevated load 
on the ventricles; this basically means the ventricles have to work to greater extents to 
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ensure adequate delivery of blood to all of the body’s tissues.  In response to elevated BP, 
the heart undergoes structural remodelling in three main ways: 
(i)  LV hypertrophy (LVH):  Due to the increased pressure load on the heart the major 
response is cardiomyocyte hypertrophy i.e. individual cardiomyocytes of the heart become 
enlarged through parallel addition of sarcomeres (Frey & Olson, 2003) in attempts to 
enhance contractile function and cope with the persistent afterload.  Cardiomyocyte 
hypertrophy is driven by local growth factors (such as angiotensin II (AngII) and 
endothelin (Sadoshima et al., 1993;Shubeita et al., 1990), inflammatory cytokines (e.g. 
interleukin-1β) (Thaik et al., 1995) and mechanical stretch (Sadoshima & Izumo, 1993).  
These trigger the MAP kinase cascade causing an activation of cardiac nuclear 
transcription factors (e.g. GATA4) which in turn activate genes involved in the 
hypertrophy process of the cell (e.g. β myosin heavy chain), further details on cardiac 
transcription factors involved in this process are covered in Section 1.4.2.4.  Hypertensive-
induced hypertrophy affects the cardiomyocytes of the LV only causing an overall increase 
in LV mass (RV cardiomyocytes remain normal in size until a pressure overload caused by 
pulmonary venous hypertension and LV failure is present).  LVH is considered an 
important feature of hypertensive heart disease: firstly, it is one of the earliest responses to 
hypertension, present in children and adolescents with borderline elevation in BP (Daniels 
et al., 1990) and secondly, most importantly LVH is a major risk factor for adverse heart 
disease (see below).   
(ii) Coronary artery remodelling.  Similar to the narrowing and hardening of arteries of 
the systemic circulation, the same can also occur in the coronary arteries of the heart 
during hypertension (Jalil et al., 1991).  As described previously, the coronary arteries can 
also undergo medial thickening caused by hypertrophy and (in some cases) hyperplasia of 
the vascular smooth muscle cells (Amann et al., 1995).   
(iii) Perivascular and interstitial fibrosis.  Vascular smooth muscle cells can also 
undergo structural realignment with enhanced accumulation of ECM proteins such as 
collagen and elastin which is evident as a perivascular fibrosis (Jalil et al., 1991).  This 
occurs in response to the pressure-overload on the heart triggering the activation of 
neurohormonal factors including catecholamines, the RAA system and endothelin (Kai et 
al., 2005) leading to production of collagen by fibroblasts and vascular smooth muscle 
cells.  The accumulation of collagen can spread progressively from the perivascular space 
into the adjacent interstitial areas (reactive fibrosis) (Silver et al., 1990).  The reactive 
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fibrosis occurs when individual cardiomyocytes are encircled by collagen fibres which 
impair their ability to contract and relax causing increased myocardial stiffness (which is 
different to reparative fibrosis which replaces dead cardiomyocytes).  Cardiac fibrosis is 
not present in all types of LVH, for example it does not tend to occur with infrarenal aortic 
banding or volume-overload uninephrectomy and high Na+ diet (Brilla et al., 1990), 
compensated arteriovenous fistula (Salzmann et al., 1986), atrial septal defects (Marino et 
al., 1985) or chronic thyroxine administration (Bartosova et al., 1969). 
1.2.2.5 Progression to HF 
Persistent hypertensive heart disease can push the structural remodelling to a level where it 
become detrimental and can eventually lead to HF.  It has been estimated that hypertension 
is responsible for causing HF in 39% of men and 59% of women (Levy et al., 1996).  The 
structural adaptations outlined above which occur during hypertension can lead to cardiac 
dysfunction in several ways.  Both LVH and increased interstitial fibrosis lead to increased 
LV stiffness resulting in diastolic dysfunction (Kahan & Bergfeldt, 2005;Kai et al., 2005).  
Cardiomyocytes begin to die by necrosis and apoptosis which is believed to occur because 
of the increased diffusion distance into thickened myocardium causing local intracellular 
hypoxia (Kahan & Bergfeldt, 2005).  This is supported by the observations that discrete 
foci of reparative fibrosis (replacing necrotic myocytes) become evident throughout the 
myocardium (Lopez et al., 2001).  Loss of cardiomyocytes can lead to a dilated 
cardiomyopathy and according to Laplace’s Law, as radius increases, wall stress increases 
which further exacerbates cardiomyocyte death rate.  Hypertension-related LVH also 
increases a patient’s risk of MI which can also be the cause of dilated cardiomyopathy 
(Scarborough, 2010).  Dilated cardiomyopathy is a serious problem for patients as once 
this stage is reached it is very difficult to reverse.  About 1 in 3 cases of congestive HF are 
due to a dilated cardiomyopathy (Jameson et al., 2005). 
1.3 Mechanisms contributing to progression to HF in   
both MI and hypertension 
As described in the preceding sections the heart has the capability to adapt structurally and 
functionally as a protective mechanism in response to pathological conditions.  While 
remodelling is initially protective, over time persistent remodelling eventually begins to 
exacerbate rather than maintain normal function and this leads to eventual HF in the 
majority of CVD.  HF is defined by the chronic inability of the heart to maintain a 
sufficient CO to adequately perfuse the body’s tissues. Researchers have devoted many 
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years to the study of remodelling and the precise mechanisms by which this leads to HF.  
Although this still remains an area of intense investigation there are a number of cellular 
and molecular changes which occur during remodelling that are known to contribute to the 
functional decline associated with HF.  While HF can have distinctly different causes (e.g. 
MI or hypertension/hypertrophy) the functional characteristics of failing myocardium is 
very similar as detailed below. 
1.3.1 Abnormal Ca2+ handling 
Morgan et al. (1991) were the first to observe altered Ca2+ handling in failing human 
ventricular tissue (traberculae carneae); they demonstrated prolonged time to peak (93.6% 
greater than control) and prolonged relaxation (60.6% longer time to reach 50% relaxation 
from peak than control) (Gwathmey et al., 1987;Morgan, 1991).  It has been well-
established that the dysfunction in contractility and generation of life-threatening 
arrhythmias observed in HF is largely due to abnormal Ca2+ handling (Pogwizd et al., 
2001).  Failing human cardiomyocytes demonstrate prolongation of action potential 
duration (Gwathmey et al., 1990;Nabauer & Kaab, 1998;Ohler & Ravens, 1994), reduced 
amplitude of the intracellular [Ca2+]i transient (Beuckelmann et al., 1992;Gwathmey et al., 
1991;Morgan, 1991), impaired force development (Gwathmey et al., 1990;Mulieri et al., 
1992) and slowed relaxation (Beuckelmann et al., 1992;Schwinger et al., 1992).   
1.3.1.1 Alterations in Ca2+ handling proteins 
Many of these changes occur due to alterations in the expression and/or interactions 
between the Ca2+ regulatory proteins.  The reduced contractility of failing cardiomyocytes, 
as stated above, is primarily due to a reduced systolic Ca2+ transient amplitude arising from 
ineffective CICR.  CICR is reduced in HF often because of a decrease in SR Ca2+ content, 
the cause of which is believed to be for two reasons: (i) there is a reduced expression and 
activity of SERCA2 in human failing cardiomyocytes (Arai et al., 1993;Meyer et al., 
1995), although some studies have shown no change in SERCA2 expression but reduced 
Ca2+ uptake activity (Movsesian et al., 1989;Schwinger et al., 1995).  The second reason 
(ii) is due to diastolic leak of Ca2+ as a result of altered function and/or abundance of the 
Ca2+ release channel, RyR.  There is also evidence that the abundance of L-type Ca2+ 
channels is reduced in HF which would also play a role in reduced CICR (Chen et al., 
2002).  Ca2+ ‘leak’ is generally defined as loss of Ca2+ from the SR during resting or 
quiescent conditions and is believed to occur from abnormalities in RyR phosphorylation 
which increase the open probability of the channel (Shannon et al., 2000).  Together the 
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diastolic Ca2+ leak and slow Ca2+ uptake by SERCA2 impair diastolic relaxation which 
may be a contributory mechanism for diastolic dysfunction.  HF also induces abnormal 
alterations in the SERCA regulatory protein, PLN: for example alterations have been 
shown in the abundance of PLN (Kiss et al., 1995;Linck et al., 1996), the PLN/SERCA2 
stoichiometry (Koss et al., 1997), basal level of PLN phosphorylation (Schmidt et al., 
1999) and the ability of β-adrenergic signalling to mediate PLN phosphorylation (Huang et 
al., 1999).  Reduced phosphorylation of PLN and increase in PLN/SERCA2a ratio both 
contribute to contractile dysfunction in HF (Schmidt et al., 1999).  Each of these 
abnormities in PLN has been demonstrated in HF however the observations are not always 
consistent suggesting there are other factors involved.  Finally, the NCX has also been 
shown to be misregulated in HF with increased abundance and activity reported (Hasenfuss 
et al., 1999).  The functional significance of this is believed to be that increased NCX 
activity may compensate for reduced SERCA2 function – this has been demonstrated 
through use of transgenic mice overexpressing NCX whereby a 2.4 fold increase in NCX 
activity compensated for reduced SERCA function by 28% allowing maintenance of the 
duration of the Ca2+ transient (Terracciano et al., 2001).  Furthermore these changes in the 
NCX are not always consistently observed in HF, particularly in animal models – in a 
review by Sipido et al., of the 29 different studies investigating hypertrophy-induced HF, 
14 showed an increase in NCX expression and/or function, 10 showed a decrease and 5 
showed no change (Sipido et al., 2002).   
Relevant to this thesis, in a mouse model isolated cardiomyocytes from viable septum 10-
wk post-MI showed prolongation of the Ca2+ transient time to peak (15% greater than 
sham) indicative of slowed Ca2+ release (Mork et al., 2009).  In another study, mouse 
cardiomyocytes isolated from the whole LV post-MI showed a 14.7% reduction in the Ca2+ 
transient amplitude compared to sham (Zhang et al., 2010). 
Collectively these findings demonstrate that the abnormalities in Ca2+ handling are 
predominantly due to altered Ca2+ handling proteins but due to the conflicting evidence it 
is unlikely to be due to a change in any single protein but rather a disturbance in the 
balance and/or regulatory interactions between them that is responsible. 
1.3.2 Contractile elements 
The contractile apparatus of the cardiomyocytes is another potential site of functional 
abnormality that is believed to contribute to the functional decline during HF.  The 
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contractile mechanism consists of two major structural proteins (actin and myosin) and a 
complex of regulatory proteins consisting of tropomyosin, troponin C, troponin I and 
troponin T for the regulation of normal contraction and relaxation of the cell.  Troponin T, 
a regulator of the actin-myosin interaction, is an example of a contractile element found to 
be altered in human HF: in the normal heart the troponin T isoform T1 predominates, 
however in patients with HF there is an increased abundance of the T2 isoform which 
normally only accounts for ~2% of the total troponin (Anderson et al., 1992) although the 
significance of this shift is unknown. 
1.3.3 ECM alterations 
The ECM is a mesh of connective tissue which interconnects cardiomyocytes and other 
cell types of the heart.  It is composed of collagens, proteoglycans, glycoproteins, peptide 
growth factors and proteases and its primary functions are to maintain alignment of cardiac 
muscle fibres and neighbouring vasculature, and provide an orderly transmission of force 
to the entire ventricle during systole.  The ECM is an important determinant of the 
structural integrity of the heart and is a very important central feature in structural 
remodelling during heart disease – disproportionate deposition of ECM proteins or loss of 
ECM proteins are the major causes of stiffened myocardium (diastolic dysfunction) and 
dilation, respectively which are two major causes of decompensatory HF.  During HF, the 
release of endothelin influences the synthesis or degradation of collagen in the 
myocardium (Guarda et al., 1993).  The most commonly observed ECM remodelling 
during disease is the adverse accumulation of fibrillar collagen, expressed as cardiac 
fibrosis (both reactive and reparative) which has been demonstrated in diseased post-
mortem human hearts (Beltrami et al., 1994;Pearlman et al., 1982).  This is largely 
controlled by effector hormones of the RAA system (Weber et al., 1991b) e.g. AngII 
increases collagen synthesis in a dose-dependent manner by (i) induction of fibroblast 
hyperplasia, (ii) activation of collagen synthesis pathways, and (iii) inhibition of collagen 
degradation pathways (Gonzalez et al., 2004).  Fibrosis can provide structural support to 
thinned myocardial infarcts however it can also exacerbate normal functioning as it can 
limit normal diastolic ‘suction’ (recoil), impair myocardial compliance and compromise 
the length-dependent muscle fibre shortening during contraction (Moreo et al., 2009). 
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1.4 Altered gene expression in cardiac disease 
Many of the changes above which contribute to functional decline during pathological 
remodelling with regard to Ca2+ handling proteins, the contractile proteins and the ECM 
proteins occur due to alterations in the gene messenger RNA (mRNA) levels that encode 
these proteins.  An important pattern of altered gene expression during cardiac disease 
involves the re-expression of foetal genes not normally expressed in adult myocardium, for 
example up-regulation of atrionatriuretic peptide receptor C (Takahashi et al., 1992).  As 
well as re-induction of foetal genes, cardiac disease can elicit alterations in a diverse range 
of adult cardiac genes.  These genes are extremely important in cardiac research as they 
could represent potential therapeutic targets for disease treatment.   
1.4.1 Differential gene expression in different cardiac diseases 
As detailed earlier, different cardiac diseases lead to different morphological forms of 
structural remodelling (MI vs. hypertensive heart disease and LVH) and each are also 
associated with distinct patterns of gene expression.  Genes can therefore be altered 
differently in different cardiac diseases, and by examining changes in a single gene in 
different diseases represents a powerful means of elucidating the functional significance of 
target genes which could represent potential therapeutic targets in CVD.  This is important 
because different forms of cardiac disease are characterised by different pathophysiology, 
prognosis and response to therapy.  For example it has been shown that the same gene can 
be altered differently in ischaemic versus non-ischaemic human cardiomyopathy – e.g. the 
gene for the leptin receptor which is involved in the regulation of adipose tissue mass was 
shown to be down-regulated (~1.8-fold) in ischaemic cardiomyopathy but up-regulated 
(~2-fold) in non-ischaemic cardiomyopathy compared to control healthy hearts (Kittleson 
et al., 2005).  The gene encoding lumican, a regulator of fibrillogenesis, followed a very 
similar pattern with down-regulation in ischaemic (~1.8-fold) but up-regulation in non-
ischaemic cardiomyopathy (~2.5-fold) (Kittleson et al., 2005).  Altered gene patterns have 
been well characterised in animal models of MI which show altered expression of genes 
encoding proteins involved in calcium-handling (Swynghedauw, 1999), contractile 
function (Yue et al., 1998), ECM (Weber, 1997) and the RAA system (Holtz, 1998).     
Microarray techniques have emerged as a large-scale approach for the identification of 
target genes altered during cardiac disease (Kaab et al., 2004); however, this may involve 
large numbers of genes and targets still require validation using qRT-PCR.  Gene 
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expression profiles are complex and require detailed understanding of the precise 
regulatory mechanisms underlying the control of their expression patterns.  It is for this 
reason that transcription factors have emerged as important targets in elucidating the 
intricate mechanisms of altered gene expression during the pathophysiology of HF 
(Buermans et al., 2005). 
1.4.2 Transcription factors 
A transcription factor is a protein which regulates the precise location, timing and rate of 
the process of transcription which is the transfer of genetic information from DNA by the 
synthesis of an RNA molecule copied from a DNA template.  Transcription factors are 
essential to life as they directly control the expression of genes in response to specific 
physiological stimuli and developmental signals (Latchman, 1997).  Transcription factors 
therefore lie at the core of regulatory and developmental processes (Lee & Young, 
2000;Mitchell & Tjian, 1989).  They are also extremely important in disease as they 
respond to pathophysiological stimuli and are often recruited to direct gene expression for 
protective mechanisms against the disease (Semenza, 1999).  In addition they represent 
important therapeutic targets - approximately 10% of currently prescribed drugs directly 
target the nuclear receptor class of transcription factors (Overington et al., 2006) an 
example of this is tamoxifen for the treatment of breast cancer (Gronemeyer et al., 2004). 
1.4.2.1 Transcriptional regulation of gene expression 
Every cell in the body, with a few exceptions, has identical DNA but there are very distinct 
cell types and tissue types which vary in structure and function, this is because of 
transcriptional control (selective gene expression) by transcription factors.  Transcription 
factors initiate the transcription process for subsequent translation into proteins.  The 
process is discussed briefly and summarised in Figure 1.4.  Transcription factors bind to a 
specific region of DNA and recruit an enzyme known as RNA polymerase to synthesise a 
complementary mRNA strand based on the gene sequence from the DNA template.  Once 
the mRNA strand is synthesised, it leaves the nucleus and enters the cytoplasm where it 
attaches to a ribosome to begin translation (the process of protein synthesis from the 
mRNA template).  A different RNA molecule called transfer RNA (tRNA) bearing a three-
base (anti-codon) sequence joined to an amino acid binds to the complementary anti-codon 
sequence of the mRNA strand.  The ribosome continues along the mRNA strand adding 
more tRNA-amino acid sequences to form a growing polypeptide chain that forms the 
protein for which the original gene sequence encodes. 




Figure 1.4  Summary process from transcription to translation. 
Transcription occurs in the nucleus with the synthesis of an mRNA strand from a DNA template containing the gene 
sequence.  The mRNA strand leaves the nucleus into the cytoplasm for the synthesis of the protein (translation).  Steps 1-
5 summarise the process.  mRNA; messenger RNA. tRNA; transfer RNA.  Amino acids are illustrated by the blue 
circular shapes.  Figure taken from Benjamin-Cummings, Addison Wesley Longman Inc. 
1.4.2.2 Transcription factors bind to DNA 
Transcription factors bind to specific DNA sequences located in regulatory regions 
(usually promoters or enhancers) found near the transcription initiation site of a gene 
which is the first nucleotide of the DNA that will be transcribed into RNA.  These 
regulatory regions can include elements such as the TATA box (a core promoter DNA 
sequence) and CpG islands (high frequency linear cytosine and guanidine DNA 
sequences).  These regulatory sequences are generally located 30 bp upstream of the 
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initiation site and serve to direct binding of RNA polymerase II (Pol II) (Figure 1.5).  
Transcription factors contain functional domains which are clusters of amino acids which 
allow the protein to carry out a specific function, namely a DNA-binding domain for 
binding to DNA and a transactivation domain which activates transcription via interaction 
with other proteins.  The DNA binding domain usually takes one of three structures which 
allow it to bind to DNA; (i) helix-turn-helix (HTH) which consists of two adjacent α-
helices separated by a turn of several amino acids; (ii) zinc finger which co-ordinates zinc 
ions with a combination of cysteine and histidine residues or (iii) basic leucine zipper 
consisting of four leucine residues at 7-residue intervals which form an α-helix with 
protruding leucine residues such that when two leucine residues dimerize the motif’s ‘zip’ 
together (Klug & Cummings, 2005). 
1.4.2.3 Transcription initiation complex 
In eukaryotes, transcription is initiated by a group of general transcription factors that form 
an initiation complex (Figure 1.5).  A sequence-specific transcriptional activator protein 
(TATA binding protein; TBP) is a protein that binds to the TATA sequence of a promoter 
on the DNA to activate the assembly of a well-known group of general transcription 
factors (TFII).  These transcription factors are responsible for the positioning and 
activation of the Pol II enzyme which catalyses the transcription process.  The complex is 
assembled in the following order.  Once TBP is bound to the promoter, TBP-associated 
factors (TAF) bind and this recruits the binding of TFIIB and TFIIA first which are 
responsible for positioning Pol II in the correct place.  Next, Pol II complexed with TFIIF 
are positioned in place.  Finally a multi-subunit complex containing TFIIH binds and 
through helicase activity facilitates the separation of the DNA strands and phosphorylates 
Pol II via its C-terminal domain which activates Pol II for transcription at the start site.  
Collectively this forms the transcription pre-initiation complex (PIC) that accompanies all 
eukaryotic transcription but is sufficient only for a low basal level of transcription.  The 
final stage involves the induced level of transcription which represents the higher, 
stimulated stage – this involves other areas of the promoter region, enhancers and the 
binding of other transcription factors. 




Figure 1.5  Assembly of the transcription initiation complex in eukaryotes. 
TBP binds to the TATA box which initiates the binding of a combination of general transcription factors (TF) to 
assemble the initiation complex required for mRNA synthesis.  Following TBP binding, the next to bind are TFIIB and 
TFIIA (which position Pol II), followed by TFIIF which is complexed with Pol II.  TFIIE is then added followed by 
TFIIH, which separates the two DNA strands and phosphorylates the Pol II C-terminus for initiation of transcription at 
the start site.  TBP = TATA-binding protein; TAFs = TBP-associated factors; TFIIA,B,E,F,H,J = transcription factors 
required to direct RNA polymerase II binding; Pol II = RNA polymerase II. 
1.4.2.4 Role of transcription factors in the heart 
Much of the alterations in the structural properties of the heart during remodelling (both 
physiological and pathophysiological) are due to altered gene expression by the action of 
transcription factors.  One clear example of this is during cardiac hypertrophy.  In response 
to specific stimuli, transcription factors such as GATA, MEF2, Gx/Nkx2-5 and HAND 
direct the expression of various genes necessary for enlargement of the cardiomyocytes, 
including the transcription of genes responsible for the production and assembly of 
contractile proteins to increase sarcomeric unit number (Glennon et al., 1995).  These 
cardiac transcription factors are known to play a crucial role in the heart during 
embryogenesis; however in recent years they have received increasing interest in the post-
natal heart particularly during disease of the heart.  Their role is crucial during hypertrophy 
as cardiomyocytes are terminally differentiated and do not have the ability to proliferate.  
Therefore transcription factors control the cellular alterations necessary for cardiomyocytes 
to adapt under various conditions.  Transcription factors integrate a wide range of stress 
signals (e.g. mechanical load, neurohormones and cytokines) and therefore represent a 
point of convergence in the pathway from cardiac stress to cardiac remodelling and failure 
(Frey & Olson, 2003).  Further details on the transcription factors which have been 
implicated in the regulation of myocardial gene expression during the pathogenesis of 
cardiac disease are detailed below: 
The GATA transcription factor family bind to the specific consensus DNA sequence 
(A/T)GATA(A/G) via a highly conserved domain containing double zinc fingers (Patient 
& McGhee, 2002).  There are three members of the GATA family which are known to be 
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expressed in the heart: GATA4, GATA5 and GATA6.  GATA4 and GATA6 are expressed 
in the nuclei of cardiomyocytes (Koutsourakis et al., 1999;Perrino & Rockman, 2006) 
while GATA5 is restricted to endothelial cells (Morrisey et al., 1997).  Of the three, 
GATA4 plays the more prominent role as it directly regulates the expression of a range of 
cardiac-specific genes including: α-myosin heavy chain (α-MHC), myosin light chain 1/3 
(MLC1/3), atrial natriuretic peptide (ANP), brain natriuertic peptide (BNP), cardiac 
troponin C, cardiac troponin I, cardiac sodium-calcium exchanger (NCX1) and cardiac-
restricted ankyrin repeat protein (CARP) (Liang & Molkentin, 2002;Molkentin, 2000).  
GATA4 is also critically involved in inducing gene expression in the heart in response to 
various hypertrophic stimulations (Herzig et al., 1997).  For example GATA4 is essential 
for the up-regulation of β-MHC and the AngII type 1α receptor in response to transverse 
aortic constriction (TAC) (Hasegawa et al., 1997) and GATA4 DNA-binding activity is 
significantly enhanced in response to pressure-overload by intravenous infusion of 
arginine(8)-vasopressin (AVP) in conscious rats (Hautala et al., 2001).  GATA1 has been 
reported to be up-regulated 2-3 fold in the remote LV 24-48 h post-MI in a rat model 
(LaFramboise et al., 2005). 
MEF2 transcription factors bind to specific A/T rich consensus DNA sequences to regulate 
a number of cardiac genes including α-MHC, SERCA, cardiac troponin T, cardiac 
troponin C, cardiac troponin I and desmin (Bhavsar et al., 2000;Black & Olson, 1998).  
MEF2 is expressed in cardiomyocyte nuclei (Wang et al., 2011) and is also critically 
involved in the regulation of genes during cardiac hypertrophy (Zhu et al., 1991).  The 
regulatory DNA-binding of MEF2 increases in the cardiomyocytes of rat hearts exposed to 
pressure or volume overload (Molkentin & Markham, 1993).  MEF2 also functions as an 
important effector of intracellular Ca2+ signalling pathways as its activity is stimulated by 
Ca2+/calmodulin-dependent protein kinase (CaM kinase) (Passier et al., 2000). 
Csx/Nkx2-5 are homeobox transcription factors with a helix-turn-helix DNA-binding 
motif which binds to a specific consensus DNA sequence T(C/T)AAGTG (Chen & 
Schwartz, 1996).  Homeobox refers to a sequence of DNA ~180bp long which encodes a 
60 amino acid DNA-binding protein domain (homeodomain) for transcriptional regulation.  
Csx/Nkx2-5 are expressed in cardiomyocyte nuclei (Zhu et al., 2000) and directly regulate 
a number of cardiac-specific genes such as ANP (Shiojima et al., 1999), cardiac α-actin 
(Chen & Schwartz, 1996), connexin40 (Bruneau et al., 2001) and NCX1 (Muller et al., 
2002).  Csx/Nkx2-3 has been shown to be essential during embryogenesis as the 
Csx/Nkx2-3-null phenotype results in embryonic lethality due to arrested looping 
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morphogenesis of the heart tube (Lyons et al., 1995).  Csx/Nkx2-3 is also expressed in the 
adult mammalian heart (Kasahara et al., 1998) but its roles post-natal are less understood.  
It has been shown that Csx/Nkx2-3 expression is up-regulated in hypertrophic hearts 
(Saadane et al., 1999) and protects against cytotoxic damage in the heart (Toko et al., 
2002). 
HAND transcription factors (eHAND and dHAND) bind DNA via basic helix-loop-helix 
motifs to regulate genes specific to cardiac development (Srivastava, 1999).  eHAND and 
dHAND are expressed in human hearts but the eHAND isoform is significantly down-
regulated in hearts from patients with cardiomyopathies (Natarajan et al., 2001).  eHAND 
has been shown to be expressed in the nucleus of cardiomyocytes (Togi et al., 2004) and 
dHAND has been shown to be expressed in the endocardium and myocardium by RT-PCR 
(although cell types were not specified) (Yamagishi et al., 2000).  In a mouse model of 
hypertrophy, eHAND expression is down-regulated in the LV only and dHAND 
expression is down-regulated in the RV only (Thattaliyath et al., 2002).  Knowledge of the 
direct downstream genes regulated by HAND is at present limited. 
Forkhead box (FOX) transcription factors are present in other tissue types as well as the 
heart such as skeletal muscle, lung, liver, thymus and nervous system (Hoekman et al., 
2006;Maiese et al., 2008) and have recently been implicated as having a major role during 
cardiac disease.  FOX transcription factors are up-regulated in early (1-wk) post-MI rat 
hearts by ~5.5 fold (FoxO1) and in advanced human HF by 4-8 fold (Hannenhalli et al., 
2006;Philip-Couderc et al., 2008).  Abundant expression of FOXP1 protein has been 
localised to nuclei of failing human cardiomyocytes by IHC (Hannenhalli et al., 2006).  
FOX transcription factors activate the expression of genes encoding ATP-dependent 
potassium (KATP) channels (e.g. KIR6.1) in the peri-infarct region in a rat model of MI 
(Philip-Couderc et al., 2008) and promote autophagy in cardiomyocytes by activating 
autophagy pathway genes Gabarapl1 and Atg12 (Sengupta et al., 2009).  Therefore, even 
small changes in the expression of transcription factors in the heart can have important 
phenotypic and functional consequences.   
Other:  In another study by Hannenhalli et al. (2006), the investigators used a combination 
of microarrays and a computational approach to identify particular transcription factors 
which were responsible for the changes in gene expression between failing and non-failing 
hearts and their study revealed that the following transcription factor-binding sites were 
responsible for many of the altered gene expression patterns involved in HF: GATA, MEF-
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2, Nkx, NF-AT, polyA, TATA, FOX, Octamer, IRF, CDP, AIRE, C/EBP, AFP1 and Msx-
1 (Hannenhalli et al., 2006).  The regulation of cardiac gene expression is known to be a 
complex process mediated by interactions between transcription factors, coactivators, 
corepressors and epigenetic modifications (e.g. histone acetylation); however 
transcriptional genomics – assessing single transcription factors - (as opposed to a 
microarray-based identification of a large number of genes) may provide a more 
integrative analysis to identify therapeutic targets against transcription factors through 
targeting of a number of genes rather than just a single target gene. 
1.5 RUNX transcription factors 
The RUNX family are a group of transcription factors which represent a novel group of 
proteins in the context of myocardial injury.  This section will provide background 
information on the RUNX family followed by their recent interest in cardiac disease. 
1.5.1 Identification and structure 
1.5.1.1 Nomenclature 
The RUNX proteins are a family of transcription factors which regulate gene expression 
for normal metazoan development (Coffman, 2003).  RUNX proteins are encoded by the 
RUNX genes and are defined by the ‘runt box’ which is a highly conserved protein domain 
important for DNA binding and protein-protein interactions and represents a unique 
characteristic of all members of the RUNX family (Kagoshima et al., 1993).  The runt box 
derives its name from the first member of the family to be discovered, the Drosophila 
melanogaster gene Runt which is responsible for segmentation of the Drosophila fly 
embryo during development (Gergen & Butler, 1988).  Over the years alternative names 
have been assigned to RUNX proteins which have been derived from their roles in disease 
such as acute myeloid leukemia (AML), core-binding factor α (CBFα) and polyoma 
enhancer-binding protein-2α (PEBP2α).  In this thesis they will be referred throughout as 
the RUNX family.  Where the description refers to the protein (human, rat and mouse) this 
will be written in uppercase (RUNX) and for references to the gene this will be written in 
italics either with all letters uppercase, RUNX (human) or only the first letter in uppercase, 
Runx (rat or mouse) according to standard genetic nomenclature (Elsevier, 1998). 
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1.5.1.2 Chromosomal location of RUNX genes 
Runx genes are present in a diverse range of organisms (Rennert et al., 2003) and the 
number of RUNX genes can vary depending on phylogenetic background; for example 
mammals have three, Drosophila have four and lower invertebrates such as the eukaryotic 
nematode C. elegans and the sea urchin S. purpuratus have only a single Runx gene (Nam 
et al., 2002;Robertson et al., 2002).  Relevant to this thesis, the three mammalian RUNX 
genes, RUNX1, RUNX2 and RUNX3 are located on human chromosome 21, 6 and 1; 
mouse chromosome 16, 17 and 4; and rat chromosome 11, 9 and 5 respectively (GenBank, 
National Centre for Biotechnology Information; NCBI).   
1.5.1.3 Structure of RUNX genes 
A summary diagram of the structure of the RUNX genes is depicted in Figure 1.6.  Each 
RUNX gene (RUNX1, RUNX2 and RUNX3) encodes the respective named protein 
(RUNX1, RUNX2 and RUNX3).  The RUNX genes are very closely related and share 
extensive regulatory elements and functional coding regions known as exons (Levanon & 
Groner, 2004).  Firstly, each of the three genes is transcriptionally regulated from two 
promoters; P1 (distal) and P2 (proximal) (Bangsow et al., 2001;Levanon et al., 2001b;Park 
et al., 2001).  Both promoters direct transcription of adjacent 5’-untranslated regions 
(5’UTR) which are regions transcribed but not translated.  The P1-5’UTR (452 bp long) 
contains four exons and two RUNX-binding sites (which allow the RUNX protein to bind 
to the RUNX gene) within a highly conserved 18 bp sequence found at the beginning of the 
P1 5’-CAACCACAGAACCACAAG-3’ (the underlined bases represent the two RUNX-
binding sites) (Drissi et al., 2000;Bangsow et al., 2001).  The fourth exon encodes the 
initiator ATG and the highly conserved P1 N-terminal peptide (MAS) (Pozner et al., 
2000).  The P2-5’UTR contains a single exon which directs translation of the P2 N-
terminal peptide (MRIPV), contains an internal ribosome entry site (IRES) and terminates 
with an in-exon splice site (Pozner et al., 2000).  The P2-5’UTR is the larger of the two 
5’UTRs (1631 bp) and is distinctly nested within a very large CpG island (high frequency 
of linear cytosine and guanidine sequences) not found in the P1-5’UTR (Levanon et al., 
2001a).  The RUNX genes also contain exons which encode different functional domains of 
the RUNX proteins including the Runt domain and the transactivation domain (Levanon & 
Groner, 2004).  In addition they also share similarities outwith the RUNX locus itself with 
highly conserved neighbouring genes such as the CLIC6 and DSCR1 genes (Levanon & 
Groner, 2004).  The RUNX3 gene is the smallest of the three with the fewest exons 
(Bangsow et al., 2001).  Major features of the RUNX genes are summarised in Table 1.1.   
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Table 1.1  Functional roles of the regulatory regions of RUNX genes. 
Gene Region Function 
ATG initiator First codon (start codon) of mRNA transcript which is translated into 




Functional coding region. 
Encodes Runt domain. 
Encodes transactivation domain. 
UTR Regions of DNA which can influence translation but are themselves 
not translated. 
MAS N-terminal sequence encoded by the P1-5’UTR. 
MRIPV N-terminal sequence encoded by the P2-5’UTR. 
 
 
Figure 1.6  RUNX genes structure and elements involved in expression regulation. 
(A)  Structure of the three mammalian RUNX  genes; RUNX1, RUNX2 and RUNX3.  All RUNX genes have similar 
genomic organisation with two promoters (P1 and P2) and a very large first intron.  Common exons are shown in the 
same colour.  5’ untranslated regions (UTRs) are shown in yellow and orange, and 3’ UTRs shown in blue.  The highly 
conserved Runt domain is encoded by three exons (green boxes).  The exons comprising the transactivation domain are 
shown in black and grey.  The conserved neighbouring genes are also shown (CLIC6 & DSCR1).  RUNX3 is the smallest 
of the three RUNX genes with the fewest exons.  (B)  Schematic showing the common structure of the P1-5’UTR (yellow 
in diagram A) which contains four exons; the two RUNX binding sites are indicated by RR (for binding by the RUNX 
protein to the RUNX gene); and the fourth exon encodes the initiator ATG and the highly conserved P1 N-terminal 
peptide (MAS).  (C) Schematic showing the P2-5’UTR (orange in diagram A) which has a single exon which terminates 
with an in-exon splice site (AG) which is preceded by a branch point signal CTRAY.  The P2-5’UTR contains an internal 
ribosome entry site (IRES) and is nested within a very large CpG island depicted by the grey cloud.  Figure taken from 
(Levanon & Groner, 2004). 
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1.5.1.4 Structure of RUNX proteins 
Runt homology domain 
A schematic representation of the domain structures of each mammalian RUNX protein is 
shown in Figure 1.7.  The most important and defining feature of the RUNX proteins is a 
highly conserved region known as the Runt homology domain (RHD) (Ito, 1999).  The 
RHD is located in the N-terminus of the protein and is necessary for DNA binding and 
protein-protein interactions (Kagoshima et al., 1993;Crute et al., 1996).  The RHD is an s-
type immunoglobulin (Ig) fold domain similar to the DNA-binding domains found in other 
transcription factors such as NFκB, p53, NFAT and STAT, but differs in that the RHD 
loops at both ends of the Ig-fold rather than just the end which contacts the DNA.  This is 
believed to give the RHD the ability to substantially bend the DNA more (Berardi et al., 
1999).   
Other functional domains 
Another highly conserved region among all three proteins is the nuclear localisation signal 
(NLS) domain which is immediately adjacent to the RHD and is responsible for the sub-
cellular nuclear localisation of the RUNX proteins (Choi et al., 2001).  Together the RHD 
and the NLS comprise the very highly conserved 128 amino acid sequence of the RUNX 
proteins (Choi et al., 2001).  Other functional domains common to all three RUNX 
proteins are the transactivation domain which is required for transcriptional activity, the 
inhibitory domain (ID) which is necessary for repressing transcriptional activity (Coffman, 
2003), the nuclear matrix targeting signal (NMTS) which is important for attachment to the 
nuclear matrix once directed into the nucleus by the NLS (Tang et al., 1999) and the 
VWRPY motif which mediates transcriptional repression by recruiting the transcription co-
repressor, Groucho and its mammalian homologue transducin-like enhancer of split (TLE) 
and directing them to the target promoter regions (Levanon et al., 1998).  The NLS, 
transactivation domain, ID, NMTS and VWRPY are all located in the C-terminus of the 
protein (Coffman, 2003).  RUNX2 has an additional two domains within the N-terminus 
which are not present in RUNX1 or RUNX3 which is the polyglutamine and polyalanine 
(23Q/17A) domains (Thirunavukkarasu et al., 1998).   
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Amino acid composition 
Beyond their common functional domains, the RUNX proteins are similar in the 
composition of amino acids but the sequences can vary between each.  In all three RUNX 
proteins, the C-terminus is rich in proline, serine and threonine residues (PST) (Coffman, 
2003).  Given that the two promoters (P1 and P2) generate different 5’UTRs and therefore 
different N-terminal regions of the protein this can lead to multiple gene products with 
variable N-terminal peptide sequences.  The different UTRs can lead to differences in 
peptide amino acid sequences at the N-terminal due to the difference in translational-
regulatory mechanisms of each: for example, for RUNX1 the P1-5’UTR directs cap-
dependent translational control while the P2-5’UTR regulates translation by the IRES 
mechanism.  All eukaryotic mRNA have a cap structure (a 5’ terminal nuclear 
modification) which affects RNA splicing, stabilisation, transport and translation which 
acts as a ‘molecular tag’ to direct the 40S ribosomal subunit in place.  IRES is a 
mechanism which allows a ribosome to bind in the middle of the mRNA strand rather than 
at the cap-end (Levanon & Groner, 2004).  The RUNX1 sequence derived from P1 begins 
with a MASDS amino acid sequence at the N-terminal, and from P2 begins with a MRIPV 
amino acid sequence.  Transcription from the two alternative promoters can give rise to 
splice variants of the RUNX protein which differ in their N-termini sequences and as a 
result, have alterations in the functioning of the protein.  The use of multiple promoters in 
gene expression confers versatility to the final protein where it may be required to be 
expressed in different tissue types or at different developmental stages for which a single 
promoter may not be sufficient (Ayoubi & Van De Ven, 1996).  In particular this can have 
significant effects for RUNX1 in that it can cause the protein to have reverse roles in 
selected cell types.  For example, the short isoform of RUNX1 (RUNX1/p26 or RUNX1A) 
lacks much of the C-terminus including the transactivation domain which can therefore 
affect transcriptional activity, but also lacks some of the domains which inhibit DNA 
binding via the Runt domain (Kim et al., 1999;Gu et al., 2000) and therefore has the ability 
to bind DNA more effectively in some cases.  RUNX1A has been shown to block 
differentiation and promote proliferation in a murine myeloid cell line whereas the normal 
RUNX1/p46 protein (p46 refers to the isoform) does the opposite (blocks proliferation and 
promotes differentiation).  Therefore it is possible that alternatively spliced RUNX proteins 
can play opposing roles. 




Figure 1.7  Schematic representation of the functional domains of the RUNX proteins. 
Schematic representation of the structure of RUNX1, RUNX2 and RUNX3 proteins.  The numbers refer to amino acids.   
The N-terminus (N) and C-terminus (C) are shown.  The functional domains conserved across each RUNX protein are 
shown in colour; the Runt Homology Domain (RHD) in red which mediates DNA-binding and protein-protein 
interactions and the Nuclear Localisation Signal (NLS) domain shown in green which is responsible for nuclear 
localisation.  The C-terminus contains motifs common to all RUNX proteins including the inhibitory domain (ID) which 
represses transcriptional activity, the nuclear matrix targeting signal (NMTS) important for nuclear targeting and the 
VWRPY motif which mediates transcriptional repression through its association with a transcription co-repressor, 
Groucho/transducin-like enhancer of split (TLE).  The letters Q and A on RUNX2 designate homopolymeric stretches of 
glutamine and alanine residues present at the N-terminus which are unique to RUNX2 as was referred to in the text 
above. 
Multimeric complex formation 
All RUNX proteins bind via the RHD to the same specific DNA consensus sequence 
(TGTGGT) in the promoter region of a target gene through recruitment of common 
transcriptional modulators (Bae & Ito, 1999).  Additionally they all bind to DNA as part of 
a multimeric complex containing a number of different proteins (Kamachi et al., 1990).  
These include a partner protein known as the core binding factor beta subunit (CBFβ) as 
well as other transcription factors and co-activators/co-repressors (Durst & Hiebert, 2004).  
CBFβ binds to RUNX via the RHD and helps stabilize the complex and increase the 
affinity for DNA-binding but does not itself bind to DNA (Ogawa et al., 1993).  The 
mechanism by which CBFβ stabilizes the complex is understood to be that it maintains the 
RHD in an open conformation serving as a kind of ‘molecular clamp’ (Habtemariam et al., 
2005).  Once bound to CBFβ, RUNX recruits other DNA binding transcription factors to 
build a multi-protein complex for regulated transcription.  For example, RUNX binding 
sites are often located adjacent to DNA-binding sites for other transcription factors such as 
members of the Ets family, Myb and C/EBP (Lund & van, 2002;Durst & Hiebert, 2004).  
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RUNX can also interact with a number of co-activators (HAT, p300, CBP) or co-
repressors (mSin3A, TLE and HDACs) which can activate or repress transcription 
respectively (Pelletier et al., 2002) as shown in Figure 1.8. 
 
Figure 1.8  Schematic representation of RUNX transcriptional regulatory complexes for activation and repression 
of gene expression. 
(A)  Schematic representation of a RUNX activation complex.  The Runt Homology Domain (RHD) of the RUNX 
protein (red) binds DNA and facilitates binding of CBFβ (blue) and various DNA-binding factors such as Ets, Myb and 
C/EBP (green) which recruit co-activating factors such as p300 and CBP (yellow) - together results in activation of the 
target gene of interest.  (B)  Schematic representation of a RUNX repression complex.  The RHD of the RUNX protein 
(red) binds DNA and facilitates binding of CBFβ (blue) and various co-repressors such as mSin3A, TLE and HDACs 
which together results in repression of the target gene of interest. 
1.5.2 Function of RUNX proteins 
All RUNX proteins function as transcription factors which regulate specific gene 
expression in developmental pathways.  It is well-established that RUNX transcription 
factors have opposing functioning as both activators and repressors of transcriptional 
regulation depending on the context of the regulatory region (Coffman, 2003;Blyth et al., 
2005).  There are sequences in the C-terminus that control this through recruitment of 
associative activators or repressor proteins to the complex.  For example, RUNX can 
activate transcription through interactions with histone acetyl-transferases (e.g. MOZ and 
MORF) (Kitabayashi et al., 2001;Pelletier et al., 2002) or they can also inhibit 
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transcription by interacting with the dominant co-repressor Groucho/TLE (Aronson et al., 
1997) or the mSin3A co-repressor (Lutterbach et al., 2000).  However, despite the highly 
conserved structural similarities between the RUNX proteins and their shared properties in 
binding to the same DNA consensus sequence through pairing with CBFβ, each of the 
RUNX proteins have distinct functional roles in different lineage-specific development.  
This is reflected in the different phenotypes which have been elucidated from the 
respective genetic knockouts. 
1.5.2.1 RUNX1 functions as a regulator of haematopoiesis 
Haematopoiesis is the formation and development of blood cells.  In the embryo two 
waves of haematopoiesis occur; primitive and definitive haematopoiesis, which give rise to 
the embryonic precursor cells and the adult HSCs that form specific blood cells capable of 
self-renewal, respectively (Lensch & Daley, 2004).  RUNX1 is absolutely critical for 
definitive haematopoiesis by controlling haematopoietic stem cell development and 
differentiation (initiation phase only) (Okuda et al., 1996;Okuda et al., 2001;Hoogenkamp 
et al., 2009).  This has been clearly demonstrated by Runx1-/- mice which die at an early 
embryonic stage (E11.5-E13.5) from an early block in blood development (Okuda et al., 
1996). These mice exhibit normal primitive haematopoiesis but a complete lack of 
definitive haematopoiesis (Okuda et al., 1996;North et al., 1999). 
1.5.2.2 RUNX2 is required for bone development 
RUNX2 is involved in the regulation of osteogenesis which is the development of bones; 
this has been verified in Runx2-/- mice which die shortly after birth from a complete lack of 
bone formation although they do form the cartilage of an ossified skeleton (Otto et al., 
1997;Komori et al., 1997).   
1.5.2.3 RUNX3 is involved in neurogenesis 
RUNX3 regulates the development and survival of proprioceptive neurons in dorsal root 
ganglia (Inoue et al., 2002), this has been confirmed by Runx3-/- mice which demonstrate 
severe limb ataxia due to defective development of proprioceptive neurons (Levanon et al., 
2002).  However there are discrepancies between the Runx3-/- phenotype as others have 
shown a hyperproliferation of epithelial cells in the gastric mucosa which led to death of 
the Runx3-deficient animals shortly after birth from starvation (Li et al., 2002); an 
observation not seen by Levanon et al. (2002).  RUNX3 is also known to be a putative 
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gastric tumour repressor as it controls cell proliferation and apoptosis of gastric epithelium 
(Li et al., 2002). 
1.5.3 Tissue-specific expression of RUNX 
In addition to their distinct roles, each RUNX protein also shows a very specific 
spatio/temporal expression pattern in different tissue types.  It is believed that the RUNX1 
protein can promote its own expression by binding to the Runx1 gene promoters or 
enhancers and down-regulate its own expression by recruiting the repressor Smad6 
(Pimanda et al., 2007).  The RUNX protein binds to distinct RUNX-binding sites located 
within the P1 promoter which is indicated by the yellow box in Figure 1.6A and by RR in 
Figure 1.6B.  It has been proposed that the highly conserved CpG islands present at both 
ends of RUNX genes may be involved in the tissue-specific expression (Ehrlich, 2003) 
although the precise role by which this occurs remains unclear.  Tissue sites for RUNX 
expression are detailed below and summarised in Table 1.2.    
RUNX1 is first detected in mouse embryos within definitive haematopoietic stem cells 
(HSC) and in endothelial cells at HSC emergence sites, for example the yolk sac, umbilical 
arteries, aorta-gonad-mesonephros (AGM) and liver (North et al., 1999;Cai et al., 2000).  
RUNX1 is also expressed in the bronchi, mucosa of the oesophagus and stomach, epithelia 
of palatal ridges, in ectodermal invaginations (e.g. salivary and mammary glands) and 
epidermal appendages (e.g. whiskers and teeth; epithelia only) of the embryo.  RUNX1 is 
also expressed in the mesenchyme of the heart (see later) and central nervous system 
(CNS) of the embryo. 
RUNX2 is expressed predominantly in chrondrocytes (prehypertrophic and hypertrophic) 
and osteoblasts which is not surprising given its role in the developing skeleton.  RUNX2 
is also expressed in fibroblasts of periodontal ligament fibroblast cell lines (Saito et al., 
2002) and in primary murine fibroblasts (Kilbey et al., 2007).  RUNX2 has also been 
shown to be expressed in the epidermal appendages (whiskers and teeth) but confined to 
the papilla regions (Levanon & Groner, 2004). 
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Table 1.2  Summary of RUNX expression sites. 
Tissue/Cell Type RUNX1 RUNX2 RUNX3 References 
Haematopoietic System 
        
(Embryonic) 
        
Aorta-gonad-mesonephros +     North et al. 1999 
Liver (haematopoietic 
precursors) 
+   + 
Levanon et al. 2001 
Thymus + + + Woolf et al. 2003 
Spleen +   + Levanon et al. 2004 
(Adult) 
      
  
Thymus +  + + Woolf et al. 2003 
Myeloid, B and T lymphoid 
cells 
+     
Lorsbach et al. 2003 
  
      
  
Skeleton 
      
  
Immature and permanent 
cartilage 
+     
Prehypertrophic cartilage 
    + 
Hypertrophic cartilage 
  + + 
Osteoblasts + +   
Membranous bone + +   
Levanon et al. 2001 
  
      
  
Dorsal Root Ganglia 
      
  
(Embryonic) 
      
  
TrkA neurons +     
TrkC neurons 
    + 
Levanon et al. 2001 
(Adult) 
      
  
Mature dendritic cells 
    + 
Fainaru et al., 2004 
Epidermal appendages 
      
  
Epithelial +     
Mesenchymal 
  + + 
Levanon et al. 2001 
+ indicates positive expression at the respective sites. 
RUNX3 is also expressed in prehypertrophic and hypertrophic chrondrocytes (however in 
the latter, RUNX2 predominates).  RUNX3 is not detected in osteoblasts.  RUNX3 is also 
expressed in the salivary and mammary glands, and the whiskers and teeth (although 
confined to the mesenchyme) (Levanon et al., 2001). 
Collectively, it can be seen that there are overlap of the RUNX proteins in the tissue in 
which they are expressed but there are differences in the regional distribution within the 
shared tissues. 
1.5.4 Regulatory mechanisms of RUNX gene and RUNX protein 
expression 
1.5.4.1 Transcriptional control 
RUNX genes can be regulated by SMAD5 signalling pathways; the up-regulation of Runx2 
mRNA for osteoblastic differentiation is preceded by an increase in Smad5 expression 
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(Lee et al., 2000).   A number of cytokines can also regulate RUNX expression; TGF-β is 
known to regulate RUNX2 and RUNX3 expression.  However depending on the tissue type 
or cell line, TGF-β can either induce or repress RUNX2 and RUNX3 expression.  Inhibition 
by TGF-β is believed to occur through inhibition of the RUNX P1 promoter (Alliston et al., 
2001).  The Notch signalling pathway has also been implicated as a regulatory mechanism 
of RUNX expression as the Notch-RUNX pathway has been shown to be critical for the 
developmental specification of HSCs (Burns et al., 2005).  The FGF pathway can also 
activate or repress RUNX expression depending on the cell type - for example FGF 
activates Runx2 in the mesenchymal pluripotent cell line C3H1OT1/2 but represses Runx2 
in the rat osteosarcoma cell line ROS17/2.8 (Zhou et al., 2000).  RUNX can also be 
regulated by signalling pathways via GATA, FOG and FOXP3 (Levanon & Groner, 2004). 
1.5.4.2 Translational control 
In addition to transcriptional control, RUNX expression can also be controlled through 
transcription-coupled translational control mechanisms (e.g. cap- and IRES-mediated 
translational control as described previously in Section 1.5.1.3) (Pozner et al., 2000).  The 
two 5’UTRs are the key players in the translational regulation of RUNX directing cap-
dependent (P1-5’UTR) and IRES-dependent (P2-5’UTR) as described previously.  The 
functional significance of cap and IRES-mediated translation is that IRES is believed to 
control translation when the cap system is impaired (e.g. during mitosis, differentiation or 
stress conditions).  The presence of both cap- and IRES-mediated control indicates the 
complexity of how RUNX genes are regulated. 
1.5.5 RUNX in human disease 
Due to their essential roles in cell proliferation and differentiation, it is not surprising that 
RUNX genes have been implicated in human disease.  RUNX genes are best known for 
their altered expression levels in human cancers (Look, 1997;Planaguma et al., 
2004;Sakakura et al., 2005).  The most notable is the link with RUNX1 and human 
leukaemia, caused by chromosomal translocations of RUNX1 – the most frequently 
observed (seen in 10-20% of acute myeloid leukaemia cases) is the t(8;21) translocation 
which results in fusion of the N-terminal half of RUNX1 (containing the entire Runt 
domain) with the C-terminus of the ETO (for eight-twenty one translocation) partner 
protein (Miyoshi et al., 1991).  RUNX1 is also over-expressed in endometrioid carcinoma 
tumours (Planaguma et al., 2004) and down-regulated in gastric cancer tumours (Sakakura 
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et al., 2005).  Mutations of RUNX2 can cause cleidocranial dysplasia (CCD), a congenital 
bone malformation disease caused by haploinsufficiency (Otto et al., 1997) consistent with 
its roles in osteogenesis.  Deletion or inactivation of the RUNX3 gene has also been shown 
to be involved in gastric cancers (Li et al., 2002).  The role of RUNX in cancer 
development however is very complex in that they have dualistic roles as both dominant 
oncogenes as well as tumour repressors in a highly context-dependent manner (Blyth et al., 
2005).  It is clear that precise regulation of RUNX is critical for normal function.  The 
same may be true in the heart. 
1.5.6 RUNX in damaged muscle 
Recently it has been increasingly documented that RUNX genes may also be linked to 
conditions of metabolic stress following tissue injury (Wang et al., 2005;Ghosh et al., 
2010;Custodio et al., 2012).  This has been found to be the case in injured skeletal muscle; 
in the healthy muscle Runx1 levels were measured using a labelled RNA probe and were 
found to be barely detectable (0.0001% mRNA) in the nuclei of skeletal myocytes; 
however, following denervation of the muscle Runx1 mRNA expression was increased 50-
100 fold (Zhu et al., 1995;Wang et al., 2005).  Interestingly, under these conditions the 
muscle retained much of its structural features intact.  However when these experiments 
were repeated in animals with genetic ablation of Runx1 in the muscle, this led to severe 
distortion of the muscle’s structure during denervation including (i) misaligned and 
irregularly spaced Z-discs, (ii) a lack of thick filaments, (iii) a severely dilated SR and (iv) 
presence of autophagic vacuoles (Wang et al., 2005).  Runx1 is therefore necessary for the 
prevention of muscle atrophy in denervated skeletal muscle.  Skeletal muscle shares many 
structural similarities with cardiac muscle in that they are both part of the striated muscle 
group with sarcomeres and the primary structural proteins in each are actin and myosin, 
therefore the role of Runx1 in protecting the structural malformations of the muscle may be 
applicable to cardiac muscle.  Furthermore, the disrupted electrical activity that triggers 
Runx1 expression in denervated skeletal muscle could also be possible under conditions of 
altered electrical activity in the heart during MI.  In the heart under normal conditions, 
electrical signals propagate freely between cardiomyoctes via gap junctions; however 
following an MI, disruptions in electrical activity in the remodelled peri-infarct arise due to 
marked changes in gap junction organisation and connexin43 distribution in addition to the 
physical loss of communication between viable and dying cardiomyocytes (Peters, 1995). 
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1.5.7 RUNX in the heart 
Despite knowledge of its expression and protective role in other striated muscle tissue, 
very little is known about the expression and functional role of RUNX1 and the other 
RUNX proteins in the heart.   
1.5.7.1 RUNX1 
Normal tissue 
The presence of RUNX1 in the heart under healthy conditions is not clear; one study 
revealed that RUNX1 was present in all adult human tissues except the heart and brain 
(Miyoshi et al., 1995).  However RUNX1 has been shown to be present in the mammalian 
heart during mouse embryogenesis (Levanon et al., 2001a).  Telfer and colleagues (2001) 
have also confirmed expression of RUNX1 in the murine whole heart homogenates, 
although it was not clear from their study whether this was embryonic or adult tissue 
(Telfer & Rothenberg, 2001).  RUNX1 has been shown to be present within the nucleus of 
mesenchymal cells in the valvular regions of the heart at E16.5 during mouse 
embryogenesis (Levanon et al., 2003).   
Diseased tissue 
Gattenohner et al. (2003) found that RUNX1 was detectable in healthy human hearts by 
Western Blot but shows elevated expression in the heart after ischaemic cardiomyopathy, 
although it was also not clear from which region of the heart the samples were taken 
(Gattenlohner et al., 2003).  In the same study, it was found that over-expression of 
RUNX1 in the human heart during ischaemic cardiomyopathy occured in parallel with 
increased expression of a Neural Cellular Adhesion Molecule (NCAM) (Gattenlohner et 
al., 2003).  NCAM is a glycoprotein present on select cell type surfaces that mediates 
adhesive interactions between cells (Edelman, 1986).  NCAM levels are low in the healthy 
adult human heart relative to neonatal tissue with expression confined to the intercalated 
discs as detected by IHC (Gordon et al., 1990b;Gattenlohner et al., 2003).  In addition to 
cardiomycocytes NCAM is also expressed in endothelial cells (Gerety & Watanabe, 1997), 
mesothelial cells (Lackie et al., 1991) and neuronal cells that innervate the heart 
(Watanabe et al., 1992).  NCAM has been reported to be up-regulated after human MI, 
preferentially in the infarct and peri-infarct regions (Gattenlohner et al., 2003).  This has 
also been found to be the case in animal models of MI, both in rat (Gattenlohner et al., 
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2003) and mouse (Nagao et al., 2010) which both show up-regulation of NCAM post-MI 
in areas within or around the infarcted myocardium.  RUNX1 has been identified to have a 
binding site within the NCAM promoter (Gattenlohner et al., 2003) and therefore promotes 
NCAM expression.  Furthermore NCAM is shown to be specific for ischaemic damage, 
compared to other forms of cardiac disease (e.g. myocarditis and sarcoidosis) and its 
expression is believed to be as a result of a loss of cell-cell communication (Gattenloner et 
al., 2004).  Ischaemia-specific damage as a trigger for NCAM expression is further 
supported by the evidence that NCAM is also up-regulated in hypoxia-induced rat model 
of hypertrophy relative to control animals (Gordon et al., 1990) and increased in human 
transplanted hearts where there is extrinsic denervation relative to non-transplanted hearts 
(both shown by immunofluorescence and western blots but not quantified) (Gordon et al., 
1990b).  Furthermore, another cause of NCAM up-regulation has been reported to be 
metabolic stress (reduced intracellular ATP) via the p38 mitogen-activated protein kinase 
(MAPK) dependent pathway which has been demonstrated in isolated rat neonatal 
cardiomyocytes (Nagao et al., 2010).  It may be that the loss of communication between 
cells (i.e. loss of the ability for molecules/ions to cross one from cell to the next) or stress 
stimuli across the remodelled peri-infarct zone may also be an important stimulus in the 
up-regulation of RUNX1.   
Knockout studies in skeletal muscle identified 29 genes which were selectively regulated 
by RUNX1 and are responsible for the expression of various structural and signalling 
proteins, many of which are also present in cardiac muscle e.g. phospholamban, 
osteopontin, sodium channel type V and thrombospondin (Wang et al., 2005).  These 
proteins are critical proteins in the heart which highlights the potential importance of 
RUNX1 in the heart during disease.  RUNX proteins may therefore be prime candidates in 
understanding the mechanisms underlying the pathophysiology of adverse remodelling as 
their regulation may be important for post-infarction healing and modified SR-mediated 
Ca2+ handling.   
1.5.7.2 RUNX2 
RUNX2 expression in the heart is relatively unknown; a recent study has shown that it is 
undetectable in the rat heart – negative with IHC but is up-regulated in the nuclei of 
cardiomyocytes under conditions of uremia-induced myocardial hypertrophy and fibrosis 
during high phosphorous conditions or parathyroid hormone infusion (Custodio et al., 
2012).  Inhibition of the Notch receptor protein involved in cell signalling has been found 
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to cause a ~2-fold increase in the expression of RUNX2 in aortic valve interstitial cells and 
under these circumstances RUNX2 can contribute to aortic valve calcification in humans 
(Garg et al., 2005) and mice (Nigam & Srivastava, 2009).  Notch signalling has been 
reported to inhibit RUNX2 transcriptional activity through stimulated expression of the 
Hey1 gene (a direct Notch target gene) which represses RUNX2 during osteogenesis 
(Zamurovic et al., 2004).  Notch signalling has been shown to be increased in a mouse MI 
model (Gude et al., 2008) which may have implications for reduced expression or activity 
for RUNX2.  It also been reported that RUNX2 is crucial for vascular remodelling 
observed in atherosclerosis and RUNX2 expression is increased in calcifying human 
atherosclerotic plaques and artery lesions obtained from human patients with ischaemic 
heart disease (Tyson et al., 2003) therefore RUNX2 may play an important role in 
coronary artery disease (including MI for which the main cause is atherosclerotic plaque 
disruption in coronary vessels) (Hansson, 2005) through activation of chrondrocytic and 
osteoblastic proteins that contribute to the calcification process (Tyson et al., 2003).  
Recently, a preliminary report revealed that increased RUNX2 in the heart may promote 
cardiac fibrosis and further deteriorate function (Nakahara et al., 2008).  Another study 
revealed similar findings in which transgenic mice with cardiomyocyte-specific double 
genetic ablation of dystrophin (a protein which links the cytoskeleton to the ECM in 
muscle) and β1-integrin (a cellular adhesion molecule) showed increased myocardial 
dysfunction, cardiac fibrosis and calcification which was concurrent with a ≈10-fold 
increase in Runx2 mRNA (measured by qRT-PCR) in whole heart homogenates (Elsherif 
et al., 2008).  A review by Sanoudou et al. (2005) into the genes altered in human end-
stage HF as analysed by microarray revealed that RUNX2 was significantly up-regulated in 
human cardiomyopathies such as dilated cardiomyopathy (DCM) and hypertrophic 
cardiomyopathy (HCM) although exact quantification was not specified (Sanoudou et al., 
2005). 
1.5.7.3 RUNX3 
RUNX3 has also been shown to be expressed in the mouse embryonic heart (Levanon et 
al., 2001a).  RUNX3 has also been located in the endocardial cushion in mouse embryonic 
hearts which is a specialised region that gives rise to the septum and valves at E10.5 during 
heart development (Fu et al., 2011).  Similar to RUNX2, RUNX3 is a direct target of Notch 
signalling in endocardial cells however in the case of RUNX3, Notch activation 
significantly increases RUNX3 mRNA rather than inhibit as it does for RUNX2 (Fu et al., 
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2011).  As above, Notch signalling is activated in mice post-MI and this may have 
implications for potential increased expression of RUNX3 post-MI.     
Despite the information detailed above, RUNX expression in the heart remains somewhat 
unclear and information is lacking in the following areas:  (i) RUNX has been shown to be 
expressed in embryonic murine tissue however there are discrepancies in the expression of 
RUNX in the adult mammalian heart, with limited knowledge on its expression in 
cardiomyocytes, (ii) the altered expression patterns of RUNX have not been assessed in 
animal models of MI or hypertension; (iii) at present, there is no quantitative data for the 
altered expression of RUNX in the heart during disease and (iv) no evidence exists on the 
expression of Runx genes in different regions of the heart, or (v) over different time-points 
post-MI or any links with the cardiac expression in relation to the functioning of the heart.  
These areas were the main focus of this thesis. 
1.6 Animal models of cardiac disease 
1.6.1 Need for animal models of disease 
As mentioned above although RUNX expression has been reported to be altered in human 
cardiac disease, very little is known about the quantifiable levels of altered expression in 
the diseased heart nor the potential functional significance of this altered expression.  
Unfortunately performing such measurements on human heart samples to investigate this 
further is associated with a number of problems.  Firstly, it can be very difficult to acquire 
a sufficient number of human cardiac samples for medical research as tissue is often in 
short supply or needed for other uses such as transplantation.  Secondly, human heart 
samples may be highly variable in terms of disease stage or from patients being on 
different treatments and tend to come from an end-stage (therefore usually severe stage) 
only rather than during the transition phase from compensated remodelling to HF.  Thirdly, 
it is difficult to obtain healthy hearts for control tissue.  Despite these limitations human 
heart tissue is extremely valuable to medical research.  However it is for the reasons named 
above that animal models of cardiac disease have become invaluable as an alternative for 
the study of cardiac disease progression (Patten & Hall-Porter, 2009).  The most common 
pathophysiological changes in human cardiovascular disease including MI, hypertension 
and cardiac hypertrophy have been successfully reproduced in animal models. 
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1.6.2 Criteria for use of animal models 
An ideal model for any human cardiovascular disease must satisfy the following criteria: 
(i) mimic the human disease as closely as possible, (ii) produce symptoms and 
characteristics which are predictable and controllable, (iii) allow studies in a stable, chronic 
condition (iv) conform to appropriate ethical and animal welfare considerations and 
appropriate legislation and (v) allow measurement of relevant cardiac, haemodynamic and 
biochemical parameters (Doggrell & Brown, 1998;Houser et al., 2012).  Animal models 
provide a means of studying a specific disease condition in a controlled way.  These 
experimental models can provide vital information on the structural and functional 
alterations which occur during different cardiac diseases as well as cellular and molecular 
alterations associated with the disease (Hasenfuss, 1998).  The use of mice as animal 
models is particularly useful due to the ability to manipulate their genome and generate 
transgenic strains (Fox, 2007).  Through over-expression or targeted disruption of a 
particular gene, mouse models provide a unique approach to studying specific genes which 
is of great benefit in understanding the pathophysiology of HF (Rockman et al., 1994;Lin 
et al., 1995).   
1.6.3 Use of animal models to investigate RUNX expression in 
the heart during disease 
The investigation of altered RUNX gene expression in cardiac disease is possible through 
use of clinically-relevant animal models of cardiac disease.  For this thesis, the two animal 
models of interest include: (a) a mouse model of MI and (b) a rat model of hypertension 
and congenic rat model of altered LV mass (LVH).  A very brief description of each 
model is described below but more details on each model will be provided in the respective 
later chapters (Chapter 3 and Chapter 5). 
1.6.4 Mouse model of MI 
Human MI is caused by chronic narrowing or acute occlusion of coronary arteries by 
atherosclerotic plaques and thrombosis respectively (Libby, 2001).  The most common 
approach for inducing MI experimentally in an animal model is by surgical coronary artery 
ligation (CAL).  This involves placing the animal under anaesthesia with mechanical 
ventilation and the heart is accessed from between two ribs in a thoracotomy procedure; a 
fine thread or suture is then placed around the left coronary artery and tied to induce 
permanent MI.  Animals are permitted to recover and researchers can then study 
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myocardial changes such as remodelling and dysfunction over different time periods and 
under different conditions according to the nature of the study.  Animal models of MI have 
been widely used in different species such as dog (Kass et al., 1988), pig (Eising, 1994), 
rabbit (Masaki et al., 1993) and rat (Flaim et al., 1981).  CAL-induced MI in a mouse 
model was first described in 1978 by Zolotareva and Kogan (Zolotareva & Kogan, 1978).  
With the advent of genetic modifications possible in the mouse, this species has gained 
popularity for the use of models of cardiac disease such as MI (Patten, 1998;Michael et al., 
1999;Gao et al., 2010).       
1.6.5 Rat model of hypertension and congenic models of altered 
LV mass 
The spontaneously hypertensive rat (SHR) is an animal model of human essential 
hypertension and represents the most commonly used model of cardiovascular disease 
(Doggrell & Brown, 1998).  The strain originates from a colony of male Wistar rats in 
Kyoto, Japan in the 1960s which were bred by Okamoto et al. (1963) for high blood 
pressure (Okamoto & Aoki, 1963).  The SHR is normotensive for the first 6-8 weeks of its 
life with systolic blood pressures (SBP) of 100-120 mmHg and then hypertension develops 
over the next 12-14 weeks with SBP >150 mmHg reaching 180-200 mmHg in its adult life.  
Like the human condition, the SHR develops characteristic symptoms of the disease such 
as cardiac hypertrophy and renal disease (Doggrell & Brown, 1998).  A second strain of rat 
has been developed from the SHR known as the stroke-prone spontaneously hypertensive 
rat (SHRSP) as having a higher incidence of stroke by selective mating of offspring with at 
least one parent with spontaneous stroke (Okamoto et al., 1974).  Like SHR, the SHRSP 
strain develops hypertension from 5 weeks of age but the SBP can increase to 250 mmHg 
in males (compared to 200 mmHg in SHR males) with a higher incidence of stroke.  There 
is a significant positive correlation between BP and the incidence of stroke.  Additionally, 
salt loading accelerates the onset of hypertension and the occurrence of stroke (Okamoto et 
al., 1974;Vacher et al., 1996).  Post-mortem examination of the brains of SHRSP rats show 
lesions in the cortex or subcortex of frontal, medial or occipital areas (Okamoto et al., 
1974) similar to those observed in humans (Bogousslavsky, 2003). 
1.6.5.1 Use of congenic sub-strains for particular genes of interest 
Inbred animal models offer the advantage of genetic homogeneity and complete control of 
environmental factors but most importantly they allow for specific inter-crosses to generate 
sub-strains which can provide insights into genetic determinants of hypertension which are 
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beyond the scope of human studies.  These sub-strains are useful for the study of specific 
genetic regions important for hypertension such as altered LV mass.  This approach 
involves the identification of quantitative trait loci (QTL), which are regions of a 
chromosome containing genes for a particular trait.  This then makes it possible to narrow 
down the genes contained within the QTL interval.  This novel congenic rat model permits 
exploration of possible triggers for RUNX expression.   
1.7 Characterisation of cardiac function in the two 
models 
1.7.1 Use of PV catheters to assess cardiac function 
PV measurements are regarded as the gold standard for measuring cardiac function, 
particularly in vivo (Kass et al., 1986;Burkhoff et al., 2005).  The simultaneous 
measurement of LV pressure and volume, both during steady-state conditions and during 
varying load on the heart have established a very comprehensive means of understanding 
cardiac mechanics.  The ability to assess both load-dependent and load-independent 
measures of cardiac function is an important feature of the PV technique which is not 
possible using alternative measures of LV function such as echocardiography.  This 
however has recently become possible using magnetic resonance imaging (MRI) in 
combination with a pressure catheter with MRI-based volume measurements to create the 
PV loop (Lederman, 2005).  The PV catheter technique uses a single impedance 
(conductance) catheter which is designed to lie along the long axis of the LV and contains 
sensors that measure both pressure and volume simultaneously.  PV methodology has been 
applied to humans (Kass et al., 1988b) and large animals (Little & Cheng, 1993); however 
with recent technological advances in miniature sensors this technique can now be applied 
to smaller animals, including rats and mice (Georgakopoulos et al., 1998).  The PV 
technique offers many advantages over other techniques such as the ability to assess more 
accurate load-independent indices of function; it does not rely on geometric assumptions, 
and can easily be applied to small rodents.  However the procedure is invasive and can 
normally only be performed once in the animal prior to termination meaning that 
longitudinal or repeated measurements in the same animal are not easily achievable (unlike 
echo and MRI).  However, it has recently become possible to do the PV technique in 
conscious mice (Joho et al., 2007).  The technique also relies on appropriate volume 
calibration methods such as the hypertonic saline dilution method and independent 
assessments of SV (details on this can be found in the General Methods chapter).  Despite 
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these limitations, the PV technique is considered to be one of the most accurate methods of 
assessing cardiac function and was therefore selected as the method of choice for 
functional measurements in this thesis. 
1.8 Measurement of gene expression 
The expression level (mRNA levels) of a particular gene in a tissue sample may be 
measured using a technique known as the polymerase chain reaction (PCR).  The PCR 
technique was developed in 1983 by Kary Mullis and it completely revolutionised the 
detection of nucleic acids; Mullis was later awarded the Nobel Prize for Chemistry 
together with Michael Smith in 1993 for his work in developing the PCR method (Bartlett 
& Stirling, 2003).  The technique is based upon the amplification of a specific target 
sequence of DNA (specific to gene of interest) by repeated cycles of heating and cooling to 
permit melting and subsequent replication of specific regions of double-stranded DNA by 
the enzyme DNA polymerase directed by short oligonucleotide sequences known as 
primers.  The DNA generated by each cycle serves as the template for further replication 
and therefore sets in motion a “chain reaction” during which the target DNA sequence is 
exponentially amplified.  By measuring the amount of cellular mRNA this provides 
information on the extent a particular gene is expressed.  Full details on the technique are 
covered in the General Methods (Chapter 2). 
1.9 Aims 
The RUNX family of transcription factors have been shown to have a protective role in 
skeletal muscle and have been recently shown to have altered expression in cardiac 
disease.  However, quantitative data on the degree to which Runx expression in the heart is 
altered during cardiac disease is limited.  The major aim of this thesis was to characterise 
the changes in expression of Runx mRNA levels in two separate animal models of cardiac 
disease; a mouse model of MI and a rat model of hypertension and altered LV mass.  
RUNX expression has not been measured in the cardiac tissue of either of these animal 
models previously. 
1. The first aim (i) was to establish and characterise a mouse model of MI which would 
later be used as an experimental model for measuring altered Runx expression during 
MI.  This was a new model in the laboratory therefore this involved developing a 
technique to perform CAL-induced MI in mice which was reproducible with low 
mortality.  It was then further aimed to (ii) perform a detailed characterisation of the 
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mouse MI model in terms of assessing structural alterations of the heart through 
histological and morphological measurements, and changes in cardiac function using in 
vivo electrocardiograms and PV methodology.  The associated survival characteristics 
of the model were also investigated.  These measurements were performed at two 
separate time points (4 or 8 weeks after the procedure) to assess whether the model 
demonstrated cardiac remodelling and dysfunction associated with MI.  It was 
hypothesised that performing CAL in mice would produce a model with characteristics 
of MI comparable to other published murine MI models and mimic human MI. 
2. The second set of aims was to assess alterations in the expression of the three Runx 
genes (Runx1, Runx2 and Runx3) in cardiac tissue from the mouse MI model using 
qRT-PCR methodology.  This was to investigate whether there were differences in 
Runx mRNA levels after MI, and whether there were (i) changes in different regions of 
the infarcted heart, (ii) temporal alterations as the MI developed, and (iii) whether the 
different Runx genes showed different patterns of expression.  It was also aimed to 
perform immunohistochemical experiments of heart tissue sections to visualise the 
localisation of RUNX within the cells of the heart.  Given the data on RUNX1 up-
regulation in human MI, it was hypothesised that a similar patten of increased Runx 
expression would occur in response to MI in the mouse model. 
3. The final set of aims were to characterise the structural and functional changes in two 
different but related animal models of cardiac disease – a rat model of hypertensive 
heart disease and novel congenic sub-strains of the hypertensive rat model for altered 
LV mass.  It was therefore aimed to characterise each model in terms of structural 
alterations through assessment of cardiac fibrosis and hypertrophy and assess LV 
function using PV methodology.  Runx1 mRNA levels were also quantified in these 
two models using qRT-PCR permitting: (i) investigation of altered patterns of Runx1 
expression and (ii) comparison with the MI model to further dissect the role of RUNX 
in the heart during cardiac disease and therefore assess its potential as a future 
therapeutic target.  It was hypothesised that the different congenic sub-strains would 
demonstrate different patterns of cardiac mechanical dysfunction and fibrosis patterns, 
and altered Runx gene expression levels in response to CVD similar to MI.
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All surgical procedures were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 and were approved by the University of Glasgow’s ethics 
committee.  All animal experiments conformed to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). 
2.1 Experimental mouse model of MI 
After a period of approximately 1 year of microsurgical training by Dr Christopher 
Loughrey, MI was independently induced in mice using the CAL method.  This was a new 
model in our laboratory, therefore it was important to develop a method which was 
reproducible and efficient with low mortality; but most importantly that would demonstrate 
features of dysfunction and remodelling as described in human MI (Chapter 3).  
Development of this model therefore required rigorous optimisation and refinement.  Due 
to their small size, the use of mice presented additional challenges in the need for precise 
microsurgical skills and meticulous intra-operative technique.  A detailed description of the 
development of the mouse MI model is found in the sections that follow. 
2.1.1 Animals 
The strain of mice used was the C57Bl/6 strain.  All mice were obtained from a licensed 
commercial breeder in the U.K. (Harlan Laboratories, U.K.) and were housed 5-10 
animals per cage (or singly post-procedure) in the Biological Services facility at the 
University of Glasgow with 12/12 hour light and dark cycles and free access to water and 
food pellets.  Adult males were used (8-10 weeks of age; 18-25 g); at this age the 
developmental growth of the heart is complete (Tarnavski et al., 2004).   
2.1.2 Anaesthesia and pre-surgical preparation 
The surgical set-up and surgical instruments used for this procedure are shown in Figure 
2.4A and B, respectively.  As this was recovery surgery, the operations were performed 
under aseptic conditions as much as possible.  The surgical instruments were autoclaved 
once (at the beginning of the day prior to surgery) and decontaminated between surgeries 
using a hot-bead steriliser (Germinator 500, SouthPointe Surgical Supply Inc, USA).  The 
surgical operating area was disinfected with a chlorhexidine gluconate spray (Ecolab, 
U.K.) and sterile towels were laid down on the surgical table.  A sterile drape was used for 
the animal and a new pair of sterile gloves was used for each animal.  The mouse was 
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collected and weighed.  The type of anaesthesia used was isofluorane (Isoflo, Abbott 
Laboratories, USA) mixed with 100% oxygen.  Inhalable anaesthetics were preferred 
because these offer more precise control over depth of anaesthesia and have the least 
depressive effects on the cardiovascular and respiratory systems compared to other forms 
of anaesthetics (e.g. injectables) (Richardson & Flecknell, 2005).  Anaesthesia was induced 
by placing the mouse in a pre-filled closed induction box (Figure 2.4C).  Following loss of 
the righting reflex, animals were moved to a face mask (4% isofluorane; 1.5 L.min-1).  The 
fur was clipped from the entire chest area using an electric shaver and the skin was 
thoroughly cleansed with clean gauze swabs using a warm surgical skin disinfectant 
(Hibiscrub, Ecolab Ltd, U.K.) (Figure 2.4D).  To minimise body heat loss, the solution was 
prepared warm with very minimal wetting of the skin.  Pre-operative analgesia of 5 mg/kg 
carprofen (Rimadyl, Pfizer Animal Health, U.K.; injected 20 µl of the 5 mg/ml stock 
concentration) and 0.1 mg/kg buprenorphine (Vetergesic, Reckitt Benckiser Healthcare 
Ltd, U.K.; injected 30 µl of the 0.03 mg/ml stock concentration) along with sterile saline 
(0.9% sodium chloride; 500 ml bag) were administered at this stage as a single 
intraperitoneal injection - final combined volume of all three components was 0.4 ml 
(Figure 2.4E).  Pre-operative administration allowed sufficient time for the drugs to take 
effect in time for the animal awakening from surgery.  A sterile ocular lubricant (Lacri-
lube ointment, Allergen Inc, USA) was then applied to both eyes to protect corneal drying 
during the procedure (Figure 2.4F).   
2.1.2.1 Endotracheal intubation 
There are numerous methods for the intubation of mice described in the literature ranging 
from non-invasive oral intubation (Spoelstra et al., 2007;Hamacher et al., 2008) to more 
invasive tracheostomy (Moldestad et al., 2009).  The ability to intubate mice quickly, 
reproducibly and with as little damage as possible is imperative for a survival model.  For 
our model, we preferred not to use the tracheostomy approach as the animal would be 
subjected to further surgical intervention which could also lead to serious complications 
post-operatively such as bleeding, infection and incomplete tracheal seal (Spoelstra et al., 
2007).  In cases where the trachea was exposed through a cervical incision to guide 
intubation, this also led to fatal respiratory complications after the operation and it was for 
this reason that this method was no longer used.  The best success in our model with 
endotracheal intubation has been with direct visualisation of the glottis and vocal cords 
using a method which was quick, efficient and as minimally invasive as possible.  A 
number of different methods were adopted to achieve this.  The earliest method tried was 
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placing the mouse on a polystyrene board at a 45° angle and using a fibre optic light source 
shone on to the neck to illuminate the trachea.  However this did not provide sufficient 
visualisation of the structures of the throat and led to potential tissue trauma and incorrect 
placement of the tracheal cannula into the oesophagus.  The next step was to find a way to 
position the mouse under the microscope (at the appropriate height for x 25 magnification) 
to allow for improved visualisation of the vocal cords and tracheal opening.  This approach 
required the mouse to be held vertically so that the microscope could be used to look 
directly down into the oral cavity.  For this, an L-shaped stand made of acrylic plastic with 
a ring of thick silk suture (3-0) was utilised (Figure 2.1).  The (anaesthetised) mouse was 
suspended from a suture loop by its front incisors on the vertical side of the L-shaped 
support.  The tongue was held aside with the thumb and forefinger and the animal’s body 
was supported with the rest of this hand, freeing the other hand to insert the cannula 
(Figure 2.1B; Figure 2.4G).  Using this manoeuvre the opening of the oral cavity was 
parallel to the microscope lens and therefore provided a very clear view of the tracheal 
opening which ensured accurate placement of the cannula into the trachea and markedly 
reduced any tissue trauma or accidental placement into the oesophagus.  The cannula (0.8 
mm O.D.) was then gently inserted into the trachea until the Y-piece connector just entered 
the mouth.  By doing it this way, endotracheal intubation of the mouse took < 20s and 
therefore it was not necessary to maintain the supply of isofluorane to the animal during 
this time (mouse remained unconscious throughout intubation).  This method therefore 
proved to be a quick, non-invasive and reproducible approach to endotracheal intubation of 
the mice.  
 
Figure 2.1  Development of a method for endotracheal intubation of mice. 
(A)  Schematic illustration of the L-shaped plastic stand used to support the mouse during endotracheal intubation.  This 
consists of an acrylic plastic stand with a loop of thick suture fixed in place with tape.  (B)  Positioning of the mouse and 
retraction of the tongue for cannula insertion (all performed under a surgical microscope).  (C)  Tracheal cannula used 
with silicone tubing placed around the cannula (indicated) with connector Y-piece attached. 
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Tracheal cannula and ventilator settings 
The tracheal cannula was a stainless steel tube custom-designed (25 mm long; 0.8 mm 
O.D.) (Harvard Apparatus, U.K.) as shown in Figure 2.1C.  A number of different 
cannulae were tried previously including intravenous catheters and polyethylene (PE) 
tubing; however these were found to lack rigidity and resulted in greater dead space.  Metal 
cannulae manufactured for mice (Harvard Apparatus, U.K.) were found to be more 
suitable as their rigidity meant they remained in position within the trachea better.  A range 
of sizes of metal cannulae ranging in length and diameter were tested including (i) 1.0 mm 
O.D & 28 mm long; (ii) 1.2 mm O.D & 30 mm long but these were found to be too large in 
diameter that they caused too much trauma to the vocal cords and surrounding throat 
structures, and their long lengths were not suitable for the size of mice in our studies and 
risked damage to the bronchial bifurcation.  A 0.8 mm O.D cannula was manufactured 
courtesy of Harvard Apparatus, U.K. and the smaller O.D and shorter length were safer 
and minimised the risks of damage.  In order to increase the O.D of the shaft of the cannula 
(to improve fit within the trachea but minimise damage during insertion) a piece of thin 
silicone tubing was used over the cannula which served as a cuff-like design which also 
improved the ‘grip’ within the trachea.  Once inserted, the tube was connected (via the Y-
piece) to a mouse ventilator (Hugo-Sachs, Harvard Apparatus, Germany) and the animals 
were ventilated at 120 breaths per min with a tidal volume of 120 µl as recommended by 
the supplier (Harvard Apparatus, Germany) for mice of BW 20-25g by the equations 
below.  Chest movements in synchrony with the ventilator confirmed successful intubation 
and mechanical ventilation.  The connection tubes were taped down securely to prevent 
accidental extubation during the procedure. 
26.05.53 −×= BWmin)per(breathsRate nRespiratio    Eq. 1 
04.12.6)( BWlVolumeTidal ×=µ     Eq. 2 
Where BW is the body weight of the animal in g. 
2.1.3 Surgical procedure 
2.1.3.1 Positioning of the animal 
The mouse was then positioned for surgery on a warm heat mat (to maintain body heat 
throughout) in a supine position slightly turned towards its right side and left forearm 
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retracted with soft tubing (Figure 2.2; Figure 2.4H,I).  The remaining limbs on the right 
side were taped down (leaving the left leg free for toe-pinch checks to assess depth of 
anaesthesia).  The positioning of the animal was a key part of the procedure as it can 
largely influence the access to the heart and how much the left lung permits or impedes the 
window of access.  Where the animals were positioned supine or fully on their right side 
proved to be problematic as the sternum or left lung would restrict access to the heart, 
respectively.  Thus it was found that a positioning of the animal between supine and right 
lateral was the most suitable.  The orientation of the animal with respect to the surgeon was 
also found to be important, with lateral positioning proving to create problems with the 
lung collapse, requiring physical movement of the lung with a swab or tissue.  This was 
found to lead to problems with respiration post-operatively likely as a result of damage to 
the lung.  A longitudinal positioning of the mouse (with the head furthest away and the 
caudal end closest to the operator) meant that the manipulation and ligation of the coronary 
artery was at a more favourable angle and the lung would collapse away naturally without 
the need for swabs that could cause damage. 
 
Figure 2.2  Positioning of the mouse for CAL surgery. 
Photograph shows the view from operator’s point of view in which the animal is placed supine and turned slightly on its 
right side with right limbs taped down, the left arm retracted with tubing and the left leg left free for toe-pinch withdrawal 
reflex (anaesthesia depth) checks. 
2.1.3.2 Lateral left thoracotomy 
The surgical procedure was performed with the aid of a microsurgical microscope which 
was set up at the beginning of the surgical procedure by performing the following in this 
order: (1) the dioptre eyepieces were set to zero, (2) a small object (usually a pin tack) was 
placed in the centre of the field of view on a flat surface, (3) the highest magnification 
(x40) was selected and the object was focused using the coarse focus dial, (4) the lowest 
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magnification was then selected (x10) and the right eyepiece dioptre was adjusted until 
sharp focus of the object was achieved without altering the coarse focus dial, (5) the 
highest magnification was selected to ensure the object still remained in sharp focus, (6) if 
this was the case, the lowest magnification was selected and this time the left eyepiece 
dioptre was adjusted until sharp focus of the object, (7) it was then verified that the 
microscope was parfocal at each magnification by switching through each magnification 
ensuring the object remained in sharp focus at each.  Prior to incision, a final check for 
sufficient depth of anaesthesia was confirmed by lack of response to toe-pinch reflex 
(isofluorane was reduced to ~3.5% by this point gradually from 4% at induction; 
anaesthesia was continually reduced by 0.25% gradually to a minimum of 1.5% thereafter).  
A 1 cm-long incision was then made laterally across the left side of the chest perpendicular 
to the sternum in line with the ribs (approximately 5 mm above the xiphoid) (Figure 2.4J-
L).  The skin and thoracic muscles overlaying the rib cage were retracted using elastic 
blunt-hook retractors (Harvard Apparatus, U.K.) (Figure 2.4M,N).  The position of the left 
lung prior to opening the chest was noted by marking with a line either side of the incision 
using a surgical marker pen.  This was to ensure that the lungs were reinflated back to this 
point during close-up to limit complications due to insufficient lung reinflation.  The 
muscle between the ribs of the fourth intercostal space was perforated using angled forceps 
and incised using a battery-operated cauteriser (Harvard Apparatus, U.K.) taking care not 
to damage the heart or left lung.  This was achieved by gripping the rib above gently and 
pulling upwards to create distance between the cauteriser and major organs beneath (Figure 
2.4O).  The ribs were then retracted using a further two blunt-hook retractors to fully 
expose the heart (Figure 2.4P).  Due to the positioning of the animal, opening the thoracic 
cavity caused the left lung to fall away naturally and negated the need for any swabs and/or 
touching of the lung as described previously. 
2.1.3.3 Left anterior descending (LAD) coronary artery ligation 
Experiments to improve visualisation of the LAD coronary artery 
Visualisation of the LAD coronary artery in mice is more difficult than in other species 
due to its very small size and deep embedment within the myocardium.  Intense lighting 
and high magnification were found to be essential for this.  Generally, the anatomy of the 
left coronary artery (LCA) in mice is believed to be comparable with other mammals; 
however it has also been known to be highly variable in mice even within inbred strains 
(Michael et al., 1995).  There are also discrepancies in the origin, course and branching 
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structures of the LCA in mice.  Through use of plastic casts, groups have found that the 
LCA does not branch into a septal portion (Kumar et al., 2005) whereas others have found 
it does (Fernandez et al., 2008) but what seems to be consistent is that whether there is a 
septal branch or not, ligation of the LCA tends to produce infarction of the LV only while 
the septum is still perfused (Salto-Tellez et al., 2004).  Although investigation into the 
anatomy of the LCA in mice was beyond the scope of this thesis, some experiments were 
performed on a cohort of isolated mouse hearts (n=6) in which a coloured dye was used to 
facilitate identification of the LAD coronary artery.  Briefly, hearts were excised and 
following an initial perfusion with saline to remove the blood, hearts were then perfused 
very gradually with a small amount of blue dye (Evan’s Blue) to highlight the location of 
the LAD, taking care only to perfuse as far as the arteries (not veins).  The hearts were 
then photographed and an example is shown in Figure 2.3.  This method was effective in 
identifying anatomical landmarks, reduce blind ligating, and improve reproducibility.   
 
Figure 2.3  Location of the mouse LAD coronary artery using Evan’s Blue dye. 
LCA indicated by arrow.  RA = right atrium, LA = left atrium and Ao = aorta. 
LAD ligation in vivo 
In vivo the LAD was visible as a bright orange tortuous-shaped vessel running through the 
LV from under the left atrium.  The pericardium was gently removed and tucked behind 
the heart and a 9-0 nylon non-absorbable suture (W2829 Ethilon, Johnson & Johnson, 
U.K.) was passed around the LAD coronary artery approximately 1.5 mm below the left 
atrium and tied to produce permanent occlusion (Figure 2.4Q).  Ligating any closer to the 
left atrium than this (<1.5 mm) was found to markedly affect survival and was often fatal, 
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most likely as a result of too severe an infarction (based on observation only).  This is in 
agreement with what others have found (Salto-Tellez et al., 2004).  Ligating at the 1.5 mm 
mark produced statistically reproducible infarct sizes (Chapter 3, Figure 3.8) within the 
threshold required for survival and produced adequate dysfunction and structural 
remodelling associated with MI (Chapter 3).  Ligation was deemed successful when the 
LV became pale in colour and in some animals by the ST-elevation on the ECG.   
2.1.3.4 Closing up 
The rib retractors were removed and three sutures were evenly pre-placed along the ribs 
using 6-0 non-absorbable prolene sutures (W8711, Johnson & Johnson, U.K.) (Figure 
2.4R).  The lungs were reinflated by pinching the expiration tube for 3-4 respiration cycles 
and then placing the tube underwater in a small beaker (250 ml water) to allow sufficient 
positive end-expiratory pressure (PEEP) to keep the lungs fully inflated during close-up.  
This action of placing the tube beneath a depth of ~200 ml water proved more successful 
than allowing it to remain attached to the machine as it led to a 65% reduction in 
respiratory-related deaths (data shown in Chapter 3, Figure 3.2).  The rib sutures were tied 
to seal the thoracic cavity, middle suture first, then the adjacent ones.  The thoracic 
muscles were returned back together with the aid of some drops of sterile saline (no 
sutures) and the skin was sutured with 5-6 simple interrupted sutures using absorbable 6-0 
vicryl (W9575, Johnson & Johnson, U.K.) (Figure 2.4S).  The isofluorane was gradually 
reduced before being switched off during skin suturing.  The mice were given at least 5 
min on 100% oxygen before switching to room air while still on the ventilator.  Animals 
were extubated only when they regained consciousness at which point they were placed 
into a warm recovery cage with soft bedding (Figure 2.4T).  The control for this procedure 
was a sham operation in which the animals underwent exactly the same procedure but 
without CAL.  The suture was initially placed but not tied in the sham animals; however 
this was found to (i) fall into the thorax and risk infection and (ii) risked causing local 
damage which may lead to some ischaemia.  Therefore sham animals underwent the 
procedure but without placement of the suture in the heart.   
2.1.3.5 Recovery and post-operative care 
Animals were monitored closely immediately after surgery to ensure sufficient warmth and 
oxygen provision if necessary until they were mobile, and then daily thereafter at least 
three times a day.  Post-operative analgesia was provided in the form of buprenorphine (0.1 
mg/kg) administered orally in a soft custard feed for three days after the operation and 
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wounds and body weight were also closely monitored according to Home Office 
regulations.  Mice were given the custard feed in the week before surgery to acclimatise 
them to it (which was found to improve their interest in it post-surgery) and the custard 
was provided in a small dish on the cage floor to enhance the animal’s ability to reach it.  
The eating habits and body weight of the animals were recorded daily to ensure the food 
was being eaten and the analgesia received.  After the first week the animals were then 
returned to normal cages and moved back to the housing area until the time of sacrifice.  
Any animals found dead underwent autopsy to ascertain the cause of death and a record of 
the date of death (as day post-operative) was logged. 













Figure 2.4  Photographs of various stages of the surgical method used for inducing MI in mice. 
See details in Section 2.1 describing each image.  Dotted line in (J) indicates first incision site and arrows in (Q) indicates 
the LAD coronary artery. 
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2.2 Congenic rat model of altered LV mass 
2.2.1 Generation of congenic strains 
WKY and SHRSP animals, originally obtained from the University of Michigan, were 
brother-sister mated to produce colonies of WKY and SHRSP at Glasgow as previously 
described (Dominiczak et al., 1993).  Congenic strains were generated using a marker-
assisted speed strategy where segments of SHRSP chromosome 14 were introgressed into 
WKY (to produce a WKY-congenic) and segments of WKY chromosome 14 were 
introgressed into SHRSP (to produce an SHRSP-congenic).  The breeding protocols for 
these two congenic strains is outwith the scope of this thesis but details have been 
previously published (Davidson et al., 1995).   
2.2.2 Genotyping of congenic strains 
Genotyping was previously performed by Dr Delyth Graham’s laboratory at the University 
of Glasgow.  Animals were anaesthetised (isofluorane) and a 4 mm tip from the tail was 
removed at 4 weeks of age.  DNA was extracted from a tail biopsy and analysed using 
PCR around the 83 polymorphic microsatellite markers from total genomic DNA with the 
use of specific primer pairs (Research Genetics, Alabama, USA or Sigma Genosys 
Biotechnology, Cambridge, U.K.).  
2.3 PV measurements 
2.3.1 The PV loop 
LV pressure can be plotted against LV volume to produce the PV loop (Figure 2.5).  The 
PV loop diagram illustrates instantaneous PV points throughout an entire cardiac cycle and 
proceeds in an anticlockwise direction depicting the four main stages of the cardiac cycle. 




Figure 2.5  LV pressure and volume and the PV loop. 
(A) Example pressure (upper blue) and volume (red line) recordings for two cardiac cycles with electrocardiogram (lower 
blue) also shown.  (B)  Example PV loop (red line) showing the four stages of a single cardiac cycle.  A, mitral valve 
opens; AB, filling phase; B, mitral valve closes; BC, isovolumetric contraction; C, opening of aortic valve; CD, ejection 
phase; D, closure of aortic valve; DA, isovolumetric relaxation.  Figure (A) taken from (Guyton & Hall, 2006) and (B) 
taken from (Burkhoff et al., 2005). 
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2.3.2 Principle of operation 
The catheter uses an electric field to measure the volume of blood in the heart.  Baan and 
colleagues (Baan et al., 1984) first proposed a method of correlating the changes in LV 
volume to the change in electrical resistance of the blood pool within the LV.  The 
conductance catheter has four electrodes located along its axis for the measurement of 
conductance; two outer excitation electrodes and two inner sensing electrodes.  A low-
amplitude constant current is applied from the two outer electrodes to produce a local 
electric field.  This electric field passes into the blood, the myocardium and the 
surrounding structures.  The voltage change across these electrodes is inversely 
proportional to the conductance and is measured by the two inner electrodes.  A pressure 
transducer is located between the two inner electrodes of the catheter for direct pressure 
measurements within the ventricle (Figure 2.6). 
 
Figure 2.6  Scisense PV catheter. 
The pressure transducer and electrodes for measuring volume are indicated.  Picture adapted from Scisense Inc. 
2.3.3 Volume signal correction 
The conductance signal is linearly proportional to the volume but requires appropriate 
calibration (correction) to provide accurate absolute volume measurements.  The 
conductance signal is converted to volume using the following equation described by Baan 
(Baan et al., 1984) : 
( )PCT VVLV −= α
ρ 2
     Eq. 3 
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Where VT is the true volume (µl), VC is the volume measured by the catheter (µl) and VP is 
the parallel volume from surrounding conductive structures, ρ represents the resistivity of 
blood (Ωcm), L represents the length between the electrodes (mm) and α is a constant gain 
factor dependent on the SV.  As the resistivity of blood and the catheter recording segment 
length remained constant in all experiments, the equation could be simplified to the 
following (2): 
( )PCT VVV −= α
1
     Eq. 4 
Two factors are required to correct the volume signal in the above equation, these are: the 
alpha gain coefficient (α) and the parallel volume offset correction factor (VP). 
2.3.3.1 α gain coefficient  
α is a correction factor used to calibrate the SV of the resulting conductance signal to 
match a standard of comparison (usually by use of a flow probe or echocardiography).  
This is required because the PV catheter uses point electrodes which means the electric 
current lines are not straight but curved, introducing non-linearity to the volume signal.  
α is calculated by adjusting stroke volume (or cardiac output – the product of SV and HR) 
measured by the catheter to that of stroke volume (or cardiac output) measured by an 





=α       Eq. 5 
Where COC is the cardiac output measured by the catheter and COTrue is the independently 
measured cardiac output. 
2.3.3.2 Parallel volume (VP) 
Conductance measurements should correspond to the LV blood pool alone but in reality 
some of the current leaks into the surrounding myocardium and other structures which are 
conductive.  This introduces an error into the volume calculations and must be corrected to 
avoid inaccurate over-estimation of the true volume.  This is commonly performed using 
the hypertonic saline dilution method.  This involves injecting a bolus of ~10 µl (mice) or 
~35 µl (rats) of high salt solution (e.g. 15% NaCl) intravenously into the animal to 
transiently increase the conductance with no effect on the pressure.  This leads to a 
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rightward shift in the PV loops.  VP was calculated by solving a series of linear equations 
to locate the intersection of two lines; one represented by the saline data (plotting EDV 
against ESV for each beat during the rise phase of the volume trace following the injection 
of hypertonic saline) and the other by plotting ESV = EDV.  The latter line (ESV = EDV) 
represents the LV chamber when ESV = EDV (i.e. LV devoid of blood).  The value of the 
intersection between the two lines is equal to the VP of the surrounding tissue and can be 
subtracted from the measured volume to obtain true volume – an example of this is shown 
in Figure 2.7 below. 
 
Figure 2.7  Example of parallel volume estimation. 
(A-i,ii) Pressure and volume during the hypertonic saline bolus injection and (A-iii) resulting PV loops showing a 
rightward shift in the loops corresponding to an increase in volume with no change in pressure. (B) ESV and EDV points 
during the hypertonic saline bolus are plotted and extrapolated – the intersection with the line of unity (ESV=EDV) 
represents the parallel volume.  This is an example taken from a stock rat.   
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2.3.4 Calibration of PV catheters 
Prior to in vivo PV experiments, the catheter was appropriately calibrated for pressure and 
volume. 
2.3.4.1 Pressure 
The catheter was pre-soaked in saline at 37°C in a water bath for at least 45 min before 
each experiment.  The reasons for this were to ensure adequate equilibration with the 
temperature at which the recordings will be made in vivo (37°C) and to ensure maximal 
stability of the pressure signal.  The equipment is also given the same amount of time to 
warm up before use to minimise electrical drift of the hardware.  The signal was calibrated 
prior to the start of the experiment by a 2-point linear calibration method using built-in 
values on the power unit (0 mmHg = -2.86 V; 100 mmHg = -0.56 V).  Additionally, the 
pressure sensor was tested using a pressure transducer calibration device (Delta-Cal 650-
950, Utah Medical Products, USA) which allowed the pressure sensor of the catheter to be 
calibrated against known output pressures.  Immediately prior to use, the sensor was 
balanced (reset to 0 mmHg) for any electrical drift that may have occurred since calibration 
by submerging it just below the surface of saline in a bijou at 37°C and adjusting the 
balance dial until the catheter read 0.00 mmHg. 
2.3.4.2 Volume 
There are two ways by which the volume signal can be calibrated prior to the beginning of 
the experiment; (i) using the in-built values on the catheter control unit or (ii) using two 
cuvette wells of known volume. 
(i)  Built-in volume calibration 
The Scisense Model FV898B power unit contains an in-built calibration scale for volume 
calibration.  These are electronic calibration voltage outputs that correspond to specific 
volumes (5 values for mouse and 5 for rat), two of which can be used for a 2-point 
calibration similar to the method described above for pressure calibration.  However, 
before using the in-built calibration system a series of calibration experiments were 
performed to verify the accuracy of this system. 
This involved calibrating the catheter with different combinations of two in-built values 
then measuring the volume read by the catheter in standard wells to assess how closely this 
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matched the true volume of the well.  This approach allowed (i) verification of the 
accuracy of the in-built system and (ii) selection of the two most suitable in-built values to 
use based on which combination gave the most accurate result.  A polycarbonate block 
containing cylindrical wells of known volume (ADInstruments, USA) were filled with 
either fresh heparinised blood obtained from rats or mice, depending on the catheter used 
(mouse blood for the mouse catheter and rat blood for the rat catheter), or using a mock 
blood solution (described below).  These experiments were performed by myself and Heidi 
Conrad (a summer undergraduate student).   
(ii)  Cuvette well calibration 
These experiments could also be performed using two cuvette wells of known volume for 
the 2-point calibration instead of calibrating with two in-built values from the machine.  
The two wells selected were those which corresponded to the normal upper and lower 
values for LV volumes observed in the mouse or rat heart.  
For both of these methods, the preparations were maintained at 37°C in a water bath, 
clotting of the harvested blood was minimised using low concentration heparin (60 U/ml) 
added to the blood immediately after collection and the catheter was always centred 
carefully within the well.  The results of these calibration experiments are shown in Figure 
2.8.  These data reveal that the in-built values 20 and 40 µl showed the greatest unity for 
the mouse calibrations, and 200 and 300 µl for the rat and were therefore suitable to use for 
volume calibrations. 





Figure 2.8  Calibration curves using different calibration combinations from the in-built system and a cuvette 
calibration. 
(A-B)  Measurements were generated using a mouse or rat PV catheter with freshly harvested heparinised mouse or rat 
blood respectively in standard cuvette wells of known volume.  The combinations shown on the right are the different 
pairs of values used to calibrate the PV catheter and then the catheter was placed in cuvette wells of increasing known 
volume.  The different calibration curves were compared against a line of unity (black line) where measured volume = 
true volume to determine the best calibration values to use.  The dotted lines represent the normal ESV and EDV ranges 
for mouse and rat according to (Pacher et al., 2008). 
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Preparation of a mock blood solution 
Under ideal conditions, a sample of blood from the animal would be taken prior to the 
experiment and used to fill the wells for volume calibration.  However, rats and mice have 
very low circulating blood volumes and therefore would not provide enough blood 
required to fill the wells.  In order to eliminate the need for fresh animal blood before each 
experiment, an alternative ‘mock blood’ saline solution can be prepared to match the 
conductivity of blood and can be used for the calibrations instead.  Empirical data has 
shown that the conductivity of blood for mice and rats are as follows (this has also been 
verified by our experiments using direct measurement with a conductivity meter): 
Mouse blood at 37°C = 7.6 mS 
Rat blood at 37°C = 6.3 mS 
To prepare a solution that matched these values at 37°C, physiological saline (0.9% NaCl 
w/v) was diluted with double distilled water and monitored using a conductivity meter 
(Amber Science Inc, USA) calibrated with a standard solution of known conductivity (6.66 
mS; Amber Science Inc, USA).  This was done by submerging the measuring probe of the 
meter into ~25 ml of the standard solution, moving the probe up and down to dislodge any 
air bubbles which could affect the readings and adjusting the standardising dial to match 
the known conductivity.  This calibration was required to be performed at a temperature of 
25°C in order to be accurate therefore the calibration solution was heated to 25°C in a 
waterbath.  Once the mock blood solution was made it was stored at room temperature and 
used at 37°C. 
Final volume calibration methods used 
Prior to the in vivo experiments, the volume signal was calibrated either using the in-built 
volumes within the power unit (all rat experiments and stock mice experiments were 
calibrated this way), or using two standard cuvette wells (mouse MI studies were 
performed this way).  The two hardware units were different in that one had in-built 
volume values (FV866B) and the other did not (FV898B) and is designed to be used for 
variable segment length catheters.  The in-built volume unit (FV866B) was suitable for 
normal rats where physiological LV volumes were expected but in infarcted mouse hearts 
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post-MI where a dilated LV chamber is common the LV volumes were too large for the 
range of the FV866B and therefore the FV898B was used instead for these experiments. 
The in-built values used for a 2-point calibration were as follows: 20 and 40 µl for mouse, 
and 200 and 300 µl for rat.  These values were chosen based on verification using 
calibration experiments (see Section 2.3.4.2).  The in-built volumes were unsuitable for the 
mouse MI functional studies because the larger chamber volumes associated with MI were 
greater than the maximum volume the in-built system could read for mice.  As a result two 
cuvette volumes were used in combination with the FV898B VSL power unit for the 2-
point calibration and these were 31.81 and 88.36 µl cuvette wells which were chosen to 
represent the volume range expected in the mouse infarcted heart.  These values were also 
used for the sham animals.  The VSL unit has been previously calibrated in our laboratory 
and the results published (Elliott et al., 2012;Kelly et al., 2012).   
2.3.5 Surgical procedure for insertion of PV catheter into the LV 
in vivo 
2.3.5.1 Different surgical approaches available for PV catheter insertion 
There are two main surgical approaches which can be used for inserting the PV catheter 
into the LV of the rodent heart in vivo.  These are (i) an open-chest approach; involving a 
thoracotomy by transverse substernal incision of the diaphragm and subsequent insertion 
of the catheter into the LV via direct apical stab or (ii) a closed-chest approach; in which 
the catheter is inserted via the carotid artery and fed retrograde through the aortic valve 
into the LV.  Each method has both advantages and disadvantages and the surgical 
approach used tends to be largely dependent on the study and the experimental model of 
cardiac disease used (if applicable).   
The open-chest approach (via the apex of the heart) is frequently used as it tends to be 
quicker and allows for more direct control over catheter positioning within the heart.  
Furthermore in models where the aorta has been banded (e.g. in TAC models) or the aortic 
valve may be severely calcified (e.g. in advanced ageing models) this approach is the more 
appropriate over the carotid artery method.  However, the open-chest approach can be 
disadvantageous due to the associated lung collapse, compromised myocardial integrity 
and relatively large tissue trauma which can influence haemodynamic function.  In MI 
models this approach is not suitable as the apical region of the heart will have undergone 
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extensive remodelling and infarct formation making it inaccessible for the catheter with no 
stable hold.   
The closed-chest approach (via the carotid artery) is considered to be less invasive than 
the open-chest method as the lungs remain untouched, the myocardium intact with 
minimum tissue trauma.  This approach therefore tends to be favoured for prolonged 
experiments which require haemodynamic stability over a long period of time (e.g. drug 
testing) or for assessment of animals that have undergone MI to avoid damage to the 
infarcted area.   
2.3.5.2 Surgical approach chosen for the different animal models 
Mouse MI model:  For the reason outlined at the end of the previous paragraph, the 
closed-chest approach was used for the mouse MI model in this thesis (including control 
stock or sham mice for consistency).   
Hypertensive and congenic rat model:  For the hypertensive/congenic rat model study, 
there were no structural limitations associated with the phenotype to dictate which surgical 
method was to be used.  Therefore, as it was not clear how the surgical approach (including 
the choice of mechanical or spontaneous ventilation) could affect haemodynamic function, 
a series of experiments were performed using cohorts of stock control rats to test the 
suitability of the open or closed-chest surgical approaches using mechanical and 
spontaneous ventilation in order to ascertain which was the most appropriate to use.  The 
results from these experiments are covered later in this PV loop section of the chapter (see 
Section 2.3.10).  This work was published in abstract form at The Physiological Society 
Annual Meeting (Foote & Loughrey, 2010). 
The following sections describe the surgical procedure for inserting the PV catheter either 
via (a) a closed-chest approach or (b) an open-chest approach.  Where rats and mice were 
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2.3.5.3 Closed-chest surgical procedure 
PV catheter preparation 
PV experiments were performed using either a 1.2F (mouse) or 1.4F (rat) PV catheter 
(112B-C002 and 212B-B097 respectively, Scisense Inc., Canada).  The catheter was 
connected to a Scisense PV Unit System (FV866B or FV898B, Scisense Inc., Canada) and 
given at least 45 min to equilibrate at 37°C prior to use.  The catheter was calibrated for 
pressure and volume at the start of the experiment as described previously (Section 2.3.4).   
Anaesthesia and surgical preparation 
Animals were anaesthetised with isofluorane (4%) in a closed induction chamber and 
sustained on a face-mask (4% isofluorane) while the skin from the neck region and upper 
abdominal areas was shaved and cleaned with a surgical disinfectant (Hibiscrub, Ecolab 
Ltd, U.K.).  Mice underwent endotracheal intubation with a 0.8 mm tracheal cannula 
(Harvard Apparatus, U.K.) and were ventilated under 1.5% isofluorane at a respiratory rate 
of 120 min-1 and a tidal volume of 120 µl (Hugo Sachs Elektronic MiniVent Type 845, 
Germany).  Rats were either kept on the face-mask for the rest of the experiment (closed-
chest, spontaneous breathing group) or were intubated via tracheostomy with an 18G 
cannula made from an intravenous catheter (closed-chest, mechanically ventilated group).  
Rats were ventilated under 1.5% isofluorane using a small animal ventilator (Model 683, 
Harvard Apparatus, U.K.) at a respiration rate of 70 breaths.min-1 and a tidal volume of 2.4 
ml.  Animals were positioned supine on a thermostatically-controlled heat pad controlled 
by a rectal probe to maintain core body temperature at 37.0 ± 0.5°C (Harvard Apparatus, 
U.K.) and the limbs taped down in place.  A midline cervical incision was made and the 
muscles were carefully retracted on the right side of the neck to expose the right carotid 
artery.  The carotid artery was dissected taking care to avoid damage to the vagus nerve or 
other blood vesslels.  Four silk sutures (6-0) were then placed around the carotid artery; 
one at the distal (cranial) end (tied firmly) to allow anchorage and manipulation of the 
artery as necessary; one at the proximal (caudal) end (retracted with haemostats to occlude 
but not tied) to occlude blood flow during cannulation; and two loosely placed middle 
sutures to secure the catheter in place once inserted.  In rats, an arterial clip was also used 
to provide additional support to the most caudal suture to minimise accidental blood loss; 
this was not required in the mice as the suture was sufficient for their smaller arteries.  
Before the catheter was inserted, the other blood vessels required for access during the 
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experiment (left jugular vein and inferior vena cava (IVC)) were exposed at this time to 
avoid accidentally moving the catheter during recordings later.  The left jugular vein was 
exposed by extending the cervical incision towards the left shoulder and bluntly dissecting 
the surrounding muscles to expose the vein.  The IVC was exposed following an upper 
abdominal incision (at the level of the xiphoid cartilage).  A suture was placed into the 
xiphoid cartilage as a means of retraction to expose the area better.  Warm swabs soaked in 
saline were placed on the incision sites for the jugular vein and IVC to avoid heat loss until 
they were needed.   
Catheter insertion 
The catheter was then prepared for insertion by rebalancing to zero to correct for any 
electrical drift and to ensure there was no offset error in the pressure readings.  A tiny cut 
was then made into the carotid arterial wall at the distal end and the tip of the catheter was 
then inserted into the carotid artery and pushed as far as the last suture (closest to heart 
end) where it was then tied in place.  The last suture was released (and clip removed for 
rat) and the catheter was advanced into the heart, guided by changes in pressure that were 
recorded during this time.  The time taken from catheter rebalance to entry into the heart 
was usually <5 min but if for any reason this took longer than 5 min, the catheter was 
rebalanced in warm saline in the bath.  The catheter was positioned optimally with fine 
movements left or right and advancing or retracting as necessary.  Optimal positioning was 
defined as the tallest and widest loop achievable with the straightest edges; a maximum of 
15 min was permitted to reach this.  Once positioning was complete, the catheter was 
secured into place with the sutures and with blu-tak if necessary.  Baseline measurements 
were recorded for 10 min in steady state.   
IVC occlusions 
During baseline recording, the IVC was occluded using blunt forceps (with plastic 
coverings over the tips) for ~ 5 beats to transiently reduce inflow to the heart (preload) for 
the offline calculation of load-independent indices of function.  At least three IVC 
occlusions were performed for each animal to allow a mean value to be taken.   
 
 
Kirsty K. Foote, 2012  Chapter 2  
92 
 
Injection of bolus of hypertonic saline 
At the end of the experiment a series of intravenous injections of a small volume (10 µl for 
mouse; 35 µl for rat) of hypertonic saline (15% NaCl w/v) were administered using a 50 µl 
Hamilton precision syringe (Harvard Apparatus, U.K.) to the left jugular vein to allow 
subsequent correction for parallel conductance (VP).  15% NaCl was prepared by 
dissolving NaCl in double-distilled water in a final volume of 10 ml.  Three injections were 
performed for each animal to enable a mean value to be taken.  At the end of the 
experiment the animals were sacrificed. 
2.3.5.4 Open-chest surgical procedure 
This technique was applied to rats only.  Anaesthesia induction, skin preparation, 
intubation by tracheostomy and positioning of the animal with temperature control were all 
performed exactly as described in the previous section (Section 2.3.5.3).  A transverse 
substernal incision was made over the liver and a suture was placed through the xiphoid 
cartilage to allow retraction of the ribs upwards to expose the thorax.  The diaphragm was 
carefully cut transversely to expose the heart.  The catheter was rebalanced and secured on 
to the surgical table.  A small tear was made into the pericardium to free the heart and a 
23G needle was inserted into the LV through the apex to make a passage for the catheter 
which was subsequently inserted.  Optimal positioning was achieved following the same 
criteria as before (the tallest, widest loop with the straightest edges).  Baseline recording, 
IVC occlusions and hypertonic saline injections were all performed as described in the 
previous section.  At the end of the experiment the animals were sacrificed. 
2.3.6 Data acquisition 
PV data were acquired using the Scisense control system (either FV866B for stock mice 
and all rat work; or FV898B for sham and MI mice) connected via an A/D board to a Dell 
laptop using LabScribe2 software version 2.241 (iWorx, New Hampshire, USA).  All PV 
data were analysed offline using the PV module as part of the LabScribe2 programme.  
Data were taken from 20 beats in steady-state (after the 10 min stabilisation period). 
2.3.7 Calculation of volume 
As noted earlier, the conductance signal is converted to volume using the following 
equation: 
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( )PCT VVV −= α
1
     Eq. 6 
Where VT is the true volume (µl), VC is the volume measured by the catheter (µl) and VP is 
the parallel volume (the mean of the three values taken) from surrounding conductive 
structures and α is a constant gain factor dependent on the SV. 
2.3.8 Calculation of alpha (α) 
α gain coefficient 
α was ascertained using an independent measure of CO by assessing flow through the 
ascending aorta using a miniature ultrasonic aortic flow probe (Transonic Systems, USA).  
The Transonic flow probe is designed to be loosely hooked around a blood vessel and the 
operation is based on the transmission of ultrasound waves from transducers located 
opposite a reflecting plate for which the transit time is a function of volume flow 
intersecting the beam (i.e. blood flow through the vessel) as depicted in Figure 2.9.  The 
Transonic flow probe is made up of a probe body which contains two ultrasonic 
transducers on one side and an acoustic reflector positioned opposite, between the two 
transducers.  One transducer emits an ultrasound wave which intersects the blood vessel in 
the upstream direction, is reflected by the acoustic reflector, and intersects the vessel again 
before being received by the upstream transducer where it is converted into electrical 
signals by the flow meter based on the transit time from one transducer to the other.  This 
sequence of transmission is then repeated but in reverse where the transmitting/receiving 
roles of the transducers are reversed, followed by the reverse again and so on.  During the 
upstream cycle, the ultrasound wave travels against the flow (increased transit time) and 
the downstream cycle travels with the flow (decreased transit time by the same flow-
dependent amount).  The flow meter subtracts the downstream-direction transit time from 
the upstream-direction transit time and the integrated difference is a measure of the flow 
through the vessel (Transonic Systems Operations Manual). 




Figure 2.9  Transonic flow probe and mechanism of operation. 
(A) Schematic representation of a Transonic flow probe.  Two transducers emit alternating signals which intersect the 
blood flow through the vessel in upstream and downstream directions reflected by the reflector plate located opposite the 
transducers. Also shown is the view of the probe around the blood vessel from a side-angle.  (B) Photograph of a 
Transonic flow probe for measuring flow in rodents (probe shown is the 1.5PSL for mouse ascending aorta which is the 
one used for the mouse experiments in this study).  Figure courtesy of Transonic Systems. 
This approach was used for both mouse and rat studies separately.  Stock control mice 
were used for the mouse experiments.  For the rat experiments (congenic rat study), the 
measurements were performed in the parental strains, WKY and SHRSP. 
Placement of aortic flow probe in vivo 
• Prior to use the aortic flow probe was soaked in saline at 37°C for at least an hour 
before use to allow equilibration with the temperature at which the recordings will be 
made.  Data were acquired using the Transonic System (Transonic Systems, NY, USA) 
with a TS420 flow meter (Transonic Systems) and a perivascular flow probe (1.5PSL 
for mouse and 2.5PSL for rat).  A two-point calibration was used using two in-built 
values (0V = 0 ml.min-1 and 1V = 5 ml.min-1 for mouse; 0V = 0 ml.min-1 and 1V = 20 
ml.min-1 for rat).   
• Animals were anaesthetised (4% isofluorane) in a closed induction box and then 
transferred to a face-mask (4% isofluorane) while the skin across the upper chest was 
shaved and cleaned with a skin disinfectant (Hibscrub, Ecolab Ltd, U.K.).   
For mice, the animals were intubated with a 0.8 mm O.D tracheal cannula and 
ventilated at a respiration rate of 120 breaths.min-1 with tidal volume of 120 µl per 
breath (1.5% isofluorane).   
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For rats, the animals were intubated via tracheostomy (18G IV cannula) and ventilated 
at a respiration rate of 70 breaths.min-1 with tidal volume of 2.4 ml per breath (1.5% 
isofluorane).   
• Animals were then positioned in a supine-to-left lateral position with the right arm 
retracted to expose the right side of the chest.  An incision was made laterally across 
the sternum at the level of the second intercostal space.  The muscles overlaying the 
ribs cage were bluntly freed and retracted using elastic blunt-hook retractors.  The 
second intercostal space was perforated and cauterised using a battery-operated cautery 
pen (Harvard Apparatus, U.K) and the ribs were held open using an additional two 
retractors.  The thymus was gently retracted to expose the aortic arch.   
• The pericardium was carefully perforated to aid clearing of tissue from around the 
aorta.  The ascending aorta was dissected and a silk suture was loosely placed around 
this portion to facilitate lifting the aorta into the flow probe.  Only the ascending 
portion of the aorta (prior to any branchings) was used for measurements; this meant 
that as little flow as possible was missed (only coronary flow was missed).  Once the 
probe was around the aorta, an ultrasound coupling gel (Surgilube, Transonic Systems, 
USA) was injected into the air space between the probe and the aorta to increase 
acoustic coupling.   
• The probe’s positioning was adjusted using a micromanipulator until the maximum 
flow was achieved, taking care not to lose coupling or impede flow.  Ascending aortic 
flow rate was measured by the flow meter and recorded on to a Dell laptop using 
LabScribe2 software (iWorx, New Hampshire, USA).  A 10 min stabilisation period 
was permitted before taking baseline CO measurements. 
Data analysis 
Values of CO were taken as the average maximal aortic flow over a 10 s period of trace, 
defined as the highest flow reading in steady state analysed using Origin 6.1 (OriginLab, 
USA).  The results of these measurements in mice and rats are shown in Figure 2.10 and 
Figure 2.11, respectively.  These results have revealed that the values for CO obtained 
using the flow probe were not significantly different from those obtained by the PV 
catheter for mice (7.83 ± 0.75 vs. 8.25 ± 0.53 ml.min-1; flow probe (n=15) vs. PV catheter 
(n=24); P>0.05; Figure 2.10).  The same was true for both strains of rat; WKY (52.45 ± 
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4.76 vs. 46.51 ± 3.74 ml.min-1; flow probe (n=6) vs. PV catheter (n=5); P>0.05; Figure 
2.11) and SHRSP (37.94 ± 1.60 vs. 38.07 ± 4.18 ml.min-1; flow probe (n=6) vs. PV 
catheter (n=3); P>0.05; Figure 2.11).  The value for α was calculated to be 1.05 for mice, 
0.89 for WKY rats and 1.00 for SHRSP rats using Equation 3.  Therefore the CO measured 
by the PV catheter has been confirmed by the use of an independent measure and the two 
separate measures were found to be in agreement; therefore no correction for the volume 
data for α was required. 
 
Figure 2.10  Comparison of CO measurements obtained with a PV catheter and an aortic flow probe in mice. 
Measurements of CO closed-chest using the PV catheter (white circles; n=24) compared with measurements of CO open-
chest using an aortic flow probe (black circles; n=15) in control stock mice. 
 
Figure 2.11  Comparison of CO measurements obtained with a PV catheter and an aortic flow probe in rats. 
Measurements of CO closed-chest using the PV catheter in WKY rats (white circles; n=6) compared with open-chest CO 
measurements with an aortic flow probe (black circles; n=5), and in SHRSP rats with the PV catheter (white circles; n=6) 
compared with open-chest aortic flow probe (black circles; n=3). 
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α calculation limitations 
(1) Unfortunately, simultaneous measurements of CO with the PV catheter and the aortic 
flow probe in the same animal were not possible as this was associated with a very 
high mortality due to the invasive nature of both procedures.   
(2) Furthermore, for the majority of PV measurements, the carotid artery route was used 
meaning that a portion of the catheter wire would be present inside the ascending 
aorta where the flow probe was required to measure from.  This was therefore 
another reason that simultaneous measurements using both the catheter and the flow 
probe together were not possible.  As the majority of the PV catheter measurements 
were performed under closed-chest conditions (only a proportion of rat experiments 
were performed open-chest), the aortic flow measurements were initially attempted 
closed-chest for consistency.  This involved accessing the aorta from a cervical 
incision and ‘hooking’ the aorta upwards (i.e. the chest cavity was never opened by 
this method).  However this was not feasible and led to difficulty obtaining good 
probe placement and was also associated with a high level of intra-operative 
mortality.   
(3) Failing this, the next attempt involved the probe being inserted open-chest by 
thoracotomy and then closing the chest with sutures; however this was also 
problematic for the following reasons: (i) the positioning of the probe was altered and 
often lost acoustic coupling evident by a reduced signal quality; (ii) the cable of the 
probe did not allow for a complete seal when closing the ribs therefore closed-chest 
conditions could not be guaranteed, and (iii) alterations in the CO after closing the 
chest were inconsistent as in some animals CO was found to increase while in others 
it decreased.   
Therefore in light of these problems and the observation that CO data between open and 
closed chest were not significantly different (data not shown) the open-chest flow probe 
measurements were used.  Placement of the aortic flow probe on the ascending aorta meant 
that very little of the CO was missed.  Only coronary flow (CF) would be missed which is 
estimated to make up 3-4% and 7% of the total CO in rats and mice, respectively.  
Therefore there was a slight underestimation of the CO measured by the flow probe; 
however due to the small percentage contribution of CF it was decided not to correct for 
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CF in light of the fact we also did not take CF measurements from these animals to verify 
against those from the literature. 
2.3.9 Calculation of VP 
VP was estimated offline using LabScribe2 software (iWorx, New Hampshire, USA) using 
the method described in Section 2.3.3.2.  For this calibration, only the volume data from 
the rising phase following the injection was used.  At least three injections were performed 
for each animal and each one calculated individually to allow a mean value to be taken per 
animal. 
2.3.10 Calculation of load-independent indices 
Load-independent indices were obtained by analysing the section of trace corresponding to 
the IVC occlusions.  This was performed offline using LabScribe2 software (iWorx, New 
Hampshire, USA).  The end-diastolic pressure-volume relationship (EDPVR) was assessed 
by fitting the following non-linear exponential equation to the end-diastolic pressure and 
volume points from the family of loops obtained during the occlusion: 
)*( EDVCexpEDP β=     Eq. 7 
 
Where EDP is the end-diastolic pressure, EDV is the end-diastolic volume, C is a curve-
fitting constant and β is the diastolic stiffness constant (Burkhoff et al., 2005). 
2.3.11 Baseline haemodynamic data from control animals 
Following completion of all the calibration work, the PV system was then ready to be 
applied to the animals in the study.  Prior to use of the technique in the diseased animals, 
the system was first refined in a series of stock animals (mice and rats).  The main aim of 
these experiments therefore was to optimise and validate the PV technique and assess its 
suitability prior to applying the technique to the mouse and rat models of disease in this 
thesis. 
2.3.11.1 Baseline data from stock mice 
Aim:  Prior to the use of the PV system for functional studies on the MI model, PV 
measurements were performed using a closed-chest mechanically ventilated approach 
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(which was also used in sham and MI animals in control stock mice) to assess whether 
baseline data compared with normal published values for mice (to validate the technique).   
Results:  The results of these measurements are shown in Table 2.1 and demonstrate that 
the technique offers a reliable and reproducible approach to measuring LV function in 
mice with data which were comparable with published ranges for normal mice. 
Table 2.1  Baseline haemodynamic parameters of LV function in stock mice compared to published values. 
  
THIS STUDY                  
(n=24) 
PUBLISHED RANGE 
(Pacher et al., 2008) 
 
  
HR (bpm) 560.47 ± 12.0 470 - 620 
ESP (mmHg) 102.7 ± 1.4 92 - 118 
EDP (mmHg) 3.8 ± 0.6 1 - 6 
dP/dtmax (mmHg.s-1) 10015.9 ± 312.1 8,200 - 14,200 
dP/dtmin (mmHg.s-1) 9012.9 ± 419.9 6,700 - 10,500 
Tau (ms) 5.8 ± 0.3 4.4 - 7.6 
ESV (µl) 14.9 ± 1.3 7 - 21 
EDV (µl) 31.2 ± 1.9 25 - 53 
SV (µl) 17.7 ± 1.2 17 - 30 
CO (ml.min-1) 9.1 ± 0.7 8 - 16 
EF (%) 66.1 ± 3.1 55 - 72 
  
    
 
2.3.11.2 Comparison of baseine data in stock rats using different surgical 
techniques 
Aim:  In order to determine which was the best surgical approach for the rat study, PV 
measurements were performed in three groups (1-3) of control stock male Wistar rats (BW 
310.3 ± 7.2 g) each undergoing a different surgical approach: (1) open-chest approach with 
mechanical ventilation, (2) closed-chest approach with mechanical ventilation or (3) 
closed-chest approach with spontaneous ventilation.   
Results:  Baseline PV data from each group are shown in Table 2.2 and Figure 2.12.   
• There were no statistical differences in the following parameters of LV function 
between the three groups: ESP, EDP, dP/dtmin, SV, CO and EF (P>0.05 for all).  There 
were no significant differences in any parameter between the open-chest approach with 
mechanical ventilation and the closed-chest approach with mechanical ventilation.   
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• HR was significantly greater in animals that underwent closed-chest with spontaneous 
breathing approach compared to closed-chest with mechanical ventilation (9.2% 
greater; P<0.05) and compared to animals that underwent the open-chest approach with 
mechanical ventilation (11.0% greater; P<0.05).  The only differences in dP/dtmax 
observed were a significant increase (24.7% increase; P<0.05) in the closed-chest 
group with spontaneous breathing compared to the open-chest group with mechanical 
ventilation.  Similarly the relaxation time-constant (τ) was significantly reduced 
(12.2% lower; P<0.05) in the closed-chest with spontaneous breathing group compared 
to the open-chest with mechanical ventilation group.  It cannot be ruled out that these 
changes observed could be attributed to the differences in HR.   
• There was a leftward shift in the PV loops from the closed-chest with spontaneous 
breathing group compared to both other groups with significantly lower ESV (44.1 and 
39.6% lower compared to open-chest with mechanical ventilation and compared to 
closed-chest with mechanical ventilation, respectively; P<0.05 for both) and 
significantly lower EDV (32.3 and 21.1% lower compared to open-chest with 
mechanical ventilation and compared to closed-chest with mechanical ventilation, 
respectively; P<0.05 for both).   
Table 2.2  Haemodynamic PV indices of LV function in three different groups of rats. 
  
Open Chest         
(mechanical ventilation)                               
(n=9) 
Closed Chest         
(mechanical ventilation)                               
(n=4) 
Closed Chest         
(spontaneous ventilation)                               
(n=8) 
 
   
HR (bpm) 406.6 ± 7.5 413.4 ± 11.5† 451.5 ± 9.4* 
ESP (mmHg) 114.9 ± 3.3 118.0 ± 10.0 123.5 ± 4.2 
EDP (mmHg) 6.1 ± 0.6 3.9 ± 0.9 6.4 ± 0.8 
dP/dtmax (mmHg.s-1) 8208.8 ± 487.7 8462.9 ± 427.0 11238.8 ± 639. 7* 
dP/dtmin (mmHg.s-1) 9997.8 ± 510.8 9263.7 ± 682.3 10055.1 ± 289.6 
Tau (ms) 8.2 ± 0.2 7.6 ± 0.3 7.2 ± 0.3* 
ESV (µl) 99.9 ± 14.7 92.4 ± 10.1† 55.8 ± 10.0* 
EDV (µl) 252.1 ± 16.2 216.3 ± 3.1† 170.7 ± 13.5* 
SV (µl) 150.5 ± 16.4 122.9 ± 9.9 111.5 ± 10.4 
CO (ml.min-1) 61.3 ± 7.4 51.0 ± 4.9 50.6 ± 5.4 
EF (%) 62.0 ± 4.8 56.8 ± 4.5 66.7 ± 5.5 
  
      
* P<0.05 between closed-chest with spontaneous ventilation and open-chest with 
mechanical ventilation.  † P<0.05 between closed-chest with spontaneous ventilation and 
closed-chest with mechanical ventilation. 




Figure 2.12  Comparison of haemodynamic parameters using different surgical approaches for PV catheterisation 
in rats. 
(A)  Representative PV loops using each method.  (B i-iii): Comparison of systolic functional parameters, (C i-iii): 
Diastolic functional parameters, (D i-iii) Volume parameters using the open-chest (apical) approach with mechanical 
ventilation (light grey bars n=8), the closed-chest approach with mechanical ventilation (dark grey bars n=4) and the 
closed-chest approach with spontaneous breathing (black bars n=8).  Data shown are mean ± SEM. *P<0.05.  Dotted 
lines represent the normal published range for rats under closed-chest conditions (Pacher et al., 2008). 
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Summary:  Collectively, these data demonstrate that when using mechanical ventilation 
there were no differences in LV performance between an open-chest and a closed-chest 
approach.  This observation however was not in agreement with other studies which have 
reported differences in LV function using PV methodology between open and closed-chest 
- it has been shown that ventilated mice undergoing open-chest approaches have larger EF, 
larger SV and a leftward shift in volume parameters compared to ventilated closed-chest 
approaches, which the authors state may be due to the reduced intra-thoracic pressures 
caused by opening the thorax (Lips et al., 2004).  This study is not however directly 
comparable with ours due to the differences in species use and the use of different 
anaesthesia (sodium pentobarbital and not isofluorane).  HR alterations in our study may 
be as a result of the mode of ventilation: animals maintained on the facemask have greater 
HR than mechanically ventilated animals (open and closed chest).  It is possible that by 
controlled artificial ventilation there is a more constant delivery rate and volume of 
anaesthesia owing to the more cardio depressive effect than spontaneous breathing.  
However exact measurements of rate and flow during spontaneous breathing were not 
measured.  In light of these data that the least cardio depressive LV pressure effects were 
observed when using the closed-chest approach (spontaneous breathing) group, this group 
was therefore selected as the method of choice for the congenic rat PV measurements in 
Chapter 5. 
2.4 ECG 
2.4.1 ECG as a method of assessing cardiac function in vivo 
ECG is a non-invasive method for recording the electrical activity of the heart.  Electrical 
signals generated in the heart through depolarisation and repolarisation during the different 
phases of the cardiac cycle can be detected by placement of recording electrodes in a 
standard configuration on the body of the subject.  The ECG recording, displayed as 
changes in voltage over time, can then be used to measure electrical functioning of the 
heart.  ECG measurements in this study were used for to assess the frequency of cardiac 
arrhythmias in the mouse MI model.   
2.4.2 Protocol for measuring ECG 
Mice were anaesthetised with isofluorane in a closed induction box (4%; 1.5 L.min-1) and 
maintained under spontaneous breathing conditions through a face mask during recordings 
(1.5-2% isofluorane; 1.0 L.min-1).  Body temperature was maintained at 37 ± 0.5°C using a 
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rectal thermocouple probe connected to a feedback control unit with heat-pad (Harvard 
Apparatus, U.K.).  Animals were positioned supine and sub-dermal needle electrodes 
(Grass Technologies, USA) were placed subcutaneously into the right forelimb (positive 
electrode), the left hind limb (negative electrode) and the right hind limb (ground 
electrode) to form a lead II configuration.  Recordings were filtered through a high-pass 
filter of 0.03 Hz and a low-pass filter of 2 kHz at a sampling rate of 2000 samples.s-1 and 
recorded for a 5-min period after allowing ~ 1 min for stabilisation of the signal.  Electrical 
interference was minimised by switching off any electrical items on the recording table 
that were not required and by ensuring the electrode wires were not in contact with each 
other.  ECG measurements were taken 10 min prior to the induction of MI, during CAL 
and 10 min after CAL (this was only performed for a cohort of MI procedures), and was 
also performed at 4-wk/8-wk time points post-MI prior to PV catheter measurements.   
2.4.3 Data analysis 
ECG data were acquired using an ETH-256C amplifier unit (iWorx, New Hampshire, 
USA).  Signals were recorded on to a Dell laptop using LabScribe2 software (iWorx, New 
Hampshire, USA) and analysed offline by counting the number of arrhythmic events that 
occurred in the 5 min recording period only (excluding the initial 1 min stabilisation 
period).  Arrhythmic events were defined as any abnormal beats outside the normal sinus 
rhythm.  These were always counted as single beats even when they occurred one after the 
other.  Tachycardic episodes where normal P-QRS-T beats were not clear were rare and if 
encountered the episode was counted as one arrhythmic event. 
2.5 Organ harvest and weighing 
The protocol used for harvesting organs was the same for mice and rats.  Animals were 
killed using a Schedule 1 method (cervical dislocation) and the following organs were 
harvested: heart, lungs, liver and, in some cases thymus (more details on the individual 
organs are detailed below).  All organs were weighed using a precision electronic balance 
(readability 0.00001g). 
2.5.1 Heart 
The heart was rapidly excised and washed in a beaker of ice-cold saline (0.9% NaCl).  
Excess tissue was trimmed off and the aorta was cut transversely, mounted on to a cannula 
attached to a syringe and perfused retrograde with ice-cold saline to rinse all blood out of 
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the coronary vessels.  The whole heart (which included intact ventricles, atria and major 
vessels) was then blotted dry on tissue paper, photographed and weighed.  Heart tissue was 
then either fixed in formalin for histological experiments or snap-frozen in liquid nitrogen 
and stored at -80°C until needed for biochemical experiments.  Hearts fixed in formalin 
included the whole heart (intact ventricles, atria and major vessels).  Heart tissue that was 
snap-frozen was either intact ventricular tissue only (atria and major vessels removed) or 
dissected regions (infarct, peri-infarct, remote LV and RV). 
2.5.2 Lungs and liver 
For lung and liver measurements, the entire organ (including all lobes) was removed, 
blotted dry and weighed but not stored for any further experiments.   
2.5.3 Thymus 
For thymus harvest, the entire thymus was removed and rinsed in saline to remove any 
blood and then either fixed in formalin or snap-frozen in liquid nitrogen and stored at -
80°C until required.   
2.5.4 Tibial length for normalisation of organ weights 
The length of the animal’s left tibia was measured for normalisation of organ weights; this 
was performed post-mortem by making an incision along the length of the left leg and 
dissecting the tibia from surrounding muscle.  Tibial length was defined as the distance 
from the medial condyle to the medial malleolus.  
2.6 Preparation of histological sections of the heart 
2.6.1 Mouse heart sections 
All histological sectioning and sectioning of mouse tissue was performed by Mrs Lynn 
Stevenson at the University of Glasgow.  Hearts were given a minimum fixation time of 24 
hr in 10% neutral buffered formalin (CellPath, U.K.) after which time they were embedded 
into a wax block until required for sectioning.  The heart was sliced parallel to the long 
axis of the heart every 250-300 µm using a microtome to produce serial sections 1µm thick 
per heart (this equated to approximately half of the heart as a whole being used).  At every 
250-300 µm interval, two adjacent sections were taken, one for each histological stain: (i) 
Haematoxylin and Eosin (H&E), a stain in which the haematoxylin component stains cell 
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nuclei blue and the eosin component stains all other eosinophilic structures (generally 
intracellular and extracellular structures) in pink/red and (ii) Sirius red, a collagen-specific 
dye that stains nuclei black, muscle and red blood cells yellow and collagen in red (Section 
2.7.1.2 for full descriptions).  At the mid-point depth of the heart (defined by the largest 
ventricular cavity size), two sections were taken for RUNX1 staining (positive and 
negative) (see Section 2.11). 
2.6.2 Rat heart sections 
Histological sectioning and staining for the rat tissue was performed by Mr Andy Carswell 
at the University of Glasgow.  Harvested rat hearts were fixed in 10% neutral buffered 
formalin (CellPath, U.K.) for a minimum of 24 h to allow sufficient penetration of the 
tissue.  Hearts were then paraffin-embedded and sectioned transversely at the LV apex 
using a microtome to produce 3 µm-thick sections.   
2.7 Staining of heart sections 
2.7.1 Mouse heart sections 
Cut sections of the heart were deparaffinised in a clearing agent which removes alcohol 
and makes the section hydrophobic (Citroclear; TSC Biosciences, U.K.) and rehydrated 
through decreasing concentrations of ethanol: 100% ethanol for 2 min, 70% ethanol for 1 
min followed by cold tap water for 1 min.  Sections were then treated either using one of 
the following protocols depending on the stain required:   
2.7.1.1 H&E staining 
For H&E staining, the principle is as follows: Haematin is a complex formed from 
aluminium ions and an oxidation product of haematoxylin.  In acidic conditions, haematin 
binds to lysine residues of nuclear histones via a metallic ion (aluminium) mordant.  The 
stain is usually applied for longer than necessary to ensure saturation of the chemical 
binding sites and this leads to an undesirable over-staining – the discoloration is selectively 
removed by controlled leaching in acidic alcohol termed ‘differentiation’ (NovaUltra 
guidelines).  The protocol therefore involved submerging the sections in Gill’s 
haematoxylin for 5 min (which stains all nuclei blue), washed in tap water, differentiated in 
1% acid alcohol, and rinsed again in water.  Sections were then immersed in Scott’s Tap 
Water Substitute (STWS; a blueing reagent) to arrest differentiation and turn the nuclei 
Kirsty K. Foote, 2012  Chapter 2  
106 
 
blue.  Normal tap water is not alkaline enough for this and is the reason for using STWS.  
This is followed by a 5 min treatment with Eosin to turn the eosinophilic structures shades 
of pink/red before a final wash in water. 
2.7.1.2 Sirius red staining 
For Sirius red staining, the principle is based on the affinity of the Sirius red dye with 
collagen fibrils.  Collagen has a high affinity for acid (anionic) dyes of large molecular size 
which can bind through electrostatic attraction via van der Waals forces (Lyon, 1991).  The 
protocol used was as follows: sections were submerged in Celestine blue (which stains 
nuclei) for 5 min, washed in tap water, placed in Gill’s haematoxylin for 5 min (also stains 
nuclei) and washed again with water.  The sections were placed in STWS (to arrest 
differentiation and turn the nuclei blue) followed by another wash in water before staining 
with Sirius red for 6 min (which stains collagen red/orange and muscle/cytoplasm yellow) 
and a final wash in water. 
After completion of one of the above protocols, the sections were dehydrated through 
increasing concentrations of alcohol (70% for 1 min, 100% for 2 min); this was to remove 
any residual water that could affect the clearing and mounting.  The sections were then 
cleared and mounted with dibutyl phthalate xylene (DPX) mounting medium which is a 
synthetic resin used to allow a coverslip to be attached to the section while preserving the 
stain. 
2.7.2 Rat heart sections 
For Sirius red staining, sections were deparaffinised using 2 x washes with a clearing agent 
(Histoclear, Fisher Scientific, U.K) followed by rehydration in 100% ethanol, 90% ethanol, 
70% ethanol then distilled water for 7 min in each solution.  Sections were then stained for 
1 h with Sirius red, followed by differentiation in 2 x washes of acid water (for 
differentiation) and 2 x washes of tap water for 5 min each.  Sections were then dehydrated 
through 70% ethanol, 90% ethanol, 100% ethanol and Histoclear (2 x washes) for 7 min 
each.  The dehydrated sections were then coverslip-mounted with a mounting agent 
(Histomount, Invitrogen, U.K.).  Rat tissue histology was performed in a different 
laboratory which is why some of the reagents were from different suppliers compared to 
the mouse tissue work; however the principles of the technique were the same. 
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2.8 Histological morphometry of the mouse heart 
For each mouse heart, at least five serial sections (taken from a depth of at least 250 µm 
into the heart; 250-300 µm apart) were examined for morphometric and infarct size 
measurements to ensure a range of depths through the heart were examined avoiding bias.  
All sections were examined with an Olympus BX51 microscope and images were captured 
with an Olympus DP71 camera with the use of Cell D (Olympus, Germany) software.  
H&E stained images were used to identify qualitative histopathologic features in 
myocardial tissue following MI. 
2.8.1 Infarct thickness 
Infarct wall thickness was measured using serial H&E sections of the heart as shown in 
Figure 2.13.  Infarct thickness was defined as the distance between the endocardium and 
epicardium of the infarcted myocardium indicated by the red area on the corresponding 
Sirius red image (or equivalent sham apex) disregarding any papillary muscles.  This was 
performed using a line drawn perpendicular to the curvature of the ventricular wall and the 
distance measured with ImageJ.  Measurements were calculated using at least 5 sections 
taken from middle of the heart 250-300 µm apart (each 1 µm thick) and averaging 3 
equally spaced measurements along the infarct wall (starting at the apex and taking one 
either side) in each slide to yield a final mean infarct thickness for each heart. 
2.8.2 LV chamber size 
LV chamber area was measured from the same H&E sections using ImageJ by tracing the 
area of the LV using the freehand tool as shown in Figure 2.13.  This was performed on all 
sections of the heart to yield a mean value for LV area per heart. 




Figure 2.13  Diagram showing how measurements of infarct thickness and LV area were measured. 
Infarct thickness was taken at three points along the infarcted region (or equivalent sham region) as indicated by the 
arrows.  LV area was measured by drawing around the circumference of the LV cavity and calculating the area enclosed 
within, as indicated by the dotted lines.  Both infarct thickness and LV area were measured using ImageJ software. 
2.8.3 Infarct size measurements 
Infarct size was measured on sections stained with Sirius red using a length-based 
approach similar to the method published by Takagawa et al. (2007).  Briefly, four lengths 
were measured from each heart section: epicardial infarct length, endocardial infarct 
length, epicardial remaining LV circumference and endocardial remaining LV 
circumference as shown in Figure 2.14.  The infarct included all infarcted myocardium 
which was >50% of the total thickness of the myocardium.  Epicardial and endocardial 
infarct ratios were then calculated by dividing the sum of epicardial or endocardial lengths 
from all sections by the sum of all epicardial or endocardial circumferences from all 
sections respectively.  Infarct size was then calculated using the following equation: 
100
2
(%) ×+= ratioinfarctENDOratioinfarctEPIsizeInfarct   Eq. 8 
 




Figure 2.14   Measurement of infarct size using Sirius red sections of the heart. 
Four lengths were traced: epicardial infarct length (dark blue), endocardial infarct length (dark green), epicardial 
remaining LV circumference (light blue) and endocardial remaining LV circumference (light green).  These were used 
from all sections of the same heart to calculate the endocardial infarct ratio and epicardial infarct ratio (equations for each 
shown).  Infarct size was then calculated using the formula shown above. 
2.9 Collagen quantification 
Sections of the heart stained with Sirius red, either longitudinal whole heart sections 
(mouse) or transverse apical LV sections (rat) were examined and photographed under x 
10 magnification using an Olympus Bx40 microscope with a camera (3.3 RTV, QImaging, 
Canada) and associated software (QCapture, QImaging, Canada).  Images were analysed 
using ImageProPlus (Media Cybernetics, USA) software.   
2.9.1 Collagen quantification in rat hearts (perivascular vs. 
interstitial fibrosis) 
For the congenic rat model study, a square of fixed area (300 x 300 pixels which was 
equivalent to 102 µm2) was drawn and positioned over an area of interest (see below) and 
the number of red pixels, defined by a set colour threshold, was measured within this 
square by the software (Figure 2.15).  The amount of red staining inside this square could 
then be expressed as a percentage of the total pixels contained within the square (300 x 300 
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= 90,000).  Four areas were taken for each rat section (1 perivascular, 3 interstitial 
regions).  The square was placed either over a blood vessel or an area of interstitum 
adjacent to a blood vessel to assess differences in perivascular and interstitial cardiac 
fibrosis, respectively.  Perivascular fibrosis was assessed in at least 5 randomly selected 
vessels per heart.  Blood vessels with comparable lumen size were selected for as much as 
possible and only vessels which could fit into the box were used and only vessels which 
were ~<50% the size of the box  were used.  Interstitial fibrosis was measured in areas 
adjacent to the blood vessels; three separate adjacent areas to each blood vessel were used 
for this and a mean value taken.  Interstitial areas contained no obvious blood vessels or 
other structures.  All perivascular and interstitial measurements were then averaged to give 
a mean value of perivascular and interstitial fibrosis for each heart.  
 
Figure 2.15  Diagram showing how perivascular and interstitial fibrosis was measured in the rat hearts using 
ImageProPlus. 
(A) A box of fixed area (300 x 300 pixels or 100 µm2) was drawn around a blood vessel and three separate adjacent 
interstitial areas for each image.  Five different areas of each LV were performed like this. (B) Red pixels of a set 
threshold were selected to measure collagen-positive red areas.  Positive collagen area was expressed as the percentage of 
red pixels to total pixels (90,000) as defined by the fixed area box. 
2.9.2 Collagen quantification in mouse hearts 
For mouse (MI) model studies, the total number of red pixels in each heart was expressed 
as a percentage of the total pixels to measure the percentage of red-staining in each heart. 
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2.10   Mouse cardiomyocyte isolation 
2.10.1    Mouse cardiomyocyte isolation protocol 
Mice were killed by a Schedule 1 method (cervical dislocation) and then placed in a dorsal 
position with the arms and legs taped down.  The chest cavity was opened and the heart 
rapidly excised and immersed in ice-cold cell isolation buffer.  Cell isolation buffer was a 
Krebs-Henseleit (KH) solution containing the following (in mM): NaCl (130), HEPES 
(25), KCl (5.4), NaH2PO4 (0.33), MgCl26H2O (0.5) and glucose (22).  Using a dissection 
microscope, the ascending aorta was cleared of surrounding tissue and cut transversely 
(below the level of the branches), positioned on to the cannula (attached to the perfusion 
apparatus; Figure 2.16A) and secured with a silk suture (6-0).  Once the heart was secured, 
the perfusion was started and the cannula was moved to a vertical position held by a 
helping-hand device (Maplin Electronics, U.K.) (Figure 2.16B).  All perfusion solutions 
were maintained at 37°C through a heated water bath and water-jacketed perfusion system.  
The heart was initially perfused with KH solution for 2-3 min to remove all of the blood 
and then switched to KH solution containing 0.7 mg.ml-1 collagenase (type I, Worthington 
Chemicals, New Jersey, USA) and 0.07 mg.ml-1 protease (type XIV, Sigma Aldrich, U.K.) 
for 7 min at a flow rate of 4 ml.min-1.  After this time, the heart was then perfused with KH 
containing 0.7% bovine serum albumin (BSA; Sigma Aldrich, U.K.) for 6 min.  The heart 
was then cut down from the cannula and the atria and RV were removed.  The LV was cut 
into small pieces in KH with 0.7% BSA solution and gently triturated with a plastic 
transfer pastette with a large smoothed opening to minimise mechanical tearing during 
cardiomyocyte dissociation.  The cells were sedimented by gentle centrifugation and 
resupended in fresh BSA; this was repeated for a further time before finally pooling the 
two tubes of cells together.  The two tubes each contained a suspension of isolated 
cardiomyocytes; one containing the cells from the first trituration and the other from the 
second.  Ca2+ was added gradually and incrementally (by adding 0.1 mM of CaCl2 every 
10 min) to the cells until the final concentration reached 1 mM.   




Figure 2.16  Apparatus for mouse ventricular cardiomyocyte isolation. 
(A)  Experimental set-up and (B) cannula showing mouse heart cannulated during digestion. 
2.10.2 Measurements of cardiomyocyte length, width and cross-
sectional area 
Isolated cardiomyocytes were viewed using a microscope (x 20 magnification; Nikon 
Eclipse TE2000-S) and captured using a camera (Rolera-XR, QImaging, Canada) and 
associated software (QCapturePro, QImaging, Canada).  Cardiomyocyte length and width 
was measured by drawing a line end-to-end and measuring the distance using ImageJ 
software as illustrated in Figure 2.17.  Measurements were calibrated using a stage 
micrometer used at the same magnification.  Cardiomyocyte cross-sectional area was 










widthcellAreasectionalCross pi    Eq. 9 
 
Figure 2.17  Diagram showing how cardiomyocyte width and length were measured. 
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2.10.3 Filtration of cardiomyocytes to remove other cell types 
The filtration approach was based on a published method (Kosloski et al., 2009).  Isolated 
cells were kept on ice while a second cell isolation from a different heart using the same 
isolation protocol was performed.  The cells from the two hearts were then pooled to yield 
sufficient RNA for subsequent experiments.  All of the following steps were performed on 
ice to minimise RNA degradation.   
• A sample of the pooled cells was taken as a pre-filtration control (2 ml) and was lysed 
in Qiazol lysis buffer (Qiagen, U.K.) and stored at -80°C until required.  The remaining 
suspension (~ 8 ml) was poured through a 300 µm nylon mesh filter to separate large 
fragments of tissue from the cells.  5-10 ml ice-cold Hank’s Buffered Saline Solution 
was then poured through the filter to wash any trapped cells through the filter (HBSS; 
Invitrogen, U.K.).  The composition of HBSS was as follows (in mM): KCl (5.33), 
KH2PO4 (0.441), NaHCO3 (4.17), NaCl (137.93), Na2HPO4 (0.338) and glucose (5.56).   
• The filtrate was spun, supernatant removed, and resuspended in HBSS and then passed 
through a second filter mesh (40 µm).  Based on this method, cardiomyocytes were 
caught on this filter and the contents of the filter were rinsed off into a separate tube 
with ice-cold HBSS, spun and lysed in Qiazol lysis buffer and stored at -80°C until 
required as the purified cardiomyocyte sample.   
• The study on which this filtration method is based (Kosloski et al., 2009) recommends 
the use of RNAlater, a stabilising agent which permeates cells to protect RNA from 
degradation, for subsequent use of the cells in gene expression studies.  However they 
have used RNAlater as a tissue storage medium for their biopsy samples prior to the 
isolation of the cells; whereas in our study the heart was not stored prior to the 
dissociation of the cells (i.e. hearts were harvested fresh from the animal).  RNAlater 
was used initially to store the newly isolated cells based on Kosloski et al.’s paper 
which found that RNAlater significantly enhanced RNA yields; however the RNAlater 
solution was found to cause the cardiomyocytes to ‘clump’ together and due to the 
density of the solution this required higher force centrifugation to pellet the cells which 
causing greater loss of cells through mechanical damage.  Therefore RNAlater was no 
longer used; instead cells were continually kept on ice, rapidly lysed and stored at -
80°C which was sufficient to protect the RNA as was shown by comparable yields and 
quality as determined by the use of a NanoDrop spectrophotometer and Agilent 
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Bioanalyser technologies, both of which are covered in more detail in the later sections 
of this chapter (Section 2.12.2). 
2.11 Immunohistochemistry 
2.11.1 Staining protocol 
IHC refers to the process of detecting antigens (protein of interest) through the binding of 
antibodies.  A common approach to visualising this antibody-antigen interaction is using 
an antibody which is conjugated to an enzyme that catalyses a colour-producing reaction.  
This process typically utilises two antibodies, a primary and secondary antibody, which are 
added in a step-wise fashion.  The primary antibody is typically unlabelled (does not 
contain any conjugate molecules attached) and has been raised specifically against the 
antigen of interest.  The secondary antibody binds to immunoglobulins of the primary 
antibody and is conjugated to a reporter enzyme (e.g. peroxidase) which, in the presence of 
a chromogenic substrate, catalyses a colour-producing reaction to indicate the presence of 
the antigen.  A common reporter enzyme/chromogen combination is the horseradish 
peroxidase (HRP) enzyme with the chromogen 3,3’-diaminobenzidine tetrahydrochloride 
(DAB).  In the presence of HRP, DAB produces a brown precipitate which is insoluble in 
alcohol.  The overall process can therefore be summarised in three steps: (i) application of 
a primary antibody; (ii) application of a HRP-labelled secondary antibody and (iii) 
application of DAB to produce the brown colour (Figure 2.18).  Prior to this 3-step process 
the tissue often needs specific preparatory steps: these include antigen retrieval and 
blocking of endogenous peroxidase activity.  Antigen retrieval is necessary to expose the 
epitopes of the antigen which may have become obscured during the fixation process; this 
is usually performed by heating which breaks the protein cross-links formed by formalin 
thereby uncovering epitopes.  Blocking of endogenous peroxidase is necessary when using 
DAB which could react non-specifically and lead to background staining; therefore it is 
normal procedure to treat the samples with a blocking agent (commonly hydrogen 
peroxide) to block endogenous peroxidase activity.   




Figure 2.18  Schematic representation of the principle of IHC staining. 
Sequential binding of primary antibody to antigen (A) followed by an enzyme-labelled secondary antibody.  HRP 
catalyses the conversion of the chromogen DAB into a brown coloured precipitate.  A; antigen. HRP; horseradish 
peroxidase. DAB; 3,3’ diaminobenzidine tetrahydrochloride.  Diagram adapted from Leinco Technologies Inc. 
All IHC was performed by Mrs Lynn Stevenson at the University of Glasgow.  Sections 
were cut, dewaxed and rehydrated as described in the previous sections (Section 2.6.1 and 
2.7.1).  The buffer used for washing sections between applications was tris-buffered saline 
(TBS) with 0.05% Tween at pH 7.5 and is used as it lowers surface tension allowing more 
complete coverage of the reagents applied.  Sections were rinsed with buffer and incubated 
in a pressure cooker for 1 min 40 s at 125°C for antigen retrieval.  Sections were loaded 
into an autostainer machine (Dako, Glastrup, Denmark) and the following steps were 
performed by the machine all at room temperature: 1 x buffer rinse, treatment with 
peroxidase blocking reagent (Dako, Glostrup, Denmark) for 5 min followed by 3 x 5 min 
buffer rinses.  Sections were then incubated for 60 min with the primary antibody (rabbit 
polyclonal 1:400, ab61753 or ab35962; Abcam, U.K.) for RUNX1 or with antibody 
dilution buffer (negative control) followed by 2 x 5 min buffer washes.  The primary 
antibody was then labelled with a secondary antibody (anti-rabbit) attached to an HRP 
conjugate (Dako EnVision system, Dako, Denmark) for 30 min.  After 2 x 5 min further 
buffer washes, the sections were treated with 2 x 5 min incubations with the chromogen 
DAB (K5007 Dako, Denmark).  After 3 washes in water, counterstaining was performed 
using Gill’s haematoxylin for 26 s followed by one last wash with water – counterstaining 
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provides contrast to aid visualisation of the primary stain.  Sections were then dehydrated 
and mounted using DPX mounting medium.   
2.11.2 Quantification of IHC staining 
Positive RUNX1 staining was quantified by counting positively-stained nuclei (brown) as 
a percentage of the total nuclei within fields at different regions of the heart.  Sections were 
examined under a microscope (x60 lens; Olympus Bx51) and photographed using a camera 
(Olympus DP71) with accompanying software (Cell D).  Images were imported into 
ImageJ and a grid (5 boxes long x 4 boxes wide) was fitted over the full size of the image 
to facilitate nuclear counting.  Three photographs were taken from each region of the heart 
(infarct, peri-infarct, remote LV and RV) resulting in 12 in total per heart.  The total 
number of positively-stained nuclei (brown coloured) and negatively-stained nuclei (blue 
coloured) were counted in each region and the percentage positive staining was calculated 
using the following equation:              











As the different cell types present were not specifically labelled with markers, no 
discrimination was made to exclude positive nuclei from any cell type.  Positive staining 
included any nucleus which was predominantly brown.  Where it looked like there may be 
two overlapping nuclei, this was counted as one only.  This was repeated for three areas 
per region and a mean value taken.   
2.12   RNA extraction, cDNA synthesis and qRT-PCR 
2.12.1 Gene expression based on quantification of messenger 
RNA levels 
The level at which a particular gene is expressed in a given tissue can be measured by 
quantifying that gene’s messenger RNA (mRNA) levels.  An mRNA molecule contains the 
sequence of a particular gene (or the ‘blueprint’) which will later be translated into a 
protein.  A cell’s total mRNA therefore contains all the mRNA from all the genes which 
are actively being transcribed in that particular cell.  By isolating the total mRNA from a 
tissue sample and then selecting the mRNA for a particular gene only, the levels of mRNA 
can be quantified and the amount of gene expressed in that sample determined.  This is 
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achieved by the technique of qRT-PCR.  If a gene is expressed at higher levels, there will 
be a greater abundance of mRNA for that gene, therefore a greater number of cDNA 
molecules which will be detected quicker during the qRT-PCR reaction.  As RNA cannot 
serve as a template for qRT-PCR it must be synthesised into double-stranded 
complementary DNA (cDNA) by a method called reverse transcription (RT).  Therefore 
the entire process from the biological sample to gene expression data consists of three main 
stages: (i) extraction of RNA from the biological sample, (ii) synthesis of cDNA from the 
RNA template, and (iii) qRT-PCR using the cDNA.  Each of these steps will be described 
in turn and for each, the principle behind the technique will be described followed by the 
laboratory protocol used for each.   
2.12.2 RNA extraction 
2.12.2.1 Principle of the procedure of RNA extraction 
RNA extraction is the isolation and purification of RNA from biological samples.  One of 
the most common ways to do this is using a guanidine thiocyanate/phenol/chloroform 
extraction method.  Cells or tissue are homogenised in a lysis buffer containing guanidine 
thiocyanate which dissolves cells membranes releasing the cellular contents into the lysate.  
After lysis, a phenol/chloroform extraction is performed on the lysate.  The lysis buffer 
contains phenol and when chloroform is added these solvents separate into two phases by 
centrifugation: a clear upper aqueous phase (chloroform) and a bright pink lower organic 
phase (phenol).  RNA partitions to the upper phase, DNA to the interphase and proteins to 
the lower phase.  The upper phase (containing the RNA) can then be collected with a 
pipette and added to a spin column for purification.  A spin column is a small plastic 
capped tube similar to an eppendorff containing a silica membrane to which the RNA 
binds while other substances can be washed away thus permitting the purification of the 
RNA.  Ethanol is added to provide appropriate binding conditions for the RNA to bind to 
the membrane of the column followed by various wash buffers designed to support binding 
of the RNA and wash away any contaminants (such as phenol or proteins).  Finally, the 
RNA is eluted (released) from the membrane by addition of water which neutralises the pH 
and reduces the affinity for RNA-binding to the membrane.  The purified RNA can then be 
collected and used for downstream reactions. 
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2.12.2.2 Full procedure for RNA extraction 
The RNA extraction procedure was the same for mouse and rat tissue.  RNA extraction is 
complicated by the ubiquitous presence of ribonuclease enzymes (RNases) which are 
naturally present on the skin of users and can also be present on laboratory benches and 
glassware.  RNases can rapidly degrade RNA if appropriate laboratory practice is not 
adopted throughout the RNA extraction procedure.  Therefore for all RNA work, gloves 
were worn at all times, the bench was cleaned with a spray that eliminates RNases 
(RNAZap, Ambion, U.K.) and RNase/DNase-free tubes and pipette tips were used 
throughout to minimise degradation of RNA.  Total RNA was extracted from frozen heart 
tissue using the miRNeasy Mini Kit (Qiagen, U.K) according to the protocol included with 
the kit.  This kit contains the necessary reagents for the full extraction protocol: lysis 
buffer, two wash buffers (Buffer RWT and Buffer RPE), RNase-free water and spin-
columns.  The exact composition of buffers RWT and RPE are protected by the supplier 
(Qiagen) but they both contain high concentrations of ethanol and guanidine thiocyanate to 
facilitate binding of RNA to the silica membrane and remove traces of proteins and organic 
salts, respectively.  Chloroform was not supplied by the kit and was acquired separately 
(Fisher Scientific, U.K.).  The full protocol was as follows: 
• The tissue was weighed and then homogenised in 700 µl of lysis buffer provided by 
the kit through high-speed shaking (TissueLyser, Qiagen, U.K.) with steel beads 
(supplied ready-made by Qiagen, U.K.).  Homogenisation was performed in 30s 
intervals and checked after each shake to assess level of tissue breakdown and 
minimise over- homogenisation.  Homogenisation was deemed complete when no 
solid tissue pieces remained (this usually took < 5 min).   
• The steel bead was removed and the samples were treated with 140 µl chloroform 
(Fisher Scientific, U.K.) and spun at 4°C for 15 min using a temperature-controlled 
centrifuge (Model 5415R, Lab Mark, Czech Republic) for phase separation.  After this 
time, the uppermost layer containing RNA was collected with a pipette into a separate 
tube, leaving DNA (middle layer) and proteins (bottom layer) behind.   
• RNA was then treated with ethanol and applied to a spin column where the ethanol 
facilitates binding of the RNA to the silica membrane of the column.  The spin column 
was then treated with washing buffers (buffer RWT and buffer RPE) to remove any 
contaminants (e.g. proteins or organic salts) followed by a 15-min on-column digestion 
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with DNase (DNase I, Qiagen, U.K.) (i.e. DNase is added directly to the silica 
membrane of the column) to remove any accidental carry-over of genomic DNA.   
• RNA was then eluted in RNase-free water – this means that the RNA is lifted from the 
silica membrane by the water which raises the pH to >8.5 increasing the charge on the 
surface of the membrane reducing the affinity for RNA-binding which means it can be 
collected in the water that passes through the membrane.  The RNA extracted at this 
stage represents the total RNA (including all mRNA from all different genes) that was 
present in the tissue sample.   
Once the RNA has been extracted, there are three quality control checks to be performed 
which are recommended at this stage prior to further use in downstream reactions.  These 
include assessment of (i) RNA quantity (yield), (ii) RNA purity and (iii) RNA integrity.  
These factors are important because cDNA synthesis requires a minimum template amount 
(yield is important), any chemical impurities can adversely affect the reverse transcriptase 
enzyme (purity is important) and degraded RNA can lead to shorter cDNA fragments 
which could underestimate the results (integrity is important).   
(i)-(ii)  The quantity and purity of the RNA were measured using a Nanodrop ND-1000 
Spectrophotometer (Nanodrop Technologies/Thermo Scientific, U.K.).  The Nanodrop 
ND-1000 is a spectrophotometer which measures the absorbance of light between 220-320 
nm of a sample of nucleic acid - the absorbance is linearly proportional to the 
concentration of molecules within the sample and can be used to quantify the 
concentration of nucleic acid in a sample based on this (Beer-Lambert law).  The machine 
requires only a small amount of sample (0.5-1 µl) which is pipetted on to a measurement 
pedestal.  An ‘arm’ is closed down on to the pedestal and a liquid sample column is 
formed between the two surfaces through which UV light can be passed and the 
absorbance measured.  RNA absorbs light maximally at 260 nm and the absorbance ratios 
260/280 nm and 260/230 nm provide information on the purity of the RNA sample.  Pure 
RNA will have a 260/280 ratio of 1.9-2.1 (<1.9 indicates protein contamination) and a 
260/230 ratio of 1.8-2.3 (<1.8 indicates organic contamination by phenol).  
(iii)  RNA integrity was determined using the Agilent Bioanalyzer 2100 (Agilent 
Technologies, U.K.); this step was performed by Julie Galbraith or Jing Wang at the 
Functional Genomics Centre at the University of Glasgow.  This method is based on 
capillary electrophoresis with a fluorescent dye that binds to RNA.  Capillary 
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electrophoresis of a (total) RNA sample shows two distinct peaks corresponding to the two 
ribosomal RNA (rRNA) species in the sample: 18S and 28S and in a sample with low 
degradation the baseline between the peaks should be relatively flat (Figure 2.19).   
How the Agilent Bioanalyzer 2100 works:  The machine uses a chip which contains wells 
for the samples with micro-channels between the wells.  The chip is prepared by filling the 
micro-channels with a sieving polymer matrix gel and a fluorescence dye and the samples 
of RNA are then loaded into the wells along with a size ladder.  Once the micro-channels 
and wells are filled, a 16-electrode pin cartridge fits into the wells of the chip and the 
charged molecules of RNA are driven by the voltage gradient, separated according to size 
with smaller fragments migrating further than larger ones.  The dye molecules intercalate 
into the RNA strands which allows them to be visualised by laser-induced fluorescence.  
The result is visualised as an electropherogram where the amount of fluorescence is 
proportional to the amount of RNA at a given size.  An algorithm known as the RNA 
Integrity Number (RIN) has been developed to indicate the integrity of the RNA sample 
based on 8 different features of the electrophoretic output trace (total 28S/18S ratio, 28S 
peak height, area under 28S peak, 18S and 28S area compared to area of the fast region, 
linear regression of end-point of fast area, number of detectable fragments in fast region, 
presence or absence of 18S peak and relation of the overall mean to the median) 
(Schroeder et al., 2006).  Based on these criteria, computer software calculates the RIN 
number on a scale from 1-10 by order of increasing RNA integrity (1-badly degraded; 10-
highly intact).  It is generally accepted that samples with a RIN >5 (but preferably >8) are 
suitable for qRT-PCR experiments (Fleige & Pfaffl, 2006) although this is largely 
dependent on the individual study.  For this thesis, only RNA that met the following 
criteria were used (A260/A280 > 1.8 and RIN>7). 




Figure 2.19  Example electrophoresis output traces from the Agilent Bioanalyzer showing analysis of RNA 
integrity. 
(A) Good quality RNA is visible with two prominent 18S and 28S peaks with a 28S/18S ratio of ~2 and a flat baseline – 
RIN value of 9.8. (B) Example where RNA degradation is visible as a decrease in the 18S and 28S peaks with an increase 
in smaller degradation fragments resulting in a noisier baseline – RIN value of 5.1.  Figure courtesy of Agilent 
Technologies. 
2.12.3 Synthesis of cDNA 
2.12.3.1 Principle of procedure of cDNA synthesis 
RNA is not a suitable template for a qRT-PCR experiment which requires double-stranded 
DNA to work therefore the RNA must be transcribed into cDNA.  This is performed by the 
process of reverse transcription in which single-stranded mRNA is transcribed into double-
stranded DNA (i.e. the reverse to the normal transcription process in which DNA is 
transcribed to mRNA) as depicted in Figure 2.20.  This is performed using oligonucleotide 
primers of poly-thymine (oligo-dT primers) that specifically bind to the poly-A tail of all 
mRNAs and direct the enzyme reverse transcriptase (RNA-dependent) to synthesise a new 
strand using dNTPs (A, T, C and G).  This forms an mRNA:DNA hybrid (one strand is the 
mRNA and the other the newly synthesised cDNA strand) for all the mRNAs in the 
sample.  In order to synthesise a new cDNA strand to replace the mRNA strand, the 
mRNA must be digested with an enzyme, usually RNase H.  Once the mRNA strand is 
digested, the single-stranded cDNA forms a hairpin loop on itself due to its hydrophobic 
nature and this serves as the ‘primer’ to direct synthesis of the complementary new strand 
of cDNA by a DNA-dependent DNA polymerase.  The result is double-stranded cDNA 
derived from the original template mRNA sequence.  




Figure 2.20  cDNA synthesis by reverse transcription. 
 
2.12.3.2 Full protocol for cDNA synthesis 
As was the case with the RNA extraction protocol, the cDNA synthesis protocol was the 
same for mouse and rat samples.  Prior to the synthesis of cDNA, the RNA was given a 
second treatment of DNase to ensure complete removal of contaminating genomic DNA; 
this was done by incubating the RNA with a different DNase I (Turbo DNA-free, Ambion, 
U.K.) for 25 min at 37°C.  After this time a DNase-inhibitor was added to inactivate the 
DNase enzyme (DNase Inactivation Reagent provided with Turbo DNA-free kit, Ambion, 
U.K.).  First strand cDNA was synthesised from 1 µg RNA (measured by the Nanodrop 
Spectrophotometer as previously described) by reverse transcription using the Omniscript 
Reverse Transcription kit (Qiagen, U.K.).  This kit contains the reagents necessary for the 
protocol including the reverse transcriptase enzyme (catalyses synthesis of cDNA strands 
and degrades RNA in RNA:cDNA hybrids), dNTPs (‘building blocks’ for the new cDNA 
strands), buffer RT (contains Mg2+ for optimal reverse transcriptase activity) and 
RNase/DNase free water for dilutions or as a substitution for the reverse transcriptase 
enzyme in control reactions.  The Omniscript reverse transcriptase enzyme contains three 
distinct enzymatic functions: (i) RNA-dependent reverse transcription (catalyse the 
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synthesis of cDNA from an RNA template), (ii) DNA-dependent reverse transcription 
(catalyse the synthesis of cDNA from a cDNA template) and (iii) RNase H (degradation of 
RNA in RNA:cDNA hybrids only).  Additional reagents that were not provided in this kit 
but were necessary for the reaction were oligo-dT primers (Qiagen, U.K.) and an RNase 
inhibitor (RNase-Out, Invitrogen, U.K.) for removal of contaminating RNases (this does 
not affect the RNase activity of the Omniscript reverse transcriptase enzyme).  The final 
composition of the reaction is shown in Table 2.3 to give a final volume of 50 µl and the 
reaction was performed in an incubator at 37°C for 1 h.  Reactions containing 
RNase/DNase-free water instead of reverse transcriptase enzyme served as negative RT 
controls (denoted RT-).  The resulting cDNA produced at this stage contains all the cDNA 
of all the genes that were present in the original tissue sample, transcribed from all the 
mRNAs in the sample.  The cDNA corresponding to the gene of interest (e.g. Runx or 
Gapdh) is selectively amplified in the final stage using gene-specific primers by qRT-PCR 
allowing quantification of the expression of the gene of interest. 
Table 2.3  Reverse transcription reaction components. 
Component Volume (per reaction) Final concentration 
Master mix   
10x Buffer RT 5 µl 1x 
dNTP mix (5 mM each 5 µl 0.5 mM each dNTP 
Oligo-dT primer (10 mM) 5 µl 1 µM 
RNase inhibitor (10 units/ul) 2.5 µl 25 units (per 50 µl reaction) 
Reverse transcriptase 2.5 µl 10 units (per 50 µl reaction) 
RNase-free water Variable* - 
   
RNA Variable* 1 µg 
Total Volume 50 µl - 
* Variable depending on available RNA concentration.  Final volume is made up with 
RNase/DNase-free water. 
2.12.4 Verification of cDNA synthesis 
Prior to qRT-PCR, newly synthesised cDNA (including RT- controls) were tested for the 
presence of double-stranded DNA to verify successful reverse transcription.  This was 
done using conventional PCR amplification.  Conventional PCR amplification is based on 
the same principle of exponential amplification by the three-step process of denaturing, 
primer annealing, and strand extension as previously described.  It differs from qRT-PCR 
in that the reactions do not contain any fluorescence labelling therefore the product is not 
detected as it accumulates but rather at the end-stage post-amplification by agarose gel 
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electrophoresis.  Conventional PCR was sufficient for this stage in verifying presence of 
cDNA.  The protocol for this was as follows:   
Conventional PCR:  For these experiments the PCR was run beyond 27 cycles to ensure 
the product is collected from the plateau phase (maximum accumulated product).  PCR 
reactions were conducted in 10 µl final volume containing 0.5 µl cDNA, 1 µl PCR custom-
made master mix (Thermo Scientific, U.K.), 2 µl primers (10 µM) for Runx1 (rat-specific 
or mouse-specific as appropriate; Quantitect, Qiagen, USA) or glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) (Eurofins MWG Operon, Germany) and 0.1 µl Taq DNA 
polymerase (Thermo Scientific, U.K.).  A layer of oil was placed on the top of the reaction 
mix to avoid loss of solution by evaporation in the machine.  Reactions were performed 
using a Stratagene RoboCycler PCR machine (which provided cyclic heating conditions) 
for either 30 cycles (Gapdh) or 40 cycles (Runx1) to ensure analysis was taken from the 
plateau phase of the reaction (Figure 2.23).  Each cycle was 50s at 95°C, 50s at 55°C and 1 
min at 65°C.  Amplified PCR products were then visualised by gel electrophoresis.   
Gel electrophoresis:  Gel electrophoresis can be used to separate DNA fragments by size 
and charge.  DNA from the PCR reaction can be loaded into wells of an agarose gel and by 
application of an electric field, the negatively-charged DNA moves through the agarose 
matrix towards the positive electrode with shorter fragments migrating further than longer 
fragments.  The gel is treated with a fluorescent dye called ethidium bromide which allows 
the final bands on the gel to be visualised under UV light.   
Preparation of the gel:  A 2% agarose gel was prepared fresh using powdered agarose 
(NuSieve; Fisher Scientific, U.K.) dissolved in 0.5x Tris/Borate/EDTA (TBE) buffer in a 
final volume of 250 ml and heating in a standard microwave for approximately 2.5 min.  
The composition of TBE buffer for a 0.5x stock was (in mM): Tris (44.5), boric acid (44.5) 
and EDTA (1.0).  Once the agarose was completely dissolved the liquid gel was cooled 
prior to pouring to prevent damage to the plastic gel tray (to approximately below 60°C) by 
holding the bottle containing the gel under cold running tap water for 5 min.  After this 
time, 10mg/ml EtBr (Invitrogen, U.K.) was added to the liquid gel, swirled to mix, and the 
gel was then poured into a Perspex gel tray and left for 30 min to set with gel combs in 
place to create the wells.  Once the gel was set, the gel combs were removed and the gel 
was placed into a gel tank with 0.5x TBE buffer.   
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Loading and running the gel:  3 µl PCR product (final amplified cDNA) was mixed with 2 
µl loading dye and added to each well.  Loading dye (6x; Promega, U.K.) contains 
bromophenol blue dye (which allows coloured visualisation of the gel electrophoresis 
progress) and Ficoll, a high molecular weight (MW) polysaccharide (which increases the 
density of the sample to a level greater than the surrounding TBE buffer to ensure it falls to 
the bottom of the well).  A 100 bp DNA size ladder (5 µl) was run alongside each run 
(Promega, U.K.) to allow size comparisons of the fragments to be made.  The gel 
electrophoresis was run for 30 min at 160V.  Successful RT reactions were confirmed by 
positive single bands of correct size for RT+ samples (120 bp for Runx1 and 140 bp for 
Gapdh) and no band in RT-  control samples (RT negative reaction - water instead of RT 
enzyme) (Figure 2.21). 
 
Figure 2.21  Example gels from DNA gel electrophoresis to verify reverse transcription and appropriate size 
products. 
(A) Samples of cDNA from positive (+) and negative (-) reverse transcription reactions amplified with conventional PCR 
using Gapdh primers.  Positive samples show a single, distinct band of appropriate length (140 bp) with no bands present 
in negative control reactions.  (B) Samples of cDNA from positive (+) samples only to verify a single, distinct band of 
appropriate size for Runx1 amplicons (120 bp). Primers for Gapdh were used to confirm positive and negative samples 
(Runx1 primers were used when confirming amplicon length for Runx1).  
2.12.5 qRT-PCR 
2.12.5.1 Principle of PCR 
The principle of PCR (both qRT-PCR and conventional PCR) is based on the amplification 
or replication of DNA (derived from the mRNA) to produce more DNA.  This involves 
first denaturing double-stranded DNA by applying a high temperature (~90-98°C) which 
separates the DNA into two single strands.  Short DNA sequences known as primers which 
have been selected to flank the DNA sequence of interest can then anneal to the single 
strands when the temperature is reduced to 50-65°C.  At a slightly higher temperature of 
72-80°C an enzyme known as DNA polymerase begins synthesising two new strands 
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which are complementary to the template strands by incorporating nucleotide bases 
(adenine, thymine, cytosine and guanine) provided in the reaction (this process is directed 
by the primers which indicate the start site).  This results in two new strands and doubling 
of the original DNA (1 copy to 2 copies of DNA).  This represents two new templates for 
the next cycle in which these three main temperature-dependent steps are repeated again.  
The entire process is continually repeated in cycles to produce exponential doubling of 
DNA at each cycle for the sequence of interest.  PCR reactions take place in plastic tubes 
within a thermal cycler machine and require the following components: 
Component Function 
Master-mix: 




Provide energy and nucleotides for the synthesis of 
DNA.  Each nucleotide base must be added in equal 
concentration to avoid mismatch of bases. 
Primers specific to gene of 
interest 
Short pieces of DNA (20-30 bp) that bind to the DNA 
allowing the polymerase enzyme to initiate the 
incorporation of dNTPs. 
Polymerase A heat-stable enzyme that adds dNTPs to the DNA 
template strand. 
DNA sample: 
Template DNA Sample of DNA to be amplified by the PCR reaction. 
 
The PCR process:  PCR usually consists of 20-40 repeated cycles with each cycle made 
up of a defined series of temperature steps depending on the activity of the DNA 
polymerase, the concentration of dNTPs and divalent cations, and the melting temperature 
of the primers, as outlined below and summarised in Figure 2.22: 
(1) Initiation: This step involves heating the reaction to 94-98°C and held for 1-9 min 
and is only required if the DNA polymerase requires ‘heat-start’ activation. 
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(2) Denaturation: The reaction is then heated to 94-98°C for 20-60s which disrupts 
the hydrogen bonds between the complementary bases which hold the two DNA 
strands together, therefore causing the two strands to separate (or ‘melt’). 
(3) Annealing: The reaction is lowered to 50-65°C for 20-60s which allows the 
primers to anneal to the single-stranded DNA template.  DNA polymerase then 
binds to the primer-template hybrid. 
(4) Elongation (extension): The reaction is then heated to 72-80°C which is the 
optimum temperature for DNA polymerase (a temperature of 72°C is used for Taq 
polymerase).  The DNA polymerase synthesises a new strand by adding dNTPs to 
the template strand in the 5’ to 3’ direction.  Under optimal conditions the amount 
of target DNA doubles at each extension step.  
(5) Final elongation: A single step may be performed after the last cycle to ensure any 
remaining single-stranded DNA is fully extended.  This step usually involves 
heating to 70-74°C for 5-15 min. 
(6) Final hold: The final step can be applied for an indefinite time at 4-15°C which 
holds the reaction until the user is ready to collect it from the machine. 




Figure 2.22  Schematic representation of the PCR process.  
(1) Denaturation at 94-98°C (2) Annealing at 50-65°C (3) Elongation at 72-80°C.  Three cycles are shown.  Blue lines 
represent the DNA template to which primers (red lines) anneal and are extended by DNA polymerase (green circle) to 
produce shorter DNA products (green lines) which are then used as templates as the PCR progresses. 
Stages of a PCR reaction:  The complete PCR process can be divided into three main 
phases; (1) exponential phase, during which there is exact doubling of the product after 
each cycle; (2) linear phase, during which the reaction components are being consumed 
and the reaction is slowing; and (3) plateau phase, during which the reaction components 
have been exhausted and no more product is being made (Figure 2.23).  




Figure 2.23  Phases of a conventional PCR reaction. 
 
Conventional vs. quantitative qRT-PCR:  Conventional PCR uses agarose gel with 
ethidium bromide for detection of PCR product (which is the amplified DNA) at the final 
phase or end-point of the reaction as described previously in Section 2.12.4.  Conventional 
PCR is sufficient for simply detecting the presence of double-stranded cDNA to verify 
appropriate RT as described; however for gene expression studies it is limited in that it 
permits only semi-quantitative analysis of target gene levels (due to the insensitivity of the 
ethidium bromide) and since the analysis is taken from near the end-point of the reaction it 
is often associated with poor precision as the reaction has often proceeded past the 
exponential stage and products may therefore have begun to degrade.  Conventional PCR 
has been replaced by real-time quantitative reverse transcription PCR (qRT-PCR) which 
differs in that it includes a fluorescent dye into the reaction to allow detection of target 
DNA as the reaction is occurring (i.e. in real time) rather than at the end-point of the 
reaction.  This makes qRT-PCR more accurate than the conventional PCR method.  
Reporter dyes may be sequence-specific, for example the well-known Taqman probe, an 
oligonucleotide specific to the target sequence labelled with two fluorophores (a reporter 
and a quencher dye).  As long as the two fluorophores remain in close proximity they do 
not emit a fluorescence signal; however during the extension phase of replication the 
action of Taq polymerase cleaves the 5’ end of the probe allowing the two dyes to become 
separated therefore as product accumulates the fluorescence increases.  Reporter dyes may 
also be non-specific, for example SYBR green, which binds to the minor groove of double-
stranded DNA and as the reaction proceeds and product increases the fluorescent signal 
also increases (Figure 2.24).  Further details on the processing of qRT-PCR data is covered 
in the later sections. 




Figure 2.24  SYBR green binding during PCR amplification. 
SYBR green (green circles) binds to double-stranded DNA and can be used to measure the abundance of template DNA 
at the end of the extension step of the PCR reaction. 
2.12.5.2 Full protocol for qRT-PCR 
For this thesis, qRT-PCR was used to assess Runx mRNA levels in either whole heart 
samples (LV + RV) or in dissected regions of the heart (infarct, peri-infarct, remote LV 
and RV).  For regional work, the RV was selected as the region to which other regions 
were compared as the RV represented a comparison for the LV and represented the furthest 
region from the infarcted region.   
Preparation for qRT-PCR:  All reagents were thawed and kept on ice and all qRT-PCR 
reactions were prepared in a laminar flow hood to prevent aerosol contamination of cDNA 
or primers.  Gloves and a laboratory coat were worn at all times to further minimise any 
contamination.  Synthesised cDNA was diluted 1:5 with RNase/DNase-free water (final 
volume 30 µl) to allow a manageable volume (2 µl) for pipetting to reduce error.  Either 
96-well or 384-well plates specifically designed for qRT-PCR were used (Applied 
Biosystems, U.K.) depending on the number of samples.  Runx was detected with the 
appropriate Runx-specific primers (Qiagen, U.K.).  These primers have also been 
bioinformatically validated for high sensitivity (excludes short nucleotide polymorphisms 
(SNP) therefore more accurate), have high efficiency and high specificity with short 
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amplicon length (120bp) which have better efficiency as less SYBR green is incorporated.  
A master-mix was prepared to minimise variation of reagent concentration between wells; 
two were prepared, one for each gene (Runx1 and the housekeeper, Gapdh) enough to 
contain the following in each well: 
Table 2.4  qRT-PCR mastermix reaction components. 
 Gapdh Runx 
Master-Mix:   
RNase/DNase-free H2O 4 µl 6 µl 
SYBR green mix* 10 µl 10 µl 
Forward Primer (F) 2 µl 
Reverse Primer (R) 2 µl 
2 µl (F & R) 
cDNA:   
cDNA (2 µl) (2 µl) 
Final Volume: 20 µl 20 µl 
 
*The SYBR green mix (Applied Biosystems, U.K.) contains SYBR Green dye (the main 
reporter dye which intercalates with double-stranded DNA to indicate the quantity of DNA 
accumulating during the amplification process), an Amplitaq Gold DNA polymerase 
(catalyses synthesis of new DNA), dNTPs (the building blocks of the new strand) and a 
ROX dye (an internal passive reference dye to normalise non-PCR related fluorescence 
fluctuations that may be caused by pipetting error or sample evaporation).   
Sample loading:  2 µl of cDNA sample was added to each well followed by 18 µl of the 
master-mix (final volume 20 µl) with centrifugations of 1500 rpm between the addition of 
cDNA and master-mix to ensure all drops of solution fall to the bottom of the well.  An 
optical adhesive cover film was applied to the top of the plate to prevent loss of solution 
through evaporation.   
qRT-PCR reaction:  The qRT-PCR reaction was then performed in an ABI 7500 machine 
with Sequence Detection software (Applied Biosystems, U.K.) to measure relative gene 
expression.  The cycle conditions were as follows: initial 2 min at 50°C followed by 10 
min at 95°C to heat-start (activate) the Taq polymerase enzyme, then 40 cycles where each 
cycle was 95°C for 10 min, 60°C for 1 min.  Runx was detected using Runx primers 
(Qiagen, USA) normalised to Gapdh (Eurofins MWG Operon, Germany).  At the end of 
the 40 cycles, the machine was set to perform a melting curve.  This is an important step 
for SYBR green based detection as SYBR green will bind to any double-stranded DNA 
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therefore this stage was performed to ensure that no contaminating DNA is present in the 
sample which could affect the results.  The melting step is performed immediately after the 
40 cycles by slowly ramping up the temperature of the reaction from 60-95°C causing the 
DNA to denature while continually collecting fluorescence during this time.  The melting 
point is the temperature (Tm) at which the two DNA strands separate causing the 
fluorescence to rapidly decrease.  Melting curve analysis is described in the section that 
follows (Section 2.12.6.1).  In all qRT-PCR experiments, template-free (no cDNA) 
controls and RT- controls were always run in parallel with positive samples and each 
sample was run in triplicate for each experiment.  Baselines and thresholds were calculated 
automatically by the software (see below for more detail on these parameters).  
2.12.6 Interpretation of qRT-PCR data 
This section aims to cover the interpretation of qRT-PCR data and covers the following:  
(i) the theory behind the qRT-PCR amplification curve; (ii) analysis of the qRT-PCR data 
followed by (iii) example calculations showing how the data was analysed for the different 
areas of the study. 
2.12.6.1 Theory of the qRT-PCR amplification curve 
Figure 2.25 shows graphical representations of typical qRT-PCR output amplification 
plots.  An amplification plot is the normalised fluorescence signal of the reporter dye (e.g. 
SYBR green) plotted against the PCR cycle number.  DNA is being amplified at each cycle 
therefore as the PCR reaction proceeds (cycle number increases) the number of DNA 
products increases and as fluorescence is directly proportional to DNA concentration 
(more fluorescence with more DNA), the fluorescence also increases (Figure 2.25A).   
Baseline fluorescence:  In qRT-PCR, the fluorescence does not become detectable for the 
initial cycles of the reaction as the DNA concentration has not accumulated to a level 
where the fluorescence is detectable by the machine; the fluorescence during the initial 
cycles of the reaction where it is not changing is referred to as the baseline fluorescence 
(Figure 2.25A).  The fluorescence signal shown in the amplification plot is the normalised 
fluorescence of the reporter dye (Rn).  Rn is the ratio of the fluorescence by the reporter 
dye (e.g. SYBR green) to the fluorescence of a passive reference dye.  A passive reference 
dye is required to normalise non-PCR related fluctuations in fluorescence due to pipetting 
or sample evaporation, a commonly used example is the ROX dye for use in Applied 
Biosystems machines.  The software automatically normalises this.  Typically the delta-Rn 
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(∆Rn) is used in amplification plots which is Rn with the baseline fluorescence subtracted 
(∆Rn = Rn – baseline).   
Cycle threshold (Ct):  Following the initial cycles whereby the fluorescence is 
unchanged, the amount of DNA accumulating during the amplification process will begin 
to reach detectable fluorescence levels and there is a sudden increase in the fluorescence 
signal.  The cycle at which this increase in fluorescence becomes detectable is known as 
the threshold cycle (Ct).  It is the Ct which defines the quantification of gene expression.  
The higher the starting copy number of a gene (greater number of cDNA molecules 
containing the gene sequence) the earlier the increase in fluorescence (i.e. the earlier the 
Ct).  Therefore the Ct is inversely related to the level of gene expression - the smaller the 
Ct, the higher the gene expression.  The Ct is defined by a threshold fluorescence set either 
manually by the user or more often by the software package which has auto-threshold and 
auto-baseline features.  The threshold is the ∆Rn used for which above this defines the Ct 
of the reaction.  The threshold must be set above the baseline but low enough to be within 
the exponential phase of the amplification curve.  The Ct is derived from the intersection of 
the amplification plot with this threshold line (Figure 2.25A-B).      
 
Figure 2.25  Graphical representation of qRT-PCR data. 
(A) A typical qRT-PCR amplification curve where ∆Rn is plotted against PCR cycle number (Rn is the normalised 
reporter fluorescence; ∆Rn is the Rn minus the baseline).  During the initial cycles the fluorescence does not reach a 
detectable level, this is known as the baseline (indicated).  The cycle at which the amplification curve intersects the 
threshold (green line) is the Ct, as shown.  (B) An example amplification curve plotted using the log (∆Rn) against PCR 
cycle for two samples (A; blue and B; red).   The green line is the threshold (set at the same level for both samples); the 
gray line is the baseline.  As the Ct determines the expression levels of the gene present in the sample in an inverse 
manner (lower Ct, higher gene levels) and sample B has an earlier (lower) Ct (CtB) than sample A (CtA), sample B 
therefore has higher expression of the gene of interest than sample A.  Figure adapted from Applied Bioysystems guide 
Real-time PCR: understanding Ct. 
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Melting curve analysis:  Melting curves show the melting temperature (Tm) for samples 
which is dependent on the base composition and length of the DNA present in the sample.  
All DNA from the same primers should have the same Tm resulting in a single peak in the 
melting curve; the presence of other peaks indicates contamination – this may be from 
contaminating DNA or from primer-dimers (which are formed when primers anneal to 
themselves).  Primer-dimers are easily identified by smaller peaks to the left of the main 
peak as they are smaller in size and therefore have lower Tm.  An example of melting curve 
analysis is shown in Figure 2.26.  For this thesis, primer-specificity was confirmed in 
samples by single peak melting curves with no primer-dimer formations.  Only samples 
with a single peak on a melting curve were included. 
 
Figure 2.26  Example melting curves from the qRT-PCR dissociation stage. 
Melting curves are plotted as the derivative of fluorescence d(rfu)/dT against temperature.  The derivative is often plotted 
as it is useful for identifying different peaks.  (A) Melting curves with a single peak at the same Tm indicating no 
contamination.  The no template control (NTC) samples should have a straight line as there should be no DNA in the 
sample.  (B) Multiple peaks present indicating contamination.  Some of the peaks on the left may be from primer-dimers 
as there are smaller peaks melting at a lower temperature.  All samples in this thesis were tested by melting curve 
analysis and only those which showed a single peak were included.  Figure adapted from Gunster Biotech Ltd. 
2.12.6.2 Analysis of qRT-PCR data 
There are two different methods which can be used to quantify qRT-PCR data: absolute or 
relative quantification.  Absolute quantification provides an exact copy number of the gene 
using a standard curve approach whereas relative quantification presents the expression 
levels relative to a specific control (e.g. treated vs. non-treated).  Absolute quantification is 
only usually used when the precise quantity of amplified DNA is required (e.g. for viral 
load studies where the absolute number of viral copies in the sample is to be determined).  
But when comparing between groups, relative quantitation is sufficient.   
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2.12.6.3 Analysis of qRT-PCR data by the comparative Ct method 
One of the most common methods of analysing relative qRT-PCR data is using the 
comparative Ct method (known as the 2-∆∆Ct method) (Schmittgen & Livak, 2008).  The 
equation for this is: 
CtchangeFold ∆∆−= 2      Eq. 11 
Where ∆∆Ct = [(Ct target gene – Ct reference gene)SAMPLE A - (Ct target gene – Ct reference 
gene)SAMPLE B].  The derivation of this formula can be found in the appendix.   
The result is the fold change in expression of the gene of interest between one sample and 
another (e.g. treated vs. untreated).  The sample to which the others are compared against is 
known as the calibrator sample and is typically the control, for example a healthy subject 
in a disease study.  Where the data is required to be as single data points (i.e. not compared 
to a calibrator sample) it is acceptable to use 2-∆Ct or 2-Ct.  Where samples have been run in 
triplicate, the mean Ct is used for the equations above.  For this thesis qRT-PCR results 
were analysed using comparative Ct calculations; either 2-∆∆Ct (regional comparisons 
relative to RV region), 2-∆Ct (whole heart or RV region between sham and MI) or 2-Ct 
(Gapdh stability) as recommended by accepted published methods (Schmittgen & Livak, 
2008).  Example calculations for each of these are detailed below.  Statistical significance 
between regions within the same heart was tested using ANOVA with multiple regression 
analysis performed with SPSS software.  This involved selecting the RQ as the dependent 
variable for the analysis.  An example of how this was calculated is shown in Figure 2.27. 




Figure 2.27  Example outputs of statistical analysis of qRT-PCR data using SPSS software. 
(A) The data set as a grid of dummy variables by a yes (1) or no (0) system – where there is 1.00 means the RQ 
corresponds to the appropriate region in the column; RQ is selected as the dependent variable to assess whether there is a 
statistical difference between the RQ in each region.  (B) Output view showing the overall ANOVA P value and the 
individual P values for each region.  These results were also verified with separate ANOVA testing. 
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For comparisons of specific regions between sham and MI using unpaired samples, the 
student’s t-test was used.  A value of P<0.05 was considered significant.  All data were 
tested for normal distribution using a histogram plot and by plotting residuals. 
Example 1: analysis of gene expression between sham and MI – whole heart samples. 









Gapdh CT ∆CT                                                2-∆CT 
  17.37 17.80       15.16 17.68    
  16.99 17.41       15.03 17.78    
  16.89 17.94       15.22 17.87    
Mean 17.08 17.72 -0.63 1.55  Mean 15.14 17.78 -2.64 6.25 
Figure 2.28  Sample qRT-PCR data analysis of mouse MI tissue using the 2-∆Ct method.   
Samples were analysed using qRT-PCR and the Ct data from the SDS software was imported into Microsoft Excel.  Each 
sample was performed in triplicate, represented by three Ct values for each gene in this example.  Two samples are 
shown; whole heart (LV + RV) homogenate for a (i) 4-wk sham heart and a (ii) 4-wk MI heart. 
As the whole heart samples were from separate animals, there was no means to justify 
pairing any MI sample with a particular sham sample; therefore it was not appropriate to 
use the 2-∆∆Ct method, and instead the 2-∆Ct value for MI was used for the calculations.  The 
individual 2-∆Ct value (mean of the triplicates) for each MI heart was divided by the mean 
sham value (mean of all sham 2-∆Ct values) and then multiplied by 100 to calculate the 
percentage change in Runx expression using the formula shown below.  In the above 
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Example 2: analysis of gene expression between sham and MI – heart region samples. 













CT ∆ CT                                                ∆∆CT                              2
-∆∆CT
 
  25.04 18.24          24.09 18.19       
  24.92 18.19          24.86 17.94       
  25.54 18.58          24.28 18.19       
Mean 25.16 18.34 6.83 0.00 1.00  Mean 24.41 18.11 6.30 -0.53 1.44 
Figure 2.29  Sample qRT-PCR data analysis of mouse MI tissue using the 2-∆∆Ct method. 
Samples were analysed using qRT-PCR and the Ct data from the SDS software was imported into Microsoft Excel.  Each 
sample was performed in triplicate, represented by three Ct values for each gene in this example.  Two regional samples 
are shown, both from the same heart; the RV region and the peri-infarct region.  The RV region was the region to which 
all other regions of the respective hearts were normalised. 
For regional heart samples, the 2-∆∆Ct method was used to compare the infarct, peri-infarct 
and remote LV (or equivalent sham regions) to the RV region of that respective heart.  An 
example of this is shown in the table above where data from the RV region and the peri-
infarct of an MI heart is shown (both regions have come from the same heart).  The 
calculation is performed in a step-wise order:  (1) Calculate ∆Ct (mean Runx Ct – mean 
Gapdh Ct) for the region; (2) Calculate ∆∆Ct (∆Ct of region of interest – ∆Ct of RV); (3) 
Calculate 2-∆∆Ct, the value is expressed as the relative quantitation (RQ) value.  In the 
example above, Runx expression is 1.44-fold higher in the peri-infarct region of the MI 
heart than the respective RV.    
Example 3: analysis of gene expression between the four different rat strains – whole 
LV samples. 









Gapdh CT ∆ CT                                                2-∆CT 
  15.34 14.62       16.44 14.63    
  15.25 14.38       16.39 14.88    
  15.20 14.84       16.58 14.69    
Mean 15.26 14.61 0.65 0.64  Mean 16.47 14.73 1.74 0.30 
Figure 2.30  Sample qRT-PCR data analysis of congenic rat tissue using the 2-∆Ct method. 
Samples were analysed using qRT-PCR and the Ct data from the SDS software was imported into Microsoft Excel.  Each 
sample was performed in triplicate, represented by three Ct values for each gene in this example.  Two samples are 
shown; whole LV homogenates for a (i) WKY heart and a (ii) WKY-congenic heart. 
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Runx expression between the different rat strains was compared using the 2-∆Ct method.  
This method was chosen because, like the whole heart MI samples, there was no reason to 
pair samples with each other therefore the 2-∆∆Ct method was not appropriate to use.  
Instead the mean ± SEM for each strain was calculated from single data points using the 2-
∆Ct
 value.  In this example above, the WKY-congenic shows a 2-fold reduction in Runx1 
expression compared to WKY. 
2.12.7 Limitations of the technique 
qRT-PCR has several advantages in that it is fast, extremely sensitive, highly reproducible 
and can be integrated into high-throughput systems making it a very powerful tool for 
performing accurate gene expression.  However despite these advantages there are caveats 
associated with qRT-PCR.  The most common is the selection of a suitable reference gene.  
It is necessary to use a housekeeping/reference gene in qRT-PCR as a normalisation 
strategy to control for error between samples.  Performing each well in triplicate controls 
for pipetting error but the housekeeping gene is required to control for differences in 
cDNA concentration not due to pipetting error.  Housekeeping genes are usually cellular 
maintenance genes that regulate basic functions of the cell and are therefore ubiquitously 
and ideally uniformly expressed during all experimental conditions.  They serve as a 
‘common denominator’ to which the target gene is normalised and control for variation in 
the amount of starting material between samples, e.g. from variation in (i) RNA integrity, 
(ii) differences in RT efficiencies, and (iii) cDNA sample loading variation.   
(i) Variations in RNA integrity (and purity) can occur if the RNA becomes degraded due 
to exposure to RNases or improper storage, and contaminants (phenol or proteins) may 
be present from incomplete purification during the RNA extraction process.  Degraded 
RNA can lead to shorter cDNA products and contaminants in the RNA can affect the 
activity of the reverse transcriptase enzyme therefore leading to reduced cDNA.  This 
would result in a lower gene expression of the housekeeping gene and would indicate 
that the altered expression of the target gene of interest would be questionable.   
(ii) The reverse transcription process should occur with 100% efficiency (that is, 1 µg 
RNA is converted into 1 µg cDNA).  In reality, this is not always the case and this may 
be due to factors that affect the activity of the transcriptase enzyme such as the 
presence of contaminants (as described before), incorrect temperature (>42°C reduces 
the activity of the Omniscript transcriptase enzyme; Qiagen Omniscript Kit handbook) 
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or incorrect concentration of primers (including degradation of primers) and dNTPs.  
To minimise these problems, only RNA of minimum purity (A260/A280 >1.8) was 
used, reactions were performed in a controlled incubator at 37°C and reagents were 
kept on ice and stored at -20°C to minimise degradation, and primers/dNTPs were 
always mixed by gentle vortex prior to use to ensure thorough mixing.  If the efficiency 
of the reaction was markedly affected this would lead to a reduction in the 
concentration of cDNA, which would result in a lower gene expression of the 
housekeeping gene and therefore indicate that the altered expression of the target gene 
of interest would be questionable.   
(iii) The third source of variation could arise from cDNA sample loading – this means that 
if unequal cDNA concentrations were used between different samples, for example if 
the cDNA was not diluted correctly or if too little/too much was added (this does not 
include minor errors which are not always avoidable due to the nature of pipetting).  
Incorrect starting cDNA template could bias results leading to over/under-
representation of true gene expression levels which would be informed by the 
over/underexpression of the housekeeping gene.  This was avoided as much as possible 
by ensuring dilutions of 1:5 of cDNA were always performed as accurately as possible.   
2.12.7.1 Choice of suitable housekeeping gene 
Without appropriate normalisation to a housekeeping gene, small differences between 
genes of interest may be missed (variability in the housekeeping gene would obscure small 
changes making them difficult to detect), or results may be misrepresented – for example 
fluctuations in the housekeeping gene can lead to over/under-estimation in the expression 
of the gene of interest (if the housekeeper expression is reduced or increased respectively) 
and this can make it extremely difficult to interpret the real changes.  A suitable 
housekeeping gene is one which shows no differences in expression between the treatment 
groups.  It is best practice to test a number of different housekeeping genes and choose the 
most suitable rather than arbitrarily selecting a single unvalidated gene.  For this thesis a 
preliminary study was performed to test three different housekeeping genes based on some 
of the most stable in mouse MI according to previous housekeeping gene studies: Gapdh (a 
glycolysis enzyme), ribosomal protein P0 (Rplp0) and hypoxanthine-guanine 
phosphoriboyltransferase (Hprt; an enzyme involved in purine nucleotide generation).   
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Gapdh is widely used in cardiovascular studies and is the most frequently reported 
housekeeping gene in the literature for MI (as researched by Brattelid et al.,2010).  
However there are discrepancies in the literature in the suitability of Gapdh in mouse MI; 
for example Gapdh has been reported to be one of the most stable genes in mouse MI 
(Brattelid et al., 2010) but contrary to this, it has also been revealed as the one of the least 
stable in mouse infarcted tissue (Everaert et al., 2011).  Gapdh was also found to be the 
most stable housekeeping gene in rat infarcted and peri-infarct tissue (Zhao et al., 2011).  
However it is being increasingly accepted that housekeeping genes behave very differently 
depending on the study design and the experimental conditions involved.  Therefore while 
a housekeeping gene may be unsuitable for one study, it may be acceptable under similar 
conditions of another.  Following the advice of Everaert et al., 2011 which warned against 
the use of Gapdh in mouse infarction tissue, we also tested their recommended alternative 
gene reported to be the least variable in mouse MI (Hprt).  Rplp0 was additionally chosen 
as it has been shown to be stable regardless of cardiac disease state (Moniotte et al., 2001) 
and ribosomal genes also feature highly as non-variable genes in MI (Everaert et al., 
2011;Perez et al., 2007).  These three housekeeping genes (Gapdh, Rplp0 and Hprt) were 
therefore quantified using qRT-PCR and were ranked based on a criteria of low variance 
published by Mane et al., 2008 (Mane et al., 2008).  This method is based on the idea that 
under ideal conditions, fluctuations in housekeeping gene expression would not vary much 
from a mean (i.e. have low standard deviation (SD)).  Therefore the variance was assessed 
in the Ct and each candidate gene was ranked based on the SD (see example calculation 
below).   
Example 4: analysis of stability of the housekeeper gene 
MI Model – whole heart samples: 
Using the data from Example 1 above, the Gapdh Cts for sham whole heart were (17.8, 
17.4, 17.9) and whole heart MI were (17.7, 17.8, 17.9).  The method for assessing the 
suitability of the housekeeping gene between whole heart groups (sham vs. MI) was based 
on comparing the fold change between groups using the mean (of the triplicates) Ct for 2-Ct 
as recommended by published methods (Schmittgen & Livak, 2008).  For the values given 
in this example, the mean Gapdh Ct for sham and MI were 17.7 and 17.8 respectively.  
The fold change between the two is MI/sham (17.8/17.7) = 1.01 which equates to 1% fold-
change between sham and MI and by using the P value to indicate whether the differences 
were significant also aided in determining the suitability of the housekeeping gene – in this 
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example therefore it was suitable between this pair.  This method was used for all animals 
by taking the mean 2-Ct value for all animals (sham and MI).   
MI Model – regional heart samples (SD method): 
For regional variations, as there were more than two samples, fold-change between all four 
was not possible using the above method.  Therefore the method used was based on the SD 
between the regions as mentioned above and published by Mane et al. (2008).  The SD 
calculation was performed as follows: (i) firstly, the mean Ct for each individual region 
from all hearts (sham and MI) were compared and tested for stastical significant 
differences using ANOVA (with Tukey post-test) to yield a P value as shown in Figure 
2.31A(i),B(i); a P value of <0.05 signified that the raw Ct values between sham and MI 
were significantly different and the housekeeping gene being tested was unsuitable (ii) 
secondly, the regional mean Ct values were pooled to yield a single mean Ct for either 
sham or MI; (iii) the SD between this single sham and single MI mean Ct value was 







xxSD      Eq. 13 
Where ∑ is the sum of, x  is a value in the data set, x is the mean of all values in the data 
set, n is the number of values in the data set. 
The resulting SD of each housekeeping gene is shown in red in Figure 2.31; the SD value 
was used to rank the genes in order with lowest SD being most suitable and highest SD the 
least suitable gene.   
Results:  The results of this method are shown in Figure 2.31 and these data have shown 
that Gapdh was the most stable gene of the three with the lowest SD and showed no 
significant differences in expression between sham and MI.  Hprt was tested in the infarct 
region and showed that there was a small but significant difference in the Ct values 
between sham and MI with a high SD, therefore Hprt was considered the least suitable in 
this study.  Rplp0 was the neither the best nor worst of the three, however data was only 
available from n=1 sham therefore the results were somewhat inconclusive for this gene.  
Based on these validation experiments, Gapdh was chosen as the housekeeping gene for all 
mouse qRT-PCR experiments.  Based on these results, Gapdh was also tested for 
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suitability in the different strains of rat heart tissue for the congenic rat model studies and 
was also found to be stable with no significant differences observed between the 4 strains 
(Figure 2.32). 
 
Figure 2.31  Comparison of different housekeeping genes for qRT-PCR between sham and MI hearts. 
(A-i)  Comparison of raw Ct values from different regions of 4-wk sham hearts (n=5) and 4-wk MI hearts (n=8) and (A-
ii) values for the regions combined using Gapdh.  (B-i)  Comparison of raw Ct values from different regions of 4-wk 
sham hearts (n=1) and 4-wk MI hearts (n=5) and (B-ii) values for the regions combined using RPL0.  (C) Comparison of 
raw Ct values from 4-wk sham apex (n=3) and 4-wk MI infarct region (n=3).  The standard deviations (SD) between the 
two groups for each housekeeping gene are shown in red.  The P value indicates whether there were any significant 
differences in the mean Ct value between groups overall and was used in conjuction with the SD method.  *P<0.05 using 
ANOVA for more than two groups (regional data) or student’s unpaired t-test for comparisons between two groups only 
(combined regions).  
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Figure 2.32  Validation of Gapdh as a suitable housekeeping gene between four different rat strains. 
Raw Ct values are shown for each group; WKY (white bar; n=5), WKY-congenic (light grey bar; n=5), SHRSP (black 
bar; n=5) and SHRSP-congenic (dark grey bar; n=5).  Statistical significance was tested using ANOVA with a Tukey 
multiple comparisons post-test.  The resulting P  value from this ANOVA test across the four groups is shown.  These 
data indicate that there was no significant difference in the Ct value of Gapdh between the hearts from the four different 
rat strains overall.









Characterisation of a mouse model of myocardial 
infarction
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3.1 Introduction 
3.1.1 MI is a serious public health problem 
CVD is the leading cause of death in Europe and the U.S. estimated to account for 49% 
and 37% of all mortalities respectively (Petersen et al., 2005;Thom et al., 2006).  The 
majority of CVD-related deaths are due to coronary heart disease (Petersen et al., 
2005;Thom et al., 2006) which is the atherosclerotic narrowing or thrombus occlusion of 
coronary arteries, both of which can lead to MI and eventual HF (Libby, 2001) .  Despite 
considerable progress in the prevention and treatment of CVD, MI leading to HF continues 
to be a highly prevalent source of morbidity and mortality (Allender et al., 2006).  Current 
treatments for MI such as coronary artery bypass, percutaneous interventions and 
dissolution thrombotic therapies are successful in slowing the disease and improving 
patient symptoms and quality of life (Hermanides & Ottervanger, 2008), however, 
paradoxically the advances in the treatment of MI have led to an increased prevalence of 
chronic HF; this is because patients are surviving the initial insult but have to live with a 
severely compromised heart (Thomas et al., 2008).  More effective treatments are therefore 
required to slow the progression of HF.   
3.1.2 Need for an animal model of MI 
In order to manage and treat MI and HF more effectively, it is important to understand the 
pathophysiology and underlying mechanisms of the disease so that suitable therapeutic 
treatments can be developed.  Experimental animal models that closely resemble human 
disease characteristics have proven invaluable for this (Hasenfuss, 1998;Klocke et al., 
2007).  Much of the work that has advanced our understanding of MI and HF over the past 
four decades would not have been possible without the use of animal models.  CVD 
research performed on animals has yielded invaluable information about alterations in 
neurohormonal activity (McCullagh et al., 1972), myocardial function (Magovern et al., 
1992) and molecular changes (Dodd et al., 1993) that occur in the failing heart after MI.  
Animal models of MI and HF are therefore highly beneficial for CVD research. 
3.1.3 Surgical methods of inducing MI in an animal model 
As mentioned previously, human MI is characterised by atherosclerotic narrowing of 
coronary arteries (Libby, 2001).  Animal models of MI are therefore based on methods that 
result in partial or complete occlusion of a coronary artery.  This is typically performed 
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through the use of surgical intervention methods.  The advantage of using a surgical 
approach rather than alternative methods such as dietary (Wilson & Hartroft, 1970) or 
genetic-inducing strategies (Chu et al., 2002) to induce natural atherosclerotic development 
is that surgical methods allow more precise control over timing, location and extent of 
infarction which provides more reproducible results.  Depending on the nature of 
ischaemic injury required for the purposes of the study, a number of different methods 
have been described utilising physical occluders, freezing and ligation approaches.  Most 
surgical interventions involve placing the animal under anaesthesia, performing a left 
thoracotomy to expose the heart and implementing the relevant coronary artery occlusion 
method (Klocke et al., 2007). The most widely used method of inducing MI in an animal is 
by ligating a coronary artery using a band (large animals) or thin suture (small animals) 
(Klocke et al., 2007).  Alternative methods have been reported and each method has 
numerous advantages and disadvantages associated with the suitability of inducing MI 
similar to the human phenotype, descriptions of each are detailed below. 
3.1.3.1 Occluding devices 
Occluder devices such as hydraulic or ameroid occluders have been described in large 
animal models, for example swine (Harada et al., 1994) as a method of inducing MI 
through coronary artery stenosis (Roth et al., 1987).  These occluders are constriction 
devices that are implanted around the coronary artery and either inflated (balloon occluder 
or hydraulic occluder) or constricted (ameroid) to a controlled extent to cause partial or 
complete occlusion.  These occluders are useful in that they can gradually occlude over a 
long period of time that will allow formation of collaterals therefore mimicking human MI 
(St Louis et al., 2000), however implantation requires a high level of surgical expertise and 
moreover due to their size are restricted to use in larger animals only (Dixon & Spinale, 
2009).   
3.1.3.2 Embolisation 
Another example of an animal model of MI is based on intracoronary embolisation with 
microspheres or agarose beads using catheter-mediated injections (Sabbah et al., 1991).  
This technique is advantageous in that it closely resembles the clinical cause of MI in 
humans due to the embolisation of athereoscletoric and thrombus plaques that build up 
inside the artery wall (Topol & Yadav, 2000).  There is also the added advantage that the 
embolising agents are administered percutanously, therefore the risk of infection or 
inflammation associated with thoracotomy is reduced (Erbel & Heusch, 2000).  The 
Kirsty K. Foote, 2012  Chapter 3  
148 
technique has been successful at inducing LV dysfunction, myocardial fibrosis and 
hypertrophy in dogs (Sabbah et al., 1991) however due to the nature of the technique it is 
also restricted to larger animal models only (Grund et al., 1999). 
3.1.3.3 Cryoinjury 
Cryoinjury is another method of inducing infarction which has been described in smaller 
animal models such as rats (Ciulla et al., 2004) and mice (van den Bos et al., 2005).  This 
involves applying a cryoprobe to the LV free wall for approximately 10 s and the freezing 
temperature (-175 to -190°C) disrupts coronary blood flow.  Cryoinjury is unique among 
these methods in that cell death occurs immediately as a result of the freezing insult, rather 
than from a developing ischaemia process and therefore it does not induce the injury in the 
same way that a naturally developing ischaemia-induced injury occurs in human MI (van 
den Bos et al., 2005).  Cryoinfarctions in mice have been shown to cause reduced 
contractility and diastolic dysfunction to a similar extent as coronary artery ligation after 8 
weeks, however the injury results in smaller infarct sizes, not always transmural and with 
only modest LV structural remodelling (van den Bos et al., 2005). 
3.1.3.4 Coronary artery ligation 
CAL is the most commonly used approach for surgically inducing MI; this involves tying a 
ligature around a coronary artery for either transient or permanent occlusion (Klocke et al., 
2007).  CAL has been extensively used for a large number of years as a very effective 
method of inducing MI in a variety of animal species including dog (Hood, Jr. et al., 
1967), sheep (Gorman, III et al., 1998), rabbit (Smith et al., 2006), rat (Pfeffer et al., 
1979b) and mouse (Michael et al., 1999).  CAL does have some drawbacks, one being the 
damage made around the ligature; inserting a suture into the myocardium inevitably will 
include muscle mass as well as veins, nerves and lymphatic vessels which could affect the 
level of coronary artery stenosis (Klocke et al., 2007).  CAL is subject to infarcts with 
varying size which may mean a large group of animals may be required (Zimmer et al., 
1990).  Despite its limitations, the CAL technique has many advantages which make it a 
very attractive choice for surgical MI methods.  Firstly, the ability to produce a range of 
infarct sizes can also be considered a strength of the technique as it provides flexibility in 
the extent of infarction that may be useful for the study.  Secondly, CAL is not restricted to 
larger animals as some of the other techniques are, and is therefore suitable for rodents 
including mice, which have become increasingly popular in the field of cardiac research 
due to the availability of transgenic strains in this species (Rockman et al., 1994;Svenson 
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et al., 2003).  The ligature can be placed for either permanent or temporary occlusion and 
therefore can be used for ischaemia-reperfusion (I/R) models as well as permanent 
occlusion models providing greater scope for use (Michael et al., 1995). 
3.1.4 How well does CAL-induced experimental MI resemble 
human MI? 
If an animal model is to be used to study human disease it is imperative that the animal 
model closely resembles the human disease as far as possible.  MI is caused by acute 
occlusion of coronary arteries in human patients by thrombosis and leads to a cascade of 
events that ultimately alter the functional and structural properties of the heart that can 
eventually lead to the development of HF.   
3.1.4.1 Characteristics of human MI 
The loss of contractile mass from the infarcted area causes an acute reduction in cardiac 
pump function.  Stroke volume and cardiac output however are initially maintained 
through the action of adrenergic signalling pathways which increase Ca2+ influx and SR 
activity to increase contractility in the surviving cardiomyocytes (Levick, 2010).  
Enhanced contractility in the surviving myocardium is believed to induce cardiomyocyte 
hypertrophy, whereby individual cardiomyocytes through the action of increased 
sarcomeres have the ability to increase in cell size, thereby increasing contractile mass and 
offering further support against the wall stress demands (Pfeffer & Braunwald, 1990).  
Over time, the ventricles dilate further increasing the work of the surviving myocardium 
(Weisman & Healy, 1987).  The dilated ventricle is further supported by increased 
deposition of collagen within the infarcted region to provide structural support and 
preserve the structural integrity of the myocardium (French & Kramer, 2007).  These 
adaptive responses which maintain SV and CO within normal physiological ranges are 
collectively known as compensatory remodelling.  However, persistent strain on the 
surviving cardiomyocytes leads to abnormalities in their Ca2+-handling properties: Ca2+ 
transient and action potential durations are prolonged and SR Ca2+ uptake rates are slowed 
(Pogwizd et al., 2001).  Initially this can cause diastolic dysfunction but with preserved 
systolic function.  These changes are responsible for the slowing of contraction and 
relaxation rates and prolonged relaxation duration that ultimately lead to impaired 
contraction and relaxation of the ventricles.  As contraction and relaxation abnormalities 
worsen to the point where the heart cannot maintain a sufficient CO, this is classified as 
HF (McMurray & Pfeffer, 2005).  Therefore in summary, human MI can present 
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diminished systolic and diastolic function, ventricular dilation and infarct thinning with 
increased collagen deposition (French & Kramer, 2007). 
3.1.4.2 CAL-induced experimental MI 
The CAL method has been applied to large animals such as the dog and pig but it is 
reportedly problematic in these species due to high mortality rates (>50% in dog) mainly 
from ventricular tachycardia (Hood, Jr. et al., 1967).  Moreover, dogs have a very 
extensive collateral coronary circulation which therefore restricts infarct size to only 20% 
of the LV in many cases and as a result produces only minor haemodynamic alterations 
(Hood, Jr. et al., 1967).  Therefore CAL-induced MI is commonly used in smaller 
laboratory species such as the rat and mouse largely because of the lower costs associated 
and with the recent technological advances in miniature instruments for measuring cardiac 
parameters they have become popular species for use in cardiac research (Patten & Hall-
Porter, 2009).  CAL models in the rat have been well-documented.  CAL-induced MI 
results in impaired LV function with reduced systolic function and increased filling 
pressures in rats (Pfeffer et al., 1979b).  Rats with infarctions greater than 46% of the LV 
develop congestive HF after 3-6 weeks with elevated filling pressures and reduced cardiac 
output (Pfeffer et al., 1991b).  As mentioned previously, the mouse has become a popular 
species of choice for the MI model as it carries the unique ability to manipulate specific 
genes that may be important for post-infarction remodelling not possible with any other 
species (Svenson et al., 2003).  The mouse, like the rat, demonstrates both systolic and 
diastolic dysfunction (Shioura et al., 2007) with evidence of LV remodelling (Sam et al., 
2000).  Further details of the phenotype of murine models of MI reported by others are 
described in Table 3.1. 
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Table 3.1  Characteristics of murine models of MI using the permanent CAL method. 
Animals Phenotype Reference 
Male and female Kumming 
mice (24-30g). 
Myocardial necrosis after 24h 
Infarct size 44.3 ± 2.9% of LV after 24h 
Wang et al. A simple and fast 
experimental model of 
myocardial infarction in the 
mouse (2006). 
Male C57Bl/6 mice (20-
25g; 6-10 wk old). 
 
 
33% survival after 1-wk 
30.8% reduction in ESP compared to sham after 1-wk 
Degabriele et al. Critical 
appraisal of the mouse model 
of myocardial infarction 
(2004). 
Male Swiss mice (30-45g; 
10-12 wk old). 
 
 
3-fold reduction in LV wall thickness (5-wk post-MI) 
2.1-fold increase in LV diameter (5-wk post-MI) 
Infarct size 47.7 ± 5.2% of LV circumference (5-wk post-MI) 
Positive Sirius red collagen levels peaked 7.8-fold higher than sham 
at 2-wk, dropped therafter but remained ~2-fold higher at 3-wk and 
5-wk 
No differences in HW/BW ratio by 5-wk post-MI 
Reduction LV ESP, dP/dtmax, dP/dtmin (exact fold change not 
available) 
Lutgens et al. Chronic 
myocardial infarction in the 
mouse: cardiac structural and 
functional changes (1999). 
Male and female C57Bl/6 




At 2-wk post-MI: 
60% survival 
1.7-fold increase in LV mass compared to sham 
Increased systolic (1.7-fold) and diastolic (1.3-fold) diameter (echo) 
compared to sham. 
Fractional shortening reduced by 30.9% of sham (echo). 
Kumar et al. Distinct mouse 
coronary anatomy and 
myocardial infarction 
consequent to ligation (2005). 
Female C57Bl/6 mice (20-
25g; 4-6 wk old). 
At 9-days post-MI: 
60% survival 
2.5-fold increase in EDV (MRI) 
6.6-fold increase in ESV (MRI) 
EF reduced from 72 to 31% 
Caiani et al. Analysis of 
regional left ventricular 
function in the post-infarct 
mouse by magnetic resonance 
imaging with retrospective 
gating (2008). 
Male C57Bl/6 mice (6 wk 
old). 
Apoptosis of cardiomyocytes at 48h 
 
Bialik et al. Myocyte apoptosis 
during myocardial infarction in 
the mouse localizes to hypoxic 
regions but occurs 
independently of p53 (1997). 
Male C57Bl/6 mice (20-
25g; 8-10 wk old) 
At 6-wk post-MI: 
68% survival 
Infarct size 38.6 ± 15.2% 
12.4% reduction in SBP 
41.0% increase in EDP 
24.1 and 28.2% reduction in dP/dtmax and dP/dtmin 
14% increase in LV mass/BW ratio 
25.6% increase in end-diastolic diameter (echo) 
40.7% increase in end-systolic diameter (echo) 
36.4% reduction in fractional shortening (echo) 
Patten et al. Ventricular 
remodelling in a mouse model 
of myocardial infarction 
(1998). 
Male C57Bl/6 mice (10-12 
wk old). 
Collagen accumulation at days 7-14, scar completed by day 21 
Infarct size 47.3 ± 5% (4-wk), 45.3 ± 5% (8-wk) 
60% increase in HW/BW ratio at 4-wk post-MI 
No change in lung weights at 4-wk or 8-wk nor by 24-wk 
Yang et al. Myocardial 
infarction and cardiac 
remodelling in mice (2002). 
Male C57Bl.6 mice (20-
30g; 10 wk old). 
Survival after 12-mo 70% 
Decrease in EF from 64% to 33% at 6-mo 
100% increase in EDP at both 6- and 12-mo 
38% increase in LV hypertrophy at 6-mo 
53% increase in LV chamber size at 6-mo 
Infarct size 40.7 ± 1.9% 
Pons et al. Survival, 
haemodynamics and cardiac 
remodelling follow up in mice 
after myocardial infarction 
(2003). 
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Given the well-documented success of the CAL method in mouse models of MI and its 
close similarities to the human disease phenotype, the CAL model was the choice of 
method for inducing experimental MI in mice for the work in this thesis.  Furthermore, 
there are also a number of projects anticipated that require genetic manipulation in this 
model and therefore the mouse was the best species to use for this. 
3.1.5 Aims 
The aims of the work presented in this chapter were to perform a detailed characterisation 
of the mouse model of MI in terms of (i) cardiac structural and functional alterations and 
(ii) associated surgical success rates and survival characteristics of the model.  As this was 
a new model in our laboratory, it was necessary to characterise the phenotype (including 
both mechanical and electrical activity) to ensure the model developed LV dysfunction.  It 
was hypothesised that inducing MI in mice by CAL would produce a model of LV 
dysfunction and structural remodelling comparable with other published mouse models of 
MI using the CAL method. 
3.2 Methods 
3.2.1 Induction of MI 
Adult male C57Bl/6 mice (aged 8-10 weeks; 20-25 g) underwent MI by CAL as previously 
detailed in the General Methods Section 2.1.  Control sham-operated mice underwent the 
same procedure but without CAL.  Mice were permitted to recover up to 4 or 8 weeks 
following the procedure at which point they underwent in vivo functional assessment (PV 
loop and analysis) and their hearts were harvested for subsequent morphological and 
histological analyses as described in the General Methods Section 2.3 and 2.4.  Animals 
were inspected daily for mortality and any found dead underwent post-mortem analysis to 
identify the cause of death. 
3.2.2 Experimental timeline 
A schematic of the experimental timeline is shown in Figure 3.1.  Following CAL, animals 
were randomly assigned to one of the two following groups: (i) 4-wk group and (ii) 8-wk 
group as detailed above.  Sham-operated animals were also randomly assigned to one of 
the two study groups (4-wk or 8-wk). 
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Figure 3.1  CAL model experimental time line. 
 
3.2.3 Haemodynamic assessment of LV function  
Mice underwent PV measurements either at 4 wk or at 8 wk after MI as described in the 
General Method Section 2.3.  Briefly, mice were anaesthetised (4% isofluorane), intubated 
with a 0.7 mm cannula and ventilated using a rodent respirator (1.5-2% isofluorane, 120 µl 
tidal volume, 120 breaths per minute).  A rectal thermocouple probe connected to a 
feedback control unit maintained core body temperature of the animal between 37.0 ± 
0.5°C throughout the procedure.  Following a midline cervical incision, a 1.2F PV catheter 
(SciSense, Ontario, Canada) was inserted into the LV of the heart via the right common 
carotid artery.  PV data were recorded at baseline and during reduced preload by transient 
vena cava occlusion.  The parallel conductance of surrounding conductive structures was 
offset by administering an intravenous 10 µl bolus of 15% hypertonic saline. 
3.2.4 Assessment of electrical cardiac function  
Mice underwent ECG assessment either during the CAL surgery, and/or at 4 wk or at 8 wk 
after MI as described in the General Methods Section 2.4.  Briefly, mice were 
anaesthetised and sustained under spontaneous breathing conditions through a face mask 
(1.5-2% isofluorane) while a rectal thermocouple probe connected to a feedback control 
unit  maintained core body temperature at 37.0 ± 0.5°C.  Subdermal needle leads were 
placed on the front and hind forelimbs in a lead II configuration and ECG measurements 
were recorded for a 5 minute time period. 
3.2.5 Harvesting of hearts 
Animals were sacrificed at 4 or 8 wk after MI and the heart was removed and washed in 
ice-cold saline (0.9% NaCl w/v).  The aorta was cut transversely, mounted on to a 23G 
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cannula attached to a syringe and perfused retrograde with ice-cold saline to rinse blood 
out of the coronary vessels.  Hearts were blotted dry on tissue paper and weighed using a 
precision electronic balance and subsequently either fixed in formalin for histological 
analysis or snap-frozen in liquid nitrogen and stored at -80°C until needed for biochemical 
experiments. 
3.2.6 Preparation of heart sections 
Hearts taken for histological analysis included the whole intact heart (atria, ventricles and 
major blood vessels).  Hearts were given a minimum fixation time of 24 hr in formalin to 
allow sufficient time for fixative to penetrate the tissue.  After sufficient fixation, hearts 
were embedded into a wax block until required for sectioning.  The heart was sliced 
parallel to the long axis of the heart to produce multiple sections 1µm thick with an 
interval of 250-300 µm between each section.  At each interval, adjacent sections were 
taken, one for each stain: (i) H&E, (ii) Sirius red and (iii) RUNX1-specific antibody (for 
work detailed in Chapter 4). 
3.2.7 Morphometry and infarct measurements 
For each heart, at least five serial sections (approximately 250-300 µm between each 
section) were taken for morphometric and infarct size measurements to ensure a range of 
depths through the heart.  All sections were examined with an Olympus BX51 microscope 
and images were captured with an Olympus DP71 camera with the use of Cell D software.   
3.2.7.1 LV wall thickness and LV area 
LV wall thickness and LV area were measured using serial H&E sections of each heart as 
described in the General Methods Section 2.8.1 and 2.8.2.  The wall thickness was 
measured as the distance between the endocardium and epicardium of the infarcted 
myocardium using a line perpendicular to the curvature of the ventricular wall.  LV area 
was measured from the same sections by tracing around the endocardium inside the LV.  
Both chamber size and wall thickness were measured using ImageJ software and 
measurements were performed on all sections of each heart to yield a mean value for each 
heart.  Qualitative histopathological changes in myocardial tissue following MI were 
assessed using H&E and Sirius red stained sections of the heart. 
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3.2.7.2 Infarct size 
Infarct size was measured on sections stained with Sirius red using a length-based 
approach similar to the method published by Takagawa et al., 2007 as described in the 
General Methods Section 2.8.3.  Briefly, four lengths were measured from each heart 
section: epicardial infarct length, endocardial infarct length, epicardial total circumference 
and endocardial total circumference.  The infarct included all infarcted myocardium which 
was >50% of the total thickness of the myocardium.  Epicardial and endocardial infarct 
ratios were then calculated by dividing the sum of epicardial or endocardial lengths from 
all sections by the sum of all epicardial or endocardial circumferences from all sections 
respectively.  Infarct size was then calculated using the following equation: 
100
2
(%) ×+= ratioinfarctENDOratioinfarctEPIsizeInfarct   Eq. 14 
3.2.7.3 Collagen levels 
Collagen levels in the heart were estimated from Sirius red sections using ImageProPlus 
software as described in the General Methods Section 2.9.2.  The number of red pixels 
above a set threshold of red colour were counted and expressed as a percentage of total 
pixels in the heart.   
3.2.8 Lung and liver weights 
The lungs and liver were harvested, blotted dry on tissue paper and weighed using a 
precision electronic balance as described in the General Methods Section 2.3.  Tibial 
length measurements were also taken as a normalising reference for lung, liver and heart 
weights.  Since the animals were at an age where they may still be growing, the tibial 
length was used as a more accurate normalising reference than body weight. 
3.2.9 Cardiomyocyte isolation and measurements of cell length, 
width and estimated cross-sectional area 
Cardiomyocytes were isolated using a standard digestion protocol with collagenase and 
protease from 4-wk sham and 4-wk MI hearts as described in the General Methods Section 
2.10.1.  Briefly, hearts were removed and perfused retrogradely at 4 ml.min-1 with a 
modified KH solution containing 0.7 mg.ml-1 collagenase (type I, Worthington, New Jersey 
USA) and 0.07 mg.ml-1 protease (type XIV, Sigma Aldrich, UK) for 7 minutes followed by 
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6 minutes of KH solution containing 0.7% bovine serum albumin (BSA, Sigma Aldrich, 
UK).  The perfusion was then stopped and the LV free wall cut into strips and mixed in KH 
solution with 0.7% BSA to yield a cell suspension of single cardiomyocytes.  Isolated 
cardiomyocytes were visualised by light microscopy and captured using a camera (Q 
imaging Rolera-XR) and QCapturePro software.  Cardiomyocyte length and width was 
determined from a group of hearts using ImageJ software and cross-sectional area was 










widthcellAreasectionalCross pi    Eq. 15 
3.2.10 Data recording and statistical analysis 
All PV and ECG data were recorded on a Dell laptop using LabScribe2 software at a 
sampling rate of 1000 samples.s-1 and analysed offline using LabScribe2 software.  All data 
in the text and figures are expressed as mean ± SEM.  Statistical significance was 
measured using student’s paired or unpaired t-test for comparisons between a maximum of 
two groups, or ANOVA followed by the Bonferroni or Tukey post-hoc test where 
appropriate for comparing more than two groups.  For the survival study, Kaplan-Meier 
analysis was used and statistical significance tested using the Log-rank (Mantel-Cox) test.  
A P value of <0.05 was considered statistically significant. 
3.3 Results 
3.3.1 Survival following MI 
Mice underwent surgically induced MI (n=137) or a sham operation (n=60).  Survival data 
for these procedures are presented in Figure 3.2.  As shown in Figure 3.2A (i), MI leads to 
significantly reduced survival (end-point survival rate 63% after MI vs. 100% for sham 
operations; P<0.05).  Of the 197 mice that underwent surgery, 73 did not survive to the end 
of the study and reasons for this are shown in Figure 3.2A (ii).  50% of the deaths were due 
to cardiac rupture, 45% occurred intra-operatively (28% of these were attributable to 
mechanical ventilation issues; the other 17% were related to another unidentified aspect of 
the surgical procedure), 4% developed severe clinical symptoms within the first week of 
MI (extreme dyspnoea, lethargy and rapid weight loss) and were killed humanely using an 
appropriate Schedule 1 method; the remaining 1% died after the first week of the 
procedure for reasons that could not be identified from a post-mortem.  The majority of 
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deaths following MI occurred within the first week of the operation (99%) and it was very 
rare to lose animals beyond the first week (1%).  As this was a new model in our 
laboratory, efforts were made to minimise mortalities to achieve the highest possible 
success (survival) rates.  Figure 3.2A (iii) shows how mortality changed over the course of 
learning the technique and how this affected the overall survival.  The current values are 
denoted by the last point on the graph of Figure 3.2A (iii).  It can be seen that with 
experience of the technique, deaths from ventilation issues and from cardiac rupture were 
reduced by 64.8% and 86.1% respectively (current vs. highest incidence).  Intra-operative 
deaths were reduced by 100% to zero (current vs. highest incidence).  In reducing 
mortalities over the course of developing the technique, the overall survival rate of the 
model was increased by 63.3% (current vs. lowest incidence).  Current survival success 
rates were 78% for MI and 100% for sham-operated animals.   
3.3.1.1 Cardiac rupture 
The most common cause of mortality in this model was cardiac rupture.  All animals were 
monitored daily and any animals found dead were examined by autopsy for evidence of 
cardiac rupture. Cardiac rupture was confirmed by the presence of a pool of clotted blood 
surrounding the heart within the chest cavity (Figure 3.2B(i-a) and by the presence of a 
visible tear on the LV free wall of the heart (Figure 3.2B(i-b).  Cardiac rupture always 
occurred in the first week of MI between day 3-6 (Figure 3.2B (ii)); it did not occur before 
day 3 nor after day 7. 
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Figure 3.2  Survival following MI.   
(A-i) Kaplan-Meier survival curves for mice undergoing CAL to produce MI (red line) compared to sham procedure 
(black line).  Animals removed from the study at their respective time points (4 or 8 weeks) are represented by ticks at 
these time points on the survival curve to indicate removal from the study rather than death from the CAL procedure.  
*P<0.05 Log-rank (Mantel-Cox) test.  (A-ii) Reasons why mice did not survive CAL.  (A-iii) Success rates associated 
with experience of the CAL technique.  (B-i)  Photograph of an animal that died as a result of cardiac rupture showing 
blood in the chest cavity (white arrows; (a)) and the site of rupture on the heart (black arrow; (b)).  (B-ii) Incidence of 
cardiac rupture showing the frequency of rupture in the days following MI. 
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3.3.2 Effect of MI on haemodynamic LV function 
LV PV loop measurements were used to assess changes in LV function 4-wk and 8-wk 
post-MI.  The results of these measurements are presented in Figure 3.3, Figure 3.4 and 
summarised in Table 3.2 and described below.  Results are expressed as the percentage 
change compared to the respective time-matched sham. 
3.3.2.1 Effect of MI on LV pressure and volume traces and HR 
Figure 3.3A (i-iv) shows typical LV pressure and volume traces from 4-wk sham, 4-wk 
MI, 8-wk sham and 8-wk MI.  The resultant PV loops from these traces are summarised in 
Figure 3.3B.  Heart rate was not statistically different across the four groups (545.1 ± 13.3 
(4-wk sham; n=10); 552.7 ± 10.2 (4-wk MI; n=13); 572.0 ± 14.6 (8-wk sham; n=5); 546.2 
± 18.0 (8-wk MI; n=7) bpm; P>0.05; Figure 3.3C).   




Figure 3.3   Effects of MI on pressure, volume and heart rate. 
(A-i-iv) Representative pressure and volume traces from sham and MI hearts at 4-wk and 8-wk time points.  (B)  
Representative PV loops from sham and MI hearts at 4-wk and 8-wk time points.  (C)  Heart rates from 4-wk sham 
(n=10), 4-wk MI (n=13), 8-wk sham (n=5) and 8-wk MI (n=7). 
3.3.2.2 Effect of MI on systolic functional parameters of the heart 
Figure 3.4A shows the effect of MI on parameters of systolic function.  LV end-systolic 
pressure (ESP), a measure of contractility, was significantly reduced to 88.0% of control 
sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); P<0.05) and to 
82.0% of control sham levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk sham (n=5); 
P<0.05; Figure 3.3A (i-iv), B; Figure 3.4A (i)).  Similarly, the maximum rate of rise of LV 
pressure (dP/dtmax) which is another index of contractility, was significantly reduced to 
78.6% of control sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); 
P<0.05) and to 59.7% of control sham levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk 
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sham (n=5); P<0.05; Figure 3.4A (ii)).  Another measure of systolic performance is the 
ejection fraction (EF) which is equal to (stroke volume/end-diastolic volume)*100; MI led 
to a significant reduction in EF to 63.5% of control sham levels at 4-wk post-MI (4-wk MI 
(n=13) vs. 4-wk sham (n=10); P<0.05) and to 65.2% of control sham levels at 8-wk post-
MI (8-wk MI (n=7) vs. 8-wk sham (n=5); P<0.05; Figure 3.4A (iii)).  Cardiac output, 
however, remained unchanged following MI after 4-wk post-MI (7.9 ± 1.3 vs. 9.5 ± 1.2 
ml.min-1; 4-wk MI (n=13) vs. 4-wk sham (n=10): P>0.05) and 8-wk post-MI (10.1 ± 1.4 
vs. 10.1 ± 0.6 ml.min-1; 8-wk MI (n=7) vs. 8-wk sham (n=5); P>0.05; Figure 3.4A (iv)).  
There was no further decline in systolic function from 4-wk to 8-wk post-MI for any 
parameter. 
3.3.2.3 Effect of MI on diastolic functional parameters of the heart 
Figure 3.4B shows the effect of MI on parameters of diastolic function.  LV end-diastolic 
pressure (EDP) is a measure of diastolic function and was significantly increased to 
198.1% of control sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); 
P<0.05) and to 280.8%  of control sham levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk 
sham (n=5); P<0.05; Figure 3.3A (i-iv), B; Figure 3.4B (i)).  Similarly, the maximum rate 
of fall of LV pressure (dP/dtmax) which is another measure of diastolic function was 
significantly reduced to 58.9% of control sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 
4-wk sham (n=10); P<0.05) and to 58.3% of control sham levels at 8-wk post-MI (8-wk 
MI (n=7) vs. 8-wk sham (n=5); P<0.05; Figure 3.4B (ii)).  Another index of diastolic 
function is the time constant Tau (τ) which describes the rate of LV pressure decay during 
isovolumetric relaxation - τ was significantly increased to 155.9% of control sham levels at 
4-wk post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); P<0.05) and to 168.0% of control 
sham levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk sham (n=5); P<0.05; Figure 3.4B 
(iii)). 
3.3.2.4 Effect of MI on load-independent measures of LV function 
The end-diastolic pressure-volume relationship (EDPVR) was measured to assess a load-
independent measure of diastolic function in terms of myocardial compliance and stiffness.  
The myocardial stiffness constant (β; calculated from an exponential fit of the end-diastolic 
PV data points) is a load-independent measure of diastolic function in terms of stiffness of 
the myocardium and was significantly increased by 2.5-fold of control sham levels at 4-wk 
post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); P<0.05) and by 13.8-fold of control sham 
levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk sham (n=5); P<0.05; Figure 3.4B (iv)).  
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Hearts were progressively stiffer by 2.5-fold at 8-wk compared to 4-wk post-MI (8-wk MI 
(n=7) vs. 4-wk MI (n=5); P<0.05; Figure 3.3B (iv)).  EDPVR was the only diastolic 
parameter that was found to progressively change from 4-wk to 8-wk post-MI; no other 
parameters of diastolic function were found to change between 4-wk and 8-wk post-MI. 
3.3.2.5 Effect of MI on volume parameters 
Figure 3.4C shows the effect of MI on LV volume parameters.  LV end-diastolic volume 
(EDV) and end-systolic volume (ESV) are measured of the LV blood volumes at end-
diastole and end-systole, respectively and are useful indicators of any change in LV 
volume as a result of chamber dilation for example.  EDV was significantly increased to 
141.1% of control sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 4-wk sham (n=10); 
P<0.05) and to 168.4% of control sham levels at 8-wk post-MI (8-wk MI (n=7) vs. 8-wk 
sham (n=5); P<0.05; Figure 3.3A (i-iv); Figure 3.4C (i)).  Similarly, ESV was significantly 
increased to 215.0% of control sham levels at 4-wk post-MI (4-wk MI (n=13) vs. 4-wk 
sham (n=10); P<0.05) and to 301.2% of control sham levels at 8-wk post-MI (8-wk MI 
(n=7) vs. 8-wk sham (n=5); P<0.05; Figure 3.3A (i-iv); Figure 3.4C (ii)).  Stroke volume 
(SV) was unchanged after MI at both 4-wk post-MI (15.0 ± 2.2 vs. 17.6 ± 2.1 µl; 4-wk MI 
(n=13) vs. 4-wk sham (n=10): P<0.05) and at 8-wk post-MI (18.7 ± 2.1 vs. 17.8 ± 1.3 µl; 
8-wk MI (n=7) vs. 8-wk sham (n=5): P>0.05; Figure 3.4C (iii)).  There was no further 
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Table 3.2  Effect of myocardial infarction on haemodynamic indices of LV function in mice. 
  
4-wk                                
SHAM 
4-wk                        
MI   
8-wk                                
SHAM 
8-wk                                
MI 
 
     
HR (bpm) 545.1 ± 13.3 552.7 ± 10.2  572.0 ± 14.6 546.2 ± 18.0 
ESP (mmHg) 98.2 ± 1.8 86.4 ± 4.4*  100.1 ± 7.4 82.1 ± 3.9* 
EDP (mmHg) 5.2 ± 0.9 10.3 ± 1.7*  2.6 ± 0.2 7.3 ± 1.4* 
dP/dtmax (mmHg.s-1) 9872.8 ± 489.2 7761.5 ± 516.3*  11023.0 ± 893.9 6575.9 ± 399.9* 
dP/dtmin (mmHg.s-1) 8663.3 ± 292.0 5106.8 ± 351.4*  8826.9 ± 804.7  5141.7 ± 711.2* 
Tau (ms) 5.9 ± 0.3 9.2 ± 0.9*  5.0 ± 0.4 8.4 ± 0.6* 
EDPVR 0.038 ± 0.011 0.097 ± 0.018*  0.018 ± 0.002 0.246 ± 0.05*† 
ESV (µl) 12.7 ± 2.2 27.4 ± 3.4*  8.5 ± 2.0 25.6 ± 4.4* 
EDV (µl) 29.7 ± 3.9 41.9 ± 3.3*  26.3 ± 3.3 44.3 ± 5.5* 
SV (µl) 17.6 ± 2.1 15.0 ± 2.2  17.8 ± 1.3 18.7 ± 2.1 
CO (ml.min-1) 9.5 ± 1.2 7.9 ± 1.3  10.1 ± 0.6 10.1 ± 1.4 
EF (%) 58.7 ± 4.0 37.3 ± 4.6*  69.3 ± 3.5 45.2 ± 6.4* 
  
          
 
HR = heart rate; ESP = end-systolic pressure; dP/dtmax = maximal rate of rise of pressure; EF = ejection fraction; CO = 
cardiac output; EDP = end-diastolic pressure; -dP/dtmin = maximal rate of fall in pressure; Tau = time relaxation constant; 
EDPVR = end-diastolic pressure-volume relationship stiffness constant.  Values are expressed as mean ± SEM. * P < 
0.05 vs. time-matched sham control.  † P < 0.05 between 4-wk MI vs. 8-wk MI.




Figure 3.4  Effects of MI on haemodynamic indices of LV function in mice. 
Effect of MI on systolic functional parameters (A i-iv), diastolic functional parameters (B i-iv) and volume parameters (C 
i-iii) in 4-wk sham (white bar; n=10), 4-wk MI (black bar; n=13), 8-wk sham (white bar; n=5) and 8-wk MI (black bar; 
n=7).  Data shown are mean ± SEM; *P<0.05.
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3.3.3 Effect of MI on the electrical properties of the heart 
ECG measurements were used to measure changes in the electrical properties of the heart 
after MI.  ECG was used during the induction of MI in a cohort of animals as a method of 
validating successful CAL.  Representative ECG recordings before, during and after CAL 
are shown in Figure 3.5 which show an increase in the ST-segment during CAL which can 
still be seen 10 min after CAL (Figure 3.5A (i-iii)).  ECG measurements were also 
recorded 4-wk and 8-wk after MI.  Representative ECGs from sham, 4-wk MI and 8-wk 
MI are shown in Figure 3.5B.  It can be seen from these recordings that MI causes the 
development of a negative Q wave, ST depression and T-wave inversion, based on the 
morphology of the ECG alone (not quantified).  Any arrhythmic events that occurred in the 
5 min recording period were counted offline.  Sham animals showed no arrhythmic events 
and therefore the 4-wk and 8-wk shams were combined into a single group.  Animals with 
MI were found to have a significantly increased frequency of arrhythmias in the form of 
ventricular premature complexes (VPC) both at 4-wk (0.10 ± 0.04; 4-wk MI (n=18) vs. 
sham (n=18); P<0.05; Figure 3.5C (ii)) and 8-wk post-MI (0.04 ± 0.02; 8-wk MI (n=7) vs. 
sham (n=18); P<0.05; Figure 3.4C (ii)).  These arrhythmias were identified as VPC by 
their larger QRS complexes with a deflection in the opposite direction to the normal sinus 
rhythm and a larger T wave consistent with a VPC.  These were identified based on their 
morphology alone.  There were no statistical differences in the frequency of VPC 
arrhythmias between 4-wk and 8-wk post-MI (P>0.05). 




Figure 3.5  Effect of MI on the electric properties of the heart. 
(A-i-iii) Representative electrocardiograms from mice before (i), during (ii) and after CAL (iii). (B-i-iii)  Representative 
electrocardiograms from (i) sham, (ii) 4-wk MI and (iii) 8-wk MI. (C-i) Representative electrocardiograms for arrhythmia 
analysis from 4-wk sham and 4-wk MI after MI. (C-ii) Frequency of VPC arrhythmias in sham (both 4-wk and 8-wk 
shams; n=18; red circles), 4-wk MI (n=18; black circles) and 8-wk MI (n=7; open circles). 
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3.3.4 Effect of MI on the structural properties of the heart 
3.3.4.1 Heart weight 
Heart weight relative to TL was found to be significantly increased 4-wk post-MI (10.7 ± 
0.5 vs. 8.9 ± 0.4 mg/mm; 4-wk MI (n=15) vs. 4-wk sham (n=22); P<0.05; Figure 3.6A-B) 
and 8-wk post MI (13.4 ± 1.4 vs. 9.3 ± 0.4 mg/mm; 8-wk MI (n=12) vs. 8-wk sham (n=11); 
P<0.05; Figure 3.6A-B).  Hearts were also found to be progressively heavier as the MI 
developed from 4-wk to 8-wk (13.4 ± 1.4 vs. 10.7 ± 0.5 mg/mm; 8-wk MI (n=12) vs. 4-wk 
MI (n=15); P<0.05; Figure 3.6A-B). 
3.3.4.2 Cardiomyocyte size 
One factor that may be contributing to an increase in the weight of the heart after MI is an 
increase in the size of the individual cardiomyocytes.  Cardiomyocyte cell dimension 
measurements (measured at 4-wk post-MI only) indicated a small but significant increase 
in cardiomyocyte length 4-wk post-MI (148.9 ± 3.2 vs. 130.7 ± 3.1 µm; 4-wk MI (n=3 
hearts; n=63 cells) vs. 4-wk sham (n=3 hearts; n=79 cells); P<0.05; Figure 3.6C(i-ii).  
Conversely, there were no statistical differences observed in cardiomyocyte width at 4-wk 
post-MI (30.4 ± 1.3 vs. 28.1 ± 0.9 µm; 4-wk MI (n=3 hearts) vs. 4-wk sham (n=3 hearts); 
P>0.05; Figure 3.6(i,iii).  There was also no significant differences in cardiomyocyte cross-
sectional area at 4-wk post-MI (809.9 ± 73.1 vs. 665.0 ± 40.9 µm2; 4-wk MI (n=3 hearts) 
vs. 4-wk sham (n=3 hearts); P<0.05; Figure 3.6C(i,iv). 
 




Figure 3.6  Effect of MI on heart weight and cardiomyocyte size. 
(A-a-c) Representative photographs of the heart from (a) 4-wk sham, (b) 4-wk MI and (c) 8-wk after MI.  (B) Effect of 
MI on heart weight (normalised to tibial length) for 4-wk sham (n=15), 4-wk MI (n=22), 8-wk sham (n=12) and 8-wk MI 
(n=11).  (C-i) Typical cardiomyocytes from a 4-wk sham and 4-wk MI heart. C (ii-iv) Effect of MI on (ii) cell length, (iii) 
cell width and (iv) estimated cross-sectional area for 4-wk sham (n=79 cells; n=3 hearts) and 4-wk MI (n=63 cells; n=3 
hearts).  Data shown are mean ± SEM. *P<0.05. 
3.3.4.3 LV dimensions 
Histological H&E-stained sections of the heart were used to quantify LV wall thickness 
and LV chamber area (Figure 3.7A (i-iii)).   
LV wall thickness was found to be unchanged in sham-operated animals from 4-wk to 8-
wk (1.96 ± 0.46 vs. 1.30 ± 0.06 mm; 4-wk sham (n=4) vs. 8-wk sham (n=5); P>0.05; 
Figure 3.7B).  MI resulted in thinning of the LV free wall after 4-wk compared to the 
respective time-matched sham (0.19 ± 0.02 vs. 1.96 ± 0.46 mm; 4-wk MI (n=5) vs. 4-wk 
sham (n=4); P<0.05; Figure 3.7B) and after 8-wk (0.32 ± 0.10 vs. 1.30 ± 0.06 mm; 8-wk 
MI (n=4) vs. 8-wk sham (n=5); P<0.05; Figure 3.7B).  There were no statistical differences 
in the degree of LV wall thinning between 4-wk MI and 8-wk MI (0.19 ± 0.02 vs. 0.32 ± 
0.10 mm; 4-wk MI (n=5) vs. 8-wk MI (n=4); P<0.05; Figure 3.7B). 
LV chamber area in sham-operated animals was not statistically different from 4-wk to 8-
wk (5.3 ± 0.7 vs. 7.0 ± 0.3 mm2; 4-wk sham (n=4) vs. 8-wk sham (n=5); P>0.05; Figure 
3.7C).  After MI, LV area was significantly increased at 4-wk compared to the respective 
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time-matched sham (19.3 ± 3.7 vs. 5.3 ± 0.7 mm2; 4-wk MI (n=5) vs. 4-wk sham (n=4); 
P<0.05; Figure 3.7C) and at 8-wk (17.2 ± 3.5 vs. 7.0 ± 0.3 mm2; 8-wk MI (n=4) vs. 8-wk 
sham (n=5); P<0.05; Figure 3.7C).  There were no significant differences in LV area 
observed between the 4-wk MI and 8-wk MI groups (19.3 ± 3.7 vs. 17.2 ± 3.5 mm2; 4-wk 
MI (n=5) vs. 8-wk MI (n=4); P>0.05; Figure 3.7C). 
 
Figure 3.7  Altered LV dimensions after MI. 
A (i-iii) Representative H&E sections of the heart from 4-wk sham, 4-wk MI and 8-wk MI.  (B) LV infarct thickness and 
(C) LV chamber area measured using H&E sections for 4-wk sham (white bar; n=4), 4-wk MI (black bar; n=5), 8-wk 
sham (white bar; n=5) and 8-wk MI (black bar; n=4). * P<0.05 
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3.3.4.4   Infarct size 
Sirius red sections of the heart were used to quantify infarct size (Figure 3.8A (i-iii)).  The 
mean infarct size after 4-wk and 8-wk post-MI was 36.6 ± 4.2 and 39.4 ± 5.4% of the LV 
respectively (Figure 3.8B) indicating that there were no differences in the infarct size 
between the two time points (36.6 ± 4.2 vs. 39.4 ± 5.3%; 4-wk MI (n=4) vs. 8-wk MI 
(n=3); P>0.05; Figure 3.8B).  Sham animals showed no infarction.  
3.3.4.5 Collagen deposition (cardiac fibrosis) 
Collagen content was measured from the collagen positive (red-stained) area in Sirius red 
sections of the heart (Figure 3.8A (i-iii)).  4-wk and 8-wk shams were combined.  Collagen 
levels were expressed as a percentage of the whole heart.  After MI there was a significant 
increase in collagen content in the heart after 4-wk (13.2 ± 2.2 vs. 4.4 ± 0.7%; 4-wk MI 
(n=4) vs. sham (n=3); P<0.05; Figure 3.8C) and after 8-wk (20.5 ± 4.5 vs. 4.4 ± 0.7%; 8-
wk MI (n=3) vs. sham (n=3); P<0.05; Figure 3.8C).  There were no significant differences 
in collagen content between 4-wk and 8-wk hearts post-MI. 
 




Figure 3.8  Infarct size and collagen content after MI. 
(A i-iii) Representative Sirius red sections of the heart from (i) sham, (ii) 4-wk MI and (iii) 8-wk MI. (B) Infarct size after 
4-wk MI (n=4; light grey bar) and 8-wk MI (n=3; dark grey bar).  * P<0.05 compared to sham (dotted line).  (C) 
Collagen levels in the heart as a percentage of the whole heart in sham (n=3; white bar), 4-wk MI (n=4; grey bar) and 8-
wk MI (n=3; black bar). * P<0.05 between two groups indicated by connecting bars. 
3.3.5 Effect of MI on lung and liver weight 
There were no statistical differences in lung weight at 4-wk post-MI (7.1 ± 0.4 vs. 7.2 ± 0.4 
mg/mm; 4-wk MI (n=22) vs. 4-wk sham (n=15) P>0.05; Figure 3.9A) nor at 8-wk post-MI 
(7.2 ± 0.7 vs. 6.8 ± 0.2 mg/mm; 8-wk MI (n=11) vs. 8-wk sham (n=12) P>0.05; Figure 
3.9A).  Similarly, there were also no statistical differences in liver weight at 4-wk post-MI 
(67.5 ± 1.8 vs. 66.6 ± 2.8 mg/mm; 4-wk MI (n=22) vs. 4-wk sham (n=15) P>0.05; Figure 
3.9B) and at 8-wk post-MI (70.0 ± 2.1 vs. 65.9 ± 2.6 mg/mm; 8-wk MI (n=11) vs. 8-wk 
sham (n=12) P>0.05; Figure 3.9B). 




Figure 3.9  Lung and liver weights after MI. 
(A) Lung weight in 4-wk sham (n=15), 4-wk MI (n=22), 8-wk sham (n=12) and 8-wk MI (n=11).  (B) Liver weight in 4-
wk sham (n=15), 4-wk MI (n=22), 8-wk sham (n=12) and 8-wk MI (n=11). 
3.4 Discussion 
For this study, a model of MI was produced in the mouse using the well-established CAL 
method.  The results presented in this chapter demonstrate that this method produced a 
model with altered cardiac functional and structural properties consistent with LV 
remodelling during MI. 
3.4.1 Inducing MI leads to reduced survival 
Inducing MI in mice experimentally is known to be associated with a higher incidence of 
mortality compared to animals undergoing the sham procedure (Sam et al., 2000;van 
Laake et al., 2007).  The current mortality in our model was 27% for animals undergoing 
CAL (compared to 0% in shams); which saw an improvement in survival by approximately 
3-fold since first learning the technique for the study.  Mortality associated with CAL-
induced MI in mice is about 32-50% (Gehrmann et al., 2001;Kuhlmann et al., 2006) 
therefore the mortality for our model was low compared with the published literature for 
this species. 
3.4.1.1 Reasons for reduced survival 
Nearly all (99%) of the deaths from CAL occurred within the first week of the operation 
which is a consistent finding in mouse MI models (Lutgens et al., 1999;Patten, 1998).  
Sudden deaths beyond the first week were uncommon in our model (1% of all deaths) but 
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these have been known to occur in murine MI models beyond the first week although these 
tend to be a significantly smaller proportion compared to the first week drop-out: Patten 
reported a small proportion of deaths (8.8% of their deaths) which occurred at days 20, 28 
and 32 post-operative (Patten, 1998) and Yang have reported 1% of sudden deaths at 2-wk, 
4-wk and 8-wk with 3% of sudden deaths at 16-wk and 24-wk (Yang et al., 2002).   
Intra-operative mortality:  In the present study, nearly half of all mortalities (45%) 
occurred intra-operatively and were mainly due to respiratory problems from mechanical 
ventilation.  It was necessary to mechanically ventilate the animals to prevent respiratory 
insufficiency from lung collapse during thoracotomy; however, due to the animal’s small 
size and complex respiratory patterns (e.g. high respiration rate (RR) and low inspiratory 
time to total time of the respiratory cycle (Ti/Tt)), mechanical ventilation in mice can be 
inherently difficult (Schwarte et al., 2000).  There is also the associated high risk of 
pneumothorax with open-chest procedures which occurs when air is not fully displaced 
from the chest and the lungs cannot fully inflate which can also lead to respiratory 
insufficiency.  In this model, deaths from mechanical ventilation were either due to (i) 
pneumothorax as previously described, or (ii) an over-inflation of the lungs, which may 
have been caused by too great a pressure at the inlet port.  Efforts were made to minimise 
ventilation-related deaths and improve overall survival.  These included (i) placing the 
expiratory tube under water during closing up to increase PEEP and reduce the chance of 
lung collapse, (ii) ensuring patency in the tracheal cannula and associated tubing at all 
times, (iii) use of appropriate tidal volumes and respiration rates for the body weight of the 
animal (as recommended by the manufacturer of the ventilator, Harvard Apparatus, 
Germany).  Together these methods were successful in reducing ventilation-related deaths 
to 0% and improved overall survival by 65% during the course of refining the model as 
shown in Figure 3.2A(iii).  Novel methods for inducing CAL in mice without the need for 
mechanical ventilation are emerging like the method by Gao et al., (2010) in which a 
“heart pop-out” approach is used to eliminate the need for ventilation and is found to 
produce identical infarct sizes and a similar level of dysfunction as the conventional 
method but with less tissue damage and better survival.  This may be beneficial to 
investigators using mouse MI models to help reduce intra-operative mortality (Gao et al.’s 
method showed reduced mortality from 52.3% to 32.5% without need for mechanical 
ventilation).  The other intra-operative deaths observed in the present study that were not 
caused by respiratory problems were for reasons that could not be identified; it’s possible 
that the CAL may have triggered fatal arrhythmias.  Alternatively, as Figure 3.2A(iii) 
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shows, these deaths were highest at the beginning of the course of learning the technique 
therefore it may have been related to inexperience. 
3.4.1.2 The main cause of reduced survival was cardiac rupture 
The largest loss of animals after the CAL procedure was from cardiac rupture which 
occurred in 27% of animals overall (constituting 50% of all deaths) as shown in Figure 
3.2A(ii).  Cardiac rupture is a feature of acute MI which is believed to occur from 
persistent stretching of weakened myocardium causing it to rupture (Schuster & Bulkley, 
1979).  The increased abundance and activity of MMP enzymes in the early stages of acute 
MI is believed to be the major contributor to this event (Heymans et al., 1999;Matsumura 
et al., 2005).  Cardiac rupture can occur in human patients with MI although it is rare 
(occurs in 3% of MI patients) (Brener & Tschopp, 2009) and is also a feature of mouse 
models of MI; the mouse is the only laboratory species reported to demonstrate cardiac 
rupture like humans (Gao et al., 2010b;Sane et al., 2009).  Mouse rupture models have 
provided valuable insight into the principal mechanisms of rupture as well as the 
associated risk factors for developing rupture.  A common finding appears to be that the 
occurrence of rupture requires a critical extent of infarction (Gao, 2005;Gao et al., 2010b).  
It has also been reported that the gender and strain of mice plays a role in the risk of 
rupture with males being at greater risk than females (59% for males vs. 23% for females) 
(Gao, 2005) and the greatest incidence occurring in the 129sv strain compared to the 
C57Bl/6 strain (62% for 129sv vs. 33% for C57Bl/6) (Gao, 2005).  Ageing is also a factor 
for rupture incidence; older mice (12 months old) demonstrated greater LV remodelling 
with a higher incidence of rupture (40.7%) compared to younger mice (3 months old; 
18.3%) (Yang et al., 2008).  In light of these reports, a lower risk strain (C57Bl/6) and 
younger animals (8-10 weeks of age) were used for this study to try to minimise the 
incidence of rupture and promote full recovery to the 4-wk and 8-wk time points.  From 
these studies, rupture incidence for male C57Bl/6 mice were reported to be 27% and 33% 
(Gao, 2005;Gao et al., 2010b) which is very comparable with our rupture rate (27%).  
Cardiac rupture was easily identifiable at autopsy following sudden death by the presence 
of blood clots within the chest surrounding the heart and by the presence of a visible tear 
on the LV free wall, although the latter was not always clearly evident.  The time-window 
for this event was always within the first week of MI peaking at day 3-5 which is 
consistent with what others have seen in mouse models of post-infarct rupture (Gao, 
2005;van der Borne, 2009). 
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3.4.2 MI alters the structural properties of the heart 
3.4.2.1 MI causes LV chamber dilation and wall thinning 
MI induces a series of complex changes to the size, shape and function of the heart as part 
of LV remodelling (Pfeffer & Braunwald, 1990).  One of the earliest features of 
remodelling after MI is LV chamber dilation caused by infarct expansion through loss of 
cardiomyocytes (Weisman et al., 1988) or side-to-side slippage of cardiomyocytes (Gerdes 
& Capasso, 1995;Olivetti et al., 1990).  Side-slippage of cardiomyocytes occurs because of 
the loss of collagen holding the cells together through degradation by MMPs which 
permits them to move (Whittaker et al., 1991).  Cardiomyocyte cell death also contributes 
to the process because as they die, the neighbouring viable cells are no longer held in place 
and are also able to slip (Gajarsa & Kloner, 2011).  In the present study, it was found that 
after 4-wk and 8-wk post-MI, mice displayed a ≈3.6-fold and ≈2.5-fold increase 
respectively in LV chamber area together with reduction in LV infarct thickness by 90% 
and 75% respectively, findings which are consistent with a dilated LV chamber.  These 
measurements were taken from histological slices post-mortem which are acceptably less 
accurate than for example in vivo imaging methods such as echocardiography and MRI due 
to the tissue shrinkage associated with histological processing which may underestimate 
true dimensions.  However, efforts were made to enable as accurate measurements as 
possible using histology methods by use of serial sections and using area-based chamber 
size measurements rather than radius/diameter which could be subject to error if there was 
any deformation of the heart on the slide.  Despite histological limitations, a study by 
Nahrendorf et al. (2000) found that MRI vs. histologic-based methods of LV dimensions 
correlated well (R=0.97) in a rat MI model which is encouraging for the measurements in 
our study (Nahrendorf et al., 2000).  Furthermore the findings are further supported by 
increased end-diastolic LV volumes observed by PV methodology in the 4-wk and 8-wk 
infarcted heart also consistent with LV chamber dilation.  Chamber dilation leads to an 
increase in systolic and diastolic wall stress; this occurs because the increase in LV radius 
increases the wall stress and oxygen demand by Laplace’s law (Pfeffer et al., 1991a).  
Elevated wall stress triggers eccentric hypertrophy (end-to-end lengthwise cell 
enlargement) in the non-infarcted myocardium by causing altered expression of genes 
which encode contractile proteins (e.g. β myosin heavy chain) for assembly of new 
sarcomeres (Sadoshima et al., 1992).  Over time however as the heart undergoes ongoing 
remodelling, cardiac function significantly deteriorates as the LV chamber becomes so 
enlarged that it begins to severely impair contractile function.  Dilated cardiomyopathy is a 
Kirsty K. Foote, 2012  Chapter 3  
176 
 
serious problem for patients as once this stage is reached it is very difficult to reverse; 
approximately 1 in 3 cases of congestive HF are due to a dilated cardiomyopathy (Jameson 
et al., 2005). 
3.4.2.2 MI leads to cardiac hypertrophy 
A dilated ventricle can trigger hypertrophy of surviving myocardium in attempts to 
attenuate further dilation, offset the elevated load and wall stress resulting from infarct 
expansion and stabilise contractile function (Sutton & Sharpe, 2000).  There are two forms 
of hypertrophy (concentric and eccentric) which is determined by the type of load applied 
to the heart.  Pressure overload causes cardiomyocyte thicknening (concentric 
hypertrophy) by the parallel addition of new sarcomeres, while volume overload elicits 
cardiomyocyte lengthening (eccentric hypertrophy) by the in-series addition of new 
sarcomeres.  LV remodelling post-MI is primarily a state of volume overload and thus 
leads to cardiomyocyte lengthening as part of eccentric hypertrophy (French & Kramer, 
2007).  Cardiomyocytes in the non-infarcted regions can increase in length as a result of in-
series addition of sarcomeres as described previously (Gerdes & Capasso, 1995) which at 
the organ level manifests as an increase in heart weight.  In the present study, hearts 
showed a progressive increase in heart weight (increased heart weight-to-tibial length 
ratio) after MI, with heavier hearts after 4-wk which continued to increase by 8-wk.  
Concurrent with the increased heart weight was a 14% increase in cardiomyocyte length 
but no change in cardiomyocyte width at 4-wk post-MI (but no significant differences in 
cardiomyocyte cross-sectional area) as shown in Figure 3.6C(ii-iii).  This is in agreement 
with what others have found, for example Zhang et al. (1998) reported a 10% increase in 
cardiomyocyte cell length with no change in cell width 3-wk post-MI in a rat model 
(Zhang et al., 1998) and Scherrer-Crosbie et al. (2001) also found no change in 
cardiomyocyte width in a mouse model of MI after 4-wk (Scherrer-Crosbie et al., 2001).  
An increase in cardiomyocyte length with no change in cell width is consistent with 
eccentric hypertrophy observed in MI, although concentric hypertrophy has been known to 
occur during MI in addition to eccentric hypertrophy (Runge & Patterson, 2006).  Together 
these results demonstrate the hearts have undergone hypertrophy consistent with LV 
remodelling after MI and that cardiomyocyte elongation is likely to be contributing to the 
increase in heart weight observed. 
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3.4.2.3 MI causes increased collagen deposition 
Another important characteristic of remodelling is the increased synthesis and deposition 
of collagen to support the weakened myocardium and stabilise the infarct (Van et al., 
2000).  After MI, collagen levels in the heart were found to increase 3-fold and 4.7-fold 
after 4-wk and 8-wk respectively.  Collagen levels tended to be higher at 8-wk (compared 
to 4-wk) however this did not reach statistical significance.  This may be due to low n 
numbers for this group (sham n=3, 8-wk MI n=3) and larger numbers may have shown a 
statistical difference.  Increased collagen deposition could explain why no further dilation 
was observed from 4-wk to 8-wk as collagen can prevent cardiomyocyte slippage, one of 
the primary causes of LV expansion and dilation (Whittaker et al., 1991).  Fibrosis after 
MI can also decrease the compliance of the ventricle leading to stiffer myocardium during 
diastole (Raya et al., 1988;Litwin et al., 1991).  This occurs because excessive 
accumulation of collagen around myofibres reduces the passive viscoelasticity of the 
myocardium which limits normal diastolic recoil, impairs tissue compliance and 
compromises length-dependent muscle fibre shortening (Burlew & Weber, 2002).  
Therefore, the increased cardiac collagen observed may explain why the ventricles were 
stiffer after MI as PV data using the EDPVR demonstrated.  A trend towards higher 
collagen levels at 8-wk would parallel with the progressively stiffer ventricle at 8-wk.  
Increased myocardial stiffness has been known to occur in the post-MI heart during the 
healing phase in humans (Diamond & Forrester, 1972) and experimental animal models 
(Hood, Jr. et al., 1970) which is in agreement with the results found in this present study.  
However investigations have also led to variable findings regarding cardiac stiffness post-
MI, these refer to the very early stages of MI (<1 day).  Forrester et al. (1972) found a 
significant increase in LV compliance (reduced stiffness) 1 hr after induction of MI in the 
canine model (Forrester et al., 1972).  Increased myocardial stiffness is a major cause of 
diastolic dysfunction which is important because diastolic dysfunction is considered an 
independent predictor of mortality in CVD patients (Aljaroudi et al., 2012). 
 
3.4.2.4 The CAL technique produces comparable infarct sizes 
Data from other mouse MI models have reported that the CAL method can produce infarct 
sizes from 25-50% (Lutgens et al., 1999;Patten, 1998).  Using the CAL method in our 
model produced a mean infarct size of 37.6 ± 4.2 and 39.4 ± 5.4% at 4-wk and 8-wk 
respectively.  This model therefore had infarcts of comparable size with other mouse 
infarct models.  Infarct size was not different between 4-wk and 8-wk.  This suggests that 
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the size of the infarct had reached completion by 4-wk with no further increase in size 
thereafter to 8-wk.  Yang et al. (2002) reported a similar finding with identical infarct sizes 
in mice post-MI of (as % of LV) 47.3 ± 5% at 4-wk and 45.3 ± 5% at 8-wk (P>0.05) – 
through further examinations at different time points (3-wk, 4-wk, 8-wk, 16-wk and 24-
wk) they found that the infarct formation was complete by 3-wk and infarct size did not 
increase after this point (Yang et al., 2002).  Based on these findings this may explain why 
no change in infarct size was observed in our model from 4-wk to 8-wk as the infarct may 
have reached its full size by 3-wk.  Despite equivalent infarct size, the progressive increase 
in cardiac weight observed between 4-wk and 8-wk suggests the hypertrophic response 
could have occurred independently of infarct size and may be a time-related response.  
This result does however differ from previous reports: for example the current view is that 
after MI, the extent of cellular hypertrophy in surviving tissue is proportional to the 
magnitude of cardiomyocyte loss which has been demonstrated in a number of studies 
showing a positive correlation between the extent of cardiomyocyte hypertrophy with 
infarct size in rats (Anversa et al., 1986;Anversa et al., 1990).  However hypertrophy is 
known to be a progressive process which can increase over the course of the remodelling 
period with time and may not be strictly regulated by the degree of infarction as has been 
shown in mice where heart weight continued to increase with no change in infarct size 
(Yang et al., 2002). 
3.4.3 Early onset of structural remodelling can have adverse 
effects 
A small percentage (5%) of animals undergoing CAL developed very severe symptoms in 
the first week after the procedure including severe respiratory distress which autopsy 
assessment revealed may be due to severe adverse remodelling.  These animals displayed a 
marked increase in heart weight (32% greater than 4-wk MI P<0.05; data not shown) 
which was comparable to the level seen at 8-wk (15.7 ± 3.0 vs. 13.4 ± 1.4 mg/mm; severe 
MI (n=4) vs. 8-wk MI (n=11); P<0.05; data not shown).  However, these hearts developed 
a greater degree of adverse remodelling in terms of significantly greater chamber dilation 
(than 4-wk and 8-wk hearts; see below) and also evidence of severe pulmonary congestion 
in these animals which showed 65% increase in lung weight when compared to both 4-wk 
and 8-wk animals respectively.  This may explain why animals at 8-wk MI (which had 
comparable HW/TL ratio to the animals with the severe phenotype) did not exhibit the 
same symptoms.  It is likely that these animals were suffering from acute congestive HF, 
however due to the severity of their condition it was not possible to perform any functional 
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measurements on them to confirm this.  Examination of histological heart sections also 
revealed that these animals had severe LV chamber dilation compared to animals that 
survived to 4-wk and 8-wk post-MI, as mentioned above, with 1.9-fold and 2.1-fold greater 
chamber area respectively.  Advanced dilation and wall thinning does not usually occur 
until the chronic phase of MI in mice (Bayat et al., 2002), however the level of acute 
adverse remodelling observed in these animals may explain their symptoms.  Severe 
dilation causes an increase in systolic wall stress (Pfeffer & Braunwald, 1990) and loss of 
cardiomyocyte contractility (Gomez et al., 2001) to a level that significantly affects the 
pump function of the heart and reduce the EF and CO to a level insufficient to meet the 
demands of the body, leading to HF (Isaaz et al., 1989).  The findings from this small 
subset of animals (n=2) are consistent with a study by Gao et al., 2000 who have reported a 
similar small subset of mice that did not survive past the first week of CAL and showed 
significant chamber dilation compared to mice that survived to longer time points (Gao et 
al., 2000).      
3.4.4 MI leads to impairment of cardiac function 
After chronic MI in mice, chamber dilation and infarct thinning can adversely lead to 
systolic and diastolic dysfunction (Pfeffer et al., 1991b).  LV PV measurements are 
considered the ‘gold standard’ for measuring cardiac function in vivo and in this model, PV 
measurements revealed an overall decline in cardiac function after MI.  There was a 
significant reduction in contractile function at 4-wk and 8-wk post-MI as evidenced by 
reduced LVESP and reduced dP/dtmax.  There was also a significant decrease in diastolic 
function with raised LVEDP and reduced relaxation rates (-dP/dtmin) and duration of 
relaxation (τ) consistent with impaired relaxation and filling.  Systolic and diastolic 
function were reduced to the same degree at 4-wk and 8-wk, suggesting there was no 
further deterioration in function from 4-wk to 8-wk after MI.  This has been observed by 
others; one study reported no further decline in dP/dtmax and EF beyond 12-wk post-MI in 
mice (Pons et al., 2003) while another showed no further worsening of function in terms of 
ESP, dP/dtmax and dP/dtmin between 1-wk and 3-wk post MI in mice (Lutgens et al., 1999).  
This finding is consistent with the sustained structural properties between 4-wk and 8-wk 
such as infarct size, degree of LV dilation and infarct thickness.  The progressive increase 
in cardiac weight did not improve function between 4-wk and 8-wk; however it may have 
contributed towards protecting the heart from further decline.  Alternatively, it may be that 
the degree of remodelling had not reached advanced stages and the heart was still well 
compensated.  This is confirmed by the finding that, despite marked LV dysfunction, 
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hearts had preserved SV and CO after 4-wk and 8-wk.  This is known to occur during 
compensated remodelling post-MI where there is surprisingly little change in the SV due to 
a compensatory rise in LV filling pressure – an increase in both EDP and EDV (the latter 
through dilation) shifts the ventricular function curve upwards restoring contractile energy 
through the Frank-Starling mechanism allowing SV and CO to be near normal (Levick, 
2010).  Although there are reports which have observed a reduction in CO in mouse 
models of MI by 8-wk (Shioura et al., 2007), it has also been found that CO is conserved 
after 8-wk in mice with MI similar to the findings of the present study; for example it has 
been previously shown from PV loop measurements in a mouse model of MI that there 
was no reduction in CO by 12-wk post-MI compared to sham (Pons et al., 2003).  In our 
mouse model conservation of SV and CO would suggest the hearts had not reached the 
stages of HF by 8-wk.  Examinations of the liver and lung weights have further confirmed 
this by the absence of any signs of systemic or pulmonary congestion.  These findings are 
not unusual as it has been reported that it can take up to 18 weeks for mice with MI to start 
showing signs of HF (Bayat et al., 2002). 
  
3.4.5 MI alters electrical activity and increases the frequency of 
cardiac arrhythmia 
As well as mechanical dysfunction, MI can alter the normal electrical functioning of the 
heart.  This occurs because the infarcted myocardium represents an area of altered 
substrate for the normal depolarisation and repolarisation of the heart leading to conduction 
disturbances (Peters, 1995).  Our model demonstrated conduction abnormalities associated 
with ventricular depolarisation and repolarisation such as negative Q waves, ST depression 
and T-wave inversion.  These findings are consistent with what has been reported on 
changes in ECG seen in mouse MI (Wehrens et al., 2000).  These morphological changes 
observed on the ECG were very similar between 4-wk and 8-wk.  The model also showed 
an increased propensity for ventricular arrhythmias in the form of VPC.  VPC arrhythmias 
are the most common type of cardiac arrhythmia in MI and occur when an action potential 
is fired from a region other than the SA node prior to normal conduction resulting in a 
premature or ectopic beat (Horan & Kennedy, 1984).  These occur during MI as a result of 
the myocardial scarring disrupting the normal conduction system of the heart.  Furthermore 
due to the loss of cell-cell communication by the scarred tissue (Peters, 1995) neighbouring 
cardiomyocytes are more likely to depolarise spontaneously (‘irritated myoctes’) and fire 
off premature beats – this explains why VPCs usually arise from the infarct or peri-infarct 
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regions (Bogun et al., 2008).  At the molecular level, VPCs largely occur due to the 
remodelling of (i) ion channels, (ii) Ca2+ handling proteins and (iii) gap junction proteins 
which predispose the heart to electrical disturbances mainly after depolarisations.  For 
example, during MI NCX is known to be up-regulated which increases the inward INa/Ca 
during SR release leading to extrusion of a larger fraction of released Ca2+ (increasing the 
transient inward Na+ current, Iti).  There is also a reduction in the inward rectifier K+ 
current (IK1) which for any given Iti could produce a greater depolarisation which means 
that it may be more likely to trigger an AP (Pogwizd et al., 2001).  The incidence of VPC 
arrhythmias is markedly increased in heart disease (by 90% in patients with coronary 
artery disease and ischaemia) (Ghuran & Camm, 2001).  VPCs are an important predictor 
of adverse outcome; in patients with MI, a frequency of >10 VPC per hour is associated 
with a greater risk of sudden death (Laidlaw et al., 2007).  In our model, the frequency of 
VPC arrhythmia was not different between 4-wk and 8-wk which is not surprising given 
the similar degree of LV remodelling between these two groups.  Collectively, the findings 
reveal that our mouse model demonstrates cardiac arrhythmias consistent with MI. 
 
3.4.6 Summary 
In summary, these data show that the mouse model of MI developed for this study 
demonstrates both structural and functional alterations of the heart comparable with other 
published mouse models of MI using the CAL method. This model is therefore a suitable 
model of MI for use in subsequent studies in this thesis.








Expression of Runx in the heart in a mouse model 
of myocardial infarction 




MI is the leading cause of HF and premature death (Scarborough, 2010).  The loss of 
viable myocardium after MI triggers a sequence of structural and geometric alterations to 
the heart as part of LV remodelling which can eventually lead to progressive dysfunction 
and the inability of the ventricle to maintain output sufficient for the body’s metabolic 
needs (Weber et al., 1991a).  LV remodelling is a complex process involving a multitude 
of cellular and molecular mechanisms (Colucci, 1997).  While these mechanisms are 
believed to be beneficial initially, many of them can become detrimental and lead to long-
term adverse effects in patients (Pfeffer & Braunwald, 1990).  Despite extensive 
investigations, the specific pathophysiological pathways responsible for the decline into 
HF are not fully understood.  Novel insight into the regulatory mechanisms that contribute 
to the subsequent decompensatory processes of post-infarction remodelling are therefore 
required to slow this deterioration process and improve treatment strategies. 
4.1.1 Altered gene expression in MI 
Clinical and animal studies of MI have revealed a number of cellular changes that 
contribute to the functional and structural changes of remodelling including cardiomyocyte 
hypertrophy (Litwin et al., 1991) and ECM alterations (Van et al., 2000).  Although the 
molecular mechanisms involved in remodelling are numerous and complex, it is clear that 
substantial alterations in gene expression are involved to afford the changes observed.  
Altered gene expression after MI has been widely reported in both human and 
experimental animal models (Stanton et al., 2000;Gidh-Jain et al., 1998;LaFramboise et 
al., 2005).  Studies have revealed that MI can modify the expression of genes involved in 
calcium-handling (Swynghedauw, 1991), contractile function (Yue et al., 1998), the ECM 
(Weber, 1997) and the RAA system (Holtz, 1998).   
4.1.1.1 Altered gene expression in different regions of the heart in MI 
Changes in gene expression can be seen as a global change across the whole heart but 
studies particularly from rodent models of MI have shown that altered gene expression 
post-MI can occur differentially and tends to be selective for specific regions of the heart 
(Melle et al., 2006;Xu et al., 2004;Schneider et al., 2007).  Most commonly, genes are 
altered differently in the infarcted versus non-infarcted regions.  In the early post-infarction 
period (24-48 h) a broad range of genes are activated or up-regulated in the remote region 
while many are repressed in the infarct region; the specific cell types were not specified 
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(LaFramboise et al., 2005).  Early remote gene expression is largely activation of genes 
involved in the inflammatory response including the interkeukins (IL1α, IL1β, IL6, IL12α, 
IL18) which can increase 1.5 – 5 fold and the TNFα superfamily which have been 
observed in mice to increase ~2 fold compared to sham equivalent regions (LaFramboise et 
al., 2005) as part of the initial compensatory phase to limit injury expansion (Brivaniou & 
Darnell, 2002;Frangogiannis et al., 2002).  Other genes which show increased expression 
in the remote region at this early time point include homeobox genes which encode 
homeobox transcription factors which are involved in developmental processes (RAX, 
LH2, HOXA1; 2-4 fold increase compared to sham) and zinc finger factors which are a 
group of transcription factors (ZPF103, HR, GATA1; 2-3 fold increase compared to the 
matching sham region) (LaFramboise et al., 2005).   
Conversely, at a later stage of the MI (4-wk) the reciprocal pattern between infarct and 
remote regions is reversed, and many genes are up-regulated in the infarcted region while 
expression in the remote is reduced.  Genes up-regulated in the infarct region are mainly 
ECM genes (collagen 5A3, MET1A, P4HB, contactin, osteoadherin, osteopontin) 
(Frangogiannis et al., 2002a;Jugdutt, 2003).  Genes which show early increase in the 
remote but low expression in the infarct (24h) but then lower in the remote and higher in 
the infarct at the later time point (4-wk) include the genes encoding MMPs which degrade 
collagen (MMPs 2, 9, 12, 23; 2-5 fold higher in infarct compared to sham), ADAM15 
(glycoproteins for cell adhesion; up 2 fold in infarct compared to sham) and 
metallothioneine 1 and 3 involved in zinc binding which increase 2 fold in the infarct 
compared to the equivalent sham region (LaFramboise et al., 2005).  In the weeks after the 
MI, a large number of gene expression alterations are reported to occur in the infarct and 
peri-infarct regions only with little or no change in areas remote; these include genes 
encoding TGF-β1, part of a super family of cytokines although the cell type was not 
specified (Vandervelde et al., 2007), fibulin-2, a Ca2+-binding glycoprotein located in the 
vascular endothelial cells only (Tsuda et al., 2012) and fibroblast growth factor receptor 1 
(FGFR-1) found to be 1.4 fold higher in cardiomyocytes (Wang et al., 2007) which all 
show increased levels in the peri-infarct alone.  Regional patterns of altered gene 
expression are not surprising given the disparate remodelling processes in each region of 
the infarcted heart, more details on this are discussed later (French & Kramer, 2007).  This 
may largely be contributing to the difficulty in trying to resolve the molecular mechanisms 
associated with adverse remodelling and HF.   
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4.1.2 Transcription factors in MI 
Microarray technology has emerged as a large-scale approach for the identification of 
altered target genes during MI (Kaab et al., 2004).  In one study, this approach identified 
over 700 different genes which were altered after MI in the remodelled myocardium alone 
(Stanton et al., 2000) and this is believed only to represent a fraction of the genes which 
show altered expression patterns after MI.  However gene expression profiles are complex 
and require detailed understanding of the precise regulatory mechanisms underlying the 
control of their expression patterns. Transcription factors have therefore emerged as 
important targets in cardiac disease as they directly regulate the expression of many 
cardiac genes in response to specific physiological and pathophysiological signals.  
Furthermore, one of the earliest responses following cardiac injury is the activation of 
transcription factors (LaFramboise et al., 2005).  Transcription factors are therefore key for 
understanding the regulatory mechanisms and coordinated changes in cardiac gene 
expression during disease (Buermans et al., 2005;Bruneau, 2002).  Examples of 
transcription factors which have been shown to have altered expression post-MI are 
detailed below.   
CARP and TSC-22:  Additionally, the transcription factors CARP and transforming 
growth factor-β-stimulated clone (TSC)-22 both show elevated levels of expression in rat 
remodelled myocardium and have specific roles in cardiac gene regulation (Stanton et al., 
2000).  CARP is constitutively expressed in the heart (within the nucleus of 
cardiomyocytes) and is up-regulated in a variety of different cardiac pathologies; including 
failing canine ventricular tissue (Zolk et al., 2002), hypertrophied mouse hearts (Ihara et 
al., 2002), hypertrophied rat models (aortic banding, SHR and Dahl salt-sensitive rats) 
(Aihara et al., 2000) and also in explanted ventricular tissue from human HF patients (Zolk 
et al., 2002).  CARP is believed to be induced by both acute and chronic pressure-overload 
and stress pathways (Aihara et al., 2000) and leads to contractile disturbances through 
repression of genes encoding contractile proteins.  TSC-22 is also over-expressed in rat 
remodelled cardiac tissue and is believed to be important for mediating cardiac 
myofibroblast differentiation (Yan et al., 2011). 
HIF1-α:  Another example of a transcription factor which has been characterised during 
MI is the hypoxia-inducible factor 1 alpha (HIF1-α) which activates gene expression of 
glycolytic enzymes and glucose transporters (Semenza et al., 1994;Semenza, 1996).  HIF1-
α levels are increased in the nuclei of cardiomyocytes of the heart by ~ 2 fold in a rat 
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model of MI and hamster model of cardiomyopathy and HF (Kakinuma et al., 2001).  The 
same study revealed that HIF1-α mRNA was increased ~3.3 fold in cultured rat 
cardiomyocytes that were treated with a mitochondrial inhibitor Cobalt(II) Chloride 
(CoCl2), therefore this degree of mRNA increase in HIF1-α led to an increase in glycolysis 
believed to be a protective response against impaired energy metabolism during MI 
(Kakinuma et al., 2001).  Transgenic studies with HIF1-α in mice have revealed that HIF1-
α is required to reduce the extent of infarction (infarct size) and limit the progression of 
dysfunction in mice post-MI by promoting angiogenesis (Kido et al., 2005). 
WT-1:  Recently the transcription factor Wilms’ tumour protein (WT-1) has also been 
shown to have altered expression in MI (Finsen et al., 2004).  WT-1 expression was 
increased in non-infarcted myocardium (cell type not specified).  WT-1 is known to be a 
transcriptional regulator of syndecans, a family of transmembrane proteoglycans which 
have also themselves been implicated in MI (Finsen et al., 2004) as having increased 
expression in non-infarcted mouse myocardium post-MI and have been shown to be 
critical mediators in cardiac fibrosis (Frangogiannis, 2010). 
4.1.3 RUNX transcription factors 
As detailed in Introduction chapter (Chapter 1) RUNX proteins are novel transcription 
factors in the context of myocardial injury.  RUNX1 has been shown to be up-regulated in 
the human heart in response to MI relative to healthy hearts (Gattenlohner et al., 2003) and 
may represent a novel candidate gene for myocardial injury.  RUNX1 has been shown to 
selectively regulate the expression of genes that encode important muscle proteins during 
disrupted electrical activity (e.g. in skeletal muscle) which are also found in cardiac tissue 
such as phospholamban, sodium channel type V, osteopontin and thrombospondin (Wang 
et al., 2005).  During these conditions RUNX1 elicited a protective role in the diseased 
muscle which may also be applicable to similar conditions of disrupted electrical activity 
in cardiac injury.  RUNX2 has also been shown to have negligible expression in the 
healthy heart (negative with IHC in normal rat cardiomyocytes) (Custodio et al., 2012) but 
is up-regulated under conditions of myocardial disease such as human DCM and HCM 
(Sanoudou et al., 2005), aortic valve calcification (Garg et al., 2005), atherosclerosis 
plaque formation (Tyson et al., 2003) and during myocardial fibrosis and dysfunction 
(Elsherif et al., 2008).  RUNX3 expression during cardiac disease is virtually unknown.  
However, due to its links with RUNX1 cross-regulation (Levanon et al., 2001a) and, like 
RUNX2, it is a direct target of Notch signalling pathways which are known to be altered in 
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cardiac disease (Fu et al., 2011) it is therefore possible there may be altered expression 
patterns of RUNX3 like the other RUNX proteins.  Despite this information, knowledge of 
the expression of RUNX proteins within the heart during CVD is limited.  RUNX 
expression has not clearly been investigated in terms of its altered expression during 
cardiac disease in an animal model of MI.  No evidence currently exists on their expression 
in different regions of the heart, over different time-points post-MI or any links with the 
cardiac expression in relation to the functioning of the heart. 
4.1.4 Aims 
The aims of the work in this chapter were to perform a detailed characterisation of the 
expression of Runx gene/protein expression in a mouse model of MI in terms of changes in 
expression, including how these changes develop over time, and in particular regions of the 
heart, and examine the links with dysfunction in response to MI. 
4.2 Methods 
4.2.1 Induction of MI 
Mice underwent MI as described previously in the General Methods Section 2.1.  Sham 
controls underwent the same procedure but without ligation.  All subsequent experimental 
measurements detailed in this chapter were carried out either 4-wk or 8-wk post-MI except 
in the case of animals which developed severe MI (characterised by symptoms of laboured 
breathing, lung congestion and significant LV chamber dilation) which were sacrificed 
after 1-wk. 
4.2.2 Tissue harvest 
4.2.2.1 Heart tissue 
At the appropriate time-point after MI, hearts were rapidly excised and perfused retrograde 
via the aorta with ice-cold saline to remove the blood.  For heart tissue required for qRT-
PCR, the atria and blood vessels at the base of the heart were removed and then either the 
intact ventricles were snap-frozen (whole heart measurements) or hearts were dissected 
into regions (regional measurements).  This was performed using a microsurgical 
microscope by carefully dissecting away the infarct region (easily distinguishable as the 
whitened/fibrous thinned area), the peri-infarct (defined as the ring of myocardium around 
the infarct ~1mm in width; Sirius red stained images of the heart provided knowledge of 
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the location of the peri-infarct in relation to the scar), an area of remote LV furthest from 
the infarct at the base of the heart and an area of RV free wall to yield four different 
regions which were snap-frozen separately in liquid nitrogen.  Care was taken not to 
include any scar tissue in any regions other than the infarct by removing the whole scar 
region first and examining that the other regions did not contain any fibrous (whitened) 
tissue under high magnification (x25).  The ‘equivalent∗’ regions of the sham heart were 
harvested as controls by dissecting a region of apex (to match the infarct), a 1 mm region 
adjacent to the apex (to match the peri-infarct) and similar regions of remote LV and RV 
free wall as in the infarcted heart.  These will be labelled sham apex, sham ‘peri-infarct’ 
and sham remote LV throughout.  All heart tissue was stored at -80°C until needed.  Hearts 
for IHC were also perfused to remove all blood and the whole intact heart (including 
ventricles, atria and major blood vessels) was placed into 10% neutral buffered formalin 
for a minimum of 24 h. 
4.2.2.2 Positive and negative control tissue 
Adult mouse thymus was harvested either from stock mice or sham mice as positive 
control tissue for IHC as all RUNX proteins are highly expressed in adult thymus (Satake 
et al., 1995;Woolf et al., 2003).  The thymus is located in the upper thoracic region and lies 
close to the base of the heart (as shown in Figure 4.1).  Briefly, the entire thymus (both 
lobes) was removed and rinsed in ice-cold saline to remove any blood and placed in 10% 
neutral buffered formalin for a minimum of 24 h. 
 
Figure 4.1  Location of mouse thymus in the upper thorax above the base of the heart. 
Arrow indicates the location of the thymus.             
                                                     
* When referring to corresponding sham heart regions that do not by definition exist (e.g. peri-infarct) but are necessary 
to show control for the same region in the MI heart, these will be indicated by single inverted commas (e.g. sham ‘peri-
infarct’) where appropriate.  The sham control region for the infarct will be denoted as the sham apex.  Remote LV will 
be stated the same for both sham and MI hearts. 
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4.2.3 Cardiomyocyte isolation and purification 
Adult male C57Bl/6 control stock mice which had not undergone any previous surgery 
were used for these set of experiments.  LV cardiomyocytes were isolated as described 
previously in the General Methods Section 2.10.1.  The cells were kept on ice while a 
second cell isolation from a different heart using the same procedure was performed.  The 
cells from the two hearts were then pooled to yield sufficient RNA for subsequent 
experiments.  Cardiomyocytes were separated from other cell types using a filtration 
method as detailed in Section 2.10.3 of the General Methods.  All of the following steps 
were performed on ice to minimise RNA degradation.  A sample of the pooled cells (2 ml) 
was taken prior to any filtration as a pre-filtration control (i.e. containing all cell types) and 
was lysed in Qiazol lysis buffer and stored at -80°C until required.  The remaining 
suspension was passed through a series of filters:  firstly, a 300 µm nylon filter to separate 
large fragments of tissue from the cells followed by a 40 µm nylon filter to catch the 
cardiomyocytes with washes in between with ice-cold HBSS.  Cardiomyocytes caught on 
the 40 µm filter were rinsed off into a separate tube with ice-cold HBSS, spun and lysed in 
Qiazol lysis buffer and stored at -80°C until required as the purified cardiomyocyte 
sample.  This method was performed in order to verify the presence of Runx in 
cardiomyocytes alone by separating cardiomyocytes from other cell types (mostly 
fibroblasts and smooth muscle cells) using a filtration method published by (Kosloski et 
al., 2009).  The authors of this method report that this produces a purified population of 
>98% cardiomyocytes. 
4.2.4 IHC and quantitative imaging 
4.2.4.1 IHC 
The heart was removed, perfused to remove all blood and placed into 10% neutral buffered 
formalin as noted in Section 4.2.2.1 above before being submitted to the Histopathology 
Unit.  All immunohistochemistry was performed by Mrs Lynn Stevenson at the 
Histopathology Unit at the University of Glasgow as described fully in the General 
Methods Section 2.11.  Briefly, following adequate fixation hearts were embedded in 
paraffin wax and 1 µm-thick longitudinal sections were cut parallel to the long axis of the 
heart.  Sections were incubated for 60 min with a primary antibody (rabbit polyclonal 
1:400, Abcam, U.K.) for RUNX1 or with antibody dilution buffer (negative control) 
followed by 30 min with a biotinylated secondary antibody (anti-rabbit) attached to a HRP 
conjugate (Dako EnVision system, Dako, Denmark).  Sections were then treated with 2 x 5 
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min incubations with the chromagen DAB (K5007 Dako, Denmark) before the final 
dehydration and mounting.   
4.2.4.2 Quantification of IHC staining 
Sections were examined under a microscope (Olympus Bx51) and photographed using a 
camera (Olympus DP71) with accompanying software (Cell D) and analysed using ImageJ.  
A 5x4 grid (ImageJ plug-in) was fitted over the image to facilitate counting.  The total 
number of positively-stained nuclei (brown coloured) and negatively-stained nuclei (blue 
coloured) were counted in each region (using a 60x lens) and the percentage positive 
staining was calculated using the following equation: 
              











As the different cell types present were not specifically labelled with markers, no 
discrimination was made to exclude positive nuclei from any cell type.  Positive staining 
included any nucleus which was predominantly brown.  Where it looked like there may be 
two overlapping nuclei, this was counted as one only.  This was repeated for three areas 
per region and a mean value taken.   
4.2.5 RNA extraction 
Total RNA was extracted from frozen heart tissue or frozen cell lysates using the 
miRNeasy Mini Kit (Qiagen, U.K.) based on a guanidine thiocyanate/phenol/chloroform 
extraction method followed by ethanol precipitation according to the manufacturer’s 
protocol (full details are described in the General Methods Section 2.12). RNA extraction 
included on-column treatment with DNase I (Qiagen, U.K.) for 15 min at room 
temperature to remove genomic DNA.  RNA yield and purity was determined by 
measuring the absorbance at 260 nm and absorbance ratio 260/280 nm, respectively with a 
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies/Thermo Scientific, U.K.).  
RNA integrity was further determined by UV spectrophotometry and electrophoretogram 
(Bioanalyzer 2100, Agilent Technologies, U.K.).  Only RNA that met minimum purity 
standards (260/280 >1.8 and RIN >7) was used for subsequent experiments.  RNA was 
then incubated with a second DNase I treatment (Turbo DNA-free, Ambion, U.K.) for 25 
min at 37°C. 
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4.2.6 cDNA synthesis   
First strand cDNA was synthesised from 1 µg RNA by reverse transcription (RT) 
performed at 37°C for 1 h with Omniscript reverse transcriptase (Qiagen, U.K.) in a final 
volume of 50 µl containing dNTP, RNase inhibitors and oligo dT primers (Omniscipt 
Reverse Transcription kit, Qiagen, U.K.).  Reactions containing RNase/DNase-free water 
instead of reverse transcriptase enzyme served as negative RT controls (denoted RT-).   
4.2.7 Verification of cDNA synthesis 
cDNA (and RT- controls) samples were tested to verify successful RT using conventional 
PCR amplification.  PCR reactions were conducted in 10 µl final volume containing 
cDNA, PCR master mix (Thermo Scientific, U.K.), appropriate primers for Runx 
(Quantitect, Qiagen, USA) or Gapdh (Eurofins MWG Operon, Germany) and Taq DNA 
polymerase (Thermo Scientific, U.K.).  Reactions were performed using a Stratagene 
RoboCycler PCR machine for either 30 cycles (Gapdh) or 40 cycles (Runx1) to ensure 
analysis was taken from the plateau phase of the reaction.  Each cycle was 50s at 95°C, 50s 
at 55°C and 1 min at 65°C.  Amplified PCR products were then visualised by gel 
electrophoresis on a 2% agarose gel (NuSieve; prepared fresh) treated with EtBr and using 
3 µl PCR product mixed with 2 µl loading buffer into each well.  A DNA size ladder was 
run alongside each run (Promega, U.K.).  Successful RT reactions were confirmed by 
positive single bands of correct size for RT+ samples and no band in RT- control samples. 
4.2.8 qRT-PCR 
qRT-PCR was performed with cDNA and SYBR Green master mix (Applied Biosystems, 
U.K.) in 20 µl final volume reactions using the ABI 7500 machine with Sequence 
Detection software (Applied Biosystems, U.K.) to measure relative gene expression. Runx1-
3 were detected using appropriate Runx primers (1, 2 or 3; all Qiagen, USA) normalised to 
Gapdh (Eurofins MWG Operon, Germany) for heart tissue studies or PPIA (Qiagen, U.K.) 
for purified cardiomyocyte preparations.  (Gapdh was found to be the most stable gene for 
the MI heart tissue work while PPIA was recommended as a stable gene for the cell 
preparations according to the published method used for the protocol by (Kosloski et al., 
2009)).  In all qRT-PCR experiments, template-free (no cDNA) controls and RT- controls 
were always run in parallel with positive samples and each sample was run in triplicate for 
each experiment.  
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4.2.9 Interpretation of qRT-PCR data 
qRT-PCR results were analysed using comparative Ct calculations; either 2-∆∆Ct (regional 
comparisons relative to RV region), 2-∆Ct (whole heart or RV region between sham and MI) 
or 2-Ct (Gapdh stability) as recommended by accepted published methods (Schmittgen & 
Livak, 2008).  Statistical significance between regions within the same heart was tested 
using multiple regression analysis performed with SPSS software.  For comparisons of 
specific regions between sham and MI using unpaired samples, the student’s unpaired t-
test was used.  A value of P<0.05 was considered significant.  All data were tested for 
normal distribution using a histogram plot and by plotting residuals.  Triplicate 
measurements of Ct were assessed and any outliers removed using the Grubb’s Test for 
removing outliers as an accepted published method for normalising qRT-PCR data (Burns 
et al., 2005b).  This was only used when Cts were >1 Ct different to the others in the 
triplicate set.  A Grubb’s statistic of >1.00 was the criteria for removing an outlier value.  






=      Eq. 17 
 
Where G is the test statistic associated with the Grubb’s Test, Yi is the ith observation from 
the data set (suspected outlier), Ῡ is the sample mean (with outlier included) and SD is the 
standard deviation of the data set (with outlier included). 




4.3.1 Expression of Runx1 in the whole heart post-MI 
Runx1 mRNA levels were assessed in whole heart homogenates (LV + RV) 4-wk post-MI 
using qRT-PCR.  The results demonstrated firstly that Runx1 was present in sham hearts 
indicating a basal expression of Runx1 in the normal mouse heart (mean Runx1 Ct value of 
20.6 ± 0.7).  Although acceptable Ct ranges for detectable expression have not been 
specifically defined, it is generally considered in the literature (and from personal 
communication with companies specialising in qRT-PCR) that Cts ≤30 represent strong 
abundance of the gene, Cts of 31-35 indicate very low expression but in some cases can 
still be acceptable, and Cts of 38-40 indicate extremely weak/barely detectable expression 
(Goni et al., 2009;Sigma Aldrich, 2010).  The second finding was that Runx1 expression 
was significantly increased in the MI heart 4-wk post-MI to 247.7% of levels in 4-wk sham 
hearts (247.7 ± 66.3% increase; 4-wk MI (n=7) compared to 4-wk sham (100%; n=6); 
P<0.05; Figure 4.2A).  This was calculated using the ratio of (2-∆Ct (MI)/mean 2-∆Ct (sham)) 
* 100.  Expression of the housekeeping gene Gapdh was not different between sham and 
MI for whole heart expression as shown by equivalent Ct values (15.7 ± 0.5 vs. 15.6 ± 0.3 
raw Ct; 4-wk sham (n=6) vs. 4-wk MI (n=7); P>0.05; Figure 4.2B(i)) and equivalent 
expression (2.6 x 10-5 ± 8.9 x 10-6 vs. 2.3 x 10-5 ± 6.1 x 10-6; 2-Ct (Gapdh); 4-wk sham (n=6) 
vs. 4-wk MI (n=7); P>0.05; Figure 4.2B(ii)) between sham and MI indicating that Gapdh 
was a suitable internal control gene for these measurements.




Figure 4.2  Runx1 expression and Gapdh stability in the whole heart 4 weeks post-MI. 
(A) Runx1 gene expression measured by qRT-PCR using Runx1 specific primers on whole heart homogenates (LV + RV) 
from 4-wk MI hearts (n=7; black bar) relative to 4-wk sham hearts (n=6; dotted line).  (B (i)) Raw Ct values for the 
housekeeping gene Gapdh between sham (n=6; white bar) and 4-wk MI hearts (n=7; black bar).  (B (ii)) Resulting fold 
change in Gapdh between sham (n=6; white bar) and 4-wk MI hearts (n=7; black bar). Data presented are mean ± SEM. * 
P<0.05. 
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4.3.2 Expression of Runx1 in different regions of the heart post-
MI 
Runx1 expression was measured in different regions of the heart: infarct, peri-infarct, 
remote LV and RV to assess regional variation at 4-wk post-MI.  Expression in each region 
was normalised to Gapdh and expressed relative to the non-infarcted RV region of the 
same heart (RV set to 1.0) using the comparative Ct (2-∆∆Ct) method.  Runx1 levels in the 
RV region were not different between 4-wk sham and 4-wk MI as analysed using the 2-∆Ct 
method (0.23 ± 0.06 vs. 0.20 ± 0.09 2-∆Ct; 4-wk sham (n=5) vs. 4-wk MI (n=6); P>0.05; 
Figure 4.3A(ii)) which permitted regional comparisons between sham and MI.   
4.3.2.1 Runx1 expression in regions of the 4-wk sham heart 
Results from qRT-PCR revealed that Runx1 expression was uniform across all regions of 
the sham heart with no differences between any of the regions compared to the sham RV 
which was set to 1.0.  These differences were measured using the 2-∆∆Ct method.  This was 
true for the sham apex (1.4 ± 0.2 vs. 1.0 RQ; sham apex (n=4) vs. sham RV (n=4); P>0.05; 
Figure 4.3A(i)), the ‘peri-infarct’ equivalent sham region (1.1 ± 0.1 vs. 1.0 RQ; sham ‘peri-
infarct’ (n=4) vs. sham RV (n=4); P>0.05; Figure 4.3A(i)) and the sham remote LV (1.2 ± 
0.1 vs. 1.0 RQ; sham remote LV (n=4) vs. sham RV (n=4); P>0.05; Figure 4.3A(i)).      
4.3.2.2 Runx1 expression in regions of the 4-wk MI heart 
Runx1 expression was significantly increased in the infarct region of 4-wk MI hearts 
compared to the MI heart’s respective RV (5.1 ± 1.0 vs. 1.0 RQ; MI infarct (n=8) vs. MI 
RV (n=8); P<0.05; Figure 4.3A(i)).  The peri-infarct region of 4-wk MI hearts showed 
significantly higher Runx1 expression compared to its own RV region (1.8 ± 0.2 vs. 1.0 
RQ; MI peri-infarct (n=8) vs. MI RV (n=8); P<0.05; Figure 4.3A(i).  There were no 
significant differences observed between the remote LV region of the 4-wk MI heart 
compared to its respective RV region (1.4 ± 0.2 vs. 1.0 RQ; MI remote LV (n=8) vs. MI 
RV (n=8); P>0.05; Figure 4.3A(i).               
4.3.2.3 Comparison of regional Runx1 expression between 4-wk MI and 4-
wk sham 
Comparing each region between sham and MI (both at the 4-wk time point) showed that 
the infarct region of the MI heart had significantly higher levels of Runx1 expression than 
the equivalent apical sham region (5.1 ± 1.0 vs. 1.4 ± 0.2 RQ to its respective RV region; 
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4-wk MI (n=8) vs. 4-wk sham (n=4); P<0.05; Figure 4.3A(i)).  Runx1 was significantly 
increased in the peri-infarct region of 4-wk MI hearts compared to the equivalent ‘peri-
infarct’ region of the 4-wk sham heart (1.8 ± 0.2 vs. 1.1 ± 0.1 RQ to its respective RV 
region; 4-wk MI (n=8) vs. 4-wk sham (n=4); P<0.05; Figure 4.3A(i)).  Runx1 expression 
was not significantly different in the remote LV of 4-wk MI hearts compared to the remote 
LV region of 4-wk sham hearts (1.4 ± 0.2 vs. 1.2 ± 0.1 RQ to its respective RV region; 4-
wk MI (n=8) vs. 4-wk sham (n=4); P>0.05; Figure 4.3A(i)). 
 
Figure 4.3  Regional expression of Runx1 4 weeks post-MI. 
(A (i)) Runx1 expression measured by qRT-PCR in different regions of the heart in 4-wk sham (n=4) and 4-wk MI hearts 
(n=8); infarct, peri-infarct and remote LV were expressed relative to their respective RV region (dotted line). (A (ii)) 
Runx1 expression in the RV regions between 4-wk sham (n=5) and 4-wk MI (n=6). #P<0.05 between region of interest 
and the RV of the same heart; *P<0.05 between MI and sham. 
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4.3.3 Expression of Runx1 at different time points post-MI 
Regional Runx1 gene expression levels were additionally determined at different time 
points post-MI (Figure 4.4).  Regional expression at the 4-wk time point has been 
described in the previous section (Section 4.3.2).     
At the 8-wk time point Runx1 expression in the RV region between 8-wk sham and 8-wk 
MI was not different as analysed using the 2-∆Ct method (0.010 ± 0.004 vs. 0.010 ± 0.005 2-
∆Ct; 8-wk sham vs. 8-wk MI; P>0.05; Figure 4.4A(ii)).  This allowed for comparisons 
between 8-wk sham and 8-wk MI to be made. 
4.3.3.1 Runx1 expression in regions of the 8-wk sham heart 
As was observed in the sham heart at 4-wk, there were no differences in Runx1 expression 
between the different regions of the 8-wk sham heart (compared to the 8-wk sham heart’s 
respective RV) as measured using the 2-∆∆Ct method.  This was the case for the 8-wk sham 
apex (1.1 ± 0.2 vs. 1.0 RQ; sham apex (n=4) vs. sham RV (n=4); P>0.05; Figure 4.4A(i)), 
the ‘peri-infarct’ equivalent 8-wk sham region (1.2 ± 0.2 vs. 1.0 RQ; sham ‘peri-infarct’ 
(n=4) vs. sham RV (n=4); P>0.05; Figure 4.4A(i)) and the sham remote LV (0.8 ± 0.2 vs. 
1.0 RQ; sham remote LV (n=4) vs. sham RV (n=4); P>0.05; Figure 4.4A(i)). 
4.3.3.2 Runx1 expression in regions of the 8-wk MI heart 
All regions of the 8-wk MI heart were also compared relative to their non-infarcted RV 
region within the same heart using the 2-∆∆Ct method.  8-wk MI hearts demonstrated a 
significant increase in Runx1 expression in the infarct region compared to the respective 
RV of the 8-wk MI heart (3.7 ± 0.9 vs. 1.0 RQ; MI infarct (n=8) vs. MI RV (n=8); P<0.05; 
Figure 4.4A(i).  Runx1 expression was also significantly increased in the peri-infarct region 
compared to the respective 8-wk MI RV (2.2 ± 0.3 vs. 1.0 RQ; MI peri-infarct (n=8) vs. MI 
RV (n=8); P<0.05; Figure 4.4A(i)).  The remote LV region of the 8-wk MI heart also 
showed significantly elevated levels of Runx1 expression compared to the respective 8-wk 
MI RV (2.7 ± 0.6 vs. 1.0 RQ; MI remote LV (n=8) vs. MI RV (n=8); P<0.05; Figure 
4.4A(i)).    
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4.3.3.3 Comparison of regional Runx1 expression between 8-wk MI and 8-
wk sham 
Also similar to 4-wk MI, 8-wk MI hearts also demonstrated a significant increase in Runx1 
expression in the infarct region compared to the equivalent region in 8-wk sham (3.7 ± 0.9 
vs. 1.1 ± 0.2 RQ to respective RV region; 8-wk MI (n=8) vs. 8-wk sham (n=4); P<0.05; 
Figure 4.4A(i)).  Similar to the situation at 4-wk, the level of Runx1 expression in the peri-
infarct region at 8-wk post-MI was significantly higher compared to the corresponding 8-
wk sham region (2.2 ± 0.3 vs. 1.2 ± 0.2 RQ; 8-wk MI (n=8) vs. 8-wk sham (n=4); P<0.05; 
Figure 4.4A(i)).  Interestingly at 8-wk, Runx1 expression was significantly elevated in the 
remote region of the 8-wk MI heart compared to 8-wk sham remote (2.7 ± 0.6 vs. 0.8 ± 0.2 
RQ to respective RV region; 8-wk MI (n=8) vs. 8-wk sham (n=4); P<0.05; Figure 4.4A(i)).  
This finding of increased expression in the 8-wk remote LV compared to 8-wk sham 
remote is in contrast to the observations at 4-wk in which there was no significant change 
in Runx1 levels in the remote region between 4-wk MI and 4-wk sham.   
4.3.3.4 Runx1 expression between 4-wk MI and 8-wk MI 
Expression levels of Runx1 in the infarct region between 4-wk MI and 8-wk MI were not 
significantly different (5.1 ± 1.0 vs. 3.7 ± 0.9 RQ to respective RV region; 4-wk MI (n=8) 
vs. 8-wk MI (n=8); P>0.05; Figure 4.4B).  There were also no significant differences in the 
expression of Runx1 in the peri-infarct regions in the 4-wk and 8-wk MI heart (1.8 ± 0.2 vs. 
2.2 ± 0.3 RQ to respective RV region; 4-wk MI (n=8) vs. 8-wk MI (n=8); P>0.05; Figure 
4.4B).  However, in contrast to the similar expression levels in the infarct and peri-infarct 
regions, there was a significantly greater level of Runx1 expression in the remote LV at 8-
wk MI than the remote LV at 4-wk MI (1.4 ± 0.2 vs. 2.7 ± 0.6 RQ to respective RV region; 
4-wk MI (n=8) vs. 8-wk MI (n=8); P<0.05); Figure 4.4B). 
4.3.3.5 Runx1 expression at 1-wk in a severe MI phenotype 
The highest level of Runx1 expression was observed at a 1-wk time point following a 
severe MI phenotype (as defined by symptoms of laboured breathing, severe infarct 
thinning and lung congestion; see Section 3.4.3 Chapter 3).  It is believed that animals in 
this condition were suffering from acute HF although it was not possible to confirm this by 
functional assessment due to the severity of their condition.  These animals were killed in 
the interest of their welfare and the hearts excised immediately and treated in the same way 
as the other time points.  However, due to the small proportion of animals developing this 
phenotype, only one heart was available for qRT-PCR analysis from this group (n=1).   
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1-wk sham:  The control 1-wk sham heart showed the following levels of Runx1 
expression across the four regions: sham apex (0.3 vs. 1.0 RQ to respective RV; sham apex 
(n=1) vs. sham RV (n=1); Figure 4.4C(i)), the peri-infarct (1.1 vs. 1.0 RQ to respective 
RV; sham ‘peri-infarct’ (n=1) vs. sham RV (n=1); Figure 4.4C(i)) and the remote LV (1.4 
vs. 1.0 RQ to respective RV; sham remote LV (n=1) vs. sham RV (n=1); Figure 4.4C(i)). 
1-wk MI heart:  The 1-wk MI heart with the severe MI phenotype showed a high level of 
Runx1 expression in the infarct region compared to the respective MI RV (12.0 vs. 1.0 RQ; 
MI infarct (n=1) vs. MI RV (n=1); Figure 4.4C(i)).  A similar high level of Runx1 was 
found in the peri-infarct region (11.5 vs. 1.0 RQ; MI peri-infarct (n=1) vs. MI RV (n=1); 
Figure 4.4C(i)).  The remote LV showed the following (1.9 vs. 1.0 RQ; MI remote LV 
(n=1) vs. MI RV (n=1); Figure 4.4C(i)). 
1-wk sham vs. 1-wk MI:  Comparing the 1-wk MI with the 1-wk sham showed higher 
levels of Runx1 in the infarct region (12.0 vs. 0.3 RQ; MI infarct (n=1) vs. sham apex 
(n=1); Figure 4.4C(i)) and in the peri-infarct region (11.5 vs. 1.1 RQ; MI peri-infarct (n=1) 
vs. sham ‘peri-infarct’ (n=1); Figure 4.4C(i)).  The remote LV between the MI and sham 
were as follows: (1.9 vs. 1.4 RQ; MI remote LV (n=1) vs. sham remote LV (n=1); Figure 
4.4C(i)).  However due to a very small proportion (n=3) of animals developing this very 
severe phenotype and only 1 heart (n=1) being available for qRT-PCR measurements, this 
observation represents data from only one animal for sham and MI and therefore it was not 
possible to perform any statistics on this data set.  




Figure 4.4  Regional Runx1 expression at different time points post-MI. 
(A (i)) Regional Runx1 expression in 8-wk MI hearts (n=6; black bars) compared to 8-wk sham hearts (n=4; white bars) 
measured by qRT-PCR using Runx1 specific primers; each region is expressed relative to its respective RV region (dotted 
line).  A (ii) Runx1 expression in the RV region (normalising region) between groups.   (B) Comparison of Runx1 
expression in different regions of the infarcted heart between 4-wk (light grey bars) and 8-wk MI (dark grey bars) hearts 
as compared to the respective RV region (dotted line). (C (i)) Runx1 expression in 1-wk animals showing symptoms of 
severe MI (n=1; black bars) compared to 1-week sham (n=1; white bars); each region expressed relative to its respective 
RV region (dotted line) and (ii) Runx1 expression in the infarct and peri-infarct only of 1-wk severe MI animals using the 
mean 2-∆Ct of infarct and peri-infarct for each animal (sham; n=1) and (MI; n=1). # P<0.05 between region of interest and 
the respective RV.; *P<0.05 between MI and sham. 
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4.3.4 Comparison of regional expression of different Runx 
genes post-MI 
In addition to Runx1, the other Runx genes (Runx2 and Runx3) were also measured in 
regions of the infarcted heart 4-wk post-MI to compare mRNA expression patterns 
between the different genes of the Runx family.  Regional Runx1 expression data at 4-wk 
post-MI has been discussed previously in Section 4.3.2.   
4.3.4.1 Regional expression of Runx2 at 4-wk post-MI 
4-wk sham heart:  As has previously been observed with Runx1, the expression of Runx2 
was not different between regions of the 4-wk sham heart.  This was ascertained by 
comparing expression levels in each region relative to each heart’s respective RV using the 
using the 2-∆∆Ct method.  No differences were observed in the 4-wk sham apex (1.1 ± 0.3 
vs. 1.0 RQ; sham apex (n=3) vs. sham RV (n=3); P>0.05;Figure 4.5A), or the ‘peri-infarct’ 
equivalent 4-wk sham region (0.9 ± 0.1 vs. 1.0 RQ; sham ‘peri-infarct’ (n=3) vs. sham RV 
(n=3); P>0.05;Figure 4.5A) nor the sham remote LV (1.2 ± 0.2 vs. 1.0 RQ; sham remote 
LV (n=3) vs. sham RV (n=3); P>0.05;Figure 4.5A). 
4-wk MI heart:  Runx2 expression was also compared in different regions of the 4-wk MI 
heart.  Each region was expressed relative to the respective non-infarcted RV region within 
the same heart using the 2-∆∆Ct method.  As was observed with Runx1, Runx2 expression 
was significantly elevated in the infarct region of the heart 4-wk post-MI compared to its 
respective RV of the MI heart (5.3 ± 1.1 vs. 1.0 RQ; MI infarct (n=7) vs. MI RV (n=7); 
P<0.05; Figure 4.5A).  Runx2 was not altered in the peri-infarct region 4-wk post-MI with 
no significant differences in expression compared to the respective RV (1.4 ± 0.5 vs. 1.0 
RQ; MI peri-infarct (n=7) vs. MI RV (n=7); P>0.05; Figure 4.5A).  Similarly there was 
also no significant differences in Runx2 expression in the 4-wk MI remote LV compared to 
the respective RV (1.2 ± 0.3 vs. 1.0 RQ; MI remote LV (n=7) vs. MI RV (n=7); P>0.05; 
Figure 4.5A). 
4-wk sham vs. 4-wk MI:  Comparing Runx2 expression between 4-wk MI regions and the 
corresponding region of the 4-wk sham heart revealed that Runx2 expression was higher in 
the infarct region versus the 4-wk sham apex (5.3 ± 1.1 vs. 1.1 ± 0.3 RQ to respective RV; 
MI infarct (n=7) vs. sham apex (n=3); P<0.05; Figure 4.5A).  Runx2 expression in the 4-
wk MI heart was not significantly different to the 4-wk sham heart in the peri-infarct 
region (1.4 ± 0.5 vs. 0.9 ± 0.1 RQ to respective RV; MI peri-infarct (n=7) vs. sham ‘peri-
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infarct’ (n=3); P>0.05; Figure 4.5A) or the remote LV region (1.2 ± 0.3 vs. 1.2 ± 0.2 RQ to 
respective RV; MI remote LV (n=7) vs. sham remote LV (n=3); P>0.05; Figure 4.5A). 
4.3.4.2 Regional expression of Runx3 at 4-wk post-MI 
4-wk sham heart:  Similar to the results from Runx1 and Runx2, the results for Runx3 
expression showed no significant differences across the regions of the 4-wk sham heart.  
This was true for the sham apex compared to the respective RV (0.9 ± 0.2 vs. 1.0 RQ; 
sham apex (n=3) vs. sham RV (n=3); P>0.05; Figure 4.5B), for the sham ‘peri-infarct’ 
region (1.1 ± 0.1 vs. 1.0 RQ; sham ‘peri-infarct’ (n=3) vs. sham RV (n=3); P>0.05; Figure 
4.5B), and for the sham remote LV (1.0 ± 0.3 vs. 1.0 RQ; sham remote LV (n=3) vs. sham 
RV (n=3); P>0.05; Figure 4.5B). 
4-wk MI heart:  In the 4-wk MI heart, Runx3 expression was significantly elevated in the 
infarct region compared to the non-infarcted RV of the MI heart (11.0 ± 2.0 vs. 1.0 RQ; MI 
infarct (n=7) vs. MI RV (n=7); P<0.05; Figure 4.5B).  Runx3 levels were also significantly 
elevated in the peri-infarct region compared to the RV of the MI heart (4.3 ± 1.0 vs. 1.0 
RQ; MI peri-infarct (n=7) vs. MI RV (n=7); P<0.05; Figure 4.5B).  No differences were 
observed in Runx3 expression between the LV remote and the RV of the MI heart (2.0 ± 
0.8 vs. 1.0 RQ; MI remote LV (n=7) vs. MI RV (n=7); P>0.05; Figure 4.5B). 
4-wk sham vs. 4-wk MI:  In addition to the regional expression within the 4-wk sham and 
4-wk MI heart individually (comparing each to their respective RV of the same heart), the 
regional differences were also compared between 4-wk MI and the corresponding region of 
the sham heart.  Runx3 was found to be significantly higher in the infarct region of the MI 
heart compared to the equivalent sham apex region (11.0 ± 2.0 vs. 0.9 ± 0.2 RQ to 
respective RV region; MI infarct (n=7) vs. sham apex (n=3); P<0.05; Figure 4.5B).  Runx3 
was also significantly higher in the peri-infarct region of the MI heart compared to the 
sham ‘peri-infarct’ region (4.3 ± 1.0 vs. 1.1 ± 0.1 RQ to respective RV region; MI peri-
infarct (n=7) vs. sham ‘peri-infarct’ (n=3); P<0.05; Figure 4.5B).  No differences were 
observed in the levels of Runx3 between the LV remote of the MI heart with the LV 
remote of the sham heart (2.0 ± 0.8 vs. 1.0 ± 0.3 RQ to respective RV region; MI remote 
LV (n=7) vs. sham remote LV (n=3); P>0.05; Figure 4.5B). 
Kirsty K. Foote, 2012  Chapter 4  
203 
 
4.3.4.3 Comparison of Runx1-3 expression in the 4-wk MI heart 
Expression patterns of the three Runx genes (1-3) were assessed to compare how their 
regional differences in MI compared with each other.  Runx3 showed the greatest degree of 
elevated expression in the infarct region with expression levels significantly greater than 
Runx1 (11.0 ± 2.0 vs. 5.1 ± 1.0 RQ to respective RV region; Runx3 MI infarct (n=7) vs. 
Runx1 MI infarct (n=8); P<0.05; Figure 4.5C) and Runx2 (11.0 ± 2.0 vs. 5.3 ± 1.1 RQ to 
respective RV region; Runx3 MI infarct (n=7) vs. Runx2 MI infarct (n=7); P<0.05; Figure 
4.5C).  Runx3 also showed the greatest degree of elevated expression in the peri-infarct 
post-MI compared to Runx2 only (4.3 ± 1.0 vs. 1.4 ± 0.5 RQ to respective RV region; 
Runx3 MI peri-infarct (n=7) vs. Runx2 MI peri-infarct (n=7); P<0.05; Figure 4.5C) but not 
compared to Runx1 (4.3 ± 1.0 vs. 1.8 ± 0.2 RQ to respective RV region; Runx3 MI peri-
infarct (n=7) vs. Runx1 MI peri-infarct (n=8); P>0.05; Figure 4.5C).  Runx1 and Runx2 
were altered to the same degree as each other post-MI with equivalent expression levels in 
the infarct (5.1 ± 1.0 vs. 5.3 ± 1.1 RQ to respective RV region; Runx1 MI infarct (n=8) vs. 
Runx2 MI infarct (n=7); P>0.05; Figure 4.5C) and peri-infarct regions (1.8 ± 0.2 vs. 1.4 ± 
0.5 RQ to respective RV region; Runx1 MI peri-infarct (n=8) vs. Runx2 MI peri-infarct 
(n=7); P>0.05; Figure 4.5C).  All three Runx genes showed a similar level of expression in 
the remote LV with no significant differences between the three (1.4 ± 0.2 vs. 1.2 ± 0.3 vs. 
2.0 ± 0.8 RQ to respective RV region; Runx1 MI remote LV (n=8) vs. Runx2 MI remote 
LV (n=7) vs. Runx3 MI remote LV (n=7); P>0.05 between all three; Figure 4.5C).   




Figure 4.5  Expression of different Runx genes post-MI. 
(A)  Expression of Runx2 in different regions of sham (n=3) or 4-wk MI (n=7) hearts using qRT-PCR.  (B)  Expression of 
Runx3 in different regions of sham (n=3) or 4-wk MI (n=7) hearts using qRT-PCR.  (C)  Comparison of all three Runx 
genes for each region of the infarcted heart after 4-wk.  Data presented are mean ± SEM.  # P<0.05 between region of 
interest and the RV of the same heart; *P<0.05 between MI and sham. 
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4.3.5 Links with Runx expression and LV function 
Further analysis was performed to assess whether changes in Runx gene expression 
correlated with the extent of LV dysfunction.   The functional parameters selected for this 
analysis were the maximal rate of LV pressure rise (dP/dtmax) and the maximal rate of LV 
pressure decay (dP/dtmin).  These parameters are widely accepted as reliable indicators of 
myocardial inotropic (dP/dtmax) or lusitropic (dP/dtmin) state (Kass et al., 1987) and were 
therefore considered suitable indices of LV function for this part of the study.  The RQ 
values for the three regions of each heart were added up together then divided by 3 to give 
a single mean RQ value for Runx expression per heart for 4-wk sham and for 4-wk MI – 
calculated as shown below.  This value was then paired with the function of that heart to 





 Eq. 18 
 
4.3.5.1 Correlations between Runx1and LV function 
These results revealed that the rise in Runx1 expression in the heart showed a significant 
negative correlation with LV function for both parameters investigated.  As dP/dtmax 
decreased (myocardial contractility reduced), the expression of Runx1 increased (y=-4.4 x 
10-4x + 6.0; R=-0.74; P<0.05; Figure 4.6A(i)).  Similarly as dP/dtmin decreased (myocardial 
relaxation impaired), the expression of Runx1 also increased with significant negative 
correlation (y= -4.4 x 10-4x + 5.1; R=-0.95; P<0.05; Figure 4.6A(ii)).  
4.3.5.2 Correlations between Runx2 and LV function 
The results revealed that there was no significant relationship between Runx2 expression 
and either dP/dtmax (y=1.68 x 10-4 x + 0.1; R=0.32; P>0.05; Figure 4.6B(i)) or dP/dtmin (y=-
5.7 x 10-4x + 1.9; R=-0.24; P>0.05; Figure 4.6B(ii)). 
4.3.5.3 Correlations between Runx3 and LV function 
Although a similar trend was observed between Runx3 and dP/dtmax (as had been observed 
with Runx1) the relationship between Runx3 and dP/dtmax did not attain statistical 
significance (y=-1.7 x 10-3x + 17.8; R=-0.69; P>0.05; Figure 4.6C(i)).  There was however 
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a strongly significant negative correlation between Runx3 expression and dP/dtmin (y=-1.1 x 
10-3x + 10.6; R=-0.99; P<0.0001; Figure 4.6C(ii)). 
4.3.5.4 Correlations with Runx expression and LV function excluding the 
infarct 
To assess whether the trends observed were related to size of the infarct, the contribution 
of Runx expression from the infarct region was removed from the analysis.  As Figure 4.7 
shows the same trends remain even with the contribution of Runx expression from the 
infarct removed.




Figure 4.6  Correlations with Runx gene expression and LV function. 
(A)  Linear regression of the mean RQ value for Runx1 expression of all LV regions relative to their respective RV 
region in individual MI (4-wk n=6; 8-wk n=1) and 4-wk sham hearts (n=3) 4-wk post-MI plotted against (i) dP/dtmax or 
(ii) dP/dtmin (infarct size was not variable between hearts).  For dP/dtmax (y=-6.0 x 10-4x + 7.5; R=-0.83; P<0.05) and for 
dP/dtmin (y=-5.5 x 10-4x + 8.6; R=-0.92; P<0.05).  (B) Linear regression of the mean RQ value for Runx2 expression of all 
LV regions relative to their respective RV region in individual 4-wk MI (n=4) and 4-wk sham hearts (n=2) plotted against 
(i) dP/dtmax or (ii) dP/dtmin (infarct size was not variable between hearts).  For dP/dtmax (y=1.7 x 10-4x + 0.1; R=0.32; 
P>0.05) and for dP/dtmin (y=-5.7 x 10-5x + 1.9; R=-0.24; P>0.05).  (C) Linear regression of the mean RQ value for Runx3 
expression of all LV regions relative to their respective RV region in individual 4-wk MI (n=4) and 4-wk sham hearts 
(n=2) plotted against (i) dP/dtmax or (ii) dP/dtmin (infarct size was not variable between hearts).  For dP/dtmax (y=1.7 x 10-
3x + 17.8; R=-0.69; P>0.05) and for dP/dtmin (y=-1.1 x 10-3x + 10.6; R=-0.99; P>0.05).  Each point in the graph 
represents an individual heart. 




Figure 4.7  Correlations with Runx gene expression and LV function (excluding the infarct) 
(A)  Linear regression of the mean RQ value for Runx1 expression of all LV regions except the infarct relative to their 
respective RV region in individual MI (4-wk n=6; 8-wk n=1) and 4-wk sham hearts (n=3) 4-wk post-MI plotted against 
(i) dP/dtmax or (ii) dP/dtmin (infarct size was not variable between hearts).  For dP/dtmax (y=-3.3 x 10-4x + 4.4; R=-0.73; 
P<0.05) and for dP/dtmin (y=-2.6 x 10-4x + 3.4; R=-0.71; P<0.05).  (B) Linear regression of the mean RQ value for Runx2 
expression of all LV regions relative to their respective RV region in individual 4-wk MI (n=4) and 4-wk sham hearts 
(n=2) plotted against (i) dP/dtmax or (ii) dP/dtmin (infarct size was not variable between hearts).  For dP/dtmax (y=-2.1 x 10-
4x + 2.8; R=-0.31; P>0.05) and for dP/dtmin (y=-4.9 x 10-5x + 0.60; R=-0.29; P>0.05).  (C) Linear regression of the mean 
RQ value for Runx3 expression of all LV regions relative to their respective RV region in individual 4-wk MI (n=4) and 
4-wk sham hearts (n=2) plotted against (i) dP/dtmax or (ii) dP/dtmin (infarct size was not variable between hearts).  For 
dP/dtmax (y=1.7 x 10-3x + 17.8; R=-0.84; P>0.05) and for dP/dtmin (y=-8.1 x 10-3x + 7.7; R=-0.84; P>0.05).  Each point in 
the graph represents an individual heart. 




4.3.5.5 Infarct size measurements 
To further assess whether the differences observed may be related to infarct size, hearts 
were photographed with a digital camera and the area of infarction was estimated using 
ImageJ by drawing a line around the infarct (whitened, thinned area) and expressing the 
area of infarction as a percentage of the total heart (it was not possible to delineate LV 
from RV in these photographs and this was the reason for expressing infarct size as a 
percentage of the whole heart i.e. LV + RV).  It was not possible to quantify infarct size 
histologically as previously described in other sections of this thesis for this part of the 
study as the hearts were to be dissected and snap-frozen (and not be sent for histology).  
Therefore this method was more limited and permitted only approximation measurements.  
Infarct size measurements by this method were only possible from 3 out of 6 hearts and the 
infarct sizes were 31.9, 33.2 and 37.2% (as a % of the total heart) for these hearts.  The 
results revealed that for these specific hearts, no correlation was found between Runx1 
expression and infarct size (y=0.03x + 2.9; R=0.06; P>0.05; Figure 4.8). 
 
Figure 4.8  Correlation between infarct size and Runx1 expression. 
(A)  Example of infarct sizes for individual hearts used for Runx1 vs. LV function study; y=-6.0 x10-4x + 7.5, R=-0.83; 
P<0.05.  Infarct size was estimated for hearts using ImageJ and visual inspection.  (B)  Correlation between Runx1 
expression and infarct size in individual hearts used for the Runx1 vs. LV function study.  Each point on the graph 
represents individual hearts; y=0.04x + 1.9; R=0.14; P>0.05. 
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4.3.6 IHC localisation of RUNX1 and quantification of expression 
IHC staining was used to visualise the location of RUNX1 in cardiac tissue in sham vs. MI 
(4-wk and 8-wk post-MI).  Using two separate RUNX1-specific antibodies, IHC confirmed 
the presence of RUNX1 in cardiomyocytes (Figure 4.9C(l)), with positive nuclear staining 
consistent with the nuclear localisation of RUNX1.  IHC has confirmed that within the 
infarct there are surviving cardiomyocytes expressing RUNX1 (Figure 4.11A).  Other cell 
types within the infarct region also showed positive RUNX1 staining; these are believed to 
be inflammatory cells (lymphocytes) and fibroblasts which were confirmed by examination 
from an expert pathologist although these types were not labelled with specific markers.  
RUNX1-positive staining was identified in the sham heart (both 4-wk and 8-wk sham time 
points) further confirming a basal expression of RUNX1 in the mouse heart before insult.  
Positive RUNX1 staining was quantified in hearts at 4-wk and 8-wk post-MI using a grid 
counting method and the percentage positive nuclei in each region was expressed relative 
to the RV from the same heart using the following ratio (region of interest/RV).  Figure 
4.9A shows where each region was chosen for analysis in sham hearts and MI hearts.  An 
example of the grid system fitted over the image is shown in Figure 4.9B.  Representative 
images from each region are shown in Figure 4.9C for sham (Figure 4.9C(a-c)), 4-wk MI 
(Figure 4.9C(d-f)) and 8-wk MI (Figure 4.9C(g-i)), including negative heart tissue control 
(Figure 4.9C(j)) confirming no positive staining and positive thymus control tissue (Figure 
4.9C(k)) showing largely positive staining.  IHC results revealed that RUNX1 expression 
was not found to be different between regions of the sham heart, both at 4-wk (Figure 4.9D 
(i)) and at 8-wk (Figure 4.9D (ii)).   
4.3.6.1 RUNX1-positive staining 4-wk post-MI 
The results for RUNX-1 positive staining at the 4-wk time point are shown in Figure 
4.9D(i).   
4-wk sham hearts:  4-wk sham hearts demonstrated no significant differences in the 
proportion of RUNX1-positive cells across the different regions (each region is expressed 
relative to the RV of that heart).  This was the case for the sham apex (0.86 ± 0.07 vs. 1.00 
ratio to respective RV region; 4-wk sham apex (n=3) vs. 4-wk sham RV (n=3); P>0.05; 
Figure 4.9D(i)), the sham ‘peri-infarct’ equivalent (0.85 ± 0.02 vs. 1.00 ratio to respective 
RV region; 4-wk sham ‘peri-infarct’ (n=3) vs. 4-wk sham RV (n=3); P>0.05; Figure 
4.9D(i)) and the sham remote LV (0.83 ± 0.04 vs. 1.00 ratio to respective RV region; 4-wk 
sham remote LV (n=3) vs. 4-wk sham RV (n=3); P>0.05; Figure 4.9D(i)). 
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4-wk MI hearts:  After 4-wk MI, IHC showed that the proportion of RUNX1-positive 
nuclei was significantly higher in the infarct region of the MI heart compared to its 
respective RV region (1.81 ± 0.31 vs. 1.0 ratio to respective RV region; 4-wk MI infarct 
(n=5) vs. 4-wk MI RV (n=5); P<0.05; Figure 4.9D(i)).  Similarly RUNX1-positive cells 
were significantly higher in the peri-infarct region compared to the respective RV (1.57 ± 
0.20 vs. 1.0 ratio to respective RV region; 4-wk MI peri-infarct (n=5) vs. 4-wk MI RV 
(n=5); P<0.05; Figure 4.9D(i)).  There were no differences in RUNX1 positive nuclei 
present in the remote LV compared to the respective RV (1.05 ± 0.08 vs. 1.0 ratio to 
respective RV region; 4-wk MI remote LV (n=5) vs. 4-wk MI RV (n=5); P>0.05; Figure 
4.9D(i)).  
4-wk sham vs. 4-wk MI:  Comparisons between 4-wk MI and 4-wk sham by region 
demonstrated that there was a significantly greater proportion of RUNX1-positive staining 
in the infarct region compared to the corresponding sham apical region (1.81 ± 0.31 vs. 
0.86 ± 0.07 ratio to respective RV region; 4-wk MI infarct (n=5) vs. 4-wk sham apex 
(n=3); P<0.05; Figure 4.9D(i)).  This finding was also true for the peri-infarct region 
compared to the corresponding sham ‘peri-infarct’ region (1.57 ± 0.20 vs. 0.85 ± 0.02 ratio 
to respective RV region; 4-wk MI peri-infarct (n=5) vs. 4-wk sham ‘peri-infarct’ (n=3); 
P<0.05; Figure 4.9D(i)).  There were no statistical differences between the 4-wk remote 
LV between sham and MI (1.05 ± 0.08 vs. 0.83 ± 0.04 ratio to respective RV region; 4-wk 
MI remote LV (n=5) vs. 4-wk sham remote LV (n=3); P>0.05; Figure 4.9D(i)). 
4.3.6.2 RUNX1-positive staining 8-wk post-MI 
8-wk sham heart:  As was observed in the 4-wk sham, the 8-wk sham showed no 
significant differences in the proportion of RUNX1-positive staining between the different 
regions, with respect to the RV of the same heart.  This was observed for the sham apex 
region (1.05 ± 0.04 vs. 1.00 ratio to respective RV region; 8-wk sham apex (n=5) vs. 8-wk 
sham RV (n=5); P>0.05; Figure 4.9D(ii)), was also observed for the ‘peri-infarct’ region 
(0.99 ± 0.03 vs. 1.00 ratio to respective RV region; 8-wk sham ‘peri-infarct’ (n=5) vs. 8-wk 
sham RV (n=5); P>0.05; Figure 4.9D(ii)) and for the remote LV region (0.91 ± 0.10 vs. 
1.00 ratio to respective RV region; 8-wk sham remote LV (n=5) vs. 8-wk RV (n=5); 
P>0.05; Figure 4.9D(ii)). 
8-wk MI heart:  In the 8-wk MI heart, RUNX1-positive staining was significantly higher in 
the infarct region compared to the RV of the same heart (1.93 ± 0.34 vs. 1.00 ratio to 
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respective RV region; 8-wk MI infarct (n=4) vs. 8-wk MI RV (n=4); P<0.05; Figure 
4.9D(ii)).  The same was also true for the peri-infarct region with significantly higher 
positive staining for RUNX1 compared to the respective RV (1.63 ± 0.30 vs. 1.00 ratio to 
respective RV region; 8-wk MI peri-infarct (n=4) vs. 8-wk MI RV (n=4); P<0.05; Figure 
4.9D(ii)).  There was no significant difference in RUNX1 positive nuclei present in the 8-
wk remote LV post-MI compared to the respective RV (1.27 ± 0.40 vs. 1.0 ratio to 
respective RV region; 8-wk MI remote LV (n=4) vs. 8-wk MI RV (n=4); P>0.05; Figure 
4.9D(ii)).    
8-wk sham vs. 8-wk MI:  Comparisons between 8-wk sham hearts and 8-wk MI hearts 
revealed that there was significantly greater RUNX1-positive staining in the infarct region 
of the 8-wk MI heart compared to the equivalent sham apical region (1.93 ± 0.34 vs. 1.05 ± 
0.04 ratio to respective RV region; 8-wk MI infarct (n=4) vs. 8-wk sham apex (n=5); 
P<0.05; Figure 4.9D(ii)).  Furthermore, positive RUNX1 staining was also significantly 
higher in the peri-infarct region of the 8-wk MI heart compared to the corresponding 
region of the 8-wk sham heart (1.63 ± 0.30 vs. 0.99 ± 0.03 ratio to respective RV region; 8-
wk MI peri-infarct (n=4) vs. 8-wk sham ‘peri-infarct’ (n=5); P<0.05; Figure 4.9D(ii)).  
There were no differences between the 8-wk LV remote of the MI heart compared to the 
LV remote of the 8-wk sham heart (1.27 ± 0.40 vs. 0.91 ± 0.10 ratio to respective RV 
region; 8-wk MI remote LV (n=4) vs. 8-wk sham remote LV (n=5); P>0.05; Figure 
4.9D(ii)).  
4.3.6.3 Comparisons between RUNX1 positive staining between 4-wk and 8-
wk MI 
RUNX1 was increased in the infarct region to the same extent at 4-wk and 8-wk post-MI 
(1.81 ± 0.31 vs. 1.93 ± 0.34 ratio to respective RV region; 4-wk MI infarct (n=5) vs. 8-wk 
MI infarct (n=4); P>0.05; Figure 4.9D(iii)).  Similarly the levels of RUNX1 were 
increased by the same degree in the peri-infarct zone between 4-wk and 8-wk MI (1.57 ± 
0.20 vs. 1.63 ± 0.30 ratio to respective RV region; 4-wk MI peri-infarct (n=5) vs. 8-wk MI 
peri-infarct (n=4); P>0.05; Figure 4.9D(iii)).  There was no significant difference in the 
level of RUNX1 positive staining in the 8-wk remote LV compared to 4-wk remote LV 
post-MI (1.05 ± 0.08 vs. 1.27 ± 0.40 ratio to respective RV region; 4-wk MI remote LV 
(n=5) vs. 8-wk MI remote LV (n=4); P>0.05; Figure 4.9D(iii)).    
 




Figure 4.9  IHC expression of RUNX1 at 4-wk and 8-wk post-MI. 
(A)  Diagram showing where the different regions were analysed for RUNX1 expression in the (i) sham and (ii) MI heart 
(the peri-infarct region was chosen as accurately as possible with the aid of adjacent Sirius red sections  (iii) for each 
respective heart as they clearly showed where the fibrous infarct (red colour) interfaced the normal myocardium (yellow 
colour)).  (B)  Example diagram showing how a grid was fixed over the image to facilitate counting of positively (brown) 
versus negatively (blue) stained nuclei. (C)  Typical images showing expression within the different regions for sham (a-
c), 4-wk MI (d-f) and 8-wk MI hearts (g-i).  Negative control for heart tissue (antibody dilution buffer instead of primary 
antibody; j) and positive control tissue (thymus; k) are also shown. Immunohistochemistry of a 4-wk MI heart with a 
RUNX1-specific antibody – positive nuclear staining in cardiomyocytes indicated by arrows  (l).  (D (i)) Quantification 
of RUNX1 expression in each region after 4-wk and (ii) 8-wk MI compared to sham and (iii) comparison of 4-wk MI 
with 8-wk MI.  Each region is expressed relative to the respective RV region (dotted line). 
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4.3.6.4 Cytoplasmic staining of RUNX1 
RUNX1-postive staining was predominantly located within the nuclei of cardiomyocytes; 
however upon closer inspection it could be seen that some cardiomyocytes showed 
cytoplasmic staining as well as nuclear staining (Figure 4.10A).  The same images for each 
region (as used for the previous section 4.3.6) were examined and given a score of 0 or 1 
(indicating absence (0) or presence (1) of cytoplasmic staining) which was then used to 
calculate the percentage of hearts that showed cytoplasmic staining per region for each of 
the four groups (4-wk sham, 4-wk MI, 8-wk sham and 8-wk MI).  The results from these 
data are shown in Figure 4.10B.   
4-wk:  4-wk sham hearts showed no cytoplasmic staining in any region of the heart (0% of 
hearts showed cytoplasmic staining in the 4-wk sham apex, ‘peri-infarct’, remote LV and 
RV; n=3; Figure 4.10B).  In 4-wk MI hearts, cytoplasmic staining was present in 
cardiomyocytes of the infarct region (60% of 4-wk MI hearts) and peri-infarct region (20% 
of 4-wk MI hearts) only; this was not found in the remote LV (0% of 4-wk MI hearts) or 
RV regions (0% of 4-wk MI hearts); n=5; Figure 4.10B.  
8-wk:  8-wk sham hearts, like 4-wk sham hearts, showed no cytoplasmic staining of 
RUNX1 in any region of the heart (0% of hearts showed cytoplasmic staining in the 8-wk 
sham apex, ‘peri-infarct’, remote LV and RV; n=5; Figure 4.10B).  In 8-wk MI hearts 
RUNX1-positive cytoplasmic staining was present in the infarct region only (in 75% of 8-
wk MI hearts) but not in any other region (0% of hearts for peri-infarct, remote LV or RV); 
n=4; Figure 4.10B.  
 
Figure 4.10  Cytoplasmic staining of RUNX1. 
(A)  Representative examples of IHC staining with RUNX1-specific antibody from (i) a control 4-wk sham apex showing 
nuclear staining only and (ii) a 4-wk infarct showing nuclear and cytoplasmic staining.  Arrows indicate cytoplasmic 
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staining.  (B)  Quantification of hearts demonstrating cytoplasmic staining from each group; 4-wk sham (n=3), 4-wk 
sham (n=5), 8-wk sham (n=5) and 8-wk MI (n=4). 
4.3.7 Verification of RUNX1 expression in cardiomyocytes 
4.3.7.1 RUNX1-specific antibody staining 
In order to verify that RUNX1 was present in cardiomyocytes prior to the arrival of the 
infiltrating cells, IHC and cardiomyocyte purification with qRT-PCR approaches were 
utilised.  As previously shown, IHC showed positive nuclear staining in cardiomyocytes 
(Figure 4.9C(l)); this has been confirmed using two commercially available and tested 
polyclonal RUNX1-specific antibodies (61753 and 35962, Abcam, U.K.; Figure 4.11A(i-
ii)).  Some cytoplasmic localisation of RUNX1 was also identified in the surviving 
cardiomyocytes of the infarct region as shown in Figure 4.11B(i), an observation 
commonly observed in this region as described in Section 4.3.6.4 previously.  Figure 
4.11B(ii) shows the presence of viable cardiomyocytes in the infarct region as identified by 
the yellow colour in Sirius red staining.   
4.3.7.2 Runx1-specific primers tested on purified cardiomyocytes 
Runx1 mRNA levels were measured in a purified population of cardiomyocytes (>98%) 
according to a published method (Kosloski et al., 2009).  Runx1 was found to be present 
within this purified population with mean Ct values before purification 27.4 ± 1.0 (n=2) 
and after purification 29.1 ± 0.6 (n=2) confirming levels of Runx1 present in the purified 
population (Cts <30; Figure 4.11C).  These Ct values are significantly greater than those 
obtained from whole heart (27.4 ± 1.0 vs. 20.6 ± 0.7 raw Runx1 Ct values; cell preparations 
prior to filtration (n=2) vs. whole heart homogenates (n=6); P<0.05) or regional 
homogenates (27.4 ± 1.0 vs. 22.8 ± 1.2 raw Runx1 Ct values; cell preparations prior to 
filtration (n=2) vs. regional heart homogenates (n=4); P>0.05) indicating lower gene 
expression, which is expected given that the starting material is less (cells rather than intact 
tissue).  As described previously (Section 4.3.1), Ct values of less than 30 are generally 
regarded to represent detectable gene expression.  These results revealed that Runx1 
expression decreased following purification, which was expected given the removal of 
other Runx1-containing cell types but expression in the remaining cardiomyocyte 
population remained evident. 
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4.3.7.3 Runx1 expression in LV areas which predominantly contain 
cardiomyocytes (peri-infarct and remote only) 
To assess the levels of Runx1 gene expression without the contribution from the infarct 
region, expression levels were examined in the combined regions of the LV excluding the 
infarct by taking the average RQ of the peri-infarct and remote LV (calculated from the 2-
∆∆Ct
 method relative to the respective RV) for each heart – calculation shown below. 
2
LVremoteRQinfarctperiRQ
valueRQ +=    Eq. 19 
 
4-wk hearts:  These data revealed that the 4-wk sham hearts showed no significant 
difference in the combined ‘peri-infarct’ and remote LV compared to the RV (1.1 ± 0.1 vs. 
1.0 RQ to respective RV region; 4-wk sham combined ‘peri-infarct’ and remote LV vs. 4-
wk sham RV; n=4; P>0.05; Figure 4.11C).  However, the combined peri-infarct and 
remote LV in the 4-wk MI heart showed significantly higher expression of Runx1 than the 
RV of the same heart (1.6 ± 0.1 vs. 1.0 RQ to respective RV region; 4-wk MI peri-infarct 
and remote LV vs. 4-wk MI RV; n=8; P<0.05; Figure 4.11D).  In summary, the results 
showed that there was 41.2% greater expression of Runx1 in the combined regions of the 
4-wk MI heart. 
8-wk hearts:  The combined expression in the 8-wk sham ‘peri-infarct’ and LV remote 
showed no significant differences when compared to the RV of the same heart (1.1 ± 0.3 
vs. 1.0 RQ to respective RV region; 8-wk sham combined ‘peri-infarct’ and remote LV vs. 
8-wk sham RV; n=4; P>0.05; Figure 4.11D).  In the 8-wk MI heart, the combined peri-
infarct and remote LV regions showed significantly greater Runx1 expression compared to 
the RV of the same heart (2.4 ± 0.4 vs. 1.0 RQ to respective RV region; 8-wk MI combined 
peri-infarct and remote LV vs. 8-wk MI RV; n=6; P<0.05; Figure 4.11D) which represents 
a 114.3% increase compared to sham (2.1-fold greater; P<0.05).  Collectively these data 
have confirmed that Runx1 expression remains higher in the MI hearts (both at 4-wk and 8-
wk) compared to sham even without the contribution from the infarct region (Figure 
4.11D). 




Figure 4.11  Verification of RUNX1 expression in cardiomyocytes. 
(A) Examples of nucleic localisation of RUNX1 in cardiomyocytes (identified by striated structure alone) using two 
different commercially available RUNX1-specific antibodies ((i) ab61795; Abcam, U.K.; and (ii) ab35962; Abcam, U.K.).  
(B i) Positive RUNX1 staining in cardiomyocytes present within the infarct region (arrows indicate cardiomyoctes) and 
(ii) Confirmation of presence of viable cardiomyocytes (yellow) in the infarct region by Sirius red staining (areas of 
fibrosis stained red; arrows indicate viable cardiomyocytes).  (C) Results of qRT-PCR performed on unpurified (black 
bar) and a purified population of cardiomyocytes (grey bar) isolated from a normal mouse heart (n=2) and expressed 
relative to the housekeeping gene PPIA.  (D) The mean RQ values for Runx1 expression of the LV regions excluding the 
infarct (peri-infarct and remote LV) obtained by qRT-PCR at 4-wk and 8-wk post- MI.  #P<0.05 between region and 
respective RV (dotted line); *P<0.05 between sham and MI. 




Runx genes encode RUNX proteins which are best known as transcriptional regulators of 
gene expression in major developmental pathways with putative roles in cancer 
development (Coffman, 2003;Blyth et al., 2005).  However more recently the Runx genes 
have been increasingly implicated in specific conditions of tissue injury and/or metabolic 
stress (Wang et al., 2005;Ghosh et al., 2010;Custodio et al., 2012).  RUNX1, a member of 
the RUNX family and an important regulator of the haematopoietic system, has previously 
been shown to be up-regulated in damaged muscle including post-ischaemic myocardium 
of the human heart during ischaemic cardiomyopathy (Gattenlohner et al., 2003).  At 
present, no quantitative data exists on the altered expression of Runx1 in the heart during 
MI.  This chapter provides quantification and detailed characterisation of the expression of 
RUNX genes/proteins in response to myocardial injury providing a basis for further 
investigation into the role the RUNX family plays in the heart under these conditions. 
4.4.1 Runx1 expression is increased post-MI 
Firstly, knowledge of RUNX in the heart even under normal conditions is very limited.  
Runx1 is known to be expressed in the mammalian heart; this has been demonstrated in 
embryonic mouse tissue using β-galactosidase-tagged staining (Levanon et al., 
2001a;Telfer & Rothenberg, 2001;Levanon et al., 2003) and results from the present study 
have confirmed a basal expression of Runx1 in the normal mouse heart.  However the 
major finding from this work is an increased expression of Runx1 in the heart after MI in a 
mouse model.  In whole ventricular myocardium 4-wks post-MI, Runx1 mRNA levels 
were more than double that of sham hearts.  An up-regulation of Runx1 following MI 
concurs with a previous publication which revealed that in hearts taken from human MI 
patients there was a significant increase in RUNX1 expression compared to normal human 
heart tissue (Gattenlohner et al., 2003).  These findings combined with those in our mouse 
model suggest that RUNX1 may be activated by myocardial injury which could indicate a 
potential role for RUNX1 in the heart following MI.  It is possible that increased RUNX1 
in the heart can be attributed in part from infiltrating or deposited cells that arrive during 
the MI injury (e.g. lymphocytes and fibroblasts, respectively) as RUNX1 is known to be 
present in lymphocytes (Himes et al., 2005) and in cardiac fibroblasts (Wotton et al., 2004) 
which are present in the heart during remodelling (Nian et al., 2004;McCormick et al., 
1994).  By examination of the structure of these cell types using IHC and with 
confirmation from a pathologist we believe these to be lymphocytes (identified by their 
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small round mononuclear shape) and fibroblasts (identified by their spindled shape with 
minimal cytoplasm and wavy nuclei).  These cell types were not labelled with specific 
markers so it was not possible to positively confirm their presence.  However, the work 
from this study has shown that the RUNX1 expression does not come solely from the 
invading cells as we have evidence that RUNX1 is present in cardiomyocytes prior to any 
injury or infiltration: (i) firstly, using qRT-PCR and IHC we have shown that Runx1 
(RUNX1) is present in the normal mouse sham heart (Figure 4.3 & Figure 4.9) and (ii) 
secondly, by qRT-PCR Runx1 has been shown to be expressed in a purified population of 
healthy mouse cardiomyocytes (Figure 4.11).  Therefore a proportion of the RUNX1 
expression is attributable to invading cell types as well as existing cardiomyocytes already 
there.  As Figure 4.11 shows, RUNX1 is expressed in the surviving cardiomyocytes 
present in the infarct which are visible as layers or islets distributed throughout this region.  
Cell purification studies in which qRT-PCR was performed on a purified cardiomyocytes 
population demonstrated that cardiomyocytes contain Runx1 mRNA confirming that the 
RUNX1 protein is expressed in cardiomyocytes and not taken up from surrounding cell 
types which can occur for other proteins during MI (e.g. S100A4) (Schneider et al., 2007). 
4.4.2 Elevated Runx1 expression is localised to areas within and 
adjacent to the injury 
At present, studies that have examined Runx1 levels in the heart have been from whole 
heart homogenates only and no information is available on altered Runx1 expression within 
different regions of the heart post-MI.  The hypothesis that Runx1 expression in the heart is 
triggered by myocardial injury is further supported by the observations that increased 
Runx1 expression in the mouse heart post-MI was localised to regions within or adjacent to 
the area of injury (the infarct).  As Figure 4.3 shows, higher levels of Runx1 were observed 
in the infarct region and in the peri-infarct region compared to areas remote after 4 weeks 
(this was in contrast to sham hearts which showed no differences in expression in any 
particular region of the heart).  This observation of altered regional distribution of gene 
expression is a recurrent finding in hearts post-MI.  For instance, genes which are down-
regulated in the infarct are often increased in the remote zone (e.g. inflammatory genes as 
described previously) and vice versa (when compared to matching sham regions) 
(LaFramboise et al., 2005).  The initial up-regulation of genes in the remote region is 
important as these tend to be switched on as a compensatory response against the adjacent 
tissue injury.  Regional differences can result from variations in the mechanical, electrical, 
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remodelled and/or metabolic properties of each region (Kramer et al., 1993;McCormick et 
al., 1994) as detailed below. 
4.4.2.1 Potential triggers in the infarct region 
The infarct region represented the region with the highest levels of Runx1, Runx2 and 
Runx3 in the heart post-MI compared to an area remote (RV) and compared to the 
equivalent region of the sham heart.  The infarct is primarily made up of a collagen-based 
matrix and contains infiltrating macrophages, monocytes and neutrophils as part of the 
inflammatory cascade during infarct repair (Frangogiannis et al., 2002b).  These cells are 
known to express RUNX1 and therefore a contribution of the RUNX1-positive signal in 
the infarct may be coming from these invading cell types (Himes et al., 2005;Wotton et al., 
2004).  The repair process and early infarct expansion (characterised by slippage and/or 
loss of cardiomyocytes) can also trigger changes in gene expression within the surviving 
cardiomyocytes of the infarct zone (Swynghedauw, 1999).  Due to loss of contractile mass 
in the infarcted region, mechanical function in this region is markedly reduced (Fomovsky 
& Holmes, 2010).  Mechanical instability is known to induce Runx2 expression in arthritic 
cartilage (Kamekura et al., 2006); the same may be true for the infarct region and may 
contribute to the increase in Runx2 expression in the infarct region.  Runx2 has also been 
shown to be up-regulated in cardiomyocytes under conditions of myocardial fibrosis 
during high phosphorous conditions or parathyroid hormone infusion (Custodio et al., 
2012) – this is relevant to the present work as the model in our study has been shown to 
demonstrate myocardial fibrosis and therefore it is possible that the increase in Runx2 may 
also be attributed to conditions of myocardial fibrosis in the infarct region in the same way. 
4.4.2.2 Potential triggers in the peri-infarct myocardium 
The peri-infarct region also demonstrated a significant increase in Runx1 expression post-
MI compared to areas remote and when compared to the equivalent region of the sham 
heart.  The possible triggers for Runx up-regulation in the peri-infarct during MI are 
unclear.  Studies investigating the over-expression of NCAM (believed to be linked to 
RUNX1) in MI have postulated that possible triggers may be related to (i) “communication 
failures” from disrupted electrical activity in the infarct and peri-infarct, (ii) increased wall 
stress, or (iii) loss of cell-cell interaction. 
(i)  Disruptions in electrical activity may be a key stimulus for Runx1 expression.  This 
has been shown to be the case in injured skeletal muscle in which disruptions in electrical 
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activity (via denervation) are responsible for an increased expression of RUNX1 (Wang et 
al., 2005).  It’s possible that alterations in electrical activity which are known to occur in 
the infarct and peri-infarct (due to loss of cardiomyocytes and remodelling of gap junctions 
as described previously) (Peters, 1995) may relate to increased RUNX1 expression in the 
same way.   
(ii)  Increased wall stress:  Close contact between thin-walled infarct and viable 
myocardium results in an abnormally increased radius of curvature of the myocardium at 
the infarct margin, leading to elevated wall stress and associated energy demands in the 
peri-infarct region (Buda et al., 1986;Guccione et al., 2001;Walker et al., 2005).  Therefore 
the peri-infarct is also exposed to high mechanical stress which could also be a trigger for 
Runx2.  This is because RUNX2 over-expression during injury, for example in the 
pathogenesis of osteoarthritis, has been linked to mechanical instability and tensile strain 
factors (Kamekura et al., 2006).  Interestingly, the over-expression of RUNX2 under these 
conditions was limited to the affected areas with little or no change in the unaffected 
regions of the tissue at a distance from the injury.  These findings further support the up-
regulation of Runx genes under conditions of insult and a similar pattern of expression 
bordering areas of the injury.   
(iii)  Persistent ischaemia in infarct and peri-infarct and the infarct may also be an 
important trigger for altered Runx levels.  At present little is known about how the 
mechanisms by which ischaemic stimuli can regulate gene expression but it may be related 
to the activation of specific protein kinase cascades (Shimizu et al., 1997).  Hypoxia may 
be an important stimulus but given that RUNX3 is known to be down-regulated in 
response to hypoxia this may not be the case (Lee et al., 2009).   
Importance of altered Runx expression in the peri-infarct region:  Altered levels of 
Runx in the peri-infarct region is of particular significance because the peri-infarct region 
has been the subject of intense investigation in MI and is believed to contribute to the 
decompensatory process that eventually leads to HF (Jackson et al., 2002;Jackson et al., 
2003;Narula et al., 2000).  Importantly adverse peri-infarct remodelling is believed to be 
responsible for almost 70% of HF cases (Gheorghiade & Bonow, 1998) and is a major 
determinant of poor patient outcome as it is very difficult to reverse once established 
(Gavazzi et al., 1993).  Given the importance of the peri-infarct region in the progression 
to HF, the increased levels of RUNX1 that were observed in this region support the need 
for further investigation in the role RUNX1 plays in this region during MI. 
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4.4.2.3 Potential triggers in the remote region 
Changes in Runx1 were not evident in the remote region after 4-wk MI but were 
significantly increased in this region by 8-wk.  The remote region can be defined as the 
area of non-infarcted myocardium found beyond the peri-infarct region at a distance from 
the infarcted region.  Remote myocardium is largely normal muscle but due to the 
alterations in ventricular geometry and increased wall stress imposed by the loss of 
myocardium in the infarcted region this can lead to a hypertrophic response in the remote 
region which can be a trigger for altered mRNA expression levels.  Results from Chapter 3 
in this thesis have shown that hearts post-MI show evidence of cardiomyocyte 
hypertrophy, although it cannot be confirmed definitively if these came from the remote 
region.  However, based on the findings that the hearts showed an overall increase in heart 
weight despite loss of myocardium in the infarct, this would strongly suggest that the 
surviving myocardium had undergone hypertrophy.  However despite this, Runx 
expression in the remote LV after 4-wk MI was comparable to those seen in the equivalent 
sham heart suggesting that hypertrophy observed at 4-wk does not seem to have triggered 
changes in Runx expression.  It may be that the hypertrophy signals could repress Runx1 
expression (as has been shown in a different animal model of hypertrophy in this thesis; 
Chapter 5).  However Runx1 was found to be higher in the remote LV region at 8-wk; and 
from the heart weight data the hearts showed greater muscle mass at 8-wk (compared to 4-
wk) therefore it is also possible there may be a hypertrophic threshold below which Runx1 
is not affected. 
A further possible trigger for Runx1 over-expression may be linked to the reactivation of 
the foetal gene programme commonly observed in the metabolically stressed heart, which 
has been found to be responsible for regional over-expression of other genes in the mouse 
infarcted heart (e.g. NCAM) (Iwamura et al., 1977). 
4.4.3 RUNX1 may be mislocalised in injured cardiomyocytes 
IHC has further confirmed that RUNX1 expression is confined to areas within and around 
the area of injury in the 4-wk infarcted heart.  The RUNX antibodies used in this study 
have been previously published - ab61753 (Abcam, U.K.) was used to detect RUNX1 in 
the cells of the inferior vena cava in mouse embryos (Nagamachi et al., 2010) and ab35962 
(Abcam, U.K.) was used to detect RUNX1 in haematopoietic progenitor cells in mouse 
embryos (Tsunoda et al., 2010).  Immunohistochemical analysis has demonstrated that the 
expression of RUNX1 is localised predominantly to the nuclei of cardiomyocytes, but 
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upon closer inspection RUNX1 can also be found within the cytoplasm of a proportion of 
cardiomyocytes within and around the infarct - a difference observed only in the infarcted 
heart and not present in sham hearts.  This may represent a mislocalisation of RUNX1 as 
RUNX proteins are normally expressed exclusively within the nucleus only (Lu et al., 
1995).  There are transcription factors which can be expressed both in the nucleus and 
cytoplasm, for example RBCK1, a protein kinase C-interacting transcription factor located 
in human embryonic kidney cells (HEK293) (Tatematsu et al., 2005) and HOXA10, a 
regulator of RUNX2 transcriptional activity located in endometrial stromal cells (Bae et 
al., 2004).  The FOXO transcription factors (FOX01 and FOX03) are present in both the 
nucleus and cytoplasm of embryonic cardiomyocytes (Sengupta et al., 2009).  However, 
RUNX transcription factors have a unique targeting signal in the C terminus called the 
NLS which is responsible for directing RUNX to discrete foci within the nucleus (Choi et 
al., 2001) and the sole presence of RUNX protein in the cytoplasm can render it inactive 
(Choi et al., 2001).  Mislocalisation of RUNX1 into the cytoplasm has been reported 
previously under disease conditions e.g. translocation of the CBFβ partner can lead to a 
CBFβ-MYH11 fusion gene (Liu et al., 1995) which has the ability to sequester RUNX1 in 
the cytoplasm increasing leukamogenic potential (Adya et al., 1998;Lukasik et al., 2002).  
RUNX3 mislocalisation to the cytoplasm is present in 38% of gastric cancer tumour cells 
and interestingly it has been shown that hypoxic culture conditions can induce this 
mislocalisation to the cytoplasm in gastric tumour cells, identified by IHC (Lee et al., 
2009).  It may be therefore that the hypoxic conditions within the infarcted region of the 
heart could be responsible for RUNX1 expression within the cytoplasm; this is further 
supported by the finding that this occurs in cardiomyocytes within the infarct and peri-
infarct region only and not in the areas remote.  Another possibility is that RUNX1 can be 
mislocalised to the cytoplasm bound to CBFβ, the precise mechanisms by which this 
occurs remain to be fully elucidated but it is thought to be related to a direct disruption of 
the NLS (Michaud et al., 2002). CBFβ is normally cytoplasmic (Tanaka et al., 1997) and 
its entry into the nucleus required interaction with the Runt domain (Lu et al., 1995) but 
the regulatory mechanism involved in this is not clear, it has been proposed that a portion 
of CBFβ remains in the nucleus (Lu et al., 1995); Figure 4.12.  Therefore it may be 
complex underlying pathways initiated as a result of the injury to the heart that could be 
responsible for causing this mislocalisation. 




Figure 4.12  Diagram showing possible mechanism for how the CBFβ partner unit enters the nucleus to permit 
formation of the heterodimer complex required for transcription. 
(A) CBFβ resides in the cytoplasm but a portion is believed to remain inside the nucleus to permit binding to the Runt 
domain which allows CBFβ to enter the nucleus and (B) form a heterdimeric complex to mediate transcription. 
4.4.4 Localised regional expression of other genes in MI 
Expression in areas of close contact with the injury has been reported by others for 
example the neural cellular adhesion molecule NCAM is also up-regulated in human MI 
(Gattenlohner et al., 2003) and in a mouse model of MI (Nagao et al., 2010) and is 
restricted only to the cardiomyocytes within the infarcted or peri-infarct regions.  RUNX1 
is believed to have a binding site within the promoter of NCAM and may therefore be 
involved in the control of its expression.  This seems very likely given the strikingly 
similar pattern in expression between the two.  The over-expression of nestin, an 
intermediate filament protein, after MI is predominantly in the infarct and peri-infarct of 
mouse infarcted hearts and human end-stage heart failure; this has been shown by 
immunofluorescence confocal microscopy to be present in cardiomyocytes as well as 
endothelial cells, smooth muscle cells, neuronal cells and fibroblasts (Scobioala et al., 
2008).  The multifunctional Ca2+-binding protein S100A4 as also been reported to show 
increased expression in injured cardiomyocytes localised to the peri-infarct in rat MI (twice 
as high compared to the remote region within the same heart and nearly 5 times higher than 
the matching sham regions) (Schneider et al., 2007).  Although S100A4 is detectable by 
immunofluorescence confocal microscopy in inflammatory cells (macrophages and 
leukocytes), fibroblasts and endothelial cells, the staining within cardiomyoctes was 
exclusively in the peri-infarct; interestingly S100A4 mRNA was not detectable by qRT-
PCR in the cardiomyocytes therefore it is believed to be uptaken by the cardiomyocytes 
rather than expressed by them (Schneider et al., 2007). 
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4.4.5 Temporal alterations in Runx1 expression post-MI 
4.4.5.1 How do Runx1 levels compare between 4-wk and 8-wk post-MI? 
Runx1 levels remained high in the infarct region by 8-wk post-MI but were not 
significantly different to those observed in the 4-wk infarct (as shown in Figure 4.4).  
Similarly, levels of Runx1 also remained high in the peri-infarct at 8-wk but were not 
significantly different to those observed at 4-wk MI.  It is possible however that the 
regional distribution is changing by 8-wk as we begin to see higher levels of expression in 
the remote LV at 8-wk.  Interestingly, this is in contrast to normal levels in the remote 
region at 4-wk signifying a possible temporal response which may be linked to advanced 
remodelling.  In our mouse model, 8-wk MI hearts do show a greater degree of 
remodelling compared to the 4-wk hearts in terms of greater muscle mass and a trend 
towards higher cardiac fibrosis (Chapter 3) and therefore this could explain the altered 
expression seen in the 8-wk remote.  Up-regulation of Runx1 in the remote region at 8-wk 
is important because it may indicate that Runx1 up-regulation is not triggered as a result of 
the initial ischaemic injury, as the remote LV region represents an area which is not subject 
to the ischaemia (still perfused).  Although Runx1 mRNA was increased in the 8-wk 
remote region, the level of RUNX1-positive staining by IHC was unchanged.  
Unfortunately one of the limitations of IHC is that it simply indicates presence or absence 
of the antigen of interest (in this case RUNX1) and does not provide indication of the 
quantity of the protein present within each cell.  Therefore it is possible that IHC may be 
underestimating the true abundance which could explain the discrepancy between high 
mRNA but unchanged RUNX1-positive IHC in 8-wk post-MI remote regions.  Other 
techniques that may have been utilised for this include Western Blotting, but for more 
specific analysis of RUNX1 levels this could involve utilising techniques designed to 
examine proteins expressed within the nucleus such as isolating nuclear extracts followed 
by electrophoresis mobility shift assay.  Other transcription factors have shown delayed 
expression post-MI similar to the RUNX1 8-wk remote result in this study; these include 
the Fox transcription factors for which the Fox03 and FoxJ2 members only begin to show 
elevated expression at 8-wk post-MI in the nuclei of cardiomyocytes in the peri-infarct 
region (Philip-Couderc et al., 2008).  Others take even longer; the FoxF2 does not appear 
higher until 20-wk post-MI (Philip-Couderc et al., 2008). 
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4.4.5.2 High levels of Runx1 in 1-wk animals with severe MI phenotype 
Interestingly, the greatest degree of Runx1 was observed during early severe MI at 1-wk 
indicating there may be a potential link with onset of HF.  As Figure 4.4 shows, Runx1 was 
over twice as high in the 1-wk infarct compared to 4-wk infarcts, and over three times 
higher than 8-wk infarcts.  1-wk animals also showed ≈ 6.5-fold and ≈ 5-fold higher Runx1 
in the peri-infarct compared to the equivalent regions in the 4-wk and 8-wk hearts, 
respectively.  Although it was not possible to functionally confirm HF in the animals that 
developed a severe phenotype at 1-wk (n=3 in total including the animals for which the 
hearts were taken for histological assessment described in the previous Chapter 3, Section 
3.4.3), previous measurements have revealed they show a marked increase in heart weight 
with severe lung congestion consistent with congestive HF (Chapter 3).  These animals 
also showed very advanced acute remodelling (substantial infarct thinning; Chapter 3) 
which may indicate a link with the high levels of Runx1 expression observed in these 
circumstances.  Unfortunately it must be noted that due to the small number of animals that 
develop this severe phenotype, the animals are limited to test this further.  It is unclear 
what may be responsible for these high levels of Runx1 expression whether it is related to 
an inflammatory response which is known to peak at this time (1-wk) (Bonvini et al., 
2005;Frangogiannis et al., 2002) or whether it is related to a more severe remodelling of 
this condition.  Genes are known to show higher levels of mRNA within the infarct and 
peri-infarct at 1-wk and fall by later time points (4-wk); this has been shown to be the case 
for a number of genes involved in inflammation, angiogenesis and stem cell factors (as 
measured by qRT-PCR) including IL-8, TGF-β1, βFGF, MIP-1α and IL-10 (Vandervelde 
et al., 2007). 
4.4.6 Other RUNX genes show similar altered expression but to 
varying extents 
Knowledge on the altered expression patterns of the other members of the RUNX family 
(RUNX2 and RUNX3) in the heart during MI is also extremely limited.  RUNX2 has been 
found to be barely detectable in normal rat heart (negative with IHC), however during 
conditions of elevated phosphorous or parathyroid hormone (both features of chronic 
kidney disease which can lead to cardiac disease), RUNX2 is found to be up-regulated in 
cardiomyocytes and coronary arteries (Custodio et al., 2012).  This finding is another 
example linking tissue stress with RUNX expression.  Tissue stress in this context refers to 
damage, injury or overload of the specialised functioning of the tissue that disturbs normal 
nutrient and/or energy supply.  In our study, all three Runx genes showed increased mRNA 
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levels post-MI with a very similar regional distribution pattern.  This is not surprising 
given that all three RUNX proteins bind via the same highly conserved DNA motif known 
as the Runt domain located at the N-terminus of the RUNX protein (Kagoshima et al., 
1993;Crute et al., 1996) and all require the CBFβ for DNA binding (Ogawa et al., 1993).  
As a result the RUNX genes employ very similar roles, albeit in different lineages.  Runx2 
showed increased expression within the infarcted region of the heart post-MI only.  The 
Notch1 gene, a member of the Notch signalling family, has been reported to be up-
regulated ~3-fold in cardiomyocytes of the peri-infarct of mice 4-days post-MI (Gude et 
al., 2008); as Notch is known to inhibit Runx2 (Zamurovic et al., 2004) this may explain 
why Runx2 showed no change in expression in this region (while the other Runx genes 
did).  Runx1 and Runx3 demonstrated expression within both the infarct and the peri-
infarct with no change in remote LV expression after 4-wk.  RUNX3 is also a known direct 
target of the Notch signalling pathway but unlike RUNX2, is activated by increased Notch 
(Fu et al., 2011).  This could explain the increased levels of Runx3 mRNA in the peri-
infarct region as Notch is activated in this region post-MI in mice (Gude et al., 2008) as 
described above which could be contributing to an increased expression of Runx3 in this 
region.  The similarity in pattern between Runx1 and Runx3 is not unusual as the two have 
been known to overlap or cross-regulate in other systems e.g. both the haematopoietic 
system and during thymopoiesis more than they do with Runx2 (Levanon et al., 
2001a;Woolf et al., 2003).  Furthermore, during murine embryogenesis Runx3 is only 
detected in organs that also express Runx1 (Levanon et al., 2001a) which also supports the 
possibility of cross-regulation.  In gastric cancer, both RUNX1 and RUNX3 are down-
regulated while no changes were observed in RUNX2 (Sakakura et al., 2005).  Although 
there were similarities to Runx1 in the expression pattern, Runx3 showed a more 
exaggerated response than the other two Runx genes within the infarct and peri-infarct 
regions, the reasons for this however are not clear.  Together these findings further support 
the idea that the RUNX family are differentially altered in the heart during MI which 
therefore warrants further investigation into the possible role RUNX may have in the heart 
during MI. 
4.4.7 Functional role of RUNX1 in cardiomyocytes 
The functional role of RUNX in the heart remains to be fully elucidated.  From Runx1-
knockout studies in skeletal muscle, a small group of 29 genes were identified as 
transcriptional targets for RUNX1, many of which are also not only important for cardiac 
myocardial structure, but demonstrate altered patterns of expression during cardiac disease.  
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For example RUNX1 can activate the expression of the gene for osteopontin (Sbp1) (Wang 
et al., 2005), a matricellular protein which is expressed at low levels in the healthy, 
unstressed heart but increases in cardiomyocytes during the onset of cardiac hypertrophy 
(Graf et al., 1997), MI (Trueblood et al., 2001) and advanced heart failure (Stawowy et al., 
2002).  RUNX2 is also known to regulate osteopontin by activating its expression (Ducy, 
2000).  This may be important as osteopontin is believed to be involved in the coordination 
of intracellular signals required to integrate myofibroblast proliferation, migration, and 
ECM deposition in the post-infarcted heart to ensure the mechanical properties of the heart 
are not compromised further (Singh et al., 2010).  There are also links to sodium channel 
type V (Scn5a) which is activated by RUNX1 (Wang et al., 2005) and mutations of the 
Scn5a gene have been associated with Long QT syndrome and fatal cardiac arrhythmias 
(Zhang et al., 2007).  Thrombospondin-1 and 4 (Tsp) are secretory proteins which are also 
induced by RUNX1 (Wang et al., 2005) and selectively over-expressed in the peri-infarct 
myocardium post-MI in cardiomyocytes as well as endothelial cells and macrophages 
(Dewald et al., 2005;Paoni & Lowe, 2001;Sezaki et al., 2005) and is believed to prevent 
adverse remodelling by regulating the inflammatory response during MI (Sezaki et al., 
2005). 
4.4.7.1 Phospholamban a key target? 
A particular key target for RUNX1 may be phospholamban (Pln), an integral regulatory 
protein which controls the rate of Ca2+ movement across the SR membrane through 
association with SERCA.  When Pln is unphosphorylated, the rate of Ca2+ movement is 
reduced through inhibition of SERCA, and upon phosphorylation of Pln, Ca2+ movement 
increases.  Failing heart muscle exhibits distinct changes in intracellular Ca2+ handling, 
including impaired removal of cytosolic Ca2+; reduced Ca2+ loading of the SR with down-
regulation of SERCA2; and defects in SR Ca2+ release (Marx et al., 2000;Morgan, 1991).  
Thus contractility impairment in heart failure has been linked to increased inhibition of 
SERCA due to (i) increases in phospholamban/SERCA2 expression and (ii) decreases in 
Pln phosphorylation (Chu & Kranias, 2006).  Increased RUNX1 levels could therefore be 
affecting the expression of Pln which may be having detrimental consequences for the 
heart during post-MI remodelling.  In denervated skeletal muscle, knockout of Runx1 led 
to an 82% reduction in Pln gene expression compared to wild-type denervated muscle 
(Wang et al., 2005).  Therefore these data suggest that Pln gene expression is activated/ 
maintained by Runx1.  It is not known whether Runx1 up-regulation in cardiac muscle 
would affect Pln to the same extent; however it is known that transgenic mice with a 2-fold 
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cardiac-specific over-expression in Pln protein (2-9 extra copies of Pln gene) demonstrate 
reduced cardiomyocyte contractility with reduced Ca2+ transient amplitude (to 83% of 
wild-type) and significant prolongation of Ca2+ decay (to 131% of wild-type) (Kadambi et 
al., 1996).  Therefore, an elevation in the Runx1 observed in the heart post-MI could lead 
to an increase in Pln expression and subsequently alter normal Ca2+ handling and overall 
functioning of the heart.   
Preliminary data supporting a link with phospholamban:  Further to potential links 
between RUNX over-expression and cardiac dysfunction, preliminary data from our 
laboratory has shown that rabbit cardiomyocytes over-expressing RUNX1 demonstrate 
altered Ca2+ handling with reduced peak systolic Ca2+, slower decay of the Ca2+ transient 
and reduced SR content all consistent with reduced contractile function (data not shown).  
These data suggest elevated RUNX1 levels may have a detrimental effect in 
cardiomyocytes.  These data would support the hypothesis of potential over-expression of 
Pln and subsequent inhibition of SERCA which may be responsible for the altered 
handling and reduced cardiomyocyte contractions observed.  These data have revealed that 
RUNX1-overexpression shows adverse effects in cardiac muscle which is in contrast to the 
protective effects of RUNX1 observed in skeletal muscle during injury.  In skeletal muscle 
RUNX1 was necessary in the muscle after denervation to protect against wasting, 
myofibrillar disorganisation and autophagy; however the data from our group suggests that 
the situation is different in cardiac muscle and that unlike skeletal muscle, RUNX1 shows 
a detrimental effect rather than a positive protective one. 
4.4.7.2 Possible links with Runx expression and degree of dysfunction. 
The work in this thesis has shown that there are significant correlations between mean 
regional Runx1 and Runx3 expression and cardiac function in the heart post-MI i.e. higher 
Runx1 and Runx3 expression in hearts with greatest dysfunction (with and without shams 
included in the analysis).  Runx2 shows no correlations with cardiac function.  However, 
the degree of LV dysfunction can be influenced by the size of the infarct which has been 
shown to be the case in a separate small cohort of hearts (in which infarct size was 
measured histologically) i.e. larger infarct size, lower function.  Runx mRNA levels are 
highest in the infarct region - therefore it becomes difficult to ascertain whether it is the 
larger infarct size or the increased Runx expression that leads to reduced cardiac function. 
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1) One way to test this would be to assess the infarct size of the hearts that have been 
used for Runx expression experiments.  If the infarct size was not different between 
hearts, it would give more confidence that the relationship is not as a result of the 
infarct size.  However, due to the nature of the tissue preparation for these experiments 
(fresh hearts dissected and immediately snap-frozen) it was not possible to accurately 
assess infarct size histologically in these hearts.  Infarct size therefore could only be 
estimated from photographs of the heart under magnification and estimated based on 
the percentage of infarcted area by means of tracing around the surface of the infarct 
using image analysis software – this was only possible from a very small number of 
hearts (n=3).  Using these three hearts by this method, there were no significant 
differences observed in infarct size and no correlation observed between infarct size 
and Runx1 expression.  This would suggest that the relationship between Runx 
expression and level of cardiac dysfunction was not influenced by infarct size.  
However when infarct size was measured histologically in a separate group of hearts 
the level of dysfunction was proportional to the infarct size.  The reasons for the 
discrepancy may be related to the method of measuring infarct size with the ‘tracing 
round’ method being less accurate than the more thorough length-based quantification 
from serial histology sections where the infarct is clearly delineated from Sirius red 
staining.  Furthermore the small sample size is a limiting factor in the accuracy of the 
results. 
2) A similar approach would be to assess whether the degree of Runx expression in the 
infarct region itself changes with degree of dysfunction; although this region shows the 
highest levels of Runx1, Runx2 and Runx3, if no correlations with function and Runx 
gene expression were observed in this region it would invalidate the original problem 
of the infarct’s contribution to Runx/dysfunction.  Following analysis however this was 
found not to be the case - when assessing the infarct alone, Runx1 and Runx3 correlate 
significantly with dysfunction (with and without shams included) indicating hearts 
with greatest dysfunction express more Runx1 and Runx3 in the infarct alone.  There 
was no correlation with Runx2 expression and function in the infarct region.  In 
attempts to eliminate the influence of the infarct on the analysis, the contribution of 
Runx expression from the infarct was removed from the analysis and the relationship 
between Runx expression and dysfunction was still the same.  This indicates that there 
was still a significant correlation between Runx expression and level of dysfunction 
even without the contribution from the infarct.  There are however some points to 
consider with this observation: (i) firstly the infarct size may have already affected the 
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function of the heart (larger infarcts do lead to reduced function) but it is unclear if this 
would play a part in the peri-infarct and remote LV Runx expression.  It is possible that 
with greater damage there was reduced function and a subsequent increase in Runx in 
the surviving regions as well as the infarcted tissue – therefore this point may only 
affect the functional side of the relationship; (ii) secondly, the peri-infarct could be 
contaminated with infarct expression (although efforts were made to ensure careful 
dissection of the infarct and peri-infarct from each other during tissue collection, it is 
very difficult to be completely certain that no overlap of scar tissue was present in the 
peri-infarct).  However, it was tested to see whether there was any correlation between 
Runx expression in the infarct and peri-infarct region of the same heart (i.e. did the 
hearts with the highest level of Runx in the infarct also have the highest level of Runx 
in the peri-infarct of the same heart?).  The results showed that there were no 
significant correlations suggesting that the peri-infarct expression had not been 
affected by the infarct of the same heart (and contamination therefore was unlikely).  
Furthermore, the remote region was tested as there would be no risk of contaminating 
scar tissue in this region, but no correlations were found between the expression of any 
Runx gene and cardiac function in this region - it must be noted that these were 4-wk 
post-MI hearts and Runx1 levels are not different from basal sham levels in the remote 
LV at 4-wk.  
3) In a separate animal model of cardiac disease in which there is no infarct 
(hypertension/LVH) the model showed the same pattern with significantly higher 
Runx1 expression in hearts with greatest dysfunction therefore owing more strength 
that it may not be related to the infarct.  This data is discussed in more detail in 
Chapter 5.  Although infarct size post-MI is an important determinant of the extent of 
dysfunction in humans (Masci et al., 2011) and mouse models (Gao et al., 
2000;Patten, 1998;Takagawa et al., 2007), the degree of adverse remodelling is not 
always solely related to the amount of damage sustained (Ambler et al., 2008).  Genes 
can influence function independently of infarct size; this has been shown in transgenic 
mouse studies: mice deficient in the gene for myeloperoxidase had improved function 
compared to wild-type mice despite equivalent infarct size (Vasilyev et al., 2005) and 
over-expression of the gene for glutathione peroxidase in mice reduces adverse LV 
remodelling independently of infarct size (Shiomi et al., 2004).  Therefore it is 
possible for Runx genes to have a potential role in the dysfunction observed 
independent of infarct size, however at present it is not clear whether infarct size is 
contributing to the effects seen in this study.  




Collectively, the findings described in this chapter have revealed in detail that during MI 
there are changes in the expression of the Runx genes in terms of abundance, regional 
distribution, time course and (very preliminary indications of) association with onset of 
severe MI and HF.  Additionally there were similarities in the regional expression pattern 
of the other Runx genes but differences in their extent of altered expression.  One of the 
first areas to investigate further would be to ascertain that RUNX1 increases in 
cardiomyocytes during MI.  The work in this chapter has shown that RUNX1 is increased 
in the heart post-MI and is present in cardiomyocytes during MI but it remains to be shown 
that the levels of RUNX in the cardiomyocytes increase.  Further experiments for this work 
would involve further over-expression of recombinant RUNX protein within cultured 
mouse cardiomyocytes to verify that the changes in Ca2+ handling could be repeated in the 
mouse (rabbit cardiomyocytes survive better in culture than mouse cardiomyocytes which 
is the reason why the preliminary experiments were performed in rabbit).  To evaluate 
whether increased expression of Runx1 is having an adverse effect on function post-MI, 
two approaches could be taken; (i) genetic over-expression of Runx1 into the heart via in 
vivo adenoviral vector delivery prior to the induction of MI (followed by functional 
measurements in vivo and at the cardiomyocyte level after MI) or (ii) genetic ablation of 
Runx1 using transgenic mice with cardiac-specific knockout of Runx1 (global knockout is 
embryonically lethal) followed by functional measurements.  Biochemical analyses of Pln 
expression (both phosphorylated and unphosphorylated forms) in the mouse MI cardiac 
tissue would also be very informative to assess whether levels of the phosphorylated Pln 
were reduced and unphosphorylated levels increased as a means to explain a possible 
mechanism by which RUNX1 may be adversely affecting cardiomyocyte function. 
Conclusion:  In conclusion, the up-regulation of RUNX in the heart post-MI may reflect 
an important role in the regulation of post-infarction remodelling and warrants further 
investigation.   








Characterisation of cardiac function and Runx1 
expression in a congenic rat model of altered left 
ventricular mass 




5.1.1 Altered RUNX gene expression in cardiac disease 
Experimental animal models of cardiac disease can provide valuable insight into the 
underlying molecular mechanisms associated with the development of HF.  This includes 
the identification of causative genes related to a particular disease or the alteration of 
specific genes during the disease.  The adverse LV remodelling process that occurs in 
response to cardiac disease can trigger changes in cardiac gene expression, for example 
genes regulating calcium (Ca2+) handling (Swynghedauw, 1991), contraction (Yue et al., 
1998), the ECM (Weber, 1997) and the RAA system (Holtz, 1998).  More recently, 
transcription factors have emerged as important targets in elucidating the mechanisms of 
altered gene expression as many genes affected during remodelling are under the control of 
transcription factors (Kaab et al., 2004).  As the previous chapter in this thesis has shown, 
the gene encoding RUNX1, a transcriptional regulator of the RUNX family is over-
expressed in the mouse heart during MI, similar to what has been shown previously in 
human MI (Gattenlohner et al., 2003).  However, although knowledge of cardiac RUNX1 
expression during MI is emerging, very little is known about its altered expression in other 
forms of cardiac disease.  By examining how RUNX1 expression is altered during different 
forms of cardiac disease, this could provide important insight into the regulatory stimuli of 
the gene and allow for comparisons between different disease models.  Therefore, to 
further characterise the altered expression of Runx1 during cardiac disease and compare it 
with the previous MI model, this involved utilising a rat model of hypertension (SHRSP) 
and congenic rat models of altered LV mass. 
5.1.2 LV mass and hypertension 
LV hypertrophy (LVH) is an accepted independent predictor of cardiovascular morbidity 
and mortality (Devereux et al., 1994;de et al., 2002).  LVH occurs in response to injury or 
elevated load as part of LV remodelling, however while initially compensatory, LVH can 
eventually lead to HF.  The pathophysological mechanisms underlying the progression of 
LVH to HF remain poorly understood.  Although the most common cause of LVH is an 
elevated BP, the correlation between the two remains very complex.  The intensity of BP 
load has been found not to always correspond to the degree of LVH observed in humans; 
for example, it has been documented that individuals with comparable levels of high BP 
demonstrate largely variable extents of LVH (Nunez et al., 1996).  Furthermore, one report 
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revealed that there was no evidence of LVH in 50% of hypertensive patients (Devereux et 
al., 1994).   
5.1.2.1 Genetic basis for LV mass 
These differences are believed to be as a result of the complex polygenic nature of LV 
mass inheritance.  Studies on twin children have revealed that LV mass is genetically 
determined in childhood (Verhaaren et al., 1991).  Body weight, BP, SV, sodium intake 
and physical activity are all known to be a strong correlate of LV mass in adults (Kupari et 
al., 1994), with >90% of the correlation between LV mass and body weight as a result of 
common genes (Verhaaren et al., 1991).  Therefore, within a normal adult population LV 
mass has a significant genetic determination (Swan et al., 2003).  One way to study 
complex genetic factors such as LV mass which could be important for cardiac disease is 
using inbred animal models. 
5.1.3 Rat model of hypertension 
Experimental models of hypertension have been developed in the rat over the last forty 
years including the spontaneously hypertensive rat (SHR) (OKAMOTO & AOKI, 1963) , 
the stroke-prone SHR (SHRSP) (Okamoto et al., 1974), Dahl salt-sensitive (DAHL et al., 
1962) and Sabra rats (Lutsky et al., 1984).  These models demonstrate many of the clinical 
features of human hypertension including LV hypertrophy (Yamori et al., 1979), impaired 
myocardial function (Conrad et al., 1991), increased susceptibility to stroke (Jeffs et al., 
1997) and renal failure (Kawabe et al., 1978).  Inbred animal models offer the advantage of 
genetic homogeneity and complete control of environmental factors but most importantly 
they allow for specific inter-crosses to generate sub-strains which can provide insights into 
genetic determinants of hypertension which are beyond the scope of human studies.  These 
sub-strains are useful for the study of specific genetic regions important for hypertension 
such as altered LV mass.  This approach involves the identification of quantitative trait loci 
(QTL), which are regions of a chromosome containing genes for a particular trait.  This 
then makes it possible to narrow down the genes contained within the QTL interval.   
5.1.3.1 Congenic strains 
In order to dissect out the QTL of interest, this usually involves the construction of a 
congenic strain whereby a chromosomal segment containing the QTL from a donor strain 
is introgressed into a recipient strain using a backcrossing breeding scheme.  If the QTL of 
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interest is successfully moved then the resulting congenic strain will be identical to the 
recipient strain except for the QTL.  The congenic strain can then be used to assess the 
QTL-related phenotype alterations.  According to Mendelian laws it can take up to 8-10 
crosses to dilute the donor genome to >99% of the recipient.  Brother-sister mating can 
then fix the congenic strain as homozygous.  This is known as the traditional congenic 
breeding method.  However this method can take up to 3-4 years to produce the desired 
congenic strain (Frantz et al., 1998).  A faster method has been developed which involves 
selecting male offspring that contain the fewest donor alleles and using these for the 
breeding; this is called marker-assisted speed breeding (Figure 5.1) and can reduce the time 
taken to produce the congenic strain by approximately half (~ 2 years) (Jeffs et al., 2000). 
5.1.3.2 QTL for LV mass 
QTLs for LV mass have been identified using this approach.  This is important for the 
study of LVH because a detailed study by Tanase et al. revealed from a study of 23 inbred 
strains of normotensive and hypertensive rats that an estimated 65-75% of the difference in 
cardiac mass between strains was genetically linked (Tanase et al., 1982).  Therefore, 
through the use of genetic crosses between normotensive and hypertensive strains 
numerous linkage studies have revealed the existence of QTL for LV mass, some BP-
dependent and others independent of BP in a number of chromosomal regions.  For 
example, BP-independent QTL for LV mass have been mapped along several different 
regions of chromosome 17 (Deng et al., 1994;Pravenec et al., 1995;Tsujita et al., 2000).  
QTL for LV mass which are found to be dependent on BP have been identified on 
chromosomes 2, 4, 19 (Pravenec et al., 1995) and 7 (Tsujita et al., 2000;Garrett et al., 
1998). 




Figure 5.1  Traditional and speed congenic breeding. 
Construction of congenic strains showing the differences between traditional and marker-assisted speed breeding.  
Arrows indicate the backcross at which the background heterozygosity is theoretically the same.  Decreasing shades of 
grey represent dilution of the donor genome.  D=donor strain alleles, R=recipient strain alleles, B=backcross, F1=first 
filial generation.  Taken from (Graham et al., 2005). 
5.1.3.3   Chromosome 14 congenic strains 
Through the use of genome-wide linkage analysis, groups here at the University of 
Glasgow previously identified a QTL for LV mass on chromosome 14 of the stroke-prone 
spontaneously hypertensive rat (SHRSP) (Clark et al., 1996).  To explore this, two 
congenic strains have been produced using SHRSP and its normotensive control strain, 
Wistar Kyoto (WKY): 
(i) WKY.SPGla14a in which the QTL on chromosome 14 from SHRSP has been 
introgressed into WKY rats (denoted WKY-congenic); 
(ii) SP.WKYGla14a in which the QTL on chromosome 14 from WKY has been 
introgressed into SHRSP (denoted SHRSP-congenic). 
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The nomenclature for these strains includes the recipient strain (first abbreviation) 
followed by the donor strain (second abbreviation); Gla denotes that the strains originate 
from Glasgow colonies and the number 14 refers to the chromosome number.  For 
simplicity, these strains will be referred throughout the rest of the thesis as WKY-congenic 
and SHRSP-congenic. 
5.1.4 Functional assessment of the models using PV 
methodology 
These congenic strains can be utilised for the identification of genes within this QTL which 
could be potential targets for hypertension therapy; however, this model also represents a 
very effective model for the investigation of Runx expression patterns during different 
cardiac diseases which will be the main focus for this thesis.  Previous phenotype 
measurements (echocardiography and radiotelemetry) of these congenic strains have 
revealed that they each show alterations in LV mass with little change in their systolic BP.  
Therefore it is likely that this QTL is being regulated without influence by BP.  However 
the measurements that were performed to measure this were largely dependent on loading 
conditions.  One way to measure LV function without the influence of BP load is using 
pressure-volume analysis.  This allows assessment of LV performance in vivo without the 
influence of load.  This method has been widely used in humans and large animals (Kass et 
al., 1988b;Little & Cheng, 1993), however the recent development of miniature PV 
catheters has made the technique applicable to smaller animals such as rodents (Pacher et 
al., 2008). 
5.1.5 Cardiac fibrosis can alter normal functioning in these 
models 
LV function in hypertensive heart disease models can be largely influenced by the level of 
structural remodelling, for example the degree of LVH as previously discussed but also 
patterns of ECM remodelling which are also characteristic of this model (Weber et al., 
1991a;Weber et al., 1991b).  The accumulation of fibrillar collagen, representing 
myocardial fibrosis is a major determinant of the LV diastolic properties: during 
hypertensive pressure-overload, the ventricles enlarge to accommodate the increased wall 
stress and this is usually accompanied by disproportionate deposition of collagen around 
the myocardial arteries and muscle fibres as a means of conferring tensile strength to the 
myocardium to further support the heart during increased load (Kai et al., 2005).  
Myocardial fibrosis affects diastolic performance in that it can limit normal diastolic 
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‘suction’, impair myocardial compliance and compromise the length-dependent muscle 
fibre shortening during contraction (Burlew & Weber, 2002). 
5.1.6 Aims 
The aims of the work presented in this chapter were therefore as follows: 
(i) Characterise systolic and diastolic function at baseline and at different preloads 
in each strain using the PV catheter system in order to assess load-independent 
analysis of cardiac function.  This would allow a functional characterisation of 
the different strains to assess the differences in phenotypes, and segregate the 
strains into different functional models of cardiac disease for the investigation 
of Runx expression levels. 
(ii) Measure Runx1 expression in these strains and identify whether the different 
models show different patterns of expression. 
(iii) Assess changes in structural cardiac fibrosis of the heart in these strains to 
characterise differences between the strains, identify possible links with 
function and assess possible links with Runx1 expression.  
5.2 Methods 
The congenic strains have been bred and maintained at the University of Glasgow since 
1991.  Genotyping and radiotelemetry probe implantation was performed by Dr. Delyth 
Graham and arterial BP and LVMI measurements were previously collected by Dr. Delyth 
Graham and Dr. Kirsten Douglas as described in the General Methods chapter. 
5.2.1 Blood pressure determination 
Radiotelemetry transmitter probes (Dataquest IV telemetry system, Data Sciences 
International) were surgically implanted into the abdominal aorta when the animals 
reached 12 weeks of age for the measurement of systolic BP over the subsequent 4 weeks.  
Measurements were taken for 10 s every 5 min and these measurements were averaged for 
each hour. 
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5.2.2  LV mass measurements 
LV mass was measured using echocardiography when the animals were 16 weeks of age.  
Animals were anaesthetised (isofuorane) and short axis 2D M-mode images were taken 
through the left parasternal window at the papillary muscle level using ACUSON Sequoia 
C512 echocardiograph.  Mean data from six consecutive cardiac cycles from each M-mode 
image were used to calculate LV mass using the ASE-cube formula with Devereux 
correction factor as previously published (Devereux et al., 1986): 
6.0)))(04.1(8.0 33 +−++= EDDAWTPWTEDDmassLV             Eq. 20 
Where EDD is the end-diastolic dimension (mm), PWT is the posterior wall thickness 
(mm), AWT is the anterior wall thickness (mm).  LV mass was normalised to tibial length 
(TL). 
5.2.3 LV PV Measurements 
16 week-old animals were induced and maintained with isofluorane on a face-mask (1.5-
2%). Body temperature was maintained at 37°C ± 0.5 using a rectal probe connected to a 
homeothermic heat blanket system (Harvard Apparatus 507221F). A 1.9F pressure-
volume catheter (SciSense) was inserted into the carotid artery and advanced through the 
aortic valve into the left ventricle guided by changes in pressure. Following a ten-minute 
stabilisation period, pressure and volume measurements were recorded in steady state and 
during reduced preloads by temporarily occluding the inferior vena cava. To offset parallel 
volume (Vp) from surrounding conductive structures, three bolus injections (35 µl each) of 
15% hypertonic saline was administered into the left jugular vein at the end of the 
experiment to allow a mean value for Vp to be taken. 
5.2.4 Harvesting of hearts 
Animals were sacrificed by cervical dislocation and the heart was removed and washed in 
ice-cold saline (0.9% sodium chloride w/v).  The aorta was cut transversely, mounted on to 
a 19G cannula attached to a syringe and perfused retrogradely with ice-cold saline to rinse 
blood out of the coronary vessels.  Hearts were blotted dry on tissue paper and weighed 
using a precision electronic balance.  The LV free wall was then dissected free and also 
weighed.  The LV free wall was then cut into small pieces approximately 5mm2 and each 
were snap-frozen in liquid nitrogen and stored at -80°C until needed for biochemical 
experiments. 
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5.2.5 Preparation of heart sections for Sirius red staining 
Harvested hearts were fixed in 10% neutral buffered formalin for a minimum of 24 h to 
allow sufficient penetration of the tissue.  Sectioning and staining of the sections was 
performed by Mr Andy Carswell.  Briefly, the hearts were paraffin-embedded and 
sectioned using a microtome (3 µm thick).  Sections were deparaffinised and hydrated 
using a clearing agent (Histoclear, Fisher Scientific, U.K) for 2 x washes followed by 
100% ethanol, 90% ethanol, 70% ethanol then distilled water for 7 min in each solution.  
Sections were then stained for 1 h with picrosirius red, which is a collagen-specific dye 
that stains collagen red, followed by 2 x washes of acidified water and 2 x washes of tap 
water for 5 min each.  Sections were then dehydrated through 70% ethanol, 90% ethanol, 
100% ethanol and Histoclear (2 x washes) for 7 min each.  The dehydrated sections were 
then coverslip-mounted with a mounting agent (Histomount, Invitrogen, U.K.). 
5.2.6 Measurement of cardiac fibrosis 
Transverse sections of LV apex stained with Sirius red were examined with an Olympus 
BX41 microscope (x20 magnification) and images were captured with a Qimaging Go-3 
camera with the use of QCapturePro software.  Collagen was quantified using 
ImageProPlus software which counted the number of red pixels of a set threshold of red 
colour using a histogram scale within a fixed area (300 x 300 pixels) for the blood vessels 
(perivascular fibrosis) and the adjacent interstitial areas (interstitial fibrosis).  Perivascular 
fibrosis was assessed in at least 5 randomly selected vessels per heart.  Blood vessels with 
comparable lumen size were selected for as much as possible and only vessels which could 
fit into the box were used and any that were <50% the size of the box were not included.  
Interstitial fibrosis was measured in areas adjacent to the blood vessels; three separate 
adjacent areas to each blood vessel were used for this and a mean value taken.  Interstitial 
areas contained no obvious blood vessels or other structures.  All perivascular and 
interstitial measurements were then averaged to give a mean value of perivascular and 
interstitial fibrosis for each heart. 
5.2.7 qRT-PCR 
RNA extraction, cDNA synthesis and qRT-PCR were performed as described in the 
General Methods Section 2.12.  RNA was extracted using a phenol-chloroform extraction-
based method using the miRNeasy RNA Extraction Kit (Qiagen) according to the 
supplier’s protocol.  Following DNase treatment of the extracted RNA, first-strand cDNA 
Kirsty K. Foote, 2012  Chapter 5  
242 
 
was synthesised from 2 µg of RNA using the Omniscript Reverse-Transcription Kit 
(Qiagen).  Runx1 gene expression in cDNA samples was measured by qRT-PCR with 
Runx1-specific primers in a SYBR green assay using a thermal cycler with accompanying 
software (ABI 7500 sequence detection system).  GAPDH was used to normalise cDNA 
levels. 
5.2.8 Data recording and statistical analysis 
All PV data were recorded on a Dell laptop using LabScribe2.0 software version 2.241 at a 
sampling rate of 2000 samples.s-1 and analysed offline using LabScribe2.0 software.  All 
data in the text and figures are expressed as mean ± SEM.  Statistical significance was 
measured using student’s paired or unpaired t-test for comparisons between a maximum of 
two groups, or ANOVA  followed by the Bonferroni or Tukey post-hoc test where 
appropriate for comparing more than two groups.  A P value of <0.05 was considered 
statistically significant. 
5.3 Results 
5.3.1 LV mass and systolic blood pressure 
Age, BW, tibial length, LV mass index (LVMI) and systolic blood pressure (SBP) for each 
strain are shown in Table 5.1.  The WKY-congenic, SHRSP and SHRSP-congenic were all 
significantly smaller in BW (P<0.05 for each strain) and had significantly shorter tibial 
lengths (TL) compared to WKY (P<0.05 for each strain).  LV mass was estimated using 
echocardiography and expressed relative to TL.  LV mass and SBP measurements were 
performed by Dr Kirsten Douglas and Dr Delyth Graham.  SHRSP demonstrated 
significantly greater LVMI than WKY (increased by 25.6% of WKY; P<0.05).  The 
WKY-congenic showed a significant increase in LVMI compared to WKY (by 17.3%; 
P<0.05) and the SHRSP-congenic demonstrated a significant decrease in LVMI compared 
to SHRSP (by 16.4%; P<0.05).  SBP was unchanged between the SHRSP and SHRSP-
congenic; both of these strains had significantly elevated SBP compared to WKY and were 
considered hypertensive as defined by SBP>150 mmHg.  The WKY-congenic showed a 
small but significant increase in SBP (by 6.1%) when compared to WKY; however both of 
these strains remained normotensive with SBP within the normal range for rats (119-146 
mmHg; (Pacher et al., 2008)). 
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Table 5.1  LVMI and SBP in the congenic and background strains. 
Animals Age                                       (weeks) 
BW                             
(g) 
Tibial Length              
(mm) 
LVMI                                     
(g/mm) 
SBP                                      
(mmHg) 
  
    
WKY (n=10) 16 337.70 ± 9.51 47.70 ± 1.25 16.33 ± 0.29 136.46 ± 2.88 
WKY-congenic 
(n=13) 16 319.46 ± 4.79* 44.31 ± 0.40* 19.16 ± 10.34* 144.83 ± 2.45* 
 
     
SHRSP (n=6) 16 257.83 ± 4.01† 40.00 ± 1.00† 20.51 ± 1.03† 192.06 ± 3.66† 
SHRSP-congenic 
(n=5) 16 247.40 ± 9.45† 39.20 ± 0.49† 17.14 ± 0.42* 181.87 ± 7.16*† 
    
        
BW = body weight; LVMI = left-ventricular mass index (LV mass normalised to tibial length) measured using 
echocardiography; SBP = systolic blood pressure, daytime recordings using radiotelemetry. * P<0.05 between the 
congenic and respective background strain.  † P<0.05 when compared to WKY. 
5.3.2 Haemodynamic LV function 
LV PV measurements were used to assess changes in LV function in each of the four 
strains.  The results of these measurements are presented in Figure 5.2, Figure 5.3 and 
summarised in Table 5.2.   
5.3.2.1 Systolic functional parameters of the heart 
Figure 5.2A shows typical pressure traces from each of the four strains and typical PV 
loops from each strain are shown in Figure 5.2B.  Figure 5.3 shows the results of systolic 
parameters of cardiac function between the groups.  Heart rate was the same in all four 
strains with no statistical differences observed (P>0.05; Figure 5.3A (i)).  Both the SHRSP 
and SHRSP-congenic showed significantly elevated ESP compared to WKY (to 148% and 
154% of WKY levels for SHRSP and SHRSP-congenic respectively; P<0.05 for both; 
Figure 5.2A-B & Figure 5.3A (ii)) and the WKY- congenic (to 133% and 138% of WKY-
congenic levels for SHRSP and SHRSP-congenic respectively; P<0.05 for both; Figure 
5.2A & Figure 5.3A (ii)).  SHRSP and SHRSP-congenic were both hypertensive with 
ESP>150 mmHg (Figure 5.2A-B & Figure 5.3A (ii)).  ESP was not different between the 
SHRSP and SHRSP-congenic (P>0.05).  The WKY-congenic showed a small but 
significant (to 111% of WKY levels) increase in ESP in the WKY-congenic compared to 
WKY (P<0.05; Figure 5.3A (ii)) but both WKY and WKY-congenic were normotensive 
ESP< 146mmHg).  There were no differences in the maximal rate of rise in pressure 
(dP/dtmax) between the WKY-congenic and WKY (P>0.05), nor between the SHRSP-
congenic and SHRSP (P>0.05; Figure 5.3A (iii)).  Both the SHRSP and the SHRSP-
congenic showed higher dP/dtmax compared to WKY (to 142% and 143% of WKY levels 
for SHRSP and SHRSP-congenic respectively; P<0.05 for both; Figure 5.3A (iii)) and 
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WKY-congenic (to 138% and 139% of WKY-congenic for SHRSP and SHRSP-congenic 
respectively; P<0.05 for both; Figure 5.3A (iii)).  CO was significantly reduced in the 
WKY-congenic compared to WKY (to 71% of WKY; P<0.05; Figure 5.3A (iv)) but 
conserved between the SHRSP-congenic and SHRSP (P>0.05; Figure 5.3A (iv)). 
5.3.2.2 Diastolic functional parameters of the heart 
The WKY-congenic showed an increase in EDP to 146% of WKY levels (P<0.05; Figure 
5.3B (i)) and the SHRSP-congenic showed a decrease in EDP to 60.7% of SHRSP levels 
(P<0.05; Figure 5.3B (i)).  Compared to WKY, the maximum rate of fall in pressure 
(dP/dtmin) increased in the SHRSP to 140% of WKY levels (P<0.05; Figure 5.3B (ii)) and 
in the SHRSP-congenic to 140% greater of WKY (P<0.05; Figure 5.3B (ii)).  Similarly, 
when compared to the WKY-congenic, dP/dtmin was increased in the SHRSP to 137% of 
WKY-congenic (P<0.05; Figure 5.3B (ii)) and in the SHRSP-congenic to 137% of WKY-
congenic (P<0.05; Figure 5.3B (ii)).  However, there were no differences in dP/dtmin 
observed between each congenic and their respective background strains (WKY-congenic 
vs. WKY P>0.05; SHRSP-congenic vs. SHRSP P>0.05; Figure 5.3B (ii)).  No differences 
in the relaxation time constant Tau (τ) were observed between the four strains (P>0.05; 
Figure 5.3B (iii)).  The EDPVR stiffness constant (β) was found to be significantly higher 
in the WKY-congenic compared to WKY (3.0-fold higher; P<0.05) and significantly lower 
in the SHRSP-congenic compared to SHRSP (3.5-fold lower; P<0.05).  SHRSP showed 
significantly greater LV stiffness than WKY (3.0-fold higher; P<0.05; Figure 5.3). 
5.3.2.3 Volume parameters 
No differences were observed in ESV between the four strains (P>0.05; Figure 5.3C (i)).  
EDV was significantly reduced in the WKY-congenic compared to WKY (by 26.2% of 
WKY; P<0.05 Figure 5.3C (ii)).  No differences in EDV were observed between the 
SHRSP-congenic and SHRSP (P>0.05) nor between SHRSP and WKY (P>0.05; Figure 
5.3C (ii)).  SV was significantly reduced in the WKY-congenic compared to WKY (to 
68.8% of WKY levels; P<0.05), however SV was not different in the SHRSP-congenic 
compared to SHRSP (P>0.05) nor between SHRSP and WKY (P>0.05; Figure 5.3C (iii)).  
EF was unchanged across all four strains (P>0.05; Figure 5.3C (iv)). 





Figure 5.2  Representative LV pressures and PV loops. 
A (i-iv).  LV intra-ventricular pressures from WKY, WKY-congenic (red), SHRSP and SHRSP-congenic (red).  B (i).  
Typical PV loops from WKY (black) and WKY-congenic (red).  B (ii) Typical PV loops from SHRSP (black) and 
SHRSP-congenic (red). 




Figure 5.3  Haemodynamic PV indices of LV function. 
Systolic functional parameters (A i-iv), diastolic functional parameters (B i-iv) and volume parameters (C i-iii) in WKY 
(n=7; white bar), WKY-congenic (n=5; light grey bar), SHRSP (n=7; black bar) and SHRSP-congenic (n=7; dark grey 
bar).  Data shown are mean ± SEM *P<0.05.
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Table 5.2  Haemodynamic PV data from the congenic and background strains. 
  
WKY                               
(n=7) 
WKY-congenic              
(n=5)   
SHRSP                          
(n=7) 
SHRSP-
congenic               
(n=7) 
 
     
HR (bpm) 325.8 ± 9.0 336.6 ± 1.8  350.9 ± 11.8 340.6 ± 7.2 
ESP (mmHg) 125.2 ± 3.1 139.9 ± 1.5*  185.6 ± 4.0† 193.3 ± 10.4† 
EDP (mmHg) 7.7 ± 0.9 11.2 ± 1.1*  11.2 ± 1.6 6.8 ± 1.1* 
dP/dt max (mmHg.s-1) 7796.4 ± 393.5 8042.9 ± 222.8  11092.7 ± 501.1† 11208.8 ± 477.3† 
dP/dt min (mmHg.s-1) 8085.0 ± 272.3 8243.0 ± 222.7  11309.4 ± 479.2 † 11293.7 ± 478.2† 
Tau (ms) 10.4 ± 0.4 10.4 ± 0.4  9.7 ± 0.3 9.8 ± 0.3 
EDPVR 0.011 ± 0.004 0.034 ± 0.006*  0.034 ± 0.009† 0.010 ± 0.03* 
ESV (µl) 71.3 ± 13.1 59.8 ± 2.6  98.2 ± 15.2 78.8 ± 18.8 
EDV (µl) 214.2 ± 21.9 158.1 ± 10.0*  221.7 ± 26.2 188.8 ± 15.9 
SV (µl) 142.9 ± 16.8 98.3 ± 7.9*  123.5 ± 18.8 122.3 ± 6.7 
CO (ml.min-1) 46.5 ± 3.7 33.1 ± 2.8*  38.1 ± 4.2 41.9 ± 2.1 
EF (%) 68.8 ± 6.5 60.7 ± 3.7  55.2 ± 4.8 63.5 ± 4.3 
  
          
HR = heart rate; ESP = end-systolic pressure; EDP = end-diastolic pressure; dP/dtmax = maximal rate of rise of 
pressure; -dP/dtmin = maximal rate of fall in pressure; Tau (τ) = relaxation time constant;  EDPVR = end-diastolic 
pressure-volume relationship stiffness constant.  ESV = end-systolic volume; EDV = end-diastolic volume; SV = 
stroke volume; EF = ejection fraction; CO = cardiac output.  Values are expressed as mean ± SEM. * P < 0.05 vs. 
time-matched sham control.  † P < 0.05 compared to WKY.
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5.3.3 Collagen content 
Collagen levels in the heart were assessed by measuring the positive collagen area from 
Sirius red histology sections of the heart.  When compared to WKY, the WKY-congenic 
showed significantly higher levels of perivascular collagen levels (13.9 ± 2.6 vs. 5.8 ± 0.4 
%; WKY-congenic (n=5) vs. WKY (n=3); P<0.05; Figure 5.4B) and interstitial collagen 
levels (4.6 ± 0.8 vs. 1.7 ± 0.2 %; WKY-congenic (n=5) vs. WKY (n=3); P<0.05; Figure 
5.4C).  Compared to SHRSP, the SHRSP-congenic demonstrated significantly reduced 
levels of interstitial fibrosis (1.9 ± 0.3 vs. 3.3 ± 0.5 %; SHRSP-congenic (n=4) vs. SHRSP 
(n=4); P<0.05; Figure 5.4B) but had significantly elevated levels of perivascular fibrosis 
(17.7 ± 2.8 vs. 8.0 ± 1.7 %; SHRSP-congenic (n=4) vs. SHRSP (n=4); P<0.05; Figure 
5.4C). 
 




Figure 5.4  Collagen levels in the congenic and background strains. 
A. Representative photographs of Sirius red sections showing areas of collagen (red) in WKY, WKY-congenic, SHRSP 
and SHRSP-congenic. B. Interstitial fibrosis measured from Sirius red sections from WKY (n=3), WKY-congenic (n=5), 
SHRSP (n=4) and SHRSP-congenic (n=4). C. Perivascular fibrosis measured from Sirius red sections from WKY (n=3), 
WKY-congenic (n=5), SHRSP (n=4) and SHRSP-congenic (n=4). Data shown are mean ± SEM. * P<0.05. 
5.3.4  Runx1 gene expression 
Runx1 mRNA levels were measured using qRT-PCR on whole LV free wall taken from 
each of the four strains.  The WKY-congenic showed a significant reduction in Runx1 
levels compared to WKY (0.11 ± 0.05 vs. 0.47 ± 0.06 RQ; WKY-congenic (n=5) vs. WKY 
(n=5); P<0.05; Figure 5.5).  There were no differences in Runx1 expression between the 
SHRSP-congenic and SHRSP (0.19 ± 0.07 vs. 0.27 ± 0.05 RQ; SHRSP-congenic (n=5) vs. 
SHRSP (n=5); P<0.05; Figure 5.5).  WKY also showed higher levels of Runx1 compared 
to the SHRSP-congenic (0.47 ± 0.06 vs. 0.19 ± 0.07 RQ; WKY (n=5) vs. SHRSP-congenic 
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(n=5); P<0.05; Figure 5.5).  Although there also appears to be a trend towards lower 
expression in the SHRSP compared to WKY, this did not reach statistical significance. 
 
 
Figure 5.5  Runx1 expression in the congenic and background strains. 
Runx1 expression as measured by qRT-PCR using Runx1-specific primers for WKY (n=5; white bar), WKY-congenic 
(n=5; light gray bar), SHRSP (n=5; black bar) and SHRSP-congenic (n=5; dark gray bar).  Runx1 levels are expressed 
using the 2-∆Ct method. * P<0.05 using ANOVA with the Tukey-Kramer multiple comparison’s post-hoc test. 
5.3.5 Links with Runx1 expression and LV function 
Regression analysis was performed to assess whether a relationship existed between Runx1 
expression and LV function.  The functional parameter used was the relaxation time 
constant (τ) as it was found to be the most sensitive to small changes in the relationship 
between function and Runx expression.  The value for τ was paired with the 2-∆Ct for the 
same heart across the different strains.  The 2-∆Ct value was used as this was the method of 
analysis for the congenic study as a single value for each heart.  Unfortunately there were 
no samples available for the WKY-congenic for this part of the study.  The results are 
shown in Figure 5.6 which revealed that a significant correlation between Runx1 
expression and dysfunction in terms of impaired relaxation: i.e. as τ increased, Runx1 
expression increased (y=0.13x-1.03; R=0.82; P<0.05). 





Figure 5.6  Relationship between Tau (τ) and Runx1 expression in the WKY, SHRSP and SHRSP-congenic 
strains. 
Linear regression analysis of the relationship between the 2-∆Ct value for Runx1 expression and the value for τ for each 
heart.  Each point on the graph is an individual heart.  WKY hearts (n=2; black circles), SHRSP hearts (n=2; open circles) 
and SHRSP-congenic hearts (n=3; red circles). 
5.4 Discussion 
QTLs that regulate LV mass are important for the study of LVH which is known to be an 
independent predictor of adverse cardiovascular outcome clinically (Devereux et al., 
1994;Verdecchia et al., 1995).  Previous work at the University of Glasgow has identified 
a QTL for LVMI on chromosome 14 of the SHRSP (Clark et al., 1996).  This QTL is 
localised between markers D14Mgh3 and R58 which are ≈12.3 cM apart (Clark et al., 
1996).  This has been verified through the construction of congenic strains: (i) 
WKY.SPGla14a (denoted WKY congenic) in which the QTL on chromosome 14 of SHRSP 
has been introgressed into WKY and (ii) SP.WKYGla14a (denoted SHRSP congenic) in 
which the QTL from WKY has been introgressed into SHRSP.  Both of these congenic 
strains demonstrate alterations in LV mass; the WKY-congenic shows increased LV mass 
and the SHRSP-congenic shows decreased LV mass.  RUNX1 has been previously shown 
to have altered expression in the heart during cardiac disease; for example in human MI 
cardiac tissue (Gattenlohner et al., 2003) and as the work in this thesis has revealed, in a 
mouse model of MI.  The hypertensive rat model (SHRSP) and the associated congenic 
strains described in this study represent two further animal models of cardiac disease for 
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which altered Runx levels have not been previously reported and offer potential further 
insight into altered patterns of Runx expression in the heart during disease. 
5.4.1 Congenic strains demonstrate a separation between LV 
mass and BP 
Changes in LVMI with little change in BP:  The chromosome 14 congenic strains 
demonstrate alterations in LVMI; however these changes occur with little (less than 12%) 
or no change in SBP.  This has been verified through both radio telemetry measurements 
and LV PV measurements which have independently shown a small but significant 
increase in SBP in the WKY-congenic (compared to WKY), although the extent of this 
change does differ between the two methods.  One reason for this discrepancy may be the 
effects of anaesthesia as PV measurements are performed under anaesthesia while radio 
telemetry measurements are recorded from conscious animals.  Isofluorane anaesthesia is 
known to reduce blood pressure as a direct result of vasodilation and depressed myocardial 
contractility (Conzen et al., 1992).  Indeed the ESPs observed from animals that underwent 
PV analysis under anaesthesia showed lower ESP than arterial SBP from radio telemetry in 
conscious animals.  Despite this, both sets of measurements have independently shown that 
although the WKY-congenic showed a small increase in arterial SBP and LVESP it 
remained normotensive, despite an increased LVMI.  Similarly, the SHRSP-congenic 
showed no differences in arterial SBP or LVESP compared to SHRSP despite having 
significantly reduced LVMI.  Changes in LV mass therefore occurred with no change in 
the normotensive or hypertensive status of the animal.   
Separation between LVMI and BP:  QTLs for LV mass can either be BP-dependent or 
BP-independent.  BP-independent QTL for LV mass can increase LVMI in normotensive 
individuals or reduce LVMI in hypertension (Llamas et al., 2005).  This is important for 
the study of LVH in which there are discrepancies in the correlation between LVH and BP 
(Nunez et al., 1996).  Elevated BP in hypertension is the most common cause of LVH; 
however the intensity of BP load does not always correspond to the degree of LVH 
observed in patients (Devereux et al., 1994).  In individuals with comparable high BP the 
level of LVH can be largely continuous (Cohn, 1998).  Similarly one report revealed no 
evidence of LVH in 50% of hypertensive patients (Devereux et al., 1994).  Several genetic 
linkage studies have identified QTL for LV mass, some of which are regulated by BP and 
others which are regulated independently of BP - for example several groups have 
identified various BP-independent QTL for LV mass at different locations on chromosome 
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17 (Deng et al., 1994;Pravenec et al., 1995;Tsujita et al., 2000;Yagil et al., 1998).  QTL 
for LV mass which are dependent on BP have been identified on chromosomes 2, 4, 19 
(Pravenec et al., 1995) and 7 (Tsujita et al., 2000;Garrett et al., 1998).   
Model of segregated LVMI and BP:  In this study, QTL on chromosome 14 for LVMI 
causes changes in LVMI without alterations to the hypertensive (or normotensive) status of 
the animal.  This is similar to the findings of Pravenec et al. (1995) who reported that for 
the LVMI QTL on chromosome 17, there was a significant correlation with LV mass but 
no correlations with systolic, diastolic or MAP;  furthermore, no correlation was found 
between BP and LV mass.  Furthermore in our study, the changes in LVMI are evident at 5 
weeks of age (data not shown) before the onset of hypertension.  This would suggest there 
is a BP-independent element to the regulation of this QTL for LVMI.  Therefore utilising 
these congenic strains represents a model which has segregated LV mass from BP.  This 
could allow for the identification of novel candidate genes for LVMI unaffected by BP in 
hypertension. 
5.4.2 Congenic strains with altered LV mass show BP-
independent diastolic dysfunction  
It is well-documented from clinical studies and data from animal models that alterations in 
LV mass can affect the systolic and diastolic functioning of the heart (Lorell & Carabello, 
2000a;Cingolani et al., 2003).  Both systolic and diastolic function can be influenced by 
the load on the heart.  In order to measure changes in cardiac function independently of 
load, the PV catheter system was utilised as a method which allows assessment of diastolic 
LV performance independently from loading conditions. 
5.4.2.1 Systolic function 
SHRSP-congenic:  These measurements confirmed enhanced systolic performance in the 
hypertensive animals (SHRSP and SHRSP-congenic) which both demonstrated elevated 
ESP of >150 mmHg confirming that they have high BP consistent with hypertension.  
These findings were in agreement with arterial SBP measurements which were generated 
using a separate method, radiotelemetry.  This was further supported by elevated dP/dtmax 
in these animals.  Both SHRSP and SHRSP-congenic were therefore confirmed as 
hypertensive with enhanced contractility; however these strains showed no differences in 
systolic parameters with each other and were hypertensive to the same degree.   
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WKY-congenic:  Despite a small increase in ESP, the WKY-congenic showed normal 
ESP (119-146 mmHg; (Pacher et al., 2008)) and was therefore considered normotensive 
like WKY.  It is unclear the cause of this slight elevation in BP however the WKY-
congenic had normal dP/dtmin not different to WKY.  Despite having normotensive 
properties of systolic function there was an overall decline in CO in the WKY-congenic 
strain which is likely because the EDV was smaller and despite equivalent EF this led to 
diminished SV as well as CO (heart rate was unchanged).  Reduced EDV indicates a 
smaller luminal LV which may be due to increased wall thickness consistent with 
concentric remodelling (Lorell & Carabello, 2000a).  Although wall thickness data was not 
available to confirm this, this finding is consistent with the increased LV mass observed in 
these animals.  As the WKY-congenic was the only strain to show any differences in EDV, 
it would suggest that introducing the QTL on chromosome 14 can alter LV mass through 
what is potentially by concentric wall thickening – however, by removing the QTL on 
chromosome 14 this does reverse the effect as no changes in EDV were observed in the 
SHRSP-congenic.  The reasons for this would require further investigation.  EF was 
unchanged across all four strains which may be as a consequence of compensatory 
remodelling (increased LVH) which is known to preserve EF (Aurigemma et al., 1995).  
This finding is not unusual for hypertensive rats at 16-wk as others have shown that EF 
remains normal in the SHR until 72-wk of age when HF begins to develop (Mirsky et al., 
1983).  Similarly CO and SV also do not begin to reduce until 90-wk in the SHR (Pfeffer 
et al., 1979a), consistent with the finding in this present study for SHRSP (and SHRSP-
congenic).    
5.4.2.2 Diastolic function 
SHRSP-congenic:  Despite no change in systolic performance between the SHRSP-
congenic and SHRSP there were alterations in diastolic function.  The SHRSP-congenic 
demonstrated reduced LV mass, despite equivalent systolic function to SHRSP showed 
improvements in diastolic function (to control WKY levels for EDP and EDPVR).  This 
was evident from a lower EDP consistent with improved filling and load-independent 
reduced end-diastolic stiffness.  In vivo measurements of diastolic dysfunction for the 
SHRSP in the literature are extremely limited, there are however findings described by 
others for this in the SHR model: for example 40-wk old SHR function characterised by 
Millar PV measurements showed increased myocardial stiffness (derived from the 
EDPVR) and impaired relaxation (Cingolani et al., 2003).  These findings were also 
confirmed by other studies in the SHR (Nishimura et al., 1985;Pfeffer et al., 1979a).  In an 
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ex vivo SHRSP working heart of the same age as the animals in this study (16-wk) there 
was a significant increase in EDP, consistent with our findings in vivo (Chen et al., 2001).  
Interestingly, the relaxation time constant (τ) was unaltered between all four strains 
suggesting the time to relax was not different between all strains despite altered filling 
pressures and myocardial stiffness.  This was an unusual finding as τ usually increases in 
hypertensive heart disease due to increased LVH and fibrosis (Leite-Moreira et al., 1999).  
This has been demonstrated in the SHR model with prolongation of τ concurrent with 
increased LVH and fibrosis (Nishimura et al., 1985;Cingolani et al., 2003).  However, in 
both of these studies the animals were at a greater age (28-50 wk and 40-wk of age) than 
the animals in our study (16-wk old).  Therefore it may be that τ is only affected when the 
animals are older and/or reached a critical threshold of hypertensive heart disease.  In dogs, 
τ is unchanged as hypertension is developing (2-4 wk) and is only increased when the 
animals reach a stable hypertensive state (>14-wk) (Gelpi et al., 1991).  It is therefore 
possible that it may take longer than 16-wk to see changes in τ in the rat model.  An 
elevated EDP and raised EDPVR with a normal τ is not uncommon as it has been 
described previously in humans (Maurer et al., 2004).  However with reduced rates of 
relaxation (using dP/dtmin) in the SHRSP in this study it does question the lack of change in 
the τ – at present the reasons behind this discrepancy are not clear.   
WKY-congenic:  In contrast, the WKY-congenic which had an increased LV mass and 
was normotensive like WKY demonstrated reduced diastolic performance with raised EDP 
and higher LV stiffness.  These data show that there were both load-dependent and load-
independent alterations in LV diastolic function in both strains.  Collectively, other than τ, 
the diastolic indices revealed diastolic dysfunction in the WKY-congenic with no change 
in systolic dysfunction.  Diastolic dysfunction with preserved systolic function is being 
increasingly recognised in humans (Redfield et al., 2003); a recent population-based 
survey revealed that diastolic dysfunction was observed 5 times more than systolic 
dysfunction (Fischer et al., 2003).  Diastolic dysfunction has become an early marker of 
cardiac damage in hypertension and is well known to precede HF during hypertensive 
heart disease (Grossman, 2000;Zile & Brutsaert, 2002). 
5.4.2.3 Volume data 
LV volumes (both ESP and EDP) were not different between SHRSP-congenic and 
SHRSP suggesting the two strains were operating at equivalent LV volumes.  These were 
also no different to WKY which suggests that, despite increased LV mass in SHRSP this is 
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not affecting LV luminal volume.  This is not uncommon as LV mass can increase with no 
change in the chamber radius (Lorell & Carabello, 2000b).  However in the WKY-
congenic reductions in EDV are present with increased LV mass suggesting that in these 
animals there is evidence of concentric hypertrophy accompanied by reduced chamber 
volume.  This would suggest that the QTL segment which has been introgressed into these 
animals may have led to concentric hypertrophy therefore this phenotype could be linked 
to the specific QTL.  When the QTL is removed (SHRSP-congenic) the effect is lost as 
EDV is found to be unchanged compared to SHRSP which further supports that there may 
be genes on the QTL linked to this phenotype observed. 
5.4.3 Altered diastolic dysfunction may be linked to altered 
cardiac fibrosis 
Possible triggers for cardiac fibrosis:  Myocardial stiffness, although influenced by many 
factors, is largely believed to be related to myocardial structural components, particularly 
myocardial fibrosis which is the accumulation of collagen within the myocardium (Brilla et 
al., 1991a).  Increased myocardial fibrosis is common during hypertension as a mechanism 
to increase tensile strength and support hypertrophied cardiomyocytes to prevent LV 
deformation during conditions of elevated load (Weber et al., 1987).  However, prolonged 
overloading can lead to excessive and/or disproportionate myocardial fibrosis which can 
reduce the compliance of the myocardium and be responsible for increased stiffening of 
the ventricle that can lead to diastolic dysfunction (Brilla et al., 1991a).  In early 
hypertensive heart disease, fibrotic collagen is observed mainly in the perivascular space 
surrounding the myocardial blood vessels (perivascular fibrosis) usually as a result of 
overload-induced vascular inflammation.  Pressure-overload occurs because the narrowed, 
stiffened arteries in the vasculature have increased MAP in hypertension (due to reduced 
arterial diameter) which creates an elevated load on the ventricles of the heart which must 
work harder to provide adequate circulation to the body’s tissues.  The increase in arterial 
pressure and elevated mechanical strain on the coronary vessels are believed to initiate a 
series of inflammatory changes in the coronary arterial wall including the activation of the 
chemokine, monocyte chemoattractant protein-1 (MCP-1) which recruits macrophages to 
the area which produce profibrotic cytokines that stimulate fibrosis in the perivascular 
space (Nicoletti & Michel, 1999).  Perivascular fibrosis can then subsequently spread into 
the adjacent interstitium (interstitial fibrosis) as part of a “reactive fibrosis” (Brilla et al., 
1991a).  Increased fibrosis during cardiac remodelling can be classified as either reactive, 
which relates to the progressive spread of collagen in the interstitial space and adventitia of 
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intramyocardial coronary arteries or reparative which occurs when areas of cardiomyocyte 
loss are replaced by fibrosis (e.g. following necrosis in myocardial infarcts).  Presence of 
interstitial fibrosis is therefore usually secondary to perivascular fibrosis and therefore by 
examining levels of both perivascular and interstitial fibrosis this allows for assessment of 
the progression of fibrosis.     
Differences in cardiac fibrosis in the congenic models:  Cardiac fibrosis was measured 
in the four strains for this study by quantifying collagen-positive areas in Sirius red 
sections of the LV.  Comparing the background strains, SHRSP shows increased levels of 
both perivascular and interstitial fibrosis compared to WKY consistent with a hypertensive 
model - increased cardiac fibrosis (both perivascular and interstitial) is a prominent feature 
of hypertensive rat models of hypertension as has been shown in SHR (Brilla et al., 
1991a;Nishimura et al., 1985) and SHRSP (Sawamura et al., 1990).  Additionally, both 
congenic strains demonstrated alterations in the level of fibrosis compared to their 
respective background strains.  The WKY-congenic showed significantly higher levels of 
both perivascular and interstitial fibrosis compared to WKY, indicating both an increase in 
collagen deposition but also to a more advanced stage (as evidenced by high interstitial in 
addition to high perivascular fibrosis).  Higher levels of interstitial fibrosis could be 
contributing to the increased myocardial stiffness observed in these animals as evidenced 
by the EDPVR measurements.  The SHRSP-congenic demonstrated reduced levels of 
interstitial fibrosis compared to its respective SHRSP which would also explain the 
reduced myocardial stiffness in these animals.  Interestingly, while there was reduced 
interstitial fibrosis in the SHRSP-congenic, there was an increase in the level of 
perivascular fibrosis.  Given that perivascular fibrosis can be associated with increased 
inflammation, it’s possible that the SHRSP-congenic, like the WKY-congenic, is sensitive 
to increased inflammation of the myocardial blood vessels.  The cause of this however 
remains unclear.  This finding would support the hypothesis that these animals have more 
inflamed blood vessels which seems likely given that when fed a salt diet they show a very 
high incidence of stroke within 24 h compared to SHRSP (personal communication with 
Dr. Delyth Graham; data not shown).  It may also be that the SHRSP-congenic is at an 
earlier stage of the fibrosis process by the absence of any spread into the interstitial areas 
or that the fibrosis is more concentrated around the perivascular space.  Increased 
perivascular fibrosis with reduced interstitial collagen has been previously reported in rats, 
albeit in volume-overload hypertrophy (Hutchinson et al., 2010;Voloshenyuk & Gardner, 
2010). 
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5.4.4 Runx1 expression is altered in the congenic strain of 
increased LV mass 
Genes may be regulated differently under different cardiac disease conditions:  
Samples of LV from each of the four strains were tested for the expression of the Runx1 
gene which has been previously shown to have altered expression in the heart during 
cardiac disease; for example in human MI cardiac tissue (Gattenlohner et al., 2003) and as 
the work in this thesis has revealed, in a mouse model of MI.  It is possible for cardiac 
genes to be regulated differently under different conditions of disease.  Some genes may be 
altered as a result of specific stimuli only and may not show the same pattern in different 
models of cardiac diseases.  For example, the gene for NCAM (CD56), a neural cellular 
adhesion molecule, is over-expressed during chronic ischaemic HF which is found to be 
specific for ischaemic damage compared to other cardiac diseases including congestive 
cardiomyopathy, hypertrophic obstructive cardiomyopathy, myocarditis and sarcoidosis 
(Gattenloner et al., 2004).  However, another study revealed that NCAM was also up-
regulated during remodelling of hypertrophy to HF in a Dahl salt-sensitive rat model 
(Ventura-Clapier et al., 2004) suggesting that the stimulus may not be ischaemia-specific. 
Differences in Runx1 expression between the congenic models and the MI model:  
While there were no differences found in the expression of Runx1 between the SHRSP-
congenic and SHRSP, there was a marked reduction in expression in the WKY-congenic 
compared to WKY.  The two congenic strains both showed lower levels of Runx1 
compared to WKY.  Runx1 expression was decreased within the rat model of increased LV 
mass and fibrosis compared to an up-regulation observed the in the mouse MI model 
suggesting there are different triggers in the different models contributing to Runx1 
expression levels.  It is possible that like NCAM, Runx1 could be sensitive to ischaemic 
insult triggering greater expression levels, and under conditions of overload-induced 
hypertrophy the Runx1 gene is repressed.  The molecular mechanism by which ischaemic 
stimuli are converted into intracellular signals are not clear, but one study has shown that 
ischaemia may preferentially activate specific protein kinase cascades which may be 
responsible for specific gene activation (Shimizu et al., 1997).  Differences in the 
expression pattern of the same gene have also been reported previously in a similar two 
models: for example an increase in mRNA for the T-type Ca2+ channel occurs in post-MI 
remodelling rat myocardium (Qin et al., 1995) but not in a rat model of overload 
hypertrophy (Vassort & Alvarez, 1994).   
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Reasons for the differences in expression patterns between the models:   
(i)  One potential reason for the differences in gene expression between an MI-induced 
injury and a pressure-overload injury may be related to the differences in the hypertrophy 
response between the models.  Hypertrophy is known to be a major cause of altered gene 
expression in the heart, particularly for transcription factors which are induced by 
hypertrophic stimuli to orchestrate the synthesis of new contractile sarcomeres for the 
protection of the heart (Akazawa & Komuro, 2003).  MI results in a regional hypertrophy, 
mainly confined to the surviving myocardium which is largely eccentric due to volume 
overload (Sadoshima et al., 1992).  Pressure-overload (like in the case of hypertension) 
results in a global hypertrophy which is largely a concentric hypertrophy (Lorell & 
Carabello, 2000a).  Therefore one possibility is that the differences in mechanical stimuli 
between the two models could explain the differences in gene expression patterns – the 
same may also be true for Runx1.   
(ii)  Another major difference in the remodelling between the two models which may 
contribute to the opposing gene expression patterns may be related to the ECM 
remodelling pattern – namely cardiac fibrosis.  In the MI heart, cardiac fibrosis is primarily 
reparative meaning that the increased collagen levels are intended to replace the lost 
cardiomyocytes (French & Kramer, 2007), while in the pressure-overload model the 
fibrosis is predominantly a reactive fibrosis whereby collagen accumulates and spreads as 
part of an inflammatory response (Brilla et al., 1991b).  It is possible therefore that the 
differences in fibrosis patterns could also contribute to the differences in Runx1 expression 
between these two models.  RUNX1 is known to be expressed in fibroblasts (Wotton et al., 
2004); however given that these two models both contain fibroblasts but show opposite 
effects on Runx1 expression it would indicate that there are other mechanisms involved 
than just Runx1 being present in fibroblast cells.     
5.4.5 Potential links with Runx1 and degree of LV dysfunction 
As was observed in the MI model, Runx1 levels correlated significantly with degree of 
cardiac dysfunction among the rat strains (in hearts with greatest diastolic dysfunction, 
Runx1 levels were highest).  Utilising a different animal model of cardiac disease (other 
than MI) offered another approach to assessing the relationship between Runx1 expression 
with cardiac dysfunction without the influence of the infarct associated with MI.  Although 
a single gene may be altered differently in different forms of cardiac disease which is an 
important consideration, it may also reveal similar patterns between expression levels of 
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the gene and its relationship with cardiac dysfunction.  Unfortunately n numbers were low 
(n=2 or 3) but from these small groups, similar trends to the MI model were observed in 
the WKY and SHRSP groups in regards to the relationship between Runx1 mRNA levels 
and degree of cardiac dysfunction – i.e. lower function (prolonged τ), higher Runx1 – 
despite differences in the overall expression pattern of Runx between the two models: a 
lower expression in the diseased state in the rat model, which was the opposite to the MI 
model (higher expression in the diseased state).  The conclusion to make from the 
comparison with the different models is that the correlation between Runx1 expression and 
degree of LV function is identical – reduced function, higher Runx1 which further supports 
a link between Runx1 expression and cardiac function without influence of an infarct size
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6.1 Rationale for the study 
The main aim of this thesis was to examine the altered expression patterns of the RUNX 
genes in different experimental models of heart disease.  The RUNX family of 
transcription factors are essential regulators of normal functioning during development but 
have received increased interest as important markers in human disease.  RUNX genes are 
up-regulated in response to injury or insult which has been observed in striated muscle 
types.  In skeletal muscle, levels of RUNX1 are relatively low but during disrupted 
electrical activity the expression increases nearly 100-fold and was shown to be a 
protective mediator in the muscle preventing harmful atrophy and further deterioration 
(Wang et al., 2005).  When the work by Gattenlohner et al. in 2003 (Gattenlohner et al., 
2003) identified an up-regulation of RUNX1 in the heart of patients with MI this raised a 
similar idea about the protective potential of RUNX1 over-expression in the heart.  The 
work from this thesis set out to characterise the altered expression in two different 
experimental models of cardiac disease; MI as had been observed for the human patient 
study, and a rat model of hypertension with further genetically altered strains with more 
specific altered LV mass.  These different models allowed a more thorough dissection of 
the expression patterns of the Runx genes in heart disease arising from different insults 
with differing patterns of remodelling and dysfunction.  The study therefore aimed to 
provide novel information on the levels of Runx gene expression in heart disease and the 
potential implications for its role during the disease.  Knowledge of the expression of 
RUNX in the heart even under healthy conditions is at present very limited and the work 
therefore aimed not only to improve knowledge of Runx levels in the normal heart and 
during disease but inform potential relevance of RUNX in future therapeutic treatments of 
CVD. 
6.2 Major aims and findings 
6.2.1 Suitability of animal models 
One of the important aspects that the work in this thesis has demonstrated is the value of 
utilising experimental animal models in research.  Each of the animal models used for this 
study conformed to the main set of criteria considered necessary for their use as disease 
models in that they mimicked the human phenotype closely, produced symptoms which 
were predictable and controllable, permitted study in a stable, chronic condition and 
allowed for relevant cardiac, haemodynamic and biochemical parameters to be measured 
(Doggrell & Brown, 1998;Houser et al., 2012).  In particular the mouse MI model was not 
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previously available in the laboratory and has since been developed with great success 
which has been made possible by a capacity building Integrative Mammalian Biology 
(IMB) award from the BBSRC designed to build and consolidate best practice in vivo 
research.  It was therefore mandatory that a significant component of this thesis involved in 
vivo studies. 
6.2.2 Development and characterisation of a mouse model of MI 
Animal models of disease are highly valuable as they allow study of the disease in a 
controlled manner.  In characterising gene expression changes in animal models for the 
future of human medicine it is imperative that the animal model mimics the human 
condition as closely as possible and represents a clinically relevant disease model for these 
experiments.  Therefore one of the initial aims of the thesis was to develop and characterise 
a model of MI in the mouse which would allow for potential genetic manipulations at a 
later stage of the project for the extended study of Runx genes in MI through knockout 
transgenic models.  Animal models of MI have been widely investigated however it was 
important to ensure the model developed a sufficient level of dysfunction and structural 
remodelling associated with this disease for subsequent gene expression studies using the 
model.  It was hypothesised that the model would reproducibly present the clinical features 
of MI and therefore be a suitable platform for the study of altered Runx expression under 
the conditions of this disease.  The mouse model of MI was successfully established in the 
laboratory using the CAL method producing a model with reproducible infarct sizes and 
low mortality that demonstrated not only features consistent with other published murine 
models but most importantly with human MI including LV systolic and diastolic 
dysfunction, altered electrical activity with increased frequency of VPC arrhythmias, 
cardiac structural remodelling including hypertrophy, wall thinning, chamber dilation and 
collagen deposition.  The model was therefore considered suitable for subsequent RUNX 
studies in the context of MI. 
6.2.3 Characterisation of congenic rat strains of altered LV mass 
The rat hypertensive model (SHRSP) developed enhanced systolic performance with 
diastolic dysfunction and increased cardiac fibrosis consistent with other published SHRSP 
models and with human hypertension.  The genetically-induced chromosome 14 congenic 
strains showed a BP-independent diastolic dysfunction or improvement in diastolic 
function with links with myocardial stiffness believed to be due to the patterns of cardiac 
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fibrosis observed.  These models therefore represented different models for further Runx 
expression studies. 
6.2.4 Runx and MI 
This is the first study to examine changes in Runx expression in the heart using an animal 
model of MI.  Present data on Runx in the heart was limited, even in the healthy non-
diseased heart.  RUNX expression in the diseased heart was also relatively unknown with 
studies that had investigated this unable to provide information on quantitative changes, 
disease progression alterations and in some cases precise cellular locations of the changes 
in expression in the heart was not available.  This work has provided novel information on 
many of these areas in which previously knowledge was lacking.  One of the first key 
findings was that Runx is present in control sham hearts therefore indicating a basal level 
of Runx in the healthy adult mouse heart.  Furthermore RUNX1 has been immunolocalised 
to cardiomyocytes as well as other cell types such as inflammatory cells and fibroblasts 
based on structural identification and observations from a qualified pathologist.  To our 
knowledge this is the first study to show the presence of RUNX1 in adult cardiomyocytes. 
Key findings:  The study findings have revealed that in hearts from mice post-MI there is 
a significant increase in the expression of all three Runx genes which was consistent with 
the finding from the human patient study, however work from the mouse model revealed 
that these changes were confined to the areas within and around the injury i.e. the infarct 
(all three Runx genes) and peri-infarct region (Runx1 and Runx3) with no change in 
expression within regions remote from the infarct (namely the remote LV and RV).  This 
was true at 4-wk after the initial insult.  At 8-wk post-insult, expression levels of Runx1 
were not different to the observations at 4-wk with higher levels of Runx1 in the infarct and 
peri-infarct; however with up-regulation in the remote LV region in addition which was 
not observed at 4-wk.  Increased expression of Runx genes in the heart post-MI does not 
solely arise from cardiomyocytes, it is accepted that there are other cell types (such as 
fibroblasts and inflammatory cells as mentioned above) that are also contributing to the 
increased expression.  It would be an important step to further dissect out the relative 
contributions from the cell types, which would be of particular relevance to potential 
altered functioning in cardiomyocytes.  This could be done by a means of cell separation 
utilising filtration techniques or FACS methods on the digested infarcted heart.  
Collectively however the results have identified spatial and temporal alterations of Runx 
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expression in the infarcted heart post-MI in a murine model warranting further 
investigation into the potential functional relevance of this. 
Possible implications:  These findings indicate that Runx expression is altered as a result 
of MI however the functional significance of this to the heart remains unclear.  Data from 
this thesis have shown there are significant correlations between the level of Runx increase 
with extent of dysfunction in that hearts with the highest level of Runx show the greatest 
dysfunction (for Runx1 and Runx3).  However the main problem with interpreting this 
finding is that there may be potential influence from the infarct size; there is a positive 
correlation with degree of dysfunction and increasing infarct size and the levels of Runx 
are known to be highest in the infarct region – therefore it became difficult to ascertain 
whether the degree of dysfunction in the heart was as a result of infarct size or increased 
Runx expression.  One thing that became evident was that when the influence from the 
infarct was removed the trends were the same.  This was performed firstly by removing the 
contribution of Runx expression from the infarct from the analysis and the relationships 
were as before with the infarct included and secondly, in a separate disease model without 
an infarct the trend also remained further giving weight to a direct link with Runx and 
function.  A direct link would be an exciting prospect in the field of cardiac medicine as it 
may indicate that Runx may be an important candidate for potential future biomarkers or a 
therapeutic target of heart disease.  However it is important to emphasise that this area 
requires a greater deal of further investigation in identifying the precise links but may 
represent a crucial component for further work. 
Further direction:  In terms of the functional role of Runx in cardiomyocytes this remains 
at present relatively unknown.  Studies have indicated that Runx2 may contribute to 
fibrosis and calcification through Notch signalling in atherosclerotic hearts.  It was 
originally hypothesised that RUNX may exhibit a similar role in cardiac muscle as had 
been shown in skeletal muscle on the basis that both muscle groups share similarities in 
structure and function and the triggering insult is very similar in the disturbances of 
electrical activity.  Preliminary data from our laboratory has shown that over-expression of 
RUNX1 in rabbit cardiomyocytes led to significantly reduced Ca2+ transient amplitudes 
and prolonged decay of Ca2+ transients versus control cardiomyocytes.  Based on these 
observations it would suggest that the increased expression of RUNX1 led to poorer 
contraction and impaired relaxation in the cardiomyocytes, which would indicate a 
detrimental rather than protective effect by RUNX1 meaning that the original point on 
similar protective features in cardiac muscle was disproved.  Given the knowledge that 
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RUNX1 is an activator of the phospholamban gene in injured skeletal muscle, it is feasible 
that RUNX1 may regulate Pln in cardiac muscle.  Pln is a key player in Ca2+ handling 
during EC coupling and an increased Pln would lead to the changes observed above which 
has been showed in Pln over-expressing mice.  It is however not clear from the data alone 
that this is the case and this would require the use of transgenic mice and measurements of 
Pln expression in the RUNX-overexpressing cells, importantly phosphorylated and 
unphosphorylated states which is essential for making the link with the Ca2+ alterations 
observed. 
6.2.5 Runx and hypertension/altered LV mass 
RUNX1 levels were also assessed in a separate experimental animal model of cardiac 
disease, in rat strains of genetic hypertension and in strains of altered LV mass.  In contrast 
to the results observed in MI, Runx1 was down-regulated in the diseased animals in the rat 
models.  Normotensive control WKY rats showed the highest levels of Runx1 expression 
in the whole LV where the WKY-congenic and SHRSP-congenic showed significantly 
reduced levels of Runx1 LV expression.  The functional significance of this has also yet to 
be investigated.  As with the MI model, a significant correlation was observed in with 
abundance of Runx1 and level of dysfunction (higher Runx1 in heart with greatest 
dysfunction) in this model. 
6.2.6 Differences in Runx expression between the different 
models 
By assessing how the behaviour of a single gene changes (in terms of its expression) in 
different cardiac diseases can provide a greater deal of information regarding the triggers 
for the gene of interest in CVD.  The assessment of Runx expression in not just a different 
animal model of CVD i.e. hypertensive rat (SHRSP) but also in specific congenic sub-
strains of this model to further dissect out the significance of Runx expression in CVD (in 
terms of a different phenotype) is highly advantageous and offers more insight into the 
behaviour of Runx in cardiac disease.  Neither of the Runx genes are located on 
chromosome 14 therefore the effects on Runx expression are likely to be related to the 
resulting phenotype rather than the manipulations to chromosome 14. 
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6.3 Future directions 
There are several directions for future work that have arisen from this work.  (i)  The first 
would be to further explore the functional relevance of altered Runx in the heart.  This is of 
crucial importance to achieve a more complete understanding of the potential clinical 
relevance of Runx in the context of heart disease.  The functional role of Runx in the heart 
could be addressed by further experimentation on RUNX over-expression in 
cardiomyocytes or by direct cardiac injection into the heart in vivo.  It would be important 
to induce over-expression to similar levels observed that endogenous RUNX was up-
regulated to within the disease model to allow for accurate comparisons.   
(ii)  Another route to further explore RUNX function in the heart would be through the use 
of a Runx-knockout model.  Transgenic animals with a cardiac specific knockout (global 
knockouts of Runx would be embryonically fatal) could be assessed for any functional 
alterations in response to MI.  This would involve inducing MI in these transgenic animals 
and assessing the effects on cardiac function as a result of this.  Based on the observations 
from this thesis the hypothesis is that Runx-ablation would lead to a reduced extent of 
dysfunction post-MI given the preliminary data indicating that RUNX1 over-expression in 
cardiomyocytes led to greater dysfunction.  The next stage from the functional 
investigation would be to investigate the mechanism of functional improvement.  The links 
with phospholamban have been proposed but a greater deal of work would be needed to 
fully elucidate this.  This could be investigated by assessing expression levels of 
phospholamban protein in its unphosphorylated and phosphorylated forms using specific 
antibodies sensitive to the two states in Western blots.  Based on the possible link with 
increased Runx1 leading to increased Pln gene expression and subsequent contractility 
impairment, it is hypothesised that an increase in Pln protein expression and a reduction in 
phosphorylated Pln would be observed in RUNX-overexpressing hearts which could 
contribute to the impairment in systolic function.  With knowledge on altered expression, 
functional role and mechanistic actions this would offer a more completed picture of the 
clinical relevance of Runx in cardiac disease.   
(iii)  The 1-wk animals which developed a severe MI phenotype and were possibly 
showing early signs of CHF have shown interesting results in the level of remodelling but 
also in the levels of Runx expression.  It is possible that Runx levels are greater in HF 
however this remains to be investigated fully.  If it were possible to produce more animals 
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with this phenotype or extend the MI period to a point where animals entered into CHF it 
could further assist in the links with Runx up-regulation.   
(iv)  The problem with contaminating cells in the infarcted heart (such as fibroblasts and 
inflammatory infiltrate) poses problems in identifying the relative contribution from the 
cardiomyocytes which is relevant for functional implications in these cells.  This could also 
be further assessed using rigorous separation techniques on the infarcted heart cells such as 
filtration or plating methods to allow gene expression measurements to be performed on 
pure populations of cardiomyocytes from the infarcted heart. 
(v)  There could also be future potential to assess Runx expression in more disease models 
such as alternative models of pressure-overload for example (e.g. transverse aortic 
constriction (TAC) models) and observe the comparisons with the pressure-overload 
models in this study.  Disease models of myocarditis and further work on valvular disease 
could also be investigated, all giving a fuller picture for triggers of Runx expression during 
heart disease.   
(vi)  Another avenue to take with this work would be to try and identify the specific stimuli 
which trigger RUNX over-expression using experiments designed to provide specific 
conditions that may be possible triggers for example: ex vivo preparations (to assess 
changes independent of neurohormonal influence present in vivo) for example use of a 
Langendorff-perfused heart subjected to various conditions present in MI including: 
hypoxia (95% N2/5% CO2 incubation ± sodium cyanide (NaCN)), oxygen radical 
production (hydrogen peroxide, H2O2), deprivation of energy sources (ATP, glucose), 
acidosis and osmotic stressors.  Furthermore a cultured papillary muscle preparation would 
allow insight into whether electrical stimulation of the heart influences RUNX1 expression 
as we can expose the muscle to pacing and non-pacing conditions.  Furthermore, we can 
use cultured papillary muscles to examine the effects of cell necrosis on RUNX1 
expression through a cryoinjury approach. 
6.4 Final conclusion 
Overall the work from this thesis has shown the value of using animal models in the ability 
to reproduce human heart disease and its many clinically relevant features for cardiac 
research, and has for the first time shown the relevance of the Runx genes in heart disease 
through use of such animal models.  The experimental data shows that in response to MI in 
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a mouse model there is an up-regulation of Runx genes in the heart located predominantly 
within and around the areas of injury that can extend into remote regions as the MI 
progresses.  In contrast to MI, in response to hypertension in rats and in genetically-altered 
sub-strains with altered LV mass there is a down-regulation of Runx1.  In both models the 
same observation was evident that Runx expression correlated positively with deterioration 
of function.  However, future work should aim to: (i) establish whether a direct link exists 
between Runx expression and level of dysfunction, and (ii) explore the functional and 
mechanistic roles of Runx in the heart.  Such work would enable us to determine the 
potential therapeutic value of the Runx family in heart disease.
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Appendix 
Derivation of the 2-∆∆Ct formula: 
The derivation for this equation has been published in the Applied Biosystems User 
Bulletin No. 2 (P/N 4303859) (Applied Biosytems, 1997) and can be described as follows: 
1. The exponential amplification of a PCR reaction can be described as: 
( )nxn EXX +×= 10  
Xn Number of target molecules at cycle number n 
X0 Initial number of target molecules 
Ex Efficiency of the amplification 
n Number of cycles 
 
2. The Ct describes the cycle number at which the fluorescence reaches a fixed threshold, 
therefore (for target gene X and housekeeping gene H): 
( ) xCxT KEXX XT =+×= ,10  
XT Threshold number of target molecules 
CT,X Threshold cycle for target amplification 
Kx Constant 
 
( ) HCHT KEHH HT =+×= ,10  
Xn Threshold number of housekeeping molecules 
X0 Initial number of housekeeping molecules 
Ex Efficiency of housekeeping reaction 
n Threshold cycle for housekeeping amplification 
KH Constant 
 
3. To normalise to the housekeeping gene, the target gene (XT) is divided by the 
housekeeping gene (HT): 






























XN X0/R0 normalised amount of target 
∆CT CT,X – CT,R difference in threshold cycles for target and 
 
As the 2-∆∆Ct method assumes the same efficiency of the reaction between the target gene 









     or   KEX TCN =+×
∆)1(     or    TCN EKX ∆−+×= )1(  
∆∆CT ∆CT,X – ∆CT,R 
 
The last step is to divide the XN for any sample Y by the calibrator CL (sample to which 























Since the efficiency is assumed to be close to 1, the final equation becomes 2-∆∆CT. 
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